BioTechCorp-Annual Report 2011

1
Annual Report 2011

Accelerating Biotechnology
Commercialisation
Through Global Collaboration
3
4
ACCELERATING
BIOTECHNOLOGY
GROWTH IN MALAYSIA
VISIONING THE FUTURE:
THE BIOECONOMY
IMPERATIVE
STATEMENT ON
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
EDITORIAL TEAM FOR
ANNUAL REPORT
2011 Operational Review
Po||cy and Regu|atory Engagement
Bus|ness lnte|||gence
Oapab|||ty Deve|opment
Agr|cu|tura| B|otechno|ogy
Hea|thcare B|otechno|ogy
lndustr|a| B|otechno|ogy
lndustry Adv|sory and Support
Operat|ona| Serv|ces
B|o-Oe||: A Ded|cated Space for
B|otechno|ogy
Techno|ogy Management Off|ce:
Enhanc|ng B|otech Exce||ence
Oa|endar of Events
B|otechOorp`s B|oeconomy
Asp|rat|ons
45
97
101
111
147
50
50
55
58
61
66
72
78
83
86
91
46
98
LAUNCHING THE
MALAYSIAN
BIOTECHNOLOGY
INDUSTRYS
PHASE 2 JOURNEY
2011 Highlights
Malaysian Biotechnology
Essentials
BiotechCorp:
Industry Catalyst at Work
About B|otechno|ogy
Nat|ona| B|otechno|ogy Po||cy
B|otechno|ogy Master P|an
About B|otechOorp
Oha|rman`s Message
OEO`s Report
The Peop|e Perspect|ve
o Board of D|rectors
o Organ|sat|on Structure
o The Management Team
07
08
11
16
11
11
13
14
16
20
26
26
40
42
In This
Report
5
ACCELERATING
BIOTECHNOLOGY
GROWTH IN MALAYSIA
VISIONING THE FUTURE:
THE BIOECONOMY
IMPERATIVE
STATEMENT ON
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
EDITORIAL TEAM FOR
ANNUAL REPORT
2011 Operational Review
Po||cy and Regu|atory Engagement
Bus|ness lnte|||gence
Oapab|||ty Deve|opment
Agr|cu|tura| B|otechno|ogy
Hea|thcare B|otechno|ogy
lndustr|a| B|otechno|ogy
lndustry Adv|sory and Support
Operat|ona| Serv|ces
B|o-Oe||: A Ded|cated Space for
B|otechno|ogy
Techno|ogy Management Off|ce:
Enhanc|ng B|otech Exce||ence
Oa|endar of Events
B|otechOorp`s B|oeconomy
Asp|rat|ons
45
97
101
111
147
50
50
55
58
61
66
72
78
83
86
91
46
98
LAUNCHING THE
MALAYSIAN
BIOTECHNOLOGY
INDUSTRYS
PHASE 2 JOURNEY
2011 Highlights
Malaysian Biotechnology
Essentials
BiotechCorp:
Industry Catalyst at Work
About B|otechno|ogy
Nat|ona| B|otechno|ogy Po||cy
B|otechno|ogy Master P|an
About B|otechOorp
Oha|rman`s Message
OEO`s Report
The Peop|e Perspect|ve
o Board of D|rectors
o Organ|sat|on Structure
o The Management Team
07
08
11
16
11
11
13
14
16
20
26
26
40
42
In This
Report
6
BiotechCorp Annual Report 2011 BiotechCorp Annual Report 2011
LAUNCHING THE
MALAYSIAN
BIOTECHNOLOGY
INDUSTRYS PHASE 2
JOURNEY
7
LAUNCHING THE
MALAYSIAN
BIOTECHNOLOGY
INDUSTRYS PHASE 2
JOURNEY
8
Key Indicators for the Biotechnology Industry at 31 December 2011
Source: BiotechCorp
Note:
* This is the total number/value at the end of each Phase. The target for 2020 is the same
as that at the end of Phase III.
** This is the total of GDP Contribution reported as at the end of Phase 1.
2011
Highlights
TARGETS
Achievements
in 2005-2011
period
INDICATORS
Phase I
(2005-2010)
Phase II
(2011-2015)
Phase III
(2016-2020)
Total
(2005-2020)
Investment by Private
Sector and Government
Number of BioNexus
companies
Employment
(at end period)
Annual Revenue
(at end period)*
Contribution to GDP
RM6 billion
25
40,000
RM20 billion
2.5%
RM9 billion
25
80,000
RM80 billion
4%
RM15 billion
50
160,000
RM170 billion
5%
RM30 billion
100
280,000
RM270 billion
5%
RM10.7 billion
210
55,904
RM14.2 billion
2.2%**
Key Investments for the Biotechnology Industry at 31 December 2011
A France based company - The first plant in the world to produce
PDO (1,3 Propanediol) using crude glycerin with a total investment of
RM100 million.
A US based company - Using proprietary platform technology to
produce technical grade ethanol using crude glycerine with a total
investment of RM46 million.
Metabolic Explorer S.A.
Glycos Biotechnology Inc.
Company Investments
An India based company - One of the largest biotech companies in
Asia and the first giant biotech company in India to establish a
biomanufacturing and research & development (R&D) facility with total
investments worth RM500 million.
A Korea-France JV company - A joint venture collaboration to
establish the worlds first green fermentation based L-methionine
plant in the East Coast Economic Region (ECER), Malaysia.
Biocon Ltd
CJ Cheiljedang Corporation
& Arkema S.A.
Total 2011 (RM)
BioNexus Companies: Approved Investment by Industry
Total 2005 2011 (RM) Industry Sector Total 2010 (RM)
Agriculture
Healthcare
Industrial
Total
184.4 million
172.4 million
115.4 million
472.2 million
86.8 million
10.0 million
88.1 million
184.9 million
867.8 million
608.6 million
669.7 million
2,146.1 million
Total 2011 (RM)
BioNexus Companies: Realised Investment by Industry
% Growth (2010 2011) Industry Sector Total 2010 (RM)
Agriculture
Healthcare
Industrial
Total
714.6 million (42%)
379.0 million (22%)
610.1 million (36%)
1,703.7 million (100%)
890.0 million (41%)
447.3 million (20%)
844.3 million (39%)
2,181.6 million (100%)
24.5%
18.0%
38.4%
28.1%
9
Key Indicators for the Biotechnology Industry at 31 December 2011
Source: BiotechCorp
Note:
* This is the total number/value at the end of each Phase. The target for 2020 is the same
as that at the end of Phase III.
** This is the total of GDP Contribution reported as at the end of Phase 1.
2011
Highlights
TARGETS
Achievements
in 2005-2011
period
INDICATORS
Phase I
(2005-2010)
Phase II
(2011-2015)
Phase III
(2016-2020)
Total
(2005-2020)
Investment by Private
Sector and Government
Number of BioNexus
companies
Employment
(at end period)
Annual Revenue
(at end period)*
Contribution to GDP
RM6 billion
25
40,000
RM20 billion
2.5%
RM9 billion
25
80,000
RM80 billion
4%
RM15 billion
50
160,000
RM170 billion
5%
RM30 billion
100
280,000
RM270 billion
5%
RM10.7 billion
210
55,904
RM14.2 billion
2.2%**
Key Investments for the Biotechnology Industry at 31 December 2011
A France based company - The first plant in the world to produce
PDO (1,3 Propanediol) using crude glycerin with a total investment of
RM100 million.
A US based company - Using proprietary platform technology to
produce technical grade ethanol using crude glycerine with a total
investment of RM46 million.
Metabolic Explorer S.A.
Glycos Biotechnology Inc.
Company Investments
An India based company - One of the largest biotech companies in
Asia and the first giant biotech company in India to establish a
biomanufacturing and research & development (R&D) facility with total
investments worth RM500 million.
A Korea-France JV company - A joint venture collaboration to
establish the worlds first green fermentation based L-methionine
plant in the East Coast Economic Region (ECER), Malaysia.
Biocon Ltd
CJ Cheiljedang Corporation
& Arkema S.A.
Total 2011 (RM)
BioNexus Companies: Approved Investment by Industry
Total 2005 2011 (RM) Industry Sector Total 2010 (RM)
Agriculture
Healthcare
Industrial
Total
184.4 million
172.4 million
115.4 million
472.2 million
86.8 million
10.0 million
88.1 million
184.9 million
867.8 million
608.6 million
669.7 million
2,146.1 million
Total 2011 (RM)
BioNexus Companies: Realised Investment by Industry
Agriculture
Healthcare
Industrial
Total
714.6 million (42%)
379.0 million (22%)
610.1 million (36%)
1,703.7 million (100%)
890.0 million (41%)
447.3 million (20%)
844.3 million (39%)
2,181.6 million (100%)
24.5%
18.0%
38.4%
28.1%
10
Note: (Employee by Industry and Knowledge Worker by Industry)
* Denotes that figures published this year differ from those published in the 2010 Annual
Report due to reclassification of categories on a number of companies in early 2011.
ABOUT BIOTECHNOLOGY
The United Nations Convention on Biological Diversity defines biotechnology as Any
technological application that uses biological systems, living organisms, or derivatives
thereof, to make or modify products or processes for specific use."
Given Malaysias history and aptitude for agriculture based economic activities, in 2005, the
Malaysian Government recognised biotechnology as one of the key strategic drivers that will
propel the nations social and economic development to greater heights. To create impetus for
this new domain, the Government created the National Biotechnology Policy (NBP) developed
according to the biotechnology Master Plan (2005-2020) to be implemented by the Malaysian
Biotechnology Corporation Sdn Bhd (BiotechCorp), a dedicated biotechnology agency.
Having completed the first phase of the policy from 2005 2010 focusing on capacity
building for the industry, BiotechCorp has entered the second phase of implementation from
2011 2015 which entails commercialisation and realising value unlocked by the industry
through various initiatives.
NATIONAL BIOTECHNOLOGY POLICY
The National Biotechnology Policy (NBP) is a landmark policy encompassing nine thrusts
which emphasise Malaysias intended direction and the Governments proposed measures
towards developing biotechnology for wealth creation and national well-being.
Thrust 1: Agricultural Biotechnology Development
Transform and enhance value creation of the agricultural sector through biotechnology.
Thrust 2: Healthcare Biotechnology Development
Capitalise on the strengths of biodiversity to commercialise discoveries in natural products
as well as position Malaysia in the bio-generics market.
Thrust 3: Industrial Biotechnology Development
Ensure growth opportunities in the application of advanced bio-processing and
bio-manufacturing technologies.
Malaysian
Biotechnology Essentials
Total 2011 (RM)
BioNexus Companies: Revenue Expenses by Industry
Agriculture
Healthcare
Industrial
Total
215.4 million (48%)
133.7 million (30%)
101.5 million (22%)
450.6 million (100%)
280.6 million (39%)
176.7 million (24%)
263.8 million (37%)
721.1 million (100%)
30.3%
32.2%
159.9%
60.0%
Total 2011
BioNexus Companies: Knowledge Worker by Industry
% Growth (2010 2011) Industry Sector Total 2010*
Agriculture
Healthcare
Industrial
Total
502 (43%)
482 (41%)
181 (16%)
1,165 (100%)
531 (42%)
511 (41%)
216 (17%)
1,258 (100%)
5.8%
6.0%
19.3%
8.0%
Total 2011
BioNexus Companies: Employee by Industry
Agriculture
Healthcare
Industrial
Total
1,177 (46%)
825 (33%)
539 (21%)
2,541 (100%)
1,292 (46%)
903 (32%)
629 (22%)
2,824 (100%)
9.8%
9.5%
16.7%
11.1%
Total 2011 (RM)
BioNexus Companies: R&D Expenses by Industry
Agriculture
Healthcare
Industrial
Total
31.5 million (49%)
27.9 million (44%)
4.7 million (7%)
64.1 million (100%)
24.5 million (31%)
42.5 million (54%)
11.6 million (15%)
78.6 million (100%)
22.2%
52.3%
146.8%
22.6%
11
Note: (Employee by Industry and Knowledge Worker by Industry)
* Denotes that figures published this year differ from those published in the 2010 Annual
Report due to reclassification of categories on a number of companies in early 2011.
ABOUT BIOTECHNOLOGY
The United Nations Convention on Biological Diversity defines biotechnology as Any
technological application that uses biological systems, living organisms, or derivatives
thereof, to make or modify products or processes for specific use."
Given Malaysias history and aptitude for agriculture based economic activities, in 2005, the
Malaysian Government recognised biotechnology as one of the key strategic drivers that will
propel the nations social and economic development to greater heights. To create impetus for
this new domain, the Government created the National Biotechnology Policy (NBP) developed
according to the biotechnology Master Plan (2005-2020) to be implemented by the Malaysian
Biotechnology Corporation Sdn Bhd (BiotechCorp), a dedicated biotechnology agency.
Having completed the first phase of the policy from 2005 2010 focusing on capacity
building for the industry, BiotechCorp has entered the second phase of implementation from
2011 2015 which entails commercialisation and realising value unlocked by the industry
through various initiatives.
NATIONAL BIOTECHNOLOGY POLICY
The National Biotechnology Policy (NBP) is a landmark policy encompassing nine thrusts
which emphasise Malaysias intended direction and the Governments proposed measures
towards developing biotechnology for wealth creation and national well-being.
Thrust 1: Agricultural Biotechnology Development
Transform and enhance value creation of the agricultural sector through biotechnology.
Thrust 2: Healthcare Biotechnology Development
Capitalise on the strengths of biodiversity to commercialise discoveries in natural products
as well as position Malaysia in the bio-generics market.
Thrust 3: Industrial Biotechnology Development
Ensure growth opportunities in the application of advanced bio-processing and
bio-manufacturing technologies.
Malaysian
Biotechnology Essentials
Total 2011 (RM)
BioNexus Companies: Revenue Expenses by Industry
Agriculture
Healthcare
Industrial
Total
215.4 million (48%)
133.7 million (30%)
101.5 million (22%)
450.6 million (100%)
280.6 million (39%)
176.7 million (24%)
263.8 million (37%)
721.1 million (100%)
30.3%
32.2%
159.9%
60.0%
Total 2011
BioNexus Companies: Knowledge Worker by Industry
Agriculture
Healthcare
Industrial
Total
502 (43%)
482 (41%)
181 (16%)
1,165 (100%)
531 (42%)
511 (41%)
216 (17%)
1,258 (100%)
5.8%
6.0%
19.3%
8.0%
Total 2011
BioNexus Companies: Employee by Industry
Agriculture
Healthcare
Industrial
Total
1,177 (46%)
825 (33%)
539 (21%)
2,541 (100%)
1,292 (46%)
903 (32%)
629 (22%)
2,824 (100%)
9.8%
9.5%
16.7%
11.1%
Total 2011 (RM)
BioNexus Companies: R&D Expenses by Industry
Agriculture
Healthcare
Industrial
Total
31.5 million (49%)
27.9 million (44%)
4.7 million (7%)
64.1 million (100%)
24.5 million (31%)
42.5 million (54%)
11.6 million (15%)
78.6 million (100%)
22.2%
52.3%
146.8%
22.6%
12
BIOTECHNOLOGY MASTER PLAN
Thrust 4: R&D and Technology Acquisition
Establish Centres of Excellence, in existing or new institutions, to bring together
multidisciplinary research teams in co-ordinated research and commercialisation initiatives.
Accelerate technology development via strategic acquisitions.
Thrust 5: Human Capital Development
Build the nations biotechnology human resource capability in line with market needs
through special schemes, programmes and training.
Thrust 6: Financial Infrastructure Development
Apply competitive lab to market funding and incentives to promote committed participation
by academia, the private sector as well as government-linked companies. Implement sufficient
exit mechanisms for investments in biotechnology.
Thrust 7: Legislative and Regulatory Framework Development
Create an enabling environment through continuous reviews of the countrys regulatory
framework and procedures in line with global standards and best practices. Develop a
strong intellectual property protection regime to support research and development (R&D)
and commercialisation efforts.
Thrust 8: Strategic Development
Establish a global marketing strategy to build recognition for Malaysian biotechnology and
benchmark progress. Establish Malaysia as a centre for Contract Research Organisations
and Contract Manufacturing Organisations.
Thrust 9: Government Support and Commitment
Establish a dedicated and professional implementation agency overseeing the development
of Malaysias biotechnology industry, under the aegis of the Prime Minister and relevant
Government ministries.
PHASE 3: GLOBAL BUSINESS (2016-2020) Attaining world class status
1. Consolidate strengths and capabilities in technology development
2. Further develop expertise and strength in drug discovery and development
3. Leading edge technology business
4. Maintain leadership in innovation and technology licensing
5. Create greater value through global Malaysian companies
6. Rebranding of Malaysia as a global biotechnology hub
PHASE 1: CAPACITY BUILDING (2005-2010) Setting up the building blocks
1. Adoption of policies, plans and strategies
2. Establishment of advisory and implementation Councils
3. Establishment of Malaysian Biotechnology Corporation Sdn Bhd (BiotechCorp)
4. Capacity building in research and development
5. Industrial technology development
6. Develop agricultural, healthcare and industrial biotechnologies
7. Develop legal and intellectual property framework
8. Incentives
9. Business and corporate development through accelerator programmes
10. Bioinformatics
11. Skills development
12. Job creation
13. Regional biotechnology hubs
14. Develop BioNexus Malaysia as a brand
PHASE 2: SCIENCE TO BUSINESS (2011-2015) Unlocking potential for the industry
1. Develop expertise in drug discovery and development based on biodiversity
and natural resources
2. New products development
3. Technology acquisition
4. Promote Foreign Direct Investment (FDI) participation
5. Intensify spin-off companies
6. Strengthen local and global brands
7. Develop capability in technology licensing
8. Job creation
13
BIOTECHNOLOGY MASTER PLAN
Thrust 4: R&D and Technology Acquisition
Establish Centres of Excellence, in existing or new institutions, to bring together
multidisciplinary research teams in co-ordinated research and commercialisation initiatives.
Accelerate technology development via strategic acquisitions.
Thrust 5: Human Capital Development
Build the nations biotechnology human resource capability in line with market needs
through special schemes, programmes and training.
Thrust 6: Financial Infrastructure Development
Apply competitive lab to market funding and incentives to promote committed participation
by academia, the private sector as well as government-linked companies. Implement sufficient
exit mechanisms for investments in biotechnology.
Thrust 7: Legislative and Regulatory Framework Development
Create an enabling environment through continuous reviews of the countrys regulatory
framework and procedures in line with global standards and best practices. Develop a
strong intellectual property protection regime to support research and development (R&D)
and commercialisation efforts.
Thrust 8: Strategic Development
Establish a global marketing strategy to build recognition for Malaysian biotechnology and
benchmark progress. Establish Malaysia as a centre for Contract Research Organisations
and Contract Manufacturing Organisations.
Thrust 9: Government Support and Commitment
Establish a dedicated and professional implementation agency overseeing the development
of Malaysias biotechnology industry, under the aegis of the Prime Minister and relevant
Government ministries.
PHASE 3: GLOBAL BUSINESS (2016-2020) Attaining world class status
1. Consolidate strengths and capabilities in technology development
2. Further develop expertise and strength in drug discovery and development
3. Leading edge technology business
4. Maintain leadership in innovation and technology licensing
5. Create greater value through global Malaysian companies
6. Rebranding of Malaysia as a global biotechnology hub
PHASE 1: CAPACITY BUILDING (2005-2010) Setting up the building blocks
1. Adoption of policies, plans and strategies
2. Establishment of advisory and implementation Councils
3. Establishment of Malaysian Biotechnology Corporation Sdn Bhd (BiotechCorp)
4. Capacity building in research and development
5. Industrial technology development
6. Develop agricultural, healthcare and industrial biotechnologies
7. Develop legal and intellectual property framework
8. Incentives
9. Business and corporate development through accelerator programmes
10. Bioinformatics
11. Skills development
12. Job creation
13. Regional biotechnology hubs
14. Develop BioNexus Malaysia as a brand
PHASE 2: SCIENCE TO BUSINESS (2011-2015) Unlocking potential for the industry
1. Develop expertise in drug discovery and development based on biodiversity
and natural resources
2. New products development
3. Technology acquisition
4. Promote Foreign Direct Investment (FDI) participation
5. Intensify spin-off companies
6. Strengthen local and global brands
7. Develop capability in technology licensing
8. Job creation
14
ABOUT BIOTECHCORP
Malaysian Biotechnology Corporation Sdn Bhd (BiotechCorp) (Company No. 691431-D)
was incorporated under provisions of the Companies Act 1965 on 13 May 2005 to identify
value propositions in research and development (R&D) and commerce and to support and
facilitate these ventures through financial assistance and advisory services.
Structure
BiotechCorp is an agency of the Ministry of Science, Technology and Innovation (MOSTI).
Its issued and fully paid share capital (95,000,002 ordinary shares of RM 1.00 each) is
owned by the Ministry of Finance Incorporated (95,000,001 shares) and Federal Lands
Commissioner (one share).
It is governed by the Biotechnology Implementation Council (BIC) and counselled by the
Biotechnology International Advisory Panel (IAP) (both chaired by the honourable Prime
Minister of Malaysia).
Key Mandates
Act as a focal point for all biotechnology initiatives in Malaysia.
Nurture and acce|erate growth of Ma|ays|an b|otechno|ogy compan|es.
Act|ve|y promote fore|gn d|rect |nvestments |n b|otechno|ogy.
Oreate a conduc|ve env|ronment for b|otechno|ogy |n Ma|ays|a.
Vision
To enhance the economic, health and social well being of the nation.
Mission
Lead the development of the biotechnology industry in Malaysia.
Corporate Values
Teamwork : In a relationship based on mutual respect and understanding, we work
together with our colleagues, clients and partners to achieve common goals.
Integrity : We conduct our business with uncompromising integrity.
Excellence : We strive to achieve excellence in all that we do.
Accountability : We drive the delivery of results for the organisation and the nation.
Business Information
Registered Office &
Principal Place of Business
Level 23, Menara Atlan
161B Jalan Ampang
50450 Kuala Lumpur
Malaysia
Principal Banker
Malayan Banking Berhad
Lot 1.01, Ampang Park
184 Jalan Ampang
50450 Kuala Lumpur
Malaysia
Auditor
Deloitte KassimChan
Chartered Accountants
Level 19, Uptown 1
1 Jalan SS21/58
Damansara Uptown
47400 Petaling Jaya
Malaysia
Tax Consultant
Ernst & Young
Level 23A, Menara Millenium
Jalan Damanlela
Pusat Bandar Damansara
50490 Kuala Lumpur
Malaysia
15
ABOUT BIOTECHCORP
Malaysian Biotechnology Corporation Sdn Bhd (BiotechCorp) (Company No. 691431-D)
was incorporated under provisions of the Companies Act 1965 on 13 May 2005 to identify
value propositions in research and development (R&D) and commerce and to support and
facilitate these ventures through financial assistance and advisory services.
Structure
BiotechCorp is an agency of the Ministry of Science, Technology and Innovation (MOSTI).
Its issued and fully paid share capital (95,000,002 ordinary shares of RM 1.00 each) is
owned by the Ministry of Finance Incorporated (95,000,001 shares) and Federal Lands
Commissioner (one share).
It is governed by the Biotechnology Implementation Council (BIC) and counselled by the
Biotechnology International Advisory Panel (IAP) (both chaired by the honourable Prime
Minister of Malaysia).
Key Mandates
Act as a focal point for all biotechnology initiatives in Malaysia.
Nurture and acce|erate growth of Ma|ays|an b|otechno|ogy compan|es.
Act|ve|y promote fore|gn d|rect |nvestments |n b|otechno|ogy.
Oreate a conduc|ve env|ronment for b|otechno|ogy |n Ma|ays|a.
Vision
To enhance the economic, health and social well being of the nation.
Mission
Lead the development of the biotechnology industry in Malaysia.
Corporate Values
Teamwork : In a relationship based on mutual respect and understanding, we work
together with our colleagues, clients and partners to achieve common goals.
Integrity : We conduct our business with uncompromising integrity.
Excellence : We strive to achieve excellence in all that we do.
Accountability : We drive the delivery of results for the organisation and the nation.
Business Information
Registered Office &
Principal Place of Business
Level 23, Menara Atlan
161B Jalan Ampang
50450 Kuala Lumpur
Malaysia
Principal Banker
Malayan Banking Berhad
Lot 1.01, Ampang Park
184 Jalan Ampang
50450 Kuala Lumpur
Malaysia
Auditor
Deloitte KassimChan
Level 19, Uptown 1
1 Jalan SS21/58
Damansara Uptown
47400 Petaling Jaya
Malaysia
Tax Consultant
Ernst & Young
Level 23A, Menara Millenium
Jalan Damanlela
Pusat Bandar Damansara
50490 Kuala Lumpur
Malaysia
16
BIOTECHCORP: INDUSTRY
CATALYST AT WORK
Chairmans Message
The National Biotechnology Policy (NBP) which spans 2005-2020 covers
three phases. The first phase was in the first five years building up
capacity, whilst the year 2011 saw the Malaysian biotechnology industry,
led by BiotechCorp stepping into the second phase of the NBP which will
last until 2015. Upon completion, from 2016 onwards our efforts will be
focused on making greater inroads into the global biotechnology
landscape and attaining a world class standard for this industry.
In the current phase, the industry undergoes an ultimate test of viability
as it embarks upon efforts to intensify the business appeal of
biotechnology initiatives. This is the stage where we are able to gauge the
effectiveness of our efforts, where they are translated into value which
can be generated for the industry. We have successfully moved from
science to business.
Indeed, the BiotechCorps mandate includes acting as the lead agency
for all biotechnology initiatives in the country which includes nurturing
biotechnology companies, creating a holistic environment to propagate
industry growth and attracting investments into this sector. We are
pleased to note that the industry has recorded significant progress,
punctuated by milestones that attest our capability of remaining on track,
with our aspiration to maximise the potential of the industry.
17
CATALYST AT WORK
Chairmans Message
The National Biotechnology Policy (NBP) which spans 2005-2015 covers
three phases. The first phase was in the first five years building up
capacity, whilst the year 2011 saw the Malaysian biotechnology industry,
led by BiotechCorp stepping into the second phase of the NBP which will
last until 2015. Upon completion, from 2016 onwards our efforts will be
focused on making greater inroads into the global biotechnology
landscape and attaining a world class standard for this industry.
In the current phase, the industry undergoes an ultimate test of viability
as it embarks upon efforts to intensify the business appeal of
biotechnology initiatives. This is the stage where we are able to gauge the
effectiveness of our efforts, where they are translated into value which
can be generated for the industry. We have successfully moved from
science to business.
Indeed, the BiotechCorps mandate includes acting as the lead agency
for all biotechnology initiatives in the country which includes nurturing
biotechnology companies, creating a holistic environment to propagate
industry growth and attracting investments into this sector. We are
pleased to note that the industry has recorded significant progress,
punctuated by milestones that attest our capability of remaining on track,
with our aspiration to maximise the potential of the industry.
18
Malaysia as a medium size economy prevails in an open competitive global market.
Nonetheless, our geographical, historical and social make-up has continued to be an excellent
backdrop for the birth of new ideas and harnessing of opportunities.
Within the biotechnology context, the richness of our natural resources and biodiversity
provides us with a perfect platform to be capitalised upon. Given the existence of Malaysias
bountiful plant-based treasures, we are confident that commercialisation of discoveries in
natural products puts Malaysia in a good position to capture opportunities in the growing
wellness market. In the past few years, we have seen the successful commercialisation of a
number of natural substances, with some attaining global acclaim.
Our racial mix provides a diverse genetic pool and positions us as a great hub for clinical trials.
With effective costs in research and development (R&D) and a well regulated framework, we
have certainly made inroads in this area. Stempeutics, a BioNexus Status company, with its
stem cell research in neurological and orthopedic areas has placed Malaysia as one of the
leading countries after USA to reach such a high level in stem cell research.
Our strengths as a manufacturing hub and proximity to raw materials and feedstock bode well
for the bioprocess and biomanufacturing sectors. Products currently being developed by our
network of BioNexus Status companies are also being produced for global markets. In terms
of the numbers doing the talking, cumulative revenue from 2007 to 2011 hit RM1.0 billion from
export sales and RM1.2 billion from local sales.
Our position as a halal hub gives us the opportunity to lead in active pharmaceutical ingredients
(APIs), vaccines and generics within the halal space. With an estimated 2 billion Muslim
consumers worldwide, the global market for halal food and non-food products is valued at
US$2 trillion. There are companies in Malaysia that are already producing halal products.
Finally, our research and development and commercialisation (R&D&C) capabilities put us in
strong stead to continue to capitalise on industry growth potential. We have made
breakthroughs in R&D on oil palm and rubber genomics. Our BioNexus Status companies have
won awards. For example, Siogen Biotech received the Most Innovative Start-up in Asia Pacific
in 2009 for the BioSingapore Asia Pacific Biotechnology Award with their proprietary
technology for drug delivery.
BiotechCorps initiatives in driving the industry forth are also bearing fruit. Bio-XCell, the first
dedicated biotechnology park and ecosystem in Malaysia is designed for healthcare and
industrial biotechnology, with focus on manufacturing and R & D. We have achieved positive
response so far as international investors identify with the infrastructure, logistics, accessibility
and connectivity that supports Bio-XCell.
Global giants Biocon, Metabolic Explorer and Glycos Biotechnologies were the early entrants
to this knowledge-intensive bio processing and bio manufacturing hub ideal as a launch pad
to unlock the potential of the Asian market.
In blazing the trail moving forward, Malaysia has ambitious plans for its biotechnology sector.
By 2020, the government expects the sector to create 280,000 employment opportunities and
contribute 5% of the countrys GDP. However, we realise that we are operating in an
increasingly challenging global economic landscape. Worries of the deepening Eurozone
continue to dominate sentiments world-wide, but that is not to say there is no silver lining to this
cloud. We offer serious global investors a conducive and competitive environment that will
make Malaysia one of the most appealing biotechnology destinations in this region.
While BiotechCorp remains firmly focused on our efforts of developing the industry in Malaysia,
I also believe, with a little perseverance this can be achieved with continued commitment from
the Government and a robust framework for regional and global collaboration.
In realising the NBP, BiotechCorp will continue to accelerate commercialisation in biotechnology
to transform Malaysia into a knowledge-based economy and an industrialised nation by year
2020.
Now that we are on the threshold of even greater achievements, I would like to acknowledge
that coming this far would not have been possible without the support of our various
stakeholders. I am especially grateful to the Government of Malaysia for the support extended
to us in bringing this industry to the level it is at today.
Also of note is the contribution of my fellow board members, the management and team at
BiotechCorp. Each of you have in your own ways been instrumental to the successes achieved
thus far and although the journey is far from over, I trust that you will continue to do what it takes
to realise the collective vision we all share for the Malaysian biotechnology industry.
Last but not least, I would like to thank all our industry players who add clout and dynamism to
the industry. You have helped us build this industry from ground up and now we stand together
at the brink of more exciting things ahead, which I am convinced, appeals for your continued
support of the Malaysian biotechnology industry.
Tan Sri Datuk Dr Ahmad Zaharudin Idrus
Chairman
19
Malaysia as a medium size economy prevails in an open competitive global market.
Nonetheless, our geographical, historical and social make-up has continued to be an excellent
backdrop for the birth of new ideas and harnessing of opportunities.
Within the biotechnology context, the richness of our natural resources and biodiversity
provides us with a perfect platform to be capitalised upon. Given the existence of Malaysias
bountiful plant-based treasures, we are confident that commercialisation of discoveries in
natural products puts Malaysia in a good position to capture opportunities in the growing
wellness market. In the past few years, we have seen the successful commercialisation of a
number of natural substances, with some attaining global acclaim.
Our racial mix provides a diverse genetic pool and positions us as a great hub for clinical trials.
With effective costs in research and development (R&D) and a well regulated framework, we
have certainly made inroads in this area. Stempeutics, a BioNexus Status company, with its
stem cell research in neurological and orthopedic areas has placed Malaysia as one of the
leading countries after USA to reach such a high level in stem cell research.
Our strengths as a manufacturing hub and proximity to raw materials and feedstock bode well
for the bioprocess and biomanufacturing sectors. Products currently being developed by our
network of BioNexus Status companies are also being produced for global markets. In terms
of the numbers doing the talking, cumulative revenue from 2007 to 2011 hit RM1.0 billion from
export sales and RM1.2 billion from local sales.
Our position as a halal hub gives us the opportunity to lead in active pharmaceutical ingredients
(APIs), vaccines and generics within the halal space. With an estimated 2 billion Muslim
consumers worldwide, the global market for halal food and non-food products is valued at
US$2 trillion. There are companies in Malaysia that are already producing halal products.
Finally, our research and development and commercialisation (R&D&C) capabilities put us in
strong stead to continue to capitalise on industry growth potential. We have made
breakthroughs in R&D on oil palm and rubber genomics. Our BioNexus Status companies have
won awards. For example, Siogen Biotech received the Most Innovative Start-up in Asia Pacific
in 2009 for the BioSingapore Asia Pacific Biotechnology Award with their proprietary
technology for drug delivery.
BiotechCorps initiatives in driving the industry forth are also bearing fruit. Bio-XCell, the first
dedicated biotechnology park and ecosystem in Malaysia is designed for healthcare and
industrial biotechnology, with focus on manufacturing and R & D. We have achieved positive
response so far as international investors identify with the infrastructure, logistics, accessibility
and connectivity that supports Bio-XCell.
Global giants Biocon, Metabolic Explorer and Glycos Biotechnologies were the early entrants
to this knowledge-intensive bio processing and bio manufacturing hub ideal as a launch pad
to unlock the potential of the Asian market.
In blazing the trail moving forward, Malaysia has ambitious plans for its biotechnology sector.
By 2020, the government expects the sector to create 280,000 employment opportunities and
contribute 5% of the countrys GDP. However, we realise that we are operating in an
increasingly challenging global economic landscape. Worries of the deepening Eurozone
continue to dominate sentiments world-wide, but that is not to say there is no silver lining to this
cloud. We offer serious global investors a conducive and competitive environment that will
make Malaysia one of the most appealing biotechnology destinations in this region.
While BiotechCorp remains firmly focused on our efforts of developing the industry in Malaysia,
I also believe, with a little perseverance this can be achieved with continued commitment from
the Government and a robust framework for regional and global collaboration.
In realising the NBP, BiotechCorp will continue to accelerate commercialisation in biotechnology
to transform Malaysia into a knowledge-based economy and an industrialised nation by year
2020.
Now that we are on the threshold of even greater achievements, I would like to acknowledge
that coming this far would not have been possible without the support of our various
stakeholders. I am especially grateful to the Government of Malaysia for the support extended
to us in bringing this industry to the level it is at today.
Also of note is the contribution of my fellow board members, the management and team at
BiotechCorp. Each of you have in your own ways been instrumental to the successes achieved
thus far and although the journey is far from over, I trust that you will continue to do what it takes
to realise the collective vision we all share for the Malaysian biotechnology industry.
Last but not least, I would like to thank all our industry players who add clout and dynamism to
the industry. You have helped us build this industry from ground up and now we stand together
at the brink of more exciting things ahead, which I am convinced, appeals for your continued
support of the Malaysian biotechnology industry.
Tan Sri Datuk Dr Ahmad Zaharudin Idrus
Chairman
20
CATALYST AT WORK
CEOs Repor t
Seven years after the establishment of the Malaysian Biotechnology Corporation
Sdn Bhd, as we move into the second phase of the implementation of the
National Biotechnology Policy (2005-2020) which focuses on commercialisation,
the impetus for industry growth continues to gain momentum.
Now more than ever, the global biotechnology industry is underscored by
tremendous dynamism and change. The Malaysian biotechnology industry too
continues to experience an exciting pace of development. Having transcended
the first part of our journey in building up the industry and putting in place
relevant mechanisms to catalyse development, in this present phase, we realise
that the impetus for us really is to create greater impact and drive synergy
between our industry and the global marketplace.
Today, sustainability has become the touchstone of discussions about
relationships between businesses and the society. It has also become absolutely
critical for corporations to meaningfully engage with its stakeholders and
respond to their needs and expectations against a backdrop of transforming
economic, regulatory and social landscapes.
In formulating our five-year Business Plan for 2011-2015, we were cognisant of
the national economic and policy agendas, particularly the New Economic
Model and the Economic Transformation Programme (ETP). We remain guided
by our role in supporting national growth needs and aspirations, while meeting
the challenges of regional competition and globalisation of the industry.
21
CATALYST AT WORK
CEOs Repor t
Seven years after the establishment of the Malaysian Biotechnology Corporation
Sdn Bhd, as we move into the second phase of the implementation of the
National Biotechnology Policy (2005-2020) which focuses on commercialisation,
the impetus for industry growth continues to gain momentum.
Now more than ever, the global biotechnology industry is underscored by
tremendous dynamism and change. The Malaysian biotechnology industry too
continues to experience an exciting pace of development. Having transcended
the first part of our journey in building up the industry and putting in place
relevant mechanisms to catalyse development, in this present phase, we realise
that the impetus for us really is to create greater impact and drive synergy
between our industry and the global marketplace.
Today, sustainability has become the touchstone of discussions about
relationships between businesses and the society. It has also become absolutely
critical for corporations to meaningfully engage with its stakeholders and
respond to their needs and expectations against a backdrop of transforming
economic, regulatory and social landscapes.
In formulating our five-year Business Plan for 2011-2015, we were cognisant of
the national economic and policy agendas, particularly the New Economic
Model and the Economic Transformation Programme (ETP). We remain guided
by our role in supporting national growth needs and aspirations, while meeting
the challenges of regional competition and globalisation of the industry.
22
Highlights of 2011
Our 2011 journey has been characterised by efforts to intensify growth and unlock value for
various stakeholders. In driving the industry forward, our focus areas continue to be the three
key segments which are agricultural biotechnology, healthcare biotechnology and industrial
biotechnology. These three institutes will serve as the industry drivers that work towards the
securing of investments and other developmental initiatives to propel the industry through its
various stages of growth.
Below are some of BiotechCorps key achievements in 2011:
BioNexus companies scale new heights - As we enter the second year of the
commercialisation of the NBP, we have now under our care 210 BioNexus (BNX) companies
with total approved investments worth more than RM2 billion. BioNexus Malaysia was
established to facilitate the marketing of biotechnology industry. It comprises a group of
specialised companies and institutions that can support each other to create a synergistic
network, which also sees the companies being incentivised to encourage participation of
companies and institutions. As at 31 December 2011, more than 50% of these companies are
already generating revenue with five currently listed in various stock exchanges with a market
capitalisation of more than RM800 million. The revenue by industry for BNX companies grew
60% in 2011 to RM721.1 million compared to RM460.6 million in 2010.
Bio-XCell gains traction - One of the biggest initiatives to come out of BiotechCorp to date
has been the Bio-XCell project, Asias new regional biotechnology hub established two years
ago as one of the industry's flag bearers. It is a platform where BiotechCorp pools soft
infrastructure financial incentives, human capital development, business and operational
set-up advisory, attractive leasing models, and the physical infrastructure that will enable
companies to springboard their biotechnology business and commercialisation activities. As of
2011, three global names are present within Bio-XCell, namely Biocon Ltd, France-based
Metabolic Explorer and US-based Glycos Biotechnologies Inc., with investments totalling
RM 650 milion.
Facilitating industry academia collaboration - BiotechCorp continues to engage with
universities and research institutes to support and enhance their role as active players in
commercialisation activities in addition to their traditional focus on education and fundamental
research. This is especially crucial as there is need for exchange of information, data and
scientific findings between industry and academia. In 2011, under the BioNexus Partners
programme, BiotechCorp is collaborating with 56 labs in universities and research institutes to
facilitate industry access which can spur the commercialisation of R&D products and services.
Pulling in global names - As a testament to the global appeal of the Malaysian biotechnology
industry, it is certainly heartening to note that Malaysia continues to be a destination of big
foreign names. This is reflected by equity participation of international investors in BioNexus
companies as well as the presence of global biotech giants within the Bio-XCell space.
Supported by BiotechCorps other initiatives in building an enabling environment, the BioNexus
Programme and Bio-XCell initiative have evolved into becoming bastions of credibility for
Malaysias emerging biotechnology sector.
Despite the global economic slowdown in 2011, Malaysia continues to attract considerable
biotechnology investments from the private sector outside of its BioNexus Programme. Some
of the more notable investments include investments by a joint-venture between South
Korea-based CJ CheilJedang and French chemical producer Arkema, to build the worlds first
bio-methionine plant, and collaboration between Japan-based Mitsui Engineering and
Shipbuilding and Sime Darby Plantation, to build a bioethanol demonstration plant by
converting empty oil palm fruit bunches.
Preparing for the future - Intensifying biotechnology proliferation in Malaysia
Looking ahead, we remain focused on accelerating the execution of our growth strategy while
continuing to build on the strength and stature of BiotechCorps developmental role in in shaping
the future of sustainable industry.
For an industry that is well - placed to capitalise on numerous strengths available to us in this
country including biodiversity, a supportive Government and a growing appetite for
entrepreneurship, we believe that there exists an urgent need to address certain areas that will
help accelerate our effort towards becoming a global player of high repute in the biotechnology
space. We are further assured by Malaysia's resilient economic fundamentals, strong domestic
demand and most importantly, the government's strategic initiatives that are directly benefiting
the industry.
Fostering innovation - The year 2012 has been declared as the Year of Science and National
Innovation Movement year. This double initiative is designed to reinforce the nations agenda in
promoting the spirit of innovation and creativity across all segments of our society. Several
strategic initiatives will be implemented to instil and inculcate innovation in schools and
institution of higher learning. The programmes will also reach rural areas and ensure that
grass-root innovation is also nurtured and supported.
The challenge now is to make a quantum leap towards developing an innovative society and a
high income economy, and for Malaysia to be a recognised innovation powerhouse in this
region. This is possible with careful planning and clear strategies. The governments focus is
also on Science Technology and Innovation (STI) as part of this transformational change.
Engaging financiers - Securing financing for viable biotechnology projects continues to
remain a challenge because the financial services industry and most investors are unfamiliar
with the industry and industry players themselves often find it hard to articulate the value of their
projects meaningfully to various stakeholders. However, one way in which this gap can be
bridged is by ensuring that viable projects gain intellectual property registration, which can then
be used as collateral to derive financing. BiotechCorp hopes to address it by facilitating the
achievement of IP rights while at the same time engaging with the financing community
including financial institutions, angel investors and venture capitalists among others to educate
them further about the industry.
23
Highlights of 2011
Our 2011 journey has been characterised by efforts to intensify growth and unlock value for
various stakeholders. In driving the industry forward, our focus areas continue to be the three
key segments which are agricultural biotechnology, healthcare biotechnology and industrial
biotechnology. These three institutes will serve as the industry drivers that work towards the
securing of investments and other developmental initiatives to propel the industry through its
various stages of growth.
Below are some of BiotechCorps key achievements in 2011:
BioNexus companies scale new heights - As we enter the second year of the
commercialisation of the NBP, we have now under our care 210 BioNexus (BNX) companies
with total approved investments worth more than RM2 billion. BioNexus Malaysia was
established to facilitate the marketing of biotechnology industry. It comprises a group of
specialised companies and institutions that can support each other to create a synergistic
network, which also sees the companies being incentivised to encourage participation of
companies and institutions. As at 31 December 2011, more than 50% of these companies are
already generating revenue with five currently listed in various stock exchanges with a market
capitalisation of more than RM800 million. The revenue by industry for BNX companies grew
60% in 2011 to RM721.1 million compared to RM460.6 million in 2010.
Bio-XCell gains traction - One of the biggest initiatives to come out of BiotechCorp to date
has been the Bio-XCell project, Asias new regional biotechnology hub established two years
ago as one of the industry's flag bearers. It is a platform where BiotechCorp pools soft
infrastructure financial incentives, human capital development, business and operational
set-up advisory, attractive leasing models, and the physical infrastructure that will enable
companies to springboard their biotechnology business and commercialisation activities. As of
2011, three global names are present within Bio-XCell, namely Biocon Ltd, France-based
Metabolic Explorer and US-based Glycos Biotechnologies Inc., with investments totalling
RM 650 milion.
Facilitating industry academia collaboration - BiotechCorp continues to engage with
universities and research institutes to support and enhance their role as active players in
commercialisation activities in addition to their traditional focus on education and fundamental
research. This is especially crucial as there is need for exchange of information, data and
scientific findings between industry and academia. In 2011, under the BioNexus Partners
programme, BiotechCorp is collaborating with 56 labs in universities and research institutes to
facilitate industry access which can spur the commercialisation of R&D products and services.
Pulling in global names - As a testament to the global appeal of the Malaysian biotechnology
industry, it is certainly heartening to note that Malaysia continues to be a destination of big
foreign names. This is reflected by equity participation of international investors in BioNexus
companies as well as the presence of global biotech giants within the Bio-XCell space.
Supported by BiotechCorps other initiatives in building an enabling environment, the BioNexus
Programme and Bio-XCell initiative have evolved into becoming bastions of credibility for
Malaysias emerging biotechnology sector.
Despite the global economic slowdown in 2011, Malaysia continues to attract considerable
biotechnology investments from the private sector outside of its BioNexus Programme. Some
of the more notable investments include investments by a joint-venture between South
Korea-based CJ CheilJedang and French chemical producer Arkema, to build the worlds first
bio-methionine plant, and collaboration between Japan-based Mitsui Engineering and
Shipbuilding and Sime Darby Plantation, to build a bioethanol demonstration plant by
converting empty oil palm fruit bunches.
Preparing for the future - Intensifying biotechnology proliferation in Malaysia
Looking ahead, we remain focused on accelerating the execution of our growth strategy while
continuing to build on the strength and stature of BiotechCorps developmental role in in shaping
the future of sustainable industry.
For an industry that is well - placed to capitalise on numerous strengths available to us in this
country including biodiversity, a supportive Government and a growing appetite for
entrepreneurship, we believe that there exists an urgent need to address certain areas that will
help accelerate our effort towards becoming a global player of high repute in the biotechnology
space. We are further assured by Malaysia's resilient economic fundamentals, strong domestic
demand and most importantly, the government's strategic initiatives that are directly benefiting
the industry.
Fostering innovation - The year 2012 has been declared as the Year of Science and National
Innovation Movement year. This double initiative is designed to reinforce the nations agenda in
promoting the spirit of innovation and creativity across all segments of our society. Several
strategic initiatives will be implemented to instil and inculcate innovation in schools and
institution of higher learning. The programmes will also reach rural areas and ensure that
grass-root innovation is also nurtured and supported.
The challenge now is to make a quantum leap towards developing an innovative society and a
high income economy, and for Malaysia to be a recognised innovation powerhouse in this
region. This is possible with careful planning and clear strategies. The governments focus is
also on Science Technology and Innovation (STI) as part of this transformational change.
Engaging financiers - Securing financing for viable biotechnology projects continues to
remain a challenge because the financial services industry and most investors are unfamiliar
with the industry and industry players themselves often find it hard to articulate the value of their
projects meaningfully to various stakeholders. However, one way in which this gap can be
bridged is by ensuring that viable projects gain intellectual property registration, which can then
be used as collateral to derive financing. BiotechCorp hopes to address it by facilitating the
achievement of IP rights while at the same time engaging with the financing community
including financial institutions, angel investors and venture capitalists among others to educate
them further about the industry.
24
Driving industrial biotechnology - Industrial biotechnology will be a key sector in which
Malaysia is gearing towards utilising its full potential. As the worlds second largest exporter of
palm oil, Malaysias palm oil waste alone holds tremendous opportunity and potential for the
creation of high value industrial applications ranging from biofuels to bioplastics that can be
generated from its biomass.
The country intends to put in place a framework and strategy for biomass utilisation to derive
the full benefits from oil palm and other agricultural waste which will contribute to energy
sustainability and environmental solutions while opening the pipeline for creating other value
propositions. Collaborations between public and private institutions must be promulgated to
unlock value from the breadth and depth of our available biomass.
Encouraging bioeconomy - The Organisation for Economic Development and Cooperation
(OECD) estimates that Bioeconomy will contribute a global average of 2.7% to GDP.
Bioeconomy will also contribute 10-14 new drugs per year over the next 5 years and will be
responsible for 10% of chemical production by 2030. Thus I do believe that latching on to the
Bioeconomy agenda where we have some clear advantage is very much a key element within
our STI strategy.
The Bioeconomy Initiative Malaysia (BIM) was announced by YAB Dato Sri Mohd Najib Tun
Razak in November 2011. With the BIM, Malaysia has taken the early critical steps to coordinate
and intensify national efforts to exploit the potential economic benefits of bioeconomy and I
believe that the BIM will further enhance the role of biotechnology as a key cross-cutting
technology driver in transforming Malaysia into a high income economy.
With effort, BiotechCorp is facilitating the bioeconomy lab under the ETP, following which will
launch projects that will complement the commercialisation efforts underway in the current
phase of the NBP.
We are enthusiastic about the prospects of Bioeconomy Initiative Malaysia as a sustainable
growth model for long-term benefits to Malaysias economy, welfare, productivity, health,
environmental and societal well-being. We also see greater potential for BiotechCorp to enhance
its role in developing the biotechnology industry in Malaysia. In light thereof, we look forward to
engage proactively with relevant stakeholders, for example, policy makers, regulators,
governmental organisations and industry participants to build win-win relationships and ensure
optimal outcomes. We remain confident in our ability to meet our targets for the coming year,
while staying on track to develop the biotechnology industry of Malaysia to greater heights.
Appreciation
Having been in office for the last one year, I believe the role for BiotechCorp in spearheading
the development of the industry is clear cut and we acknowledge that our efforts to see the
blueprint into fruition cannot be achieved without the contributions of our various stakeholders.
Whilst the formative years of BiotechCorp have passed and we are now well into the 'proof
of concept' stage for this organisation in harnessing the value of the industry, an important
group of stakeholders that I would like to thank are my entire team at this organisation. Their
talent and dedication is what propels BiotechCorp to greater heights and they are an
admirable group of people.
Our distinguished Board of Directors, led by Chairman YBhg Tan Sri Datuk Dr Ahmad
Zaharudin Idrus plays the all too important role of setting the pace for BiotechCorp and
ensuring that our roles are performed to a tee. Indeed, I am deeply grateful for the guidance
and oversight.
And finally, I would like to record my sincere appreciation to industry stakeholders and other
partners who have been instrumental in the implementation of the NBP. Without you, there
would be no biotechnology industry in Malaysia and I certainly look forward to a greater level of
engagement and collaboration in reaching our objectives.
Thank you.
Dato' Dr Mohd Nazlee Kamal
Chief Executive Officer
25
Driving industrial biotechnology - Industrial biotechnology will be a key sector in which
Malaysia is gearing towards utilising its full potential. As the worlds second largest exporter of
palm oil, Malaysias palm oil waste alone holds tremendous opportunity and potential for the
creation of high value industrial applications ranging from biofuels to bioplastics that can be
generated from its biomass.
The country intends to put in place a framework and strategy for biomass utilisation to derive
the full benefits from oil palm and other agricultural waste which will contribute to energy
sustainability and environmental solutions while opening the pipeline for creating other value
propositions. Collaborations between public and private institutions must be promulgated to
unlock value from the breadth and depth of our available biomass.
Encouraging bioeconomy - The Organisation for Economic Development and Cooperation
(OECD) estimates that Bioeconomy will contribute a global average of 2.7% to GDP.
Bioeconomy will also contribute 10-14 new drugs per year over the next 5 years and will be
responsible for 10% of chemical production by 2030. Thus I do believe that latching on to the
Bioeconomy agenda where we have some clear advantage is very much a key element within
our STI strategy.
The Bioeconomy Initiative Malaysia (BIM) was announced by YAB Dato Sri Mohd Najib Tun
Razak in November 2011. With the BIM, Malaysia has taken the early critical steps to coordinate
and intensify national efforts to exploit the potential economic benefits of bioeconomy and I
believe that the BIM will further enhance the role of biotechnology as a key cross-cutting
technology driver in transforming Malaysia into a high income economy.
With effort, BiotechCorp is facilitating the bioeconomy lab under the ETP, following which will
launch projects that will complement the commercialisation efforts underway in the current
phase of the NBP.
We are enthusiastic about the prospects of Bioeconomy Initiative Malaysia as a sustainable
growth model for long-term benefits to Malaysias economy, welfare, productivity, health,
environmental and societal well-being. We also see greater potential for BiotechCorp to enhance
its role in developing the biotechnology industry in Malaysia. In light thereof, we look forward to
engage proactively with relevant stakeholders, for example, policy makers, regulators,
governmental organisations and industry participants to build win-win relationships and ensure
optimal outcomes. We remain confident in our ability to meet our targets for the coming year,
while staying on track to develop the biotechnology industry of Malaysia to greater heights.
Appreciation
Having been in office for the last one year, I believe the role for BiotechCorp in spearheading
the development of the industry is clear cut and we acknowledge that our efforts to see the
blueprint into fruition cannot be achieved without the contributions of our various stakeholders.
Whilst the formative years of BiotechCorp have passed and we are now well into the 'proof
of concept' stage for this organisation in harnessing the value of the industry, an important
group of stakeholders that I would like to thank are my entire team at this organisation. Their
talent and dedication is what propels BiotechCorp to greater heights and they are an
admirable group of people.
Our distinguished Board of Directors, led by Chairman YBhg Tan Sri Datuk Dr Ahmad
Zaharudin Idrus plays the all too important role of setting the pace for BiotechCorp and
ensuring that our roles are performed to a tee. Indeed, I am deeply grateful for the guidance
and oversight.
And finally, I would like to record my sincere appreciation to industry stakeholders and other
partners who have been instrumental in the implementation of the NBP. Without you, there
would be no biotechnology industry in Malaysia and I certainly look forward to a greater level of
engagement and collaboration in reaching our objectives.
Thank you.
Dato' Dr Mohd Nazlee Kamal
26
1. YBhg Tan Sri Datuk Dr Ahmad
Zaharudin Idrus
2. YBhg Dato' Dr Mohd Nazlee
Kamal
3. YBhg Tan Sri Dato' Dr Jegathesan
a/l N.M. Vasagam @ Manikavasagam
27
1. YBhg Tan Sri Datuk Dr Ahmad
Zaharudin Idrus
2. YBhg Dato' Dr Mohd Nazlee
Kamal
3. YBhg Tan Sri Dato' Dr Jegathesan
a/l N.M. Vasagam @ Manikavasagam
28
5. Professor Dr Zainul Fadziruddin
Zainuddin
6. Puan Norsimah Ab Wahab 7. Tuan Haji Mohd. Radzi Hussein 4. YBhg Dato' Madinah Mohamad
29
5. Professor Dr Zainul Fadziruddin
Zainuddin
6. Puan Norsimah Ab Wahab 7. Tuan Haji Mohd. Radzi Hussein 4. YBhg Dato' Madinah Mohamad
30
9. Encik Amirul Fares Wan Zahir
1. YBhg Tan Sri Datuk Dr Ahmad Zaharudin Idrus (Chairman)
YBhg Tan Sri Datuk Dr Ahmad Zaharudin Idrus, a Malaysian, aged 67, was appointed by the
Prime Minister of Malaysia as Chairman of BiotechCorp on 16 May 2005.
He has served as the Science Advisor to the Prime Minister of Malaysia from 2001 to 2006. He
was the Vice Chancellor of Universiti Teknologi Malaysia from 1994 to 2001.
YBhg Tan Sri Datuk Dr Ahmad Zaharudin obtained his Masters and PhD degrees from the
University of Aberdeen (UK) after graduating with an Agricultural Science degree from Universiti
Malaya in 1969.
He has been highly instrumental in the development of the Malaysian science and technology
agenda. He served as Secretary of the National Council of Scientific Research and
Development under the Ministry of Science, Technology and the Environment from 1981 to
1986. He was subsequently appointed as the Controller of the Standards and Industrial
Research Institute of Malaysia (SIRIM), a position he held from 1986 to 1989.
Prior to his term at Universiti Teknologi Malaysia, YBhg Tan Sri Datuk Dr Ahmad Zaharudin
served as the Director of Petronas Petroleum Research Institute from 1989 to 1992 and later as
the Managing Director of Petronas Scientific Services from 1992 to 1994. He was also a
member of the Board of Petronas Refineries Pte. Ltd from 1989 to 1994.
Besides serving as Chairman of BiotechCorp and several other organisations, he is also a
member of the IDB Advisory Panel on Science and Technology, Islamic Development Bank,
Jeddah, Saudi Arabia.
His contributions in the field of science and technology have gained him international
recognition. In 1993, he received the Norway Award for Outstanding Contribution in the Field of
Technology and in 1997, the ASEAN Achievement Award for Science.
YBhg Tan Sri Datuk Dr Ahmad Zaharudin was conferred the D.Sc (Hons. Causa) by the
University of Portsmouth in 1998. Subsequently, the D.Sc (Honorary) by the University of
Loughborough, Universiti Teknikal Malaysia Melaka in 2003, Universiti Teknologi Malaysia in
2005 and the Open University Malaysia in 2006.
In honour of his contributions, YBhg Tan Sri Datuk Dr Ahmad Zaharudin was conferred the
award of Chevalier de la Legion dHonneur by the French Government in 2004.
8. Dr Radzuan A. Rahman
31
1. YBhg Tan Sri Datuk Dr Ahmad Zaharudin Idrus (Chairman)
YBhg Tan Sri Datuk Dr Ahmad Zaharudin Idrus, a Malaysian, aged 67, was appointed by the
Prime Minister of Malaysia as Chairman of BiotechCorp on 16 May 2005.
He has served as the Science Advisor to the Prime Minister of Malaysia from 2001 to 2006. He
was the Vice Chancellor of Universiti Teknologi Malaysia from 1994 to 2001.
YBhg Tan Sri Datuk Dr Ahmad Zaharudin obtained his Masters and PhD degrees from the
University of Aberdeen (UK) after graduating with an Agricultural Science degree from Universiti
Malaya in 1969.
He has been highly instrumental in the development of the Malaysian science and technology
agenda. He served as Secretary of the National Council of Scientific Research and
Development under the Ministry of Science, Technology and the Environment from 1981 to
1986. He was subsequently appointed as the Controller of the Standards and Industrial
Research Institute of Malaysia (SIRIM), a position he held from 1986 to 1989.
Prior to his term at Universiti Teknologi Malaysia, YBhg Tan Sri Datuk Dr Ahmad Zaharudin
served as the Director of Petronas Petroleum Research Institute from 1989 to 1992 and later as
the Managing Director of Petronas Scientific Services from 1992 to 1994. He was also a
member of the Board of Petronas Refineries Pte. Ltd from 1989 to 1994.
Besides serving as Chairman of BiotechCorp and several other organisations, he is also a
member of the IDB Advisory Panel on Science and Technology, Islamic Development Bank,
Jeddah, Saudi Arabia.
His contributions in the field of science and technology have gained him international
recognition. In 1993, he received the Norway Award for Outstanding Contribution in the Field of
Technology and in 1997, the ASEAN Achievement Award for Science.
YBhg Tan Sri Datuk Dr Ahmad Zaharudin was conferred the D.Sc (Hons. Causa) by the
University of Portsmouth in 1998. Subsequently, the D.Sc (Honorary) by the University of
Loughborough, Universiti Teknikal Malaysia Melaka in 2003, Universiti Teknologi Malaysia in
2005 and the Open University Malaysia in 2006.
In honour of his contributions, YBhg Tan Sri Datuk Dr Ahmad Zaharudin was conferred the
award of Chevalier de la Legion dHonneur by the French Government in 2004.
32
2. YBhg Dato Dr Mohd Nazlee Kamal (Chief Executive Officer)
YBhg Dato Dr Mohd Nazlee Kamal, a Malaysian, aged 48, was appointed to the Board on
18 July 2011.
He holds a PhD in Chemical Engineering (Bioprocess) from the University of Queensland
(Australia), a Masters of Applied Science in Biotechnology from the University of New South
Wales (Australia) and a Bachelor of Science in Chemical Engineering from Oregon State
University (US).
An academician, scientist and innovator with business and entrepreneurship acumen, he
brings a wealth of marketing and technical expertise to BiotechCorp. He is well-recognised for
his wide industrial leadership and has played a pivotal role in the formulation of the National
Biotechnology Policy.
YBhg Dato Dr Mohd Nazlee began his career as an academician at Universiti Teknologi Malaysia
(UTM), where he was involved in the development and establishment of the Bioprocess
Engineering programme under the Faculty of Chemical and Natural Resources. One of his other
key achievements during his 10 years tenure was the invention of the External Spinfilter, which
is now marketed by Sartorius BBI Systems (Patent No. PI9701436MY-131798-A).
He entered the corporate sector in 1997, joining B. Braun Malaysia. He subsequently served
Amersham Biosciences as the Asean Business Area Manager (Separation) where he led the
sales and marketing effort for the Separations product range in the region. In 2001, he was the
Business Development Manager in Sartorius (M) Sdn Bhd where he made significant
contribution to the companys sales and marketing effort for bioreactors in Malaysia.
YBhg Dato Dr Mohd Nazlee was instrumental in the establishment of Inno Biologics Sdn Bhd,
the first contract manufacturing organisation for biopharmaceuticals in Malaysia, and continued
at the helm of the Company as Chief Executive Officer (CEO) for 10 years. He was also the
Group Managing Director of Inno Bio Ventures Sdn Bhd, the holding company of Inno Bio
Group of Companies.
He is a member of the International Society of Pharmaceutical Engineering (ISPE), the Malaysian
Society for Molecular Biology and Biotechnology (MSMBB) and the Institution of Chemical
Engineers (IChemE). He also sits on the Advisory Panel of the Northern Corridor Implementation
Authority (NCIA) for Plant Science and Tissue Culture Node (PSTCN). His involvement as a
Council member for the National Innovation Council (NIC), Global Science and Innovation
Advisory Council (GSIAC) as well as the Steering Committee for National Biomass Strategy, is
imminent in the effort of integrating Government initiatives with industry players in biotechnology.
YBhg Dato Dr Mohd Nazlee is currently the Chairman of Malaysian Bio-XCell Sdn Bhd,
Member of the Board of BiotechCorp Investment Holdings Sdn Bhd, BiotechCorp Technology
Management Sdn Bhd and Malaysian Forestry Research and Development Board.
3. YBhg Tan Sri Dato Dr Jegathesan a/l N.M. Vasagam @ Manikavasagam
YBhg Tan Sri Dato Dr Jegathesan a/l N.M. Vasagam @ Manikavasagam, a Malaysian, aged
68, was appointed to the Board on 17 October 2011.
He graduated with a Bachelor of Medicine and Bachelor of Surgery (MBBS) from the
University of Singapore (Singapore) in 1967. He also holds a Diploma in Tropical Medicine
and Hygiene from Mahidol University (Thailand) and Diploma in Clinical Pathology from the
University of London (UK).
He is a Fellow of the Royal College of Pathologists (UK), College of American Pathologists
(US), Royal College of Pathologists of Australasia (Australia) and Academy of Medicine
(Malaysia). He is also a Senior Fellow and Academician of the Academy of Sciences (Malaysia).
Having served a full term of illustrious career in the Ministry of Health, YBhg Tan Sri Dato Dr
Jegathesan has held notable posts such as Director of the Institute of Medical Research and
Deputy Director General (Research and Technical Support) of the Ministry of Health. He has
served as adviser to international agencies such as the World Health Organisation and the
United Nations Development Programme (UNDP)-affiliated Council for Health Research and
Development in Geneva. From 2000 to 2003, he was the Chief Executive Officer of Sistem
Hospital Awasan Taraf Sdn Bhd (SIHAT), a health facilities consulting company.
YBhg Tan Sri Dato Dr Jegathesan currently holds positions as Pro-Chancellor of Universiti
Sains Malaysia, Deputy Vice-Chancellor (Research) of MAHSA University College and
Consultant Microbiologist in the private sector.
In addition to his distinguished career in the medical profession, YBhg Tan Sri Dato Dr
Jegathesan was Malaysias first Sportsman of the Year in 1966. He represented Malaysia in
three Olympics and two Asian Games where he broke records and won medals, earning him
the moniker of Fastest man in Asia. He was also the joint winner of the National Science
Award and the Rotary Club of KL Research Award in 1995.
He currently also serves on the Board of CCM Duopharma Biotech Berhad.
33
2. YBhg Dato Dr Mohd Nazlee Kamal (Chief Executive Officer)
YBhg Dato Dr Mohd Nazlee Kamal, a Malaysian, aged 48, was appointed to the Board on
18 July 2011.
He holds a PhD in Chemical Engineering (Bioprocess) from the University of Queensland
(Australia), a Masters of Applied Science in Biotechnology from the University of New South
Wales (Australia) and a Bachelor of Science in Chemical Engineering from Oregon State
University (US).
An academician, scientist and innovator with business and entrepreneurship acumen, he
brings a wealth of marketing and technical expertise to BiotechCorp. He is well-recognised for
his wide industrial leadership and has played a pivotal role in the formulation of the National
Biotechnology Policy.
YBhg Dato Dr Mohd Nazlee began his career as an academician at Universiti Teknologi Malaysia
(UTM), where he was involved in the development and establishment of the Bioprocess
Engineering programme under the Faculty of Chemical and Natural Resources. One of his other
key achievements during his 10 years tenure was the invention of the External Spinfilter, which
is now marketed by Sartorius BBI Systems (Patent No. PI9701436MY-131798-A).
He entered the corporate sector in 1997, joining B. Braun Malaysia. He subsequently served
Amersham Biosciences as the Asean Business Area Manager (Separation) where he led the
sales and marketing effort for the Separations product range in the region. In 2001, he was the
Business Development Manager in Sartorius (M) Sdn Bhd where he made significant
contribution to the companys sales and marketing effort for bioreactors in Malaysia.
YBhg Dato Dr Mohd Nazlee was instrumental in the establishment of Inno Biologics Sdn Bhd,
the first contract manufacturing organisation for biopharmaceuticals in Malaysia, and continued
at the helm of the Company as Chief Executive Officer (CEO) for 10 years. He was also the
Group Managing Director of Inno Bio Ventures Sdn Bhd, the holding company of Inno Bio
Group of Companies.
He is a member of the International Society of Pharmaceutical Engineering (ISPE), the Malaysian
Society for Molecular Biology and Biotechnology (MSMBB) and the Institution of Chemical
Engineers (IChemE). He also sits on the Advisory Panel of the Northern Corridor Implementation
Authority (NCIA) for Plant Science and Tissue Culture Node (PSTCN). His involvement as a
Council member for the National Innovation Council (NIC), Global Science and Innovation
Advisory Council (GSIAC) as well as the Steering Committee for National Biomass Strategy, is
imminent in the effort of integrating Government initiatives with industry players in biotechnology.
YBhg Dato Dr Mohd Nazlee is currently the Chairman of Malaysian Bio-XCell Sdn Bhd,
Member of the Board of BiotechCorp Investment Holdings Sdn Bhd, BiotechCorp Technology
Management Sdn Bhd and Malaysian Forestry Research and Development Board.
3. YBhg Tan Sri Dato Dr Jegathesan a/l N.M. Vasagam @ Manikavasagam
YBhg Tan Sri Dato Dr Jegathesan a/l N.M. Vasagam @ Manikavasagam, a Malaysian, aged
68, was appointed to the Board on 17 October 2011.
He graduated with a Bachelor of Medicine and Bachelor of Surgery (MBBS) from the
University of Singapore (Singapore) in 1967. He also holds a Diploma in Tropical Medicine
and Hygiene from Mahidol University (Thailand) and Diploma in Clinical Pathology from the
University of London (UK).
He is a Fellow of the Royal College of Pathologists (UK), College of American Pathologists
(US), Royal College of Pathologists of Australasia (Australia) and Academy of Medicine
(Malaysia). He is also a Senior Fellow and Academician of the Academy of Sciences (Malaysia).
Having served a full term of illustrious career in the Ministry of Health, YBhg Tan Sri Dato Dr
Jegathesan has held notable posts such as Director of the Institute of Medical Research and
Deputy Director General (Research and Technical Support) of the Ministry of Health. He has
served as adviser to international agencies such as the World Health Organisation and the
United Nations Development Programme (UNDP)-affiliated Council for Health Research and
Development in Geneva. From 2000 to 2003, he was the Chief Executive Officer of Sistem
Hospital Awasan Taraf Sdn Bhd (SIHAT), a health facilities consulting company.
YBhg Tan Sri Dato Dr Jegathesan currently holds positions as Pro-Chancellor of Universiti
Sains Malaysia, Deputy Vice-Chancellor (Research) of MAHSA University College and
Consultant Microbiologist in the private sector.
In addition to his distinguished career in the medical profession, YBhg Tan Sri Dato Dr
Jegathesan was Malaysias first Sportsman of the Year in 1966. He represented Malaysia in
three Olympics and two Asian Games where he broke records and won medals, earning him
the moniker of Fastest man in Asia. He was also the joint winner of the National Science
Award and the Rotary Club of KL Research Award in 1995.
He currently also serves on the Board of CCM Duopharma Biotech Berhad.
34
5. Professor Dr Zainul Fadziruddin Zainuddin
Professor Dr Zainul Fadziruddin Zainuddin, a Malaysian, aged 51, was appointed to the
Board on 4 September 2009.

He holds a PhD in Molecular Biology from the University of Surrey (UK) and a Bachelor of
Science in Microbiology from the University of East Anglia (UK).

Professor Dr Zainul Fadziruddin started his career in 1988 as a lecturer at the School of
Medical Sciences, Universiti Sains Malaysia (USM), Pulau Pinang. He has held various
positions in the said university including the position of Head of Department of Medical
Microbiology & Parasitology, School of Medical Sciences, Founding Dean of the School of
Health Sciences and Director of the Innovations Office, Research and Innovation Division.
Currently he is on secondment at the Malaysian Technology Development Corporation Sdn
Bhd as the Director for Advisory, Incubation and Nurturing.

He currently also sits on the Board of Xeraya Capital Sdn Bhd.
4. YBhg Dato Madinah Mohamad
YBhg Dato Madinah Mohamad, a Malaysian, aged 55, joined the Board on 12 June 2009.
She holds a Masters degree in Human Resource Development from Universiti Putra Malaysia.
She graduated with a Bachelors degree in Social Science (Political Science) from Universiti
Sains Malaysia.
She is currently the Secretary General of the Ministry of Science, Technology and Innovation,
Malaysia (MOSTI); a position she has held since 22 April 2009. As the Secretary General, she
oversees the development of policies and implementation of the science, technology and
innovation agenda in Malaysia and operations of MOSTI.
Prior to her current position, YBhg Dato Madinah served in various Government agencies such
as the Public Service Department, the Ministry of National and Rural Development, the Ministry
of Works, and the National Unity and Integration Department.
She began her civil service career as an Administrative and Diplomatic Officer in 1981 with the
Ministry of Foreign Affairs.
She was awarded the Darjah Kebesaran Sri Indera Mahkota Pahang (SIMP) by His Royal
Highness, Sultan of Pahang in 2009.
She currently also serves on the Boards of Malaysian Technology Development Corporation
Sdn Bhd, Malaysian Industry-Government Group for High Technology, Multimedia
Development Corporation Sdn Bhd, Technology Park Malaysia Corporation Sdn Bhd,
CyberSecurity Malaysia, Malaysian Foundation for Innovation, .my Domain Registry, Malaysian
Communications and Multimedia Commission, Securities Commission Malaysia, Malaysia
Nuclear Power Corporation and National Science and Research Council.
6. Puan Norsimah Ab Wahab
Puan Norsimah Ab Wahab, a Malaysian, aged 55, was appointed to the Board on 1 August
2011.
She holds a Bachelor of Science (Hons) in Biology from Universiti Sains Malaysia and a
Diploma in Administration from the National Institute of Public Administration of Malaysia.
Puan Norsimah is currently the Deputy Secretary (Operation) II of the Government Procurement
Division, Ministry of Finance.
She was awarded the Kesatria Mangku Negara (K.M.N) in the year 2010.
Puan Norsimah Ab Wahab currently also sits on the Board of Universiti Pendidikan Sultan
Idris (UPSI).
35
5. Professor Dr Zainul Fadziruddin Zainuddin
Professor Dr Zainul Fadziruddin Zainuddin, a Malaysian, aged 51, was appointed to the
Board on 4 September 2009.

He holds a PhD in Molecular Biology from the University of Surrey (UK) and a Bachelor of
Science in Microbiology from the University of East Anglia (UK).

Professor Dr Zainul Fadziruddin started his career in 1988 as a lecturer at the School of
Medical Sciences, Universiti Sains Malaysia (USM), Pulau Pinang. He has held various
positions in the said university including the position of Head of Department of Medical
Microbiology & Parasitology, School of Medical Sciences, Founding Dean of the School of
Health Sciences and Director of the Innovations Office, Research and Innovation Division.
Currently he is on secondment at the Malaysian Technology Development Corporation Sdn
Bhd as the Director for Advisory, Incubation and Nurturing.

He currently also sits on the Board of Xeraya Capital Sdn Bhd.
4. YBhg Dato Madinah Mohamad
YBhg Dato Madinah Mohamad, a Malaysian, aged 55, joined the Board on 12 June 2009.
She holds a Masters degree in Human Resource Development from Universiti Putra Malaysia.
She graduated with a Bachelors degree in Social Science (Political Science) from Universiti
Sains Malaysia.
She is currently the Secretary General of the Ministry of Science, Technology and Innovation,
Malaysia (MOSTI); a position she has held since 22 April 2009. As the Secretary General, she
oversees the development of policies and implementation of the science, technology and
innovation agenda in Malaysia and operations of MOSTI.
Prior to her current position, YBhg Dato Madinah served in various Government agencies such
as the Public Service Department, the Ministry of National and Rural Development, the Ministry
of Works, and the National Unity and Integration Department.
She began her civil service career as an Administrative and Diplomatic Officer in 1981 with the
Ministry of Foreign Affairs.
She was awarded the Darjah Kebesaran Sri Indera Mahkota Pahang (SIMP) by His Royal
Highness, Sultan of Pahang in 2009.
She currently also serves on the Boards of Malaysian Technology Development Corporation
Sdn Bhd, Malaysian Industry-Government Group for High Technology, Multimedia
Development Corporation Sdn Bhd, Technology Park Malaysia Corporation Sdn Bhd,
CyberSecurity Malaysia, Malaysian Foundation for Innovation, .my Domain Registry, Malaysian
Communications and Multimedia Commission, Securities Commission Malaysia, Malaysia
Nuclear Power Corporation and National Science and Research Council.
6. Puan Norsimah Ab Wahab
Puan Norsimah Ab Wahab, a Malaysian, aged 55, was appointed to the Board on 1 August
2011.
She holds a Bachelor of Science (Hons) in Biology from Universiti Sains Malaysia and a
Diploma in Administration from the National Institute of Public Administration of Malaysia.
Puan Norsimah is currently the Deputy Secretary (Operation) II of the Government Procurement
Division, Ministry of Finance.
She was awarded the Kesatria Mangku Negara (K.M.N) in the year 2010.
Puan Norsimah Ab Wahab currently also sits on the Board of Universiti Pendidikan Sultan
Idris (UPSI).
36
7. Tuan Haji Mohd. Radzi Hussein
Tuan Haji Mohd. Radzi Hussein, a Malaysian, aged 58, is a member of the Board since 21
May 2008.
He holds a Masters degree in Business Administration from the University of Wales,
Aberystwyth (UK) and a Bachelor of Accounting (Hons) from Universiti Malaya. He is a member
of the Malaysian Institute of Accountants.
He joined the Government in 1982 as Treasury Accountant in the Ministry of International
Trade and Industry. From 1984 to 1993, he served as a Senior Treasury Accountant in the
Accountant Generals Department, Kuala Lumpur.
Later in 1993, Tuan Haji Mohd. Radzi was seconded to Universiti Utara Malaysia as the
Deputy Bursar, a position he held until 1997. From 1997 to 2001, he served as the State
Treasurer for Kedah State Government. Tuan Haji Mohd. Radzi was then again seconded to
Kedah Akuakultur Sdn Bhd as Finance Manager for a period of one year.
He was promoted and transferred in 2002 to take up the position of Chief Accountant in the
Ministry of Home Affairs in Putrajaya.
In 2004, he was appointed as the Deputy Director, Information Technology Management
Division of the Accountant Generals Department. He was then promoted and served as the
Director of the said Division from 2008 until his retirement in 2011.
Tuan Haji Mohd. Radzi currently also serves on the Board of Pengurusan Aset Air Berhad.
Dr Radzuan A. Rahman, a Malaysian, aged 68, was appointed to the Board on 16 December
2011.
He holds a Masters and PhD in Resource Economics from Cornell University, New York (US)
and a Bachelor in Agricultural Science from Universiti Malaya.
He has an outstanding career in both the academic and corporate sectors. He was an
academician for 11 years where he rose to become the Dean of the Resource and
Agribusiness Faculty, Universiti Putra Malaysia. Subsequently, Dr Radzuan A. Rahman
joined Sime Darby Plantations as the Regional Director for Melaka, Negeri Sembilan and
Johor regions, where he was later promoted to Director of the Development Division.
In 1984, Dr Radzuan joined Golden Hope Plantations as the Director of Corporate Planning.
He was later elevated to Group Director Plantations, where he served the company for a
further 6 years. Since his retirement from Golden Hope Plantations, he has served as
Managing Director to several corporations, namely Austral Enterprises Berhad, Island &
Peninsular Berhad and Tradewinds Plantation Berhad.
Dr Radzuan currently also serves on the Boards of Kulim (Malaysia) Berhad, Idaman Unggul
Berhad, Inch Kenneth Kajang Rubber Public Limited Company, Marditech Corporation Sdn
Bhd, MAEPS Management Sdn Bhd, Green Capital Sdn Bhd and Kenangan Cergas (M)
Sdn Bhd.
37
7. Tuan Haji Mohd. Radzi Hussein
Tuan Haji Mohd. Radzi Hussein, a Malaysian, aged 58, is a member of the Board since 21
May 2008.
He holds a Masters degree in Business Administration from the University of Wales,
Aberystwyth (UK) and a Bachelor of Accounting (Hons) from Universiti Malaya. He is a member
of the Malaysian Institute of Accountants.
He joined the Government in 1982 as Treasury Accountant in the Ministry of International
Trade and Industry. From 1984 to 1993, he served as a Senior Treasury Accountant in the
Accountant Generals Department, Kuala Lumpur.
Later in 1993, Tuan Haji Mohd. Radzi was seconded to Universiti Utara Malaysia as the
Deputy Bursar, a position he held until 1997. From 1997 to 2001, he served as the State
Treasurer for Kedah State Government. Tuan Haji Mohd. Radzi was then again seconded to
Kedah Akuakultur Sdn Bhd as Finance Manager for a period of one year.
He was promoted and transferred in 2002 to take up the position of Chief Accountant in the
Ministry of Home Affairs in Putrajaya.
In 2004, he was appointed as the Deputy Director, Information Technology Management
Division of the Accountant Generals Department. He was then promoted and served as the
Director of the said Division from 2008 until his retirement in 2011.
Tuan Haji Mohd. Radzi currently also serves on the Board of Pengurusan Aset Air Berhad.
Dr Radzuan A. Rahman, a Malaysian, aged 68, was appointed to the Board on 16 December
2011.
He holds a Masters and PhD in Resource Economics from Cornell University, New York (US)
and a Bachelor in Agricultural Science from Universiti Malaya.
He has an outstanding career in both the academic and corporate sectors. He was an
academician for 11 years where he rose to become the Dean of the Resource and
Agribusiness Faculty, Universiti Putra Malaysia. Subsequently, Dr Radzuan A. Rahman
joined Sime Darby Plantations as the Regional Director for Melaka, Negeri Sembilan and
Johor regions, where he was later promoted to Director of the Development Division.
In 1984, Dr Radzuan joined Golden Hope Plantations as the Director of Corporate Planning.
He was later elevated to Group Director Plantations, where he served the company for a
further 6 years. Since his retirement from Golden Hope Plantations, he has served as
Managing Director to several corporations, namely Austral Enterprises Berhad, Island &
Peninsular Berhad and Tradewinds Plantation Berhad.
Dr Radzuan currently also serves on the Boards of Kulim (Malaysia) Berhad, Idaman Unggul
Berhad, Inch Kenneth Kajang Rubber Public Limited Company, Marditech Corporation Sdn
Bhd, MAEPS Management Sdn Bhd, Green Capital Sdn Bhd and Kenangan Cergas (M)
Sdn Bhd.
38
Encik Amirul Fares Wan Zahir, a Malaysian, aged 44, was appointed to the Board on 16
December 2011.
He holds a Masters degree in Operations Research from University Technology of Sydney
(Australia) and a Bachelors degree in Economics majoring in Actuarial Studies from
Macquarie University (Australia). He is a Chartered Financial Analyst (CFA) and an Associate
of the Society of Actuaries (ASA).
Encik Amirul is currently the Director, Head of Research of Khazanah Research & Investment
Strategy (KRIS) and he leads the Life Sciences investments for Khazanah Nasional Berhad.
He has served in the actuarial department of American International Assurance Co. Ltd
(AIA). He later joined an associate company of Schroder Investment Management, rising to
become the Fund Manager, where he was in charge of managing institutional client
portfolios and unit trusts. Prior to his current position, he was the Director of UBS Investment
Research in UBS Investment Bank.
Encik Amirul currently also serves on the Boards of Malaysian Technology Development
Corporation Sdn Bhd, SpringHill BioVentures Sdn Bhd and is the Co-Chairman of the
Malaysian Life Sciences Capital Fund.
39
Encik Amirul Fares Wan Zahir, a Malaysian, aged 44, was appointed to the Board on 16
December 2011.
He holds a Masters degree in Operations Research from University Technology of Sydney
(Australia) and a Bachelors degree in Economics majoring in Actuarial Studies from
Macquarie University (Australia). He is a Chartered Financial Analyst (CFA) and an Associate
of the Society of Actuaries (ASA).
Encik Amirul is currently the Director, Head of Research of Khazanah Research & Investment
Strategy (KRIS) and he leads the Life Sciences investments for Khazanah Nasional Berhad.
He has served in the actuarial department of American International Assurance Co. Ltd
(AIA). He later joined an associate company of Schroder Investment Management, rising to
become the Fund Manager, where he was in charge of managing institutional client
portfolios and unit trusts. Prior to his current position, he was the Director of UBS Investment
Research in UBS Investment Bank.
Encik Amirul currently also serves on the Boards of Malaysian Technology Development
Corporation Sdn Bhd, SpringHill BioVentures Sdn Bhd and is the Co-Chairman of the
Malaysian Life Sciences Capital Fund.
40
BiotechCorp
Board
BiotechCorp Technology
Management
(CEO)
BiotechCorp
Investment Holdings
Malaysian Bio-XCell
Internal
Audit
Strategic Planning
Stakeholder Engagement
Business Intelligence
Business Development
& Investment
Agriculture /
Healthcare / Industrial
Call and Application
Centre (CAC)
Business Operations
Evaluation
Operational Services
Capability Development
Chief Operating Officer
(COO)
Chief Financial Officer
(CFO)
Corporate Finance
& Services
Corporate Finance
& Planning
Monitoring &
Compliance
Financial
Transaction
Corporate Technology
& Enablement
Corporate
Affairs
Branding
Media
Business
Unit Support
Legal &
Secretarial
Legal
Secretarial
Human
Capital
Talent
Management
Talent
Services
Facilities
Management
Division
Department
Unit
41
BiotechCorp
Board
Management
(CEO)
BiotechCorp
Investment Holdings
Malaysian Bio-XCell
Internal
Audit
Strategic Planning
Stakeholder Engagement
Business Intelligence
& Investment
Agriculture /
Healthcare / Industrial
Call and Application
Centre (CAC)
Business Operations
Evaluation
Operational Services
Capability Development
(COO)
(CFO)
Corporate Finance
& Services
Corporate Finance
& Planning
Monitoring &
Compliance
Financial
Transaction
Corporate Technology
& Enablement
Corporate
Affairs
Branding
Media
Business
Unit Support
Legal &
Secretarial
Legal
Secretarial
Human
Capital
Talent
Management
Talent
Services
Facilities
Management
Division
Department
Unit
42
3
4
8
1
5
9
2
7
10
6
6. Encik Razif Abd Aziz
Senior Vice President, Business Operations
7. Mr Selvam Ramaraj
Senior Vice President, Business
Development & Investment - Healthcare
8. Encik Razwin Sulairee Hasnan Termizi
Development & Investment - Industrial
9. Dr Abdul Manaf Mohamad Radzi
Development & Investment - Agriculture
1. YBhg. Dato Dr Mohd Nazlee Kamal
2. Dr Wan Abdul Rahaman Wan Yaacob
3. Tuan Syed Agil Syed Hashim
4. Encik Mohd Yazid Abd Hamid
Senior Vice President, Strategic Planning
5. Puan Azni Hasan Basri
Senior Vice President, Human Capital
10. Cik Sharifah Hanifah Syed Abdul Aziz
Senior Vice President, Legal & Secretarial
43
3
4
8
1
5
9
2
7
10
6
6. Encik Razif Abd Aziz
Senior Vice President, Business Operations
7. Mr Selvam Ramaraj
Development & Investment - Healthcare
8. Encik Razwin Sulairee Hasnan Termizi
Development & Investment - Industrial
9. Dr Abdul Manaf Mohamad Radzi
Development & Investment - Agriculture
1. YBhg. Dato Dr Mohd Nazlee Kamal
2. Dr Wan Abdul Rahaman Wan Yaacob
3. Tuan Syed Agil Syed Hashim
4. Encik Mohd Yazid Abd Hamid
Senior Vice President, Strategic Planning
5. Puan Azni Hasan Basri
Senior Vice President, Human Capital
10. Cik Sharifah Hanifah Syed Abdul Aziz
Senior Vice President, Legal & Secretarial
44
ACCELERATING
BIOTECHNOLOGY
GROWTH
IN MALAYSIA
45
ACCELERATING
BIOTECHNOLOGY
GROWTH
IN MALAYSIA
46
14 April 2011 Sheraton Imperial Hotel Kuala Lumpur, Malaysia
OFFICIAL ANNOUNCEMENT OF THE FIRST STEM CELL BASED PRODUCT
STEMPEUCEL APPROVED FOR CLINICAL TRIALS IN MALAYSIA
BioNexus Status company, Stempeutics Research Malaysia Sdn Bhd, a company under the
Manipal Education & Medical Group have been granted an approval from Malaysian
authorities to conduct clinical trials on stem cell based investigational new drugs (IND). With
this achievement, Malaysia becomes one of the leading countries after USA to enter this
phase of stem cell research.
CALENDAR OF EVENTS 2011
14 January 2011 Four Seasons Hotel, Washington DC, USA
LAUNCHING CEREMONY OF MyBEST PROGRAMME
MyBeST was organised to provide training in bioprocess operations and other specialisation
areas to fill the demand for knowledge workers in the domestic biotechnology sector. The
event was launched by Deputy Prime Minister of Malaysia Yang Amat Berhormat Tan Sri
Muhyiddin Yassin.
31 March 2011 PNB Darby Park Kuala Lumpur, Malaysia
BUSINESS DEVELOPMENT WORKSHOP (HEALTHCARE)
A one-day Business Development workshop for the healthcare industry with objectives of
identifying current challenges, understanding immediate needs, addressing concerns of
BioNexus companies in business development as well as developing cohesive strategies for
business development.
18 April 2011 Menara Atlan, Kuala Lumpur, Malaysia
SIGNING CEREMONY AND JOINT PRESS CONFERENCE BETWEEN MAYBANK AND
BIO-XCELL
An agreement of a RM250 million Commodity Murabahah Term Financing Islamic Facility
(CMTF-i) which will partly fund the completion of Phase 1 development of the Bio-XCell
biotechnology ecosystem and park was signed at this event.
27 30 June 2011 Walter E. Washington Convention Center, USA
BIO WASHINGTON 2011
Deputy Prime Minister of Malaysia Yang Amat Berhormat Tan Sri Muhyiddin Yassin, officiated
the BIO international exhibition in Washington alongside Maryland Governor Martin O'Malley
and Biotechnology Industry Organisation (BIO) President and Chief Executive Officer James
Greenwood on 28 June 2011.
At the event, BiotechCorp completed exercises which include collaboration announcements
and exchange of documents between Lestari Pacific with Arter Biofuel Products Ltd and
collaboration between Pristine Oil and Bio Protein. Bio-XCell also completed document
exchanges with Agila Specialties Sdn Bhd and MOX-Linde Gases Sdn Bhd.
17 July 2011 Taylors University, Selangor, Malaysia
MyBIO CARNIVAL 2011
MyBio Carnival 2011 provided a glimpse into the world of biotechnology and bioscience,
educating children in an informal and interactive way. The event was jointly organised by
Taylor's University, Malaysia Biotechnology Information Centre (MABIC) and Malaysian
Biotechnology Corporation (BiotechCorp).
The carnival was launched by the Director General, Ministry of Science, Technology and
Innovation YBhg Datin Paduka Professor Dr Khatijah Yusof.
26 July 2011 Forest Research Institute Malaysia (FRIM), Selangor, Malaysia
BIONEXUS PARTNERS NETWORKING SESSION
The event was co-organised together with Forest Research Institute Malaysia (FRIM) where
the BioNexus Partners (BNP) Centre of Excellence was launched. A networking session was
also organised between BNP laboratories, units under FRIM and industry participants and
commercial entities in Malaysia.
Accelerating
Biotechnology
Growth In Malaysia
47
14 April 2011 Sheraton Imperial Hotel Kuala Lumpur, Malaysia
OFFICIAL ANNOUNCEMENT OF THE FIRST STEM CELL BASED PRODUCT
STEMPEUCEL APPROVED FOR CLINICAL TRIALS IN MALAYSIA
BioNexus Status company, Stempeutics Research Malaysia Sdn Bhd, a company under the
Manipal Education & Medical Group have been granted an approval from Malaysian
authorities to conduct clinical trials on stem cell based investigational new drugs (IND). With
this achievement, Malaysia becomes one of the leading countries after USA to enter this
phase of stem cell research.
CALENDAR OF EVENTS 2011
14 January 2011 Four Seasons Hotel, Washington DC, USA
LAUNCHING CEREMONY OF MyBEST PROGRAMME
MyBeST was organised to provide training in bioprocess operations and other specialisation
areas to fill the demand for knowledge workers in the domestic biotechnology sector. The
event was launched by Deputy Prime Minister of Malaysia Yang Amat Berhormat Tan Sri
Muhyiddin Yassin.
31 March 2011 PNB Darby Park Kuala Lumpur, Malaysia
BUSINESS DEVELOPMENT WORKSHOP (HEALTHCARE)
A one-day Business Development workshop for the healthcare industry with objectives of
identifying current challenges, understanding immediate needs, addressing concerns of
BioNexus companies in business development as well as developing cohesive strategies for
business development.
18 April 2011 Menara Atlan, Kuala Lumpur, Malaysia
SIGNING CEREMONY AND JOINT PRESS CONFERENCE BETWEEN MAYBANK AND
BIO-XCELL
An agreement of a RM250 million Commodity Murabahah Term Financing Islamic Facility
(CMTF-i) which will partly fund the completion of Phase 1 development of the Bio-XCell
biotechnology ecosystem and park was signed at this event.
27 30 June 2011 Walter E. Washington Convention Center, USA
BIO WASHINGTON 2011
Deputy Prime Minister of Malaysia Yang Amat Berhormat Tan Sri Muhyiddin Yassin, officiated
the BIO international exhibition in Washington alongside Maryland Governor Martin O'Malley
and Biotechnology Industry Organisation (BIO) President and Chief Executive Officer James
Greenwood on 28 June 2011.
At the event, BiotechCorp completed exercises which include collaboration announcements
and exchange of documents between Lestari Pacific with Arter Biofuel Products Ltd and
collaboration between Pristine Oil and Bio Protein. Bio-XCell also completed document
exchanges with Agila Specialties Sdn Bhd and MOX-Linde Gases Sdn Bhd.
17 July 2011 Taylors University, Selangor, Malaysia
MyBIO CARNIVAL 2011
MyBio Carnival 2011 provided a glimpse into the world of biotechnology and bioscience,
educating children in an informal and interactive way. The event was jointly organised by
Taylor's University, Malaysia Biotechnology Information Centre (MABIC) and Malaysian
Biotechnology Corporation (BiotechCorp).
The carnival was launched by the Director General, Ministry of Science, Technology and
Innovation YBhg Datin Paduka Professor Dr Khatijah Yusof.
26 July 2011 Forest Research Institute Malaysia (FRIM), Selangor, Malaysia
The event was co-organised together with Forest Research Institute Malaysia (FRIM) where
the BioNexus Partners (BNP) Centre of Excellence was launched. A networking session was
also organised between BNP laboratories, units under FRIM and industry participants and
commercial entities in Malaysia.
Accelerating
Biotechnology
Growth In Malaysia
48
12 October 2011 Kuala Lumpur Convention Centre, Kuala Lumpur, Malaysia
BIOMALAYSIA 2011 & 2011 PACIFIC RIM SUMMIT COUNTDOWN PRESS CONFERENCE
This media engagement exercise provided a comprehensive overview of BioMalaysia 2011,
unveiling the prestigious speaker line-up and the announcement of esteemed sponsors for
BioMalaysia 2011. BiotechCorp CEO, Dato Dr Mohd Nazlee Kamal delivered the opening
remarks, followed by presentation on BioMalaysia 2011 by Denise Ang, Group Project
Director, PROTEMP Exhibitions Sdn Bhd.
12 14 September 2011 Shangri-La Hotel, Kuala Lumpur, Malaysia
11th FORBES GLOBAL CEO CONFERENCE
This annual event was attended by some 400 global CEOs, tycoons, entrepreneurs,
up-and-comers, capitalists and thought leaders. BiotechCorp was part of the steering
committee and was given a complimentary kiosk throughout the 3-day conference.
12 August 2011 Prime Ministers Office, Putrajaya, Malaysia
ANNOUNCEMENT OF MALAYSIAS LARGEST INVESTMENT FOR INDUSTRIAL
BIOTECHNOLOGY BETWEEN CJ AND ARKEMA
Malaysia secured a RM2 billion investment for industrial biotechnology involving the
establishment of the worlds first green fermentation based L-methionine plant through a
joint venture partnership between South Koreas CJ CheilJedang Corporation (CJ) and
Frances Arkema SA (ARKEMA).
The ceremony was witnessed by Prime Minister of Malaysia Yang Amat Berhormat Dato Sri
Najib Tun Razak, Deputy Prime Minister of Malaysia Yang Amat Berhormat Tan Sri Muhyiddin
Yassin and Menteri Besar Terengganu Yang Amat Berhormat Dato Ahmad Said.
10 September 2011
Persada Johor International Convention Centre,
Johor Bahru, Malaysia
COMMENCEMENT CEREMONY FOR BIOCON INDIAS FIRST BILLION DOLLAR
BIOTECHNOLOGY COMPANY IN BIO-XCELL ISKANDAR MALAYSIA
Biocon, Asias premier biotechnology company, held the project commencement ceremony
for its biopharmaceutical manufacturing, research and development facility in Bio-XCell, a
custom-built biotechnology park and ecosystem in Iskandar Malaysia, Johor. The Chief
Minister of Johor, Yang Amat Berhormat Dato' Haji Abdul Ghani Othman unveiled the plaque
commemorating the projects initiation during this event.
10 November 2011 Luna Bar, Menara Pan Global, Kuala Lumpur, Malaysia
MEDIA APPRECIATION NIGHT 2011
Media Houses and journalists were presented with trophies, certificates and prizes at a red
carpet dinner for their meritorious work and effort in raising public awareness and interest in
biotechnology, showcasing developments in the industry and profiling Malaysia as a
biotechnology hub, in line with targets set under the National Biotechnology Policy. The
event was attended by 28 media personnel and 13 senior management staff from
BiotechCorp and Bio-XCell.
21 23 November 2011
Kuala Lumpur Convention Centre,
Kuala Lumpur, Malaysia
BIOMALAYSIA 2011 & 2011 PACIFIC RIM SUMMIT
This was the 9th consecutive premier biotechnology event for BiotechCorp. It was
co-organised with the 6th Pacific Rim Summit on Industrial Biotechnology and Bioenergy which
was held for the first time outside of the US. The event attracted over 7,400 participants.
27 December 2011 UiTM Puncak Alam, Selangor, Malaysia
The launch of BioNexus Partners (BNP) Pharmacogenomics Center (PROMISE) was
officiated by Deputy Prime Minister of Malaysia Yang Amat Berhormat Tan Sri Muhyiddin
Yassin, in conjunction with the BioNexus Partners (BNP) networking session in Universiti
Teknologi Mara (UiTM). The Center has successfully brought Malaysia to international
heights with its achievement of mapping the Malay ethnic genome for the first time, placing
Malaysia at par with other developed countries.
29 31 July 2011 Kuala Lumpur Convention Centre, Kuala Lumpur, Malaysia
MYSTI-EXPO (MALAYSIA SCIENCE TECHNOLOGY AND INNOVATION EXPOSITION 2011)
The programme was organised by MOSTI to showcase the results of technology innovation
developed by Malaysia in line with the Governments commitment in making technological
innovation a common denominator of growth towards creating a sustainable innovation
ecosystem.
49
12 October 2011 Kuala Lumpur Convention Centre, Kuala Lumpur, Malaysia
BIOMALAYSIA 2011 & 2011 PACIFIC RIM SUMMIT COUNTDOWN PRESS CONFERENCE
This media engagement exercise provided a comprehensive overview of BioMalaysia 2011,
unveiling the prestigious speaker line-up and the announcement of esteemed sponsors for
BioMalaysia 2011. BiotechCorp CEO, Dato Dr Mohd Nazlee Kamal delivered the opening
remarks, followed by presentation on BioMalaysia 2011 by Denise Ang, Group Project
Director, PROTEMP Exhibitions Sdn Bhd.
12 14 September 2011 Shangri-La Hotel, Kuala Lumpur, Malaysia
11th FORBES GLOBAL CEO CONFERENCE
This annual event was attended by some 400 global CEOs, tycoons, entrepreneurs,
up-and-comers, capitalists and thought leaders. BiotechCorp was part of the steering
committee and was given a complimentary kiosk throughout the 3-day conference.
12 August 2011 Prime Ministers Office, Putrajaya, Malaysia
ANNOUNCEMENT OF MALAYSIAS LARGEST INVESTMENT FOR INDUSTRIAL
BIOTECHNOLOGY BETWEEN CJ AND ARKEMA
Malaysia secured a RM2 billion investment for industrial biotechnology involving the
establishment of the worlds first green fermentation based L-methionine plant through a
joint venture partnership between South Koreas CJ CheilJedang Corporation (CJ) and
Frances Arkema SA (ARKEMA).
The ceremony was witnessed by Prime Minister of Malaysia Yang Amat Berhormat Dato Sri
Najib Tun Razak, Deputy Prime Minister of Malaysia Yang Amat Berhormat Tan Sri Muhyiddin
Yassin and Menteri Besar Terengganu Yang Amat Berhormat Dato Ahmad Said.
10 September 2011
Persada Johor International Convention Centre,
Johor Bahru, Malaysia
COMMENCEMENT CEREMONY FOR BIOCON INDIAS FIRST BILLION DOLLAR
BIOTECHNOLOGY COMPANY IN BIO-XCELL ISKANDAR MALAYSIA
Biocon, Asias premier biotechnology company, held the project commencement ceremony
for its biopharmaceutical manufacturing, research and development facility in Bio-XCell, a
custom-built biotechnology park and ecosystem in Iskandar Malaysia, Johor. The Chief
Minister of Johor, Yang Amat Berhormat Dato' Haji Abdul Ghani Othman unveiled the plaque
commemorating the projects initiation during this event.
10 November 2011 Luna Bar, Menara Pan Global, Kuala Lumpur, Malaysia
MEDIA APPRECIATION NIGHT 2011
Media Houses and journalists were presented with trophies, certificates and prizes at a red
carpet dinner for their meritorious work and effort in raising public awareness and interest in
biotechnology, showcasing developments in the industry and profiling Malaysia as a
biotechnology hub, in line with targets set under the National Biotechnology Policy. The
event was attended by 28 media personnel and 13 senior management staff from
BiotechCorp and Bio-XCell.
21 23 November 2011
Kuala Lumpur Convention Centre,
BIOMALAYSIA 2011 & 2011 PACIFIC RIM SUMMIT
This was the 9th consecutive premier biotechnology event for BiotechCorp. It was
co-organised with the 6th Pacific Rim Summit on Industrial Biotechnology and Bioenergy which
was held for the first time outside of the US. The event attracted over 7,400 participants.
27 December 2011 UiTM Puncak Alam, Selangor, Malaysia
The launch of BioNexus Partners (BNP) Pharmacogenomics Center (PROMISE) was
officiated by Deputy Prime Minister of Malaysia Yang Amat Berhormat Tan Sri Muhyiddin
Yassin, in conjunction with the BioNexus Partners (BNP) networking session in Universiti
Teknologi Mara (UiTM). The Center has successfully brought Malaysia to international
heights with its achievement of mapping the Malay ethnic genome for the first time, placing
Malaysia at par with other developed countries.
29 31 July 2011 Kuala Lumpur Convention Centre, Kuala Lumpur, Malaysia
MYSTI-EXPO (MALAYSIA SCIENCE TECHNOLOGY AND INNOVATION EXPOSITION 2011)
The programme was organised by MOSTI to showcase the results of technology innovation
developed by Malaysia in line with the Governments commitment in making technological
innovation a common denominator of growth towards creating a sustainable innovation
ecosystem.
50
POLICY & REGULATORY ENGAGEMENT
Embarking into Phase 2 of the National Biotechnology Policy (NBP), BiotechCorp continues its
active role in supporting the formulation of a progressive regulatory agenda for the biotechnology
sector in accordance with Thrust 7 of the NBP which emphasises the importance of establishing
a solid, balanced and supportive regulatory framework for the development of biotechnology in
Malaysia. Continuous engagement with all relevant regulatory authorities is necessary to ensure
that the foundation laid down during Phase 1 of the NBP in creating a conducive regulatory
environment will be further enhanced to support the commercialisation phase of the NBP.
Focus Areas:
B|osafety Pharmaceut|ca| Regu|at|ons
Access & Benef|t Shar|ng lnternat|ona| Accred|tat|on
lnte||ectua| Property
BiotechCorp Annua| Report 2011 BiotechCorp Annua| Report 2011
2011
Operational Review
Key Results
Biosafety Framework The B|osafety Approva| and Not|f|cat|ons} Regu|at|ons 2010 came |nto
force |n November 2010 whereby deta||ed procedures and gu|de||nes |n
regulating activities involving Living Modified Organisms (LMOs) were
established.
ln 2011, the new|y m|nted B|osafety Regu|at|ons were put to pract|ce
through applications for approvals and also notifications by the industry
and research fraternity.
BiotechCorp continued to provide regulatory advisory support for the
industry and also investors in submitting biosafety applications/
notifications.
BiotechCorp also provided strategic input to the Ministry of Natural
Resources and Env|ronment on the government comm|tment to the
Nagoya - Kua|a |umpur Supp|ementary Protoco| on ||ab|||ty and
Redress" to the Oartagena Protoco| on B|osafety wh|ch was adopted
during the Conference of the Parties to the Convention on Biological
D|vers|ty at |ts 10th meet|ng on 29 October 2010 |n Nagoya, Japan.
Issue / Activity Results
Access & Benef|t
Shar|ng ABS}
The Oonference of the Part|es to the Oonvent|on on B|o|og|ca|
D|vers|ty |n 2010 saw the f|na||sat|on and adopt|on of the Nagoya
Protoco| on Access to Genet|c Resources and the Fa|r and Equ|tab|e
Shar|ng of Benef|ts Ar|s|ng from the|r t|||sat|on to the Oonvent|on on
B|o|og|ca| D|vers|ty". The Nagoya Protoco| |s an |nternat|ona| agreement
which aims at sharing the benefits arising from the utilisation of genetic
resources |n a fa|r and equ|tab|e way, |nc|ud|ng by appropr|ate
access to genetic resources and by appropriate transfer of relevant
technologies, taking into account all rights over those resources and to
technologies, and by appropriate funding, thereby contributing to the
conservation of biological diversity and the sustainable use of its
components.
lt |s understood that domest|c |aws on Access and Benef|t Shar|ng
ABS} are current|y |n the formu|at|on stage and much of the ant|c|pated
|aw w||| prov|de a c|ear w|ndow for commerc|a| and R&D co||aborat|on
initiatives involving biological materials.
lnte||ectua| Property lP} B|otechOorp cont|nues to work towards strengthen|ng the lP framework
in Malaysia through the following measures:
Contract Patent Examiners
The lnte||ectua| Property Oorporat|on of Ma|ays|a MylPO} ear|y th|s year
introduced formal provisions for expedition of examination for patent and
trademark applications through amendments to the Patents
Regu|at|ons 1986 and Trade Marks Regu|at|ons 1997 v|a the Patents
Amendment} Regu|at|ons 2011 and Trade Marks Amendment}
Regu|at|ons 2011. Th|s came |nto force on 15 February 2011.
B|otechOorp cont|nues to fund 10 patent exam|ners on contract bas|s
|n 2011 to ass|st MylPO |n reduc|ng patent pendency and to ensure
that the target timelines as introduced in the new regulations are met
to support and spur the creation of more innovations.
Amendments to the Patents Act 1983
BiotechCorp cont|nues |ts engagement w|th MylPO w|th regards to
amendments to the Patents Act 1983 part|cu|ar|y |n re|at|on to
provisions relating to biotechnology inventions as they are being
drafted. BiotechCorp anticipates that the proposed amendments will
be put forth for stakeho|ders` consu|tat|on |n ear|y 2012 before be|ng
tabled in Parliament.
51
POLICY & REGULATORY ENGAGEMENT
Embarking into Phase 2 of the National Biotechnology Policy (NBP), BiotechCorp continues its
active role in supporting the formulation of a progressive regulatory agenda for the biotechnology
sector in accordance with Thrust 7 of the NBP which emphasises the importance of establishing
a solid, balanced and supportive regulatory framework for the development of biotechnology in
Malaysia. Continuous engagement with all relevant regulatory authorities is necessary to ensure
that the foundation laid down during Phase 1 of the NBP in creating a conducive regulatory
environment will be further enhanced to support the commercialisation phase of the NBP.
Focus Areas:
B|osafety Pharmaceut|ca| Regu|at|ons
Access & Benef|t Shar|ng lnternat|ona| Accred|tat|on
lnte||ectua| Property
2011
Operational Review
Key Results
Biosafety Framework The B|osafety Approva| and Not|f|cat|ons} Regu|at|ons 2010 came |nto
force |n November 2010 whereby deta||ed procedures and gu|de||nes |n
regulating activities involving Living Modified Organisms (LMOs) were
established.
ln 2011, the new|y m|nted B|osafety Regu|at|ons were put to pract|ce
through applications for approvals and also notifications by the industry
and research fraternity.
BiotechCorp continued to provide regulatory advisory support for the
industry and also investors in submitting biosafety applications/
notifications.
BiotechCorp also provided strategic input to the Ministry of Natural
Resources and Env|ronment on the government comm|tment to the
Nagoya - Kua|a |umpur Supp|ementary Protoco| on ||ab|||ty and
Redress" to the Oartagena Protoco| on B|osafety wh|ch was adopted
during the Conference of the Parties to the Convention on Biological
D|vers|ty at |ts 10th meet|ng on 29 October 2010 |n Nagoya, Japan.
Access & Benef|t
Shar|ng ABS}
The Oonference of the Part|es to the Oonvent|on on B|o|og|ca|
D|vers|ty |n 2010 saw the f|na||sat|on and adopt|on of the Nagoya
Protoco| on Access to Genet|c Resources and the Fa|r and Equ|tab|e
Shar|ng of Benef|ts Ar|s|ng from the|r t|||sat|on to the Oonvent|on on
B|o|og|ca| D|vers|ty". The Nagoya Protoco| |s an |nternat|ona| agreement
which aims at sharing the benefits arising from the utilisation of genetic
resources |n a fa|r and equ|tab|e way, |nc|ud|ng by appropr|ate
access to genetic resources and by appropriate transfer of relevant
technologies, taking into account all rights over those resources and to
technologies, and by appropriate funding, thereby contributing to the
conservation of biological diversity and the sustainable use of its
components.
lt |s understood that domest|c |aws on Access and Benef|t Shar|ng
ABS} are current|y |n the formu|at|on stage and much of the ant|c|pated
|aw w||| prov|de a c|ear w|ndow for commerc|a| and R&D co||aborat|on
initiatives involving biological materials.
lnte||ectua| Property lP} B|otechOorp cont|nues to work towards strengthen|ng the lP framework
in Malaysia through the following measures:
Contract Patent Examiners
The lnte||ectua| Property Oorporat|on of Ma|ays|a MylPO} ear|y th|s year
introduced formal provisions for expedition of examination for patent and
trademark applications through amendments to the Patents
Regu|at|ons 1986 and Trade Marks Regu|at|ons 1997 v|a the Patents
Amendment} Regu|at|ons 2011 and Trade Marks Amendment}
Regu|at|ons 2011. Th|s came |nto force on 15 February 2011.
B|otechOorp cont|nues to fund 10 patent exam|ners on contract bas|s
|n 2011 to ass|st MylPO |n reduc|ng patent pendency and to ensure
that the target timelines as introduced in the new regulations are met
to support and spur the creation of more innovations.
Amendments to the Patents Act 1983
BiotechCorp cont|nues |ts engagement w|th MylPO w|th regards to
amendments to the Patents Act 1983 part|cu|ar|y |n re|at|on to
provisions relating to biotechnology inventions as they are being
drafted. BiotechCorp anticipates that the proposed amendments will
be put forth for stakeho|ders` consu|tat|on |n ear|y 2012 before be|ng
tabled in Parliament.
52
Budapest Treaty for the Deposit of Microorganisms for the
Purposes of Patent Procedure
A National Seminar on the Budapest Treaty was jointly organised by
MyIPO in collaboration with the World Intellectual Property
Organisation (WIPO) in September to create awareness among
stakeholders on the workings and operations of the Budapest Treaty.
BiotechCorp remains engaged with MyIPO in its efforts for Malaysia to
accede to the Budapest Treaty.
Capacity Bui|ding Initiatives
Various capacity building initiatives were also carried throughout the
year including workshops and regulatory updates for internal and
external customers.
In 2011, BiotechCorp participated in the Technical Working Group
(TWG) for pharmaceutical, traditional medicines & health supplements
and medical devices and provided industry input for the harmonisation
of regulations in the three sectors in ASEAN. Through the ASEAN
Consultative Committee in Safety and Quality (ACCSQ) Product
Working Group (PWG) participation, we were able to keep track on the
work programme progress and the time frame targeted in harmonising
standards and reducing technical barriers towards a single market by 2015.
International
Accreditation
(GLP)
Pharma Regulations
In relation to GLP, Malaysias efforts in gaining full adherence to the
Organisation for Economic Co-operation and Development (OECD)
Mutual Acceptance of Data (MAD) system showed great results.
For some background, Malaysia was made a provisional adherent to
the Organisation for Economic Co-operation and Development (OECD)
Mutual Acceptance of Data (MAD) system in 2008. The year 2010 saw
the continued implementation of the OECD GLP framework, which is
applicable to non-clinical health and environment safety studies. The
Government then designated the National Pharmaceutical Control
Bureau (NPCB) and Department of Standards Malaysia (Standards
Malaysia) as the Compliance Monitoring Authority (CMAs) for Malaysia.
BiotechCorp has been working closely with the CMAs by organising
programmes and capacity building initiatives for the CMAs and also the
industry in order to ensure that Malaysia is fully ready for the On Site
Evaluation and Mutual Joint Visit by the OECD inspectors in order to
achieve full adherent status to the OECD MAD system.
In 2011, in preparation for the On Site Evaluation/ Mutual Joint Visit
(OSE/MJV) by OECD, the following Compliance Programmes were
conducted by the CMAs:
On 5-7 April 2011, both the CMAs attended the OECD Working Group
(WG) Meeting to present to the OECD WG on Malaysias progress in
the GLP Compliance Programme and our readiness for the MJV.
Based on the convincing progress made by Malaysia, the WG agreed
that the MJV shall take place in November 2011
On 6-10 June 2011, BiotechCorp facilitated Standards Malaysias
participation in an On Site Evaluation exercise by OECD inspectors to
evaluate Greece as part of the run up to Malaysias inspection by OECD
On 13-14 June 2011, BiotechCorp assisted the CMAs in the workshop
on Compliance of Computerised System to OECD-GLP held at
Bayview Beach Resort in Penang
Beginning in August 2011 until October 2011, a mock inspection was
conducted on the test facility chosen for the MJV (i.e. SIRIM Berhad)
for its area of expertise in toxicology and mutagenicity
Pharma Regulations
Intellectual Property (IP)
Pharmaceuticals are regulated by the National Pharmaceutical Control
Bureau (NPCB) of the Ministry of Health under the Control of Drugs and
Cosmetics Regulations 1984 which empowers the NPCB to implement
the registration of:
a. Scheduled poisons/NCE/Biotechnology
b. Non-scheduled poisons (over the counter)
c. Traditional Medicines and Health Supplements
d. Veterinary Products
e. Cosmetics (Registration of cosmetics was replaced by the Notification
Procedure with effect from 1 January 2008.)
In 2011, the following directives / guidelines were issued and/or revised:
Directive on Data Exclusivity (DE) (28 February 2011)
ASEAN |abe|||ng Requ|rements 14 Apr|| 2011}
Drug Reg|strat|on Gu|dance Document DRGD} September 2011}
O|ass|f|cat|on of Dec|s|on Tree November 2011}
In 2011, BiotechCorp completed work on its regulatory guidebook entitled
EU and US Pharmaceutical Regulations: A Guide for Malaysian Companies
wh|ch prov|des a usefu| overv|ew of the regu|atory requ|rements for
access into the EU and US markets. It also will enable Malaysian
companies to better plan and implement appropriate regulatory strategies
for successful product placement in those markets.
Throughout 2011, Malaysia continued to play an active role in
harmonisation efforts through the ASEAN Consultative Committee for
Standards and Quality (ACCSQ) Pharmaceutical Product Working Group
(PPWG), the Traditional Medicines and Health Supplement Product
Working Group (TMHS PWG) as well as the Medical Devices Product
Working Group (MDPWG).
53
Budapest Treaty for the Deposit of Microorganisms for the
Purposes of Patent Procedure
A National Seminar on the Budapest Treaty was jointly organised by
MyIPO in collaboration with the World Intellectual Property
Organisation (WIPO) in September to create awareness among
stakeholders on the workings and operations of the Budapest Treaty.
BiotechCorp remains engaged with MyIPO in its efforts for Malaysia to
accede to the Budapest Treaty.
Capacity Bui|ding Initiatives
Various capacity building initiatives were also carried throughout the
year including workshops and regulatory updates for internal and
external customers.
In 2011, BiotechCorp participated in the Technical Working Group
(TWG) for pharmaceutical, traditional medicines & health supplements
and medical devices and provided industry input for the harmonisation
of regulations in the three sectors in ASEAN. Through the ASEAN
Consultative Committee in Safety and Quality (ACCSQ) Product
Working Group (PWG) participation, we were able to keep track on the
work programme progress and the time frame targeted in harmonising
standards and reducing technical barriers towards a single market by 2015.
International
Accreditation
(GLP)
Pharma Regulations
In relation to GLP, Malaysias efforts in gaining full adherence to the
Organisation for Economic Co-operation and Development (OECD)
Mutual Acceptance of Data (MAD) system showed great results.
For some background, Malaysia was made a provisional adherent to
the Organisation for Economic Co-operation and Development (OECD)
Mutual Acceptance of Data (MAD) system in 2008. The year 2010 saw
the continued implementation of the OECD GLP framework, which is
applicable to non-clinical health and environment safety studies. The
Government then designated the National Pharmaceutical Control
Bureau (NPCB) and Department of Standards Malaysia (Standards
Malaysia) as the Compliance Monitoring Authority (CMAs) for Malaysia.
BiotechCorp has been working closely with the CMAs by organising
programmes and capacity building initiatives for the CMAs and also the
industry in order to ensure that Malaysia is fully ready for the On Site
Evaluation and Mutual Joint Visit by the OECD inspectors in order to
achieve full adherent status to the OECD MAD system.
In 2011, in preparation for the On Site Evaluation/ Mutual Joint Visit
(OSE/MJV) by OECD, the following Compliance Programmes were
conducted by the CMAs:
On 5-7 April 2011, both the CMAs attended the OECD Working Group
(WG) Meeting to present to the OECD WG on Malaysias progress in
the GLP Compliance Programme and our readiness for the MJV.
Based on the convincing progress made by Malaysia, the WG agreed
that the MJV shall take place in November 2011
On 6-10 June 2011, BiotechCorp facilitated Standards Malaysias
participation in an On Site Evaluation exercise by OECD inspectors to
evaluate Greece as part of the run up to Malaysias inspection by OECD
On 13-14 June 2011, BiotechCorp assisted the CMAs in the workshop
on Compliance of Computerised System to OECD-GLP held at
Bayview Beach Resort in Penang
Beginning in August 2011 until October 2011, a mock inspection was
conducted on the test facility chosen for the MJV (i.e. SIRIM Berhad)
for its area of expertise in toxicology and mutagenicity
Pharma Regulations
Intellectual Property (IP)
Pharmaceuticals are regulated by the National Pharmaceutical Control
Bureau (NPCB) of the Ministry of Health under the Control of Drugs and
Cosmetics Regulations 1984 which empowers the NPCB to implement
the registration of:
a. Scheduled poisons/NCE/Biotechnology
b. Non-scheduled poisons (over the counter)
c. Traditional Medicines and Health Supplements
d. Veterinary Products
e. Cosmetics (Registration of cosmetics was replaced by the Notification
Procedure with effect from 1 January 2008.)
In 2011, the following directives / guidelines were issued and/or revised:
Directive on Data Exclusivity (DE) (28 February 2011)
ASEAN |abe|||ng Requ|rements 14 Apr|| 2011}
Drug Reg|strat|on Gu|dance Document DRGD} September 2011}
O|ass|f|cat|on of Dec|s|on Tree November 2011}
In 2011, BiotechCorp completed work on its regulatory guidebook entitled
EU and US Pharmaceutical Regulations: A Guide for Malaysian Companies
wh|ch prov|des a usefu| overv|ew of the regu|atory requ|rements for
access into the EU and US markets. It also will enable Malaysian
companies to better plan and implement appropriate regulatory strategies
for successful product placement in those markets.
Throughout 2011, Malaysia continued to play an active role in
harmonisation efforts through the ASEAN Consultative Committee for
Standards and Quality (ACCSQ) Pharmaceutical Product Working Group
(PPWG), the Traditional Medicines and Health Supplement Product
Working Group (TMHS PWG) as well as the Medical Devices Product
Working Group (MDPWG).
54
On 14 - 19 November 2011, the Mutua| Jo|nt v|s|t MJv} lnspect|on by
the OEOD team of |nspectors commenced. They were |ed by Dr
Andrew Gray Med|c|nes & Hea|thcare products Regu|atory Agency,
n|ted K|ngdom} w|th two other |nspectors name|y Dr Ohr|stoph Moor
Federa| Off|ce for the Env|ronment, Sw|tzer|and} and Dr H|tosh|
Someya the Pharmaceut|ca| & Med|ca| Dev|ce Regu|atory Agency,
Japan} and Ms. Wakako Hor|k| an observer from Env|ronment Hea|th
and Safety D|v|s|on, Env|ronment D|rectorate, OEOD, Par|s.
Based on a|| the |n|t|at|ves wh|ch have been carr|ed out |n support of the
OMAs, B|otechOorp rema|ns opt|m|st|ca||y hopefu| that Ma|ays|a w||| ach|eve
|ts a|m to become a fu||-adherent to the OEOD MAD system |n 2012.
Next Steps for Policy and Regulatory Engagement:
As the Ma|ays|an b|otechno|ogy |ndustry moves |nto the next phase of Oommerc|a||s|ng
Sc|ence to Bus|ness", be|ow are some areas that need to be addressed:
Biosafety and Access and Benefit Sharing (ABS)
B|otechOorp sha|| cont|nue our hea|thy engagement w|th the B|osafety Department of
the M|n|stry of Natura| Resources and Env|ronment MoNRE} |n the area of b|osafety. We
w||| a|so part|c|pate |n the consu|tat|ve process towards the promu|gat|on of the ABS |aw
and w||| engage w|th MoNRE to prov|de awareness to the |ndustry on the ant|c|pated
domest|c ABS |aw. MoNRE`s consu|tat|on w|th stakeho|ders on the draft ABS |aw |s
expected to be carr|ed out |n 2012.
Intellectual Property
lt |s env|saged that there w||| be an |ncrease |n the number of lPs reg|stered |n the country
and we w||| cont|nue to prov|de awareness and adv|ce to the |ndustry on strateg|c lP
management. Mov|ng forward, focus sha|| be g|ven to areas such as va|uat|on and
co||atera||sat|on of lP.
Pharma Regulations
B|otechOorp w||| cont|nue to contr|bute |ts |nput to the deve|opment of pharmaceut|ca|
regu|at|ons |nc|ud|ng harmon|sat|on of regu|atory framework for ASEAN reg|on. Moreover,
|everag|ng upon our strong re|at|onsh|p w|th regu|atory stakeho|ders, we w||| prov|de
cont|nuous and construct|ve |ndustry perspect|ve |nput to dr|ve hea|thcare b|otechno|ogy
deve|opment.
BUSINESS INTELLIGENCE
T|me|y ava||ab|||ty of key bus|ness |nformat|on and know|edge |s cr|t|ca| for bus|nesses to
ma|nta|n a |ead|ng pace |n today`s compet|t|ve marketp|ace. Recogn|s|ng th|s need, a new
department ca||ed Bus|ness lnte|||gence Bl} was estab||shed |n 2011 under the Strateg|c
P|ann|ng D|v|s|on.
Focus Areas:
1. Prov|d|ng accurate and t|me|y market and |ndustry |nte|||gence to B|otechOorp`s |nterna|
stakeho|ders for better strategy deve|opment, faster dec|s|on mak|ng, targeted
government/|ndustry engagement, and |mpactfu| |ntervent|ona|/|n|t|at|ves |mp|ementat|on.
2. To be a one-stop-center for |nformat|on on b|otechno|ogy |ndustry for both |nterna| and
externa| stakeho|ders and to fac|||tate network|ng/co||aborat|on between these part|es.
Prov|d|ng market and
|ndustry |nte|||gence to
|nterna| stakeho|ders
lnternat|ona|
Accred|tat|on G|P}
Bl pub||shed Ouarter|y B|otechno|ogy lndustry Reports and Ana|ys|s for
each |ndustry sector, w|th a tota| of four quarter|y reports be|ng pub||shed
|n 2011, as fo||ows:
Rea||sed |nvestment and revenue generat|on gaps w|th|n
B|otechOorp`s 2011 Approved Bus|ness P|an as compared aga|nst the
Nat|ona| B|otechno|ogy Po||cy NBP} Phase ll targets,
Pos|t|on|ng Ma|ays|a |n attract|ng g|oba| b|otechno|ogy Fore|gn D|rect
lnvestment FDl},
Market access for Ma|ays|an b|otechno|ogy compan|es, and
lnternat|ona| ||nkages and spec|f|c fore|gn compan|es w|th s|gn|f|cant
bus|ness opportun|t|es for Bus|ness Deve|opment and lnvestment
BDl} team to approach for potent|a| FDl and co||aborat|ons.
A tota| of 12 Sen|or Management A|erts were |ssued |n 2011, |nc|ud|ng
|nformat|on on Ma|ays|a`s gross domest|c product GDP} growth, sh|fts
|n Ma|ays|an ut|||ty tar|ffs that cou|d |mpact |nvestment, potent|a|
p|atform techno|og|es and the|r prospect|ve opportun|t|es, potent|a| FDl
c||ents and co||aborat|on opportun|t|es w|th fore|gn partners, as we|| as
s|gn|f|cant deve|opments w|th|n the b|otechno|ogy |ndustry w|th strong
re|evance to Ma|ays|a.The a|erts are a mechan|sm deve|oped to a|ert
the Sen|or Management about |mportant deve|opments w|th|n the
b|otechno|ogy |ndustry |n a t|me|y manner.
Activity Results
55
On 14 - 19 November 2011, the Mutua| Jo|nt v|s|t MJv} lnspect|on by
the OEOD team of |nspectors commenced. They were |ed by Dr
Andrew Gray Med|c|nes & Hea|thcare products Regu|atory Agency,
n|ted K|ngdom} w|th two other |nspectors name|y Dr Ohr|stoph Moor
Federa| Off|ce for the Env|ronment, Sw|tzer|and} and Dr H|tosh|
Someya the Pharmaceut|ca| & Med|ca| Dev|ce Regu|atory Agency,
Japan} and Ms. Wakako Hor|k| an observer from Env|ronment Hea|th
and Safety D|v|s|on, Env|ronment D|rectorate, OEOD, Par|s.
Based on a|| the |n|t|at|ves wh|ch have been carr|ed out |n support of the
OMAs, B|otechOorp rema|ns opt|m|st|ca||y hopefu| that Ma|ays|a w||| ach|eve
|ts a|m to become a fu||-adherent to the OEOD MAD system |n 2012.
Next Steps for Policy and Regulatory Engagement:
As the Ma|ays|an b|otechno|ogy |ndustry moves |nto the next phase of Oommerc|a||s|ng
Sc|ence to Bus|ness", be|ow are some areas that need to be addressed:
Biosafety and Access and Benefit Sharing (ABS)
B|otechOorp sha|| cont|nue our hea|thy engagement w|th the B|osafety Department of
the M|n|stry of Natura| Resources and Env|ronment MoNRE} |n the area of b|osafety. We
w||| a|so part|c|pate |n the consu|tat|ve process towards the promu|gat|on of the ABS |aw
and w||| engage w|th MoNRE to prov|de awareness to the |ndustry on the ant|c|pated
domest|c ABS |aw. MoNRE`s consu|tat|on w|th stakeho|ders on the draft ABS |aw |s
expected to be carr|ed out |n 2012.
lt |s env|saged that there w||| be an |ncrease |n the number of lPs reg|stered |n the country
and we w||| cont|nue to prov|de awareness and adv|ce to the |ndustry on strateg|c lP
management. Mov|ng forward, focus sha|| be g|ven to areas such as va|uat|on and
co||atera||sat|on of lP.
Pharma Regulations
B|otechOorp w||| cont|nue to contr|bute |ts |nput to the deve|opment of pharmaceut|ca|
regu|at|ons |nc|ud|ng harmon|sat|on of regu|atory framework for ASEAN reg|on. Moreover,
|everag|ng upon our strong re|at|onsh|p w|th regu|atory stakeho|ders, we w||| prov|de
cont|nuous and construct|ve |ndustry perspect|ve |nput to dr|ve hea|thcare b|otechno|ogy
deve|opment.
BUSINESS INTELLIGENCE
T|me|y ava||ab|||ty of key bus|ness |nformat|on and know|edge |s cr|t|ca| for bus|nesses to
ma|nta|n a |ead|ng pace |n today`s compet|t|ve marketp|ace. Recogn|s|ng th|s need, a new
department ca||ed Bus|ness lnte|||gence Bl} was estab||shed |n 2011 under the Strateg|c
P|ann|ng D|v|s|on.
Focus Areas:
1. Prov|d|ng accurate and t|me|y market and |ndustry |nte|||gence to B|otechOorp`s |nterna|
stakeho|ders for better strategy deve|opment, faster dec|s|on mak|ng, targeted
government/|ndustry engagement, and |mpactfu| |ntervent|ona|/|n|t|at|ves |mp|ementat|on.
2. To be a one-stop-center for |nformat|on on b|otechno|ogy |ndustry for both |nterna| and
externa| stakeho|ders and to fac|||tate network|ng/co||aborat|on between these part|es.
Prov|d|ng market and
|ndustry |nte|||gence to
|nterna| stakeho|ders
lnternat|ona|
Accred|tat|on G|P}
Bl pub||shed Ouarter|y B|otechno|ogy lndustry Reports and Ana|ys|s for
each |ndustry sector, w|th a tota| of four quarter|y reports be|ng pub||shed
|n 2011, as fo||ows:
Rea||sed |nvestment and revenue generat|on gaps w|th|n
B|otechOorp`s 2011 Approved Bus|ness P|an as compared aga|nst the
Nat|ona| B|otechno|ogy Po||cy NBP} Phase ll targets,
Pos|t|on|ng Ma|ays|a |n attract|ng g|oba| b|otechno|ogy Fore|gn D|rect
lnvestment FDl},
Market access for Ma|ays|an b|otechno|ogy compan|es, and
lnternat|ona| ||nkages and spec|f|c fore|gn compan|es w|th s|gn|f|cant
bus|ness opportun|t|es for Bus|ness Deve|opment and lnvestment
BDl} team to approach for potent|a| FDl and co||aborat|ons.
A tota| of 12 Sen|or Management A|erts were |ssued |n 2011, |nc|ud|ng
|nformat|on on Ma|ays|a`s gross domest|c product GDP} growth, sh|fts
|n Ma|ays|an ut|||ty tar|ffs that cou|d |mpact |nvestment, potent|a|
p|atform techno|og|es and the|r prospect|ve opportun|t|es, potent|a| FDl
c||ents and co||aborat|on opportun|t|es w|th fore|gn partners, as we|| as
s|gn|f|cant deve|opments w|th|n the b|otechno|ogy |ndustry w|th strong
re|evance to Ma|ays|a.The a|erts are a mechan|sm deve|oped to a|ert
the Sen|or Management about |mportant deve|opments w|th|n the
b|otechno|ogy |ndustry |n a t|me|y manner.
Activity Results
56
Proposed collaboration with Insect Biotech Co. Ltd for Human
Capital Internship Programme;
Implementation Council Meeting Funding Proposal; and
Proposed Malaysia and Italy Collaboration in Biotechnology.
One-stop-center for
information and facilitate
networking/collaboration
between all
stakeholders
Smart partnerships In line with Malaysia entering into Phase 2 of the National Biotechnology
Policy entailing commercialisation, there is an immediate need for the
BiotechCorp Resource Centre to expand and collaborate with relevant
organisations/libraries for information sharing to assist in successful
implementation. Acknowledging the importance of close collaborations
and information sharing, BI had actively engaged and initiated several
smart partnerships in the year 2011 with several important business
intelligence/knowledge centers in the country, notably Petronas
Research Center, and Knowledge Center@Bursa, Bursa Malaysia. The
collaborations primarily aim to fulfill the educational, intellectual,
informational and social aspirations of users, through cooperative
provision, superior quality library resources and services made
available to the users.
Activity Results
Industry updates and
market developments
to external
stakeholders through
published materials
In 2011, BI has achieved the stretched target with the publication of three
articles in regionally and globally significant periodicals, as follows:
Malaysia as a destination for foreign biotechnology investments (Asia
Pacific Biotech News, September 2011);
Australia-Malaysia: Forging ahead (Roxy Media, November 2011); and
Biotech investments to target Malaysia, says BiotechCorp (Malaysian
Reserve, November 2011).
BI also publishes the BioMonthly, a monthly publication prepared with
the intention to provide stakeholders with information on BioNexus
Status companies, economy and financial outlook, and selected
developments on focus areas in Agriculture, Healthcare and Industrial
Biotechnology in Malaysia, as well as other parts of the world. A total
of twelve BioMonthly issues have been published in 2011.
BI maintained a weekly news update called BioNews, with 52 issues
released for the year 2011, in order to keep stakeholders up-to-date
with the latest on-goings in the biotechnology industry.
Creating a platform for
engagement in the
promotion of the
Bioeconomy Initiative
Malaysia (BIM)
BI has been directly involved since the inception of this master plan,
and has been instrumental at facilitating the groundwork for the BIM.
BIM is the framework for the nation to develop a high-income bioeconomy
through a sustainable ecosystem of research and development (R&D) and
commercialisation in the areas of agriculture, healthcare and industrial
biotechnology by 2020.
One of the key highlights of this drive was the launch of the BIM at
BioMalaysia 2011 by the Prime Minister of Malaysia Yang Amat Berhormat
Dato Seri Najib Tun Razak. Moving forward, BI will continue with its
contribution and involvement in the BIM, in particular the BIM workshop
and lab in March 2012, which will be held collaboratively with the
Ministry of Science, Technology and Innovation (MOSTI).
One-stop-center for
between all
stakeholders
Provided content for presentation to Cluster Working Groups/Senior
Management, where a total of six contents items were provided as follows:
Proposed Collaboration with Chungbuk Bio Valley Development
Bureau;
Proposed collaboration with Chungcheong Leading Industry Office
in Korea for Human Capital Internship Programme;
Proposed collaboration with Korean Biotechnology Industry
Organisation for Human Capital Internship Programme;
Activity Results
Next Steps for Business Intelligence:
As part of efforts to ensure that BiotechCorp remains relevant to its stakeholders moving
forward, Business Intelligence will be undertaking the following activities:
In 2012, Business Intelligence will be renamed Corporate Innovation Strategy to further reflect the
work to be undertaken in the ensuing years; and
Oont|nuous focus w||| be p|aced |n chart|ng the d|rect|on of b|otechno|ogy |ndustry, to encourage
innovation and assist commercialisation of local biotechnology industry through coordination and
collaboration with relevant agencies.
57
Proposed collaboration with Insect Biotech Co. Ltd for Human
Capital Internship Programme;
Implementation Council Meeting Funding Proposal; and
Proposed Malaysia and Italy Collaboration in Biotechnology.
One-stop-center for
between all
stakeholders
Smart partnerships In line with Malaysia entering into Phase 2 of the National Biotechnology
Policy entailing commercialisation, there is an immediate need for the
BiotechCorp Resource Centre to expand and collaborate with relevant
organisations/libraries for information sharing to assist in successful
implementation. Acknowledging the importance of close collaborations
and information sharing, BI had actively engaged and initiated several
smart partnerships in the year 2011 with several important business
intelligence/knowledge centers in the country, notably Petronas
Research Center, and Knowledge Center@Bursa, Bursa Malaysia. The
collaborations primarily aim to fulfill the educational, intellectual,
informational and social aspirations of users, through cooperative
provision, superior quality library resources and services made
available to the users.
Activity Results
Industry updates and
market developments
to external
stakeholders through
published materials
In 2011, BI has achieved the stretched target with the publication of three
articles in regionally and globally significant periodicals, as follows:
Malaysia as a destination for foreign biotechnology investments (Asia
Pacific Biotech News, September 2011);
Australia-Malaysia: Forging ahead (Roxy Media, November 2011); and
Biotech investments to target Malaysia, says BiotechCorp (Malaysian
Reserve, November 2011).
BI also publishes the BioMonthly, a monthly publication prepared with
the intention to provide stakeholders with information on BioNexus
Status companies, economy and financial outlook, and selected
developments on focus areas in Agriculture, Healthcare and Industrial
Biotechnology in Malaysia, as well as other parts of the world. A total
of twelve BioMonthly issues have been published in 2011.
BI maintained a weekly news update called BioNews, with 52 issues
released for the year 2011, in order to keep stakeholders up-to-date
with the latest on-goings in the biotechnology industry.
Creating a platform for
engagement in the
promotion of the
Bioeconomy Initiative
Malaysia (BIM)
BI has been directly involved since the inception of this master plan,
and has been instrumental at facilitating the groundwork for the BIM.
BIM is the framework for the nation to develop a high-income bioeconomy
through a sustainable ecosystem of research and development (R&D) and
commercialisation in the areas of agriculture, healthcare and industrial
biotechnology by 2020.
One of the key highlights of this drive was the launch of the BIM at
BioMalaysia 2011 by the Prime Minister of Malaysia Yang Amat Berhormat
Dato Seri Najib Tun Razak. Moving forward, BI will continue with its
contribution and involvement in the BIM, in particular the BIM workshop
and lab in March 2012, which will be held collaboratively with the
Ministry of Science, Technology and Innovation (MOSTI).
One-stop-center for
between all
stakeholders
Provided content for presentation to Cluster Working Groups/Senior
Management, where a total of six contents items were provided as follows:
Proposed Collaboration with Chungbuk Bio Valley Development
Bureau;
Proposed collaboration with Chungcheong Leading Industry Office
in Korea for Human Capital Internship Programme;
Proposed collaboration with Korean Biotechnology Industry
Organisation for Human Capital Internship Programme;
Activity Results
Next Steps for Business Intelligence:
As part of efforts to ensure that BiotechCorp remains relevant to its stakeholders moving
forward, Business Intelligence will be undertaking the following activities:
In 2012, Business Intelligence will be renamed Corporate Innovation Strategy to further reflect the
work to be undertaken in the ensuing years; and
Oont|nuous focus w||| be p|aced |n chart|ng the d|rect|on of b|otechno|ogy |ndustry, to encourage
innovation and assist commercialisation of local biotechnology industry through coordination and
collaboration with relevant agencies.
58
CAPABILITY DEVELOPMENT
Organisational or industry success often depends on dynamic human capital resources.
Innovation, knowledge and capabilities have been the central in driving industry
performance whilst, entrepreneurial and managerial knowledge have played important roles
in spurring the industry forward. In view of this, BiotechCorp has aimed to equip people
within the biotechnology industry with the latest insights and competencies to help spur the
industry.
Focus Areas
Developing skilled, knowledgeable and competent human capital to ensure adequate supply of
human capital for the biotechnology ecosystem.
Facilitating capability for those who possess the entrepreneurial and managerial knowledge to drive
the industry.
Biotechnology
Entrepreneurship
Special Training (BeST)
Programme
BeST is a part of BiotechCorps approach to develop and nurture
skilled talent within the industry in a bid to ensure a sustainable pool of
human capital for Malaysia.
BeST has expanded |ts w|ngs to the un|vers|t|es where |t serves as
one of the finishing school programmes at the biotechnology and life
sciences faculties. The industry attachment component of BeST has
been intensified into various critical focus areas of the industry.
BeST Big Ideas 2011 BeST B|g ldeas 2011 was he|d to |ncu|cate dr|ve among the BeST
trainees in a quest for big ideas and to provide meaningful and
strategic actions to realise the ideas. This programme enhanced
BeST trainees research skills, organising and managing projects.
Ideas generated by the BeST trainees will become one of the sources
of references for BiotechCorp, particularly Capability Development
Department (CDD) in developing human capital in biotechnology.
Graduate Returning
Programme
BiotechCorp seeks to provide returning overseas graduates in
biotechnology/life sciences with the opportunity to connect with the
overall Malaysian biotechnology landscape and at the same time
exp|ore job opportun|t|es ava||ab|e w|th|n the Ma|ays|an b|otechno|ogy
industry.
Issue/Activity Results
The 2 day programme prov|des graduates w|th suff|c|ent fam|||ar|ty of
key government initiatives and policies that have been formulated and
implemented in facilitating the transformation of Malaysia towards a
high income economy by 2020. Graduates will also be provided with
the opportunity to be updated on latest developments on the global,
reg|ona| and Ma|ays|an b|otechno|ogy |ndustry and be exposed to
exc|t|ng opportun|t|es |n store for them.
The programme w||| eventua||y prov|de graduates w|th the |atest
information on job opportunities within public and private sectors thus
increasing their chances of obtaining a job at the earliest possible
opportunity.
MyBio Carnival 2011
Graduate Returning
Programme
This programme is targeted at creating biotechnology awareness by
bringing together all stakeholders within the industry.
MyBio Carnival 2011 was held in two locations in the country including
Kuala Lumpur and Kedah.
Two co||aborat|ve programmes between B|otechOorp together w|th
Malaysian Biotechnology Centre (MABIC) and Taylors University
College were held at Taylors University, Subang.
Oo||aborat|on between B|otechOorp, Ma|ays|an B|otechno|ogy
Centre (MABIC), Northern Corridor Implementation Authority (NCIA)
and other Public/Private Learning Institutes was held at AIMST
University, Bedong, Kedah.
Specific Training in
Critical Areas (STCA)
STCA comprises of a blend of theory and practical teaching sessions
and support from |ead|ng |ndustry experts for tra|nees to |ncrease the|r
marketability and industry savviness. This is one of the initiatives under
the BeST Extens|on of Tra|n|ng Scope to further equ|p the BeST
trainees with skills and competencies in Specific Training in the
required Critical Areas:
B|oProcess|ng
Ana|yt|ca| |ab lnstrumentat|on
P|ant T|ssue Ou|ture
Herba| P|ant Extract|on and Product|on
Spec|a||sed Techn|ca| Seed P|ant|ng and Grow|ng
B|oMo|ecu|ar Ana|yt|ca| |ab lnstrumentat|on
Key Results
59
CAPABILITY DEVELOPMENT
Organisational or industry success often depends on dynamic human capital resources.
Innovation, knowledge and capabilities have been the central in driving industry
performance whilst, entrepreneurial and managerial knowledge have played important roles
in spurring the industry forward. In view of this, BiotechCorp has aimed to equip people
within the biotechnology industry with the latest insights and competencies to help spur the
industry.
Focus Areas
Developing skilled, knowledgeable and competent human capital to ensure adequate supply of
human capital for the biotechnology ecosystem.
Facilitating capability for those who possess the entrepreneurial and managerial knowledge to drive
the industry.
Biotechnology
Entrepreneurship
Special Training (BeST)
Programme
BeST is a part of BiotechCorps approach to develop and nurture
skilled talent within the industry in a bid to ensure a sustainable pool of
human capital for Malaysia.
BeST has expanded |ts w|ngs to the un|vers|t|es where |t serves as
one of the finishing school programmes at the biotechnology and life
sciences faculties. The industry attachment component of BeST has
been intensified into various critical focus areas of the industry.
BeST Big Ideas 2011 BeST B|g ldeas 2011 was he|d to |ncu|cate dr|ve among the BeST
trainees in a quest for big ideas and to provide meaningful and
strategic actions to realise the ideas. This programme enhanced
BeST trainees research skills, organising and managing projects.
Ideas generated by the BeST trainees will become one of the sources
of references for BiotechCorp, particularly Capability Development
Department (CDD) in developing human capital in biotechnology.
Graduate Returning
Programme
BiotechCorp seeks to provide returning overseas graduates in
biotechnology/life sciences with the opportunity to connect with the
overall Malaysian biotechnology landscape and at the same time
exp|ore job opportun|t|es ava||ab|e w|th|n the Ma|ays|an b|otechno|ogy
industry.
The 2 day programme prov|des graduates w|th suff|c|ent fam|||ar|ty of
key government initiatives and policies that have been formulated and
implemented in facilitating the transformation of Malaysia towards a
high income economy by 2020. Graduates will also be provided with
the opportunity to be updated on latest developments on the global,
reg|ona| and Ma|ays|an b|otechno|ogy |ndustry and be exposed to
exc|t|ng opportun|t|es |n store for them.
The programme w||| eventua||y prov|de graduates w|th the |atest
information on job opportunities within public and private sectors thus
increasing their chances of obtaining a job at the earliest possible
opportunity.
MyBio Carnival 2011
Graduate Returning
Programme
This programme is targeted at creating biotechnology awareness by
bringing together all stakeholders within the industry.
MyBio Carnival 2011 was held in two locations in the country including
Kuala Lumpur and Kedah.
Two co||aborat|ve programmes between B|otechOorp together w|th
Malaysian Biotechnology Centre (MABIC) and Taylors University
College were held at Taylors University, Subang.
Oo||aborat|on between B|otechOorp, Ma|ays|an B|otechno|ogy
Centre (MABIC), Northern Corridor Implementation Authority (NCIA)
and other Public/Private Learning Institutes was held at AIMST
University, Bedong, Kedah.
Specific Training in
Critical Areas (STCA)
STCA comprises of a blend of theory and practical teaching sessions
and support from |ead|ng |ndustry experts for tra|nees to |ncrease the|r
marketability and industry savviness. This is one of the initiatives under
the BeST Extens|on of Tra|n|ng Scope to further equ|p the BeST
trainees with skills and competencies in Specific Training in the
required Critical Areas:
B|oProcess|ng
Ana|yt|ca| |ab lnstrumentat|on
P|ant T|ssue Ou|ture
Herba| P|ant Extract|on and Product|on
Spec|a||sed Techn|ca| Seed P|ant|ng and Grow|ng
B|oMo|ecu|ar Ana|yt|ca| |ab lnstrumentat|on
Key Results
60
Training at Real-Time
Facilities (TRTF)
TRTF combines prior obtained theoretical knowledge with actual work
experience to produce a skilled professional who is capable of
exercising independent judgment and who subscribes to the highest
standards of professional conduct.
This programme will be a critical part of building the Biotechnology
workforce by increasing skill levels and preparing BeST trainees for the
challenge of higher level biotechnology careers from ground-up.
The TRTF programme is carried out for two years and BeST graduates
will undergo training and exposure on the following areas:
Techn|ca| Processes and Operat|ons
Oua||ty Management and Oontro|
Superv|sory and |eadersh|p Sk|||s
|aboratory Test|ng and Research
Safety, Hea|th and Env|ronment
Next Steps for Capability Development:
ln meet|ng human cap|ta| demand mov|ng forward, B|otechOorp w||| focus on the fo||ow|ng
areas:
BeST will expand its scope to create a customised programme that is unique and tailored
to universities specialisations. This tailored programme will ensure that the graduates
capture the essence of biotechnology basics and enhance themselves in line with industry
requirements.
The BeST D|p|oma and Post Degree |eve|s w||| be exam|ned at greater depth to ensure the
needs of human capital at every position level in the biotechnology industry are fulfilled.
An apprent|cesh|p scheme w||| be offered for schoo|-|eavers who have scored good
grades |n the S|j|| Pe|ajaran Ma|ays|a exam|nat|on and those who are |nc||ned to be
technologists. Those who have completed apprenticeships will be offered permanent
employment by participating biotechnology companies and also have the opportunity to
further their degree later on via scholarship.
B|otechOorp a|so expects to deve|op an advanced programme to comp||ment the BeST
Alumni competencies to ensure that the human capital pool in the biotechnology industry
possesses adequate technical as well as soft skills and executive capabilities.
AGRICULTURAL BIOTECHNOLOGY
As part of |ts comm|tment to dr|ve |ndustry deve|opment, B|otechOorp has been engaged |n
enhanc|ng the econom|c va|ue of the Ma|ays|an agr|cu|ture |ndustry through encourag|ng the
adopt|on of cutt|ng-edge b|otechno|ogy too|s, |nnovat|on and commerc|a||sat|on.
To fac|||tate th|s ach|evement, the Agr|cu|tura| B|otechno|ogy framework |s based on the
Th|rd Nat|ona| Agr|cu|tura| po||cy NAP3} and the Nat|ona| Po||cy on B|o|og|ca| D|vers|ty
1998}, and |s subd|v|ded |nto the fo||ow|ng key sectors:
Focus Areas:
1. Natura| products b|otechno|ogy wh|ch |nc|udes extract|on, standard|sat|on, product
deve|opment and va||dat|on |nc|ud|ng pre-c||n|ca|} stud|es for neutraceut|ca|s, cosmeceut|ca|s,
food |ngred|ents, funct|ona| food, pharmaceut|ca|s/botan|ca| drugs and d|etary supp|ements.
2. Orops b|otechno|ogy wh|ch |nc|udes p|ant|ng mater|a|s |nc|ud|ng, t|ssue cu|ture and seeds}
deve|opment and product|on, b|ofert|||ser/so|| enhancers, b|o-contro|s/crop protect|on
encompass|ng ornamenta|, food and |ndustr|a| crops.
3. ||vestock b|otechno|ogy wh|ch |nc|udes the breed|ng of goats, catt|e, pou|try etc, ut|||s|ng
b|otechno|ogy too|s, e.g. art|f|c|a| |nsem|nat|on, embryo transfer, etc. ||vestock
b|otechno|ogy w||| a|so |nc|ude the research, deve|opment and commerc|a||sat|on of
||vestock re|ated hea|th products and feed/feed add|t|ves.
4. Aquacu|ture b|otechno|ogy |nc|udes the breed|ng of mar|ne and fresh water f|shes t||ap|a,
grouper, sturgeons, etc}, crustaceans shr|mps, oysters, |obsters, crabs} as we|| as the
cultivation of algae for feed and other downstream activities. Aquaculture biotechnology will
a|so |nc|ude the research, deve|opment and commerc|a||sat|on of aqua re|ated hea|th
products and feed/feed add|t|ves.
Biofertiliser ln 2011, B|ofert|||ser compan|es cont|nued to expand the|r market share
|n the Asean/As|an reg|on where products were exported to lndones|a,
Vietnam and India. This included specialty products meant for different
applications such as root enhancement and pest control.
The biofertiliser sector contributed the largest revenue among the
B|oNexus Status compan|es, at approx|mate|y RM 193.4 m||||on.
Due to market demands and the deve|opment of new product ||nes,
biofertiliser companies continued to expand through land acquisitions
and production facilities.
Key Results
61
Training at Real-Time
Facilities (TRTF)
TRTF combines prior obtained theoretical knowledge with actual work
experience to produce a skilled professional who is capable of
exercising independent judgment and who subscribes to the highest
standards of professional conduct.
This programme will be a critical part of building the Biotechnology
workforce by increasing skill levels and preparing BeST trainees for the
challenge of higher level biotechnology careers from ground-up.
The TRTF programme is carried out for two years and BeST graduates
will undergo training and exposure on the following areas:
Techn|ca| Processes and Operat|ons
Oua||ty Management and Oontro|
Superv|sory and |eadersh|p Sk|||s
|aboratory Test|ng and Research
Safety, Hea|th and Env|ronment
Next Steps for Capability Development:
ln meet|ng human cap|ta| demand mov|ng forward, B|otechOorp w||| focus on the fo||ow|ng
areas:
BeST will expand its scope to create a customised programme that is unique and tailored
to universities specialisations. This tailored programme will ensure that the graduates
capture the essence of biotechnology basics and enhance themselves in line with industry
requirements.
The BeST D|p|oma and Post Degree |eve|s w||| be exam|ned at greater depth to ensure the
needs of human capital at every position level in the biotechnology industry are fulfilled.
An apprent|cesh|p scheme w||| be offered for schoo|-|eavers who have scored good
grades |n the S|j|| Pe|ajaran Ma|ays|a exam|nat|on and those who are |nc||ned to be
technologists. Those who have completed apprenticeships will be offered permanent
employment by participating biotechnology companies and also have the opportunity to
further their degree later on via scholarship.
B|otechOorp a|so expects to deve|op an advanced programme to comp||ment the BeST
Alumni competencies to ensure that the human capital pool in the biotechnology industry
possesses adequate technical as well as soft skills and executive capabilities.
AGRICULTURAL BIOTECHNOLOGY
As part of |ts comm|tment to dr|ve |ndustry deve|opment, B|otechOorp has been engaged |n
enhanc|ng the econom|c va|ue of the Ma|ays|an agr|cu|ture |ndustry through encourag|ng the
adopt|on of cutt|ng-edge b|otechno|ogy too|s, |nnovat|on and commerc|a||sat|on.
To fac|||tate th|s ach|evement, the Agr|cu|tura| B|otechno|ogy framework |s based on the
Th|rd Nat|ona| Agr|cu|tura| po||cy NAP3} and the Nat|ona| Po||cy on B|o|og|ca| D|vers|ty
1998}, and |s subd|v|ded |nto the fo||ow|ng key sectors:
Focus Areas:
1. Natura| products b|otechno|ogy wh|ch |nc|udes extract|on, standard|sat|on, product
deve|opment and va||dat|on |nc|ud|ng pre-c||n|ca|} stud|es for neutraceut|ca|s, cosmeceut|ca|s,
food |ngred|ents, funct|ona| food, pharmaceut|ca|s/botan|ca| drugs and d|etary supp|ements.
2. Orops b|otechno|ogy wh|ch |nc|udes p|ant|ng mater|a|s |nc|ud|ng, t|ssue cu|ture and seeds}
deve|opment and product|on, b|ofert|||ser/so|| enhancers, b|o-contro|s/crop protect|on
encompass|ng ornamenta|, food and |ndustr|a| crops.
3. ||vestock b|otechno|ogy wh|ch |nc|udes the breed|ng of goats, catt|e, pou|try etc, ut|||s|ng
b|otechno|ogy too|s, e.g. art|f|c|a| |nsem|nat|on, embryo transfer, etc. ||vestock
b|otechno|ogy w||| a|so |nc|ude the research, deve|opment and commerc|a||sat|on of
||vestock re|ated hea|th products and feed/feed add|t|ves.
4. Aquacu|ture b|otechno|ogy |nc|udes the breed|ng of mar|ne and fresh water f|shes t||ap|a,
grouper, sturgeons, etc}, crustaceans shr|mps, oysters, |obsters, crabs} as we|| as the
cultivation of algae for feed and other downstream activities. Aquaculture biotechnology will
a|so |nc|ude the research, deve|opment and commerc|a||sat|on of aqua re|ated hea|th
products and feed/feed add|t|ves.
Biofertiliser ln 2011, B|ofert|||ser compan|es cont|nued to expand the|r market share
|n the Asean/As|an reg|on where products were exported to lndones|a,
Vietnam and India. This included specialty products meant for different
applications such as root enhancement and pest control.
The biofertiliser sector contributed the largest revenue among the
B|oNexus Status compan|es, at approx|mate|y RM 193.4 m||||on.
Due to market demands and the deve|opment of new product ||nes,
biofertiliser companies continued to expand through land acquisitions
and production facilities.
Key Results
62
Tissue culture/micro
propagation
In 2011, other than supplying tissue cultured crop plants, tissue culture
companies have strived to increase their market share especially through
the supply of tissue cultured ornamental plants to landscaping projects
in Malaysia and in the Asean region.
Seed Production In 2011, progress was achieved to transform Malaysia into a tropical seed
production hub using marker assisted selection techniques.
Under Malaysias Economic Transformation Programmes Agriculture
National Key Economic Area (NKEA) entry point project (EPP) 4, Green
World Genetics Sdn Bhd (a BioNexus Status company) has successfully
signed a Collaboration and Scientific Services Agreement with the
Malaysian Agricultural and Research Development Institute (MARDI)s
Centre for Molecular Marker Development and Validation to expand their
development and validation of tropical hybrid seed production utilising
molecular markers. The crops will include watermelon, chillies, okra, and
corn varieties (both sweet and feed corn varieties).
Livestock BiotechCorp continues to encourage the establishment of key projects
towards enhancing the development of nucleus/multiplier farms in
Malaysia, where two BioNexus Status companies namely Kris Biotech
Sdn Bhd and Falcon Livestock Sdn Bhd have secured contracts with the
Department of Veterinary Services (DVS) to provide breeding services
using artificial reproduction systems to local cattle and goat farmers,
under the EPP 5 initiatives (NKEA Agriculture).
Aquaculture Since 2010, the Aquaculture sector in Malaysia has been growing
exponentially, evident not only in the number of BioNexus Status
companies, but also in attracting substantial investments into this
(aquaculture biotechnology) sector.
Among the key achievements is the appointment of JEFI Aquatech
Resources Sdn Bhd, a BioNexus Status company, as an anchor company
under EPP 4 (NKEA Agriculture) with a total approved investment of
RM375 million.
Projects Carried Out in 2011
In 2011, 15 companies were awarded the BioNexus Status in the various sub-sectors within
the Agriculture Biotechnology sector, as follows:
Biogrowth Sdn
Bhd
30% Singapore:
70% Malaysia
This Johor based company is involved in the
commercialisation of high quality fruits, orchids,
forestry tree species and ornamental plantlets
production through tissue culture and its related
research and development (R&D) activities. The
company is looking to expand its market in the
Asean region starting with Laos.
No Company Origin (FDI / DDI) Activity & Achievements
1
Genomic Biotech
Sdn Bhd
DDI This Johor based company is involved in the
commercialisation of high quality planting materials
production through tissue culture techniques and
will undertake related R&D activities. The company
is currently producing bananas to supply to their
parent company which is involved in banana
plantations.
2
Falcon Livestock
(NS) Sdn Bhd
DDI This Negeri Sembilan based company is involved in
the commercialisation of livestock breeding utilising
biotechnology tools and will undertake related R&D
activities. The company has been appointed as an
artificial reproduction services provider through DVS
under EPP 5 for DVS related farms.
3
Bionestro Sdn Bhd DDI This Perak based company is involved in the
commercialisation of prawn fry production through
its integrated Specific-Pathogen Free (SPF) facility
and will undertake its related R&D activities. The
company will supply their post larvae (PL) to their
parent company Manjung Aquatic Sdn Bhd as well
as to contract farmers to ensure the production of
quality shrimps.
4
Nu-Trino Synbio
(M) Sdn Bhd
DDI This Selangor based company is involved in the
commercialisation of animal feed additives and its
related R&D activities. Its technology is licensed
from Universiti Putra Malaysia (UPM). The company
has commenced construction of its facility in the
second quarter of 2011.
5
63
Tissue culture/micro
propagation
In 2011, other than supplying tissue cultured crop plants, tissue culture
companies have strived to increase their market share especially through
the supply of tissue cultured ornamental plants to landscaping projects
in Malaysia and in the Asean region.
Seed Production In 2011, progress was achieved to transform Malaysia into a tropical seed
production hub using marker assisted selection techniques.
Under Malaysias Economic Transformation Programmes Agriculture
National Key Economic Area (NKEA) entry point project (EPP) 4, Green
World Genetics Sdn Bhd (a BioNexus Status company) has successfully
signed a Collaboration and Scientific Services Agreement with the
Malaysian Agricultural and Research Development Institute (MARDI)s
Centre for Molecular Marker Development and Validation to expand their
development and validation of tropical hybrid seed production utilising
molecular markers. The crops will include watermelon, chillies, okra, and
corn varieties (both sweet and feed corn varieties).
Livestock BiotechCorp continues to encourage the establishment of key projects
towards enhancing the development of nucleus/multiplier farms in
Malaysia, where two BioNexus Status companies namely Kris Biotech
Sdn Bhd and Falcon Livestock Sdn Bhd have secured contracts with the
Department of Veterinary Services (DVS) to provide breeding services
using artificial reproduction systems to local cattle and goat farmers,
under the EPP 5 initiatives (NKEA Agriculture).
Aquaculture Since 2010, the Aquaculture sector in Malaysia has been growing
exponentially, evident not only in the number of BioNexus Status
companies, but also in attracting substantial investments into this
(aquaculture biotechnology) sector.
Among the key achievements is the appointment of JEFI Aquatech
Resources Sdn Bhd, a BioNexus Status company, as an anchor company
under EPP 4 (NKEA Agriculture) with a total approved investment of
RM375 million.
In 2011, 15 companies were awarded the BioNexus Status in the various sub-sectors within
the Agriculture Biotechnology sector, as follows:
Biogrowth Sdn
Bhd
30% Singapore:
70% Malaysia
commercialisation of high quality fruits, orchids,
forestry tree species and ornamental plantlets
production through tissue culture and its related
research and development (R&D) activities. The
company is looking to expand its market in the
Asean region starting with Laos.
1
Genomic Biotech
Sdn Bhd
commercialisation of high quality planting materials
production through tissue culture techniques and
will undertake related R&D activities. The company
is currently producing bananas to supply to their
parent company which is involved in banana
plantations.
2
Falcon Livestock
(NS) Sdn Bhd
DDI This Negeri Sembilan based company is involved in
the commercialisation of livestock breeding utilising
biotechnology tools and will undertake related R&D
activities. The company has been appointed as an
artificial reproduction services provider through DVS
under EPP 5 for DVS related farms.
3
Bionestro Sdn Bhd DDI This Perak based company is involved in the
commercialisation of prawn fry production through
its integrated Specific-Pathogen Free (SPF) facility
and will undertake its related R&D activities. The
company will supply their post larvae (PL) to their
parent company Manjung Aquatic Sdn Bhd as well
as to contract farmers to ensure the production of
quality shrimps.
4
Nu-Trino Synbio
(M) Sdn Bhd
commercialisation of animal feed additives and its
related R&D activities. Its technology is licensed
from Universiti Putra Malaysia (UPM). The company
has commenced construction of its facility in the
second quarter of 2011.
5
64
Next Steps for Agricultural Biotechnology:
Moving forward, BiotechCorp intends to carry out the following activities:
To position the Malaysian agriculture biotechnology sector as the key driver for Malaysia
to become a global high income nation, through the establishment of a sustainable
ecosystem for R&D and commercialisation in the area of agriculture, leveraging on all
existing tropical agricultural resources.
To address the nat|ona| feed/food secur|ty and safety through the var|ous EPPs under the
NKEAs of the ETP, where key sectors such as aquacu|ture, ||vestock and the deve|opment
of genetic materials are supported and facilitated.
To cont|nue to ass|st/support mu|t|-nat|ona| compan|es, espec|a||y those |n the
agr|-b|otech sector to estab||sh co||aborat|ons, jo|nt-ventures, and |nvestments |n the
Malaysian agriculture sector.
To cont|nue nurtur|ng |oca| both ex|st|ng and future} B|oNexus compan|es to expand the|r
market share in Malaysia and globally through strategic marketing strategies. This will
include providing funding avenues for expansion and product development to meet
|nternat|ona| requ|rements as we|| as key ||nkages to the g|oba| p|atform.
KHL Herbal
Biotech Sdn Bhd
DDI This Kuala Lumpur based company is involved in the
commercialisation of natural products from herbal
extracts, |n|t|a||y from Panax g|nseng and w|||
undertake related R&D activities.
13
RE M|||enn|um
Sdn Bhd
commercialisation of marine fish and its fingerlings
and will undertake related R&D activities.
14
Wibawa Biotech
Sdn Bhd
DDI Th|s Perak based company |s |nvo|ved |n the
commerc|a||sat|on of mono-sex t||ap|a f|sh and fry
and will undertake related R&D activities. The
company is working closely with their counterparts
in Thailand to enhance their brood stock development
and feed improvement.
15
Vigor Agribiotech
Solutions
Sdn Bhd
30% Singapore:
70% Malaysia
commercialisation of microbial based biofertiliser for
agricultural applications and related R&D activities.
The company is currently planning to expand its
production to penetrate the Borneo market.
6
JQ Biotech Sdn
Bhd
DDI This Sarawak based company is involved in the
research, deve|opment and commerc|a||sat|on R,
D&O} of |oca| m|crob|a| based b|ofert|||sers for the o||
palm industry.
7
Darvel Bay Sdn
Bhd
DDI This Sabah based company is involved in the
company is collaborating with Yayasan Sabah to
supp|y qua||ty f|nger||ngs for farmers under the
Yayasan Sabah community farming programme.
8
Persona Kosmet|k
Sdn Bhd
commercialisation of cosmeceutical products
produced from local herbs and medicinal plants
using advanced bioscience technology and will
9
AquaGems B|o
Sdn Bhd
DDI Th|s Penang based company |s |nvo|ved |n the
commercialisation of Arowana and other ornamental
fish species utilising biotechnology techn|ques such
as molecular markers and will undertake related
R&D activities to ensure the sustainability of
Ma|ays|a`s rare and endangered Go|den and Nam|
arowana varieties.
10
Algae
International
Sdn Bhd
55% Malaysian
45% Australian
This Negeri Sembilan based company which is a
Technofund graduate is involved in the cultivation
and commercialisation of Spirulina as biomass
using the Fluid Bed Method and will undertake
related R&D activities.
11
B|o-Fert|
Sdn Bhd
commercialisation of tissue culture products and will
undertake related R&D activities. The company is
also involved in the provision of contract research
services for tissue culture protocol development.
12
65
Next Steps for Agricultural Biotechnology:
Moving forward, BiotechCorp intends to carry out the following activities:
To position the Malaysian agriculture biotechnology sector as the key driver for Malaysia
to become a global high income nation, through the establishment of a sustainable
ecosystem for R&D and commercialisation in the area of agriculture, leveraging on all
existing tropical agricultural resources.
To address the nat|ona| feed/food secur|ty and safety through the var|ous EPPs under the
NKEAs of the ETP, where key sectors such as aquacu|ture, ||vestock and the deve|opment
of genetic materials are supported and facilitated.
To cont|nue to ass|st/support mu|t|-nat|ona| compan|es, espec|a||y those |n the
agr|-b|otech sector to estab||sh co||aborat|ons, jo|nt-ventures, and |nvestments |n the
Malaysian agriculture sector.
To cont|nue nurtur|ng |oca| both ex|st|ng and future} B|oNexus compan|es to expand the|r
market share in Malaysia and globally through strategic marketing strategies. This will
include providing funding avenues for expansion and product development to meet
|nternat|ona| requ|rements as we|| as key ||nkages to the g|oba| p|atform.
KHL Herbal
Biotech Sdn Bhd
DDI This Kuala Lumpur based company is involved in the
commercialisation of natural products from herbal
extracts, |n|t|a||y from Panax g|nseng and w|||
13
RE M|||enn|um
Sdn Bhd
and will undertake related R&D activities.
14
Wibawa Biotech
Sdn Bhd
DDI Th|s Perak based company |s |nvo|ved |n the
commerc|a||sat|on of mono-sex t||ap|a f|sh and fry
company is working closely with their counterparts
in Thailand to enhance their brood stock development
and feed improvement.
15
Vigor Agribiotech
Solutions
Sdn Bhd
30% Singapore:
70% Malaysia
commercialisation of microbial based biofertiliser for
agricultural applications and related R&D activities.
The company is currently planning to expand its
production to penetrate the Borneo market.
6
JQ Biotech Sdn
Bhd
DDI This Sarawak based company is involved in the
research, deve|opment and commerc|a||sat|on R,
D&O} of |oca| m|crob|a| based b|ofert|||sers for the o||
palm industry.
7
Darvel Bay Sdn
Bhd
DDI This Sabah based company is involved in the
company is collaborating with Yayasan Sabah to
supp|y qua||ty f|nger||ngs for farmers under the
Yayasan Sabah community farming programme.
8
Persona Kosmet|k
Sdn Bhd
commercialisation of cosmeceutical products
produced from local herbs and medicinal plants
using advanced bioscience technology and will
9
AquaGems B|o
Sdn Bhd
DDI Th|s Penang based company |s |nvo|ved |n the
commercialisation of Arowana and other ornamental
fish species utilising biotechnology techn|ques such
as molecular markers and will undertake related
R&D activities to ensure the sustainability of
Ma|ays|a`s rare and endangered Go|den and Nam|
arowana varieties.
10
Algae
International
Sdn Bhd
55% Malaysian
45% Australian
This Negeri Sembilan based company which is a
Technofund graduate is involved in the cultivation
and commercialisation of Spirulina as biomass
using the Fluid Bed Method and will undertake
related R&D activities.
11
B|o-Fert|
Sdn Bhd
commercialisation of tissue culture products and will
undertake related R&D activities. The company is
also involved in the provision of contract research
services for tissue culture protocol development.
12
66
HEALTHCARE BIOTECHNOLOGY
As the global economy is clearly on the mend in 2011, this has impacted the healthcare
biotechnology in Malaysia. The medical/healthcare segment remained to be one of the most
lucrative segments for the global biotechnology market, generating approximately 70% of the
markets overall revenue.
BiotechCorp continues to be strategically focused on approved investments targeting
local, foreign and multinational/global companies, knowledge workers and creating revenue
potential for revenue generation efforts. Action plans drawn are set to intensify the nurturing
efforts and business development initiatives, with an objective to maximise results whilst
maintaining a competitive advantage our regional competitors.
In terms of focus areas, market projections have been positive for biopharmaceuticals both
for biosimilars and biobetters, Contract Manufacturing Organisations (CMO), medical devices
and Contract Research Organisations. The pharmaceutical industry remains attractive to
foreign investment, due to growth in demand driven by the emerging economies.
Focus Areas
1. Biopharmaceuticals
2. Pharmaceuticals
3. Contract Manufacturing Organisation/Contract Research Organisation
4. High Value Medical Devices/In-Vitro Diagnostics
Total Capital
Investment
In 2011, BDI Healthcare (BDI-H) successfully engaged a total of 26
projects approved with total capital investment amounting to RM2.46
billion. Focus was given to multinational companies and companies
from emerging markets within BDI Healthcares areas of interest. The
biggest chunk of investment came from the United States of America
(USA) with 67% of the total capital investment. Local investment was the
second biggest contributor at 20.8%, followed by India at 8.4%.
BiotechCorp is the principal agency for attracting foreign and domestic
direct investments in biotechnology to Malaysia. BiotechCorp provides
the BioNexus incentives, in addition to facilitating biotech companies in
obtaining customised incentives from Economic Council (EC) and
Malaysian Industrial Development Authority (MIDA) incentives. In 2011,
there were two approved Healthcare projects for BioNexus Status, two
approved projects from MIDA and one customised incentives from EPU
(under the Public-Private Partnership initiative).
Job creation The total capital investment of approved projects has resulted in the
creation of employment opportunities for 712 knowledge workers in 2011.
Nurturing of healthcare
biotech companies
BDI Healthcare is mandated to nurture local companies business
growth, in terms of revenue generation and contribution to the nations
gross domestic product (GDP).
We have nurtured 47 Healthcare Biotechnology companies, mostly
comprising of BioNexus Status companies in generating revenue of
RM180.76 million in 2011. As at 31 December 2011, there are 72 BioNexus
Status companies in Healthcare Biotechnology.
Foreign Direct
Investment (FDI)
In 2011, BDI Healthcare targeted specific global multinational corporations
(MNCs) to secure foreign direct investments and projects. As a result of this
initiative, significant foreign biopharmaceuticals and pharmaceutical
companies with significant investment of RM2.456 billion have started to
set up their operations in Malaysia.
Part of the strategy for BDI Healthcare in attracting Foreign Direct
Investments (FDI) is by targeting multinational corporations (MNCs) from
both emerging and established markets. For example, on 17 June 2011,
AMC Life Sciences in collaboration with Johns Hopkins Medicine and Royal
College of Surgeons, Ireland announced a world class medical centre and
university in Kuala Lumpur. The Perdana University Initiative is part of the
Kuala Lumpur Academic Medical Centre (AMC) which is a proposed
development for a centre of excellence for medicine in Malaysia. The AMC
will be a custom built medical campus primarily comprising of a 600-bed
private hospital, a research centre, and Perdana University - incorporating
an undergraduate medical programme run by RCSI and a graduate entry
programme run by Johns Hopkins Medicine, Baltimore, US.
The AMC is a high profile project for Malaysia, being one of its first public
private partnerships with the Government. The project will cost over 500M
The overall project was launched under the patronage of the Prime Minister
of Malaysia, Yang Amat Berhormat Dato Seri Najib Tun Razak in
November 2010.
Key Results
67
HEALTHCARE BIOTECHNOLOGY
As the global economy is clearly on the mend in 2011, this has impacted the healthcare
biotechnology in Malaysia. The medical/healthcare segment remained to be one of the most
lucrative segments for the global biotechnology market, generating approximately 70% of the
markets overall revenue.
BiotechCorp continues to be strategically focused on approved investments targeting
local, foreign and multinational/global companies, knowledge workers and creating revenue
potential for revenue generation efforts. Action plans drawn are set to intensify the nurturing
efforts and business development initiatives, with an objective to maximise results whilst
maintaining a competitive advantage our regional competitors.
In terms of focus areas, market projections have been positive for biopharmaceuticals both
for biosimilars and biobetters, Contract Manufacturing Organisations (CMO), medical devices
and Contract Research Organisations. The pharmaceutical industry remains attractive to
foreign investment, due to growth in demand driven by the emerging economies.
Focus Areas
1. Biopharmaceuticals
2. Pharmaceuticals
3. Contract Manufacturing Organisation/Contract Research Organisation
4. High Value Medical Devices/In-Vitro Diagnostics
Total Capital
Investment
In 2011, BDI Healthcare (BDI-H) successfully engaged a total of 26
projects approved with total capital investment amounting to RM2.46
billion. Focus was given to multinational companies and companies
from emerging markets within BDI Healthcares areas of interest. The
biggest chunk of investment came from the United States of America
(USA) with 67% of the total capital investment. Local investment was the
second biggest contributor at 20.8%, followed by India at 8.4%.
BiotechCorp is the principal agency for attracting foreign and domestic
direct investments in biotechnology to Malaysia. BiotechCorp provides
the BioNexus incentives, in addition to facilitating biotech companies in
obtaining customised incentives from Economic Council (EC) and
Malaysian Industrial Development Authority (MIDA) incentives. In 2011,
there were two approved Healthcare projects for BioNexus Status, two
approved projects from MIDA and one customised incentives from EPU
(under the Public-Private Partnership initiative).
Job creation The total capital investment of approved projects has resulted in the
creation of employment opportunities for 712 knowledge workers in 2011.
Nurturing of healthcare
biotech companies
BDI Healthcare is mandated to nurture local companies business
growth, in terms of revenue generation and contribution to the nations
gross domestic product (GDP).
We have nurtured 47 Healthcare Biotechnology companies, mostly
comprising of BioNexus Status companies in generating revenue of
RM180.76 million in 2011. As at 31 December 2011, there are 72 BioNexus
Status companies in Healthcare Biotechnology.
Foreign Direct
Investment (FDI)
In 2011, BDI Healthcare targeted specific global multinational corporations
(MNCs) to secure foreign direct investments and projects. As a result of this
initiative, significant foreign biopharmaceuticals and pharmaceutical
companies with significant investment of RM2.456 billion have started to
set up their operations in Malaysia.
Part of the strategy for BDI Healthcare in attracting Foreign Direct
Investments (FDI) is by targeting multinational corporations (MNCs) from
both emerging and established markets. For example, on 17 June 2011,
AMC Life Sciences in collaboration with Johns Hopkins Medicine and Royal
College of Surgeons, Ireland announced a world class medical centre and
university in Kuala Lumpur. The Perdana University Initiative is part of the
Kuala Lumpur Academic Medical Centre (AMC) which is a proposed
development for a centre of excellence for medicine in Malaysia. The AMC
will be a custom built medical campus primarily comprising of a 600-bed
private hospital, a research centre, and Perdana University - incorporating
an undergraduate medical programme run by RCSI and a graduate entry
programme run by Johns Hopkins Medicine, Baltimore, US.
The AMC is a high profile project for Malaysia, being one of its first public
private partnerships with the Government. The project will cost over 500M
The overall project was launched under the patronage of the Prime Minister
of Malaysia, Yang Amat Berhormat Dato Seri Najib Tun Razak in
November 2010.
Key Results
68
Collaboration with other
agencies and leveraging
on their expertise e.g.
MIDA, PEMANDU, State
Agencies (JSIC)
Performance,
Management and Delivery
Unit (PEMANDU)
PEMANDU Healthcare
NKEA Medical Devices
Entry Point Projects
(EPPs)
Working closely with other sister agencies such as Malaysian Industrial
Development Authority (MIDA) has helped BDI Healthcare in closing
several high impact projects in the recent years. BDI Healthcare continues
to leverage on their manufacturing expertise and attractive incentives,
specifically for high capital investment manufacturing projects. As for
State Agencies such as JSIC and NCIA, BDI Healthcare will need to work
closely for land availability and fit-out business models to be proposed to
potential investors and corporations.
In 2011, the Ministry of Health in collaboration with PEMANDU has
announced the addition of seven (7) new EPPs under the Healthcare
NKEA. They are:
EPP 7: Tap into the fast-growing In-Vitro Diagnostics (IVD) market
through academic-industry partnerships
EPP 8: Create next generation of single-use devices (SUD)
EPP 9: Build hub for high-value medical device contract manufacturing
EPP 10: Create Malaysian clinical devices champions
EPP 11: Orchestrate contract manufacturing supply chain
EPP 12: Medical equipment refurbishment hub
EPP 13: Build medical hardware and furniture cluster
PEMANDU labs are good platforms for BDI Healthcare to propose
potential projects for the Governments uptake and implementation. In
addition, the Medical Devices EPPs are seen as a significant opportunity,
in view of the ASEANs Medical Devices Harmonisation that will be
implemented soon. There is increasing importance of diagnostics for
monitoring, testing and predicting as global healthcare shifts from 'sickness'
to 'wellness'.
Agila Specialties
(M) Sdn Bhd
India (FDI) Established Sterile Formulation, Fill & Finish Facility
and Biosimilars Project.
No Company Origin Nature of Business
1
Esclapeus
Genomics Sdn
Bhd
USA (FDI) Commercialisation of genomic-based services and
biomarkers for personalised medicine.
2
B-Crobes Sdn
Bhd
Taiwan/Australia
(FDI)
Commercialisation of bacteria strain BCMC-New
Strain for management of hypercholesterolemia.
3
Aurigene
Discovery
Technologies (M)
Sdn Bhd
India (FDI) Provision of analytical research and development
(R&D) services for drug discovery and development.
4
Cheminnova
Remedies
Pvt Ltd
India (FDI) Manufacturing of processed Active Pharmaceutical
Ingredients (API) in the form of granulates.
5
AMC Life
Science-Perdana
Life Sciences
Research Centre
&Technopark
(Johns Hopkins)
USA (FDI) Research program collaboration between Johns
Hopkins with Perdana University directed for
discovery and translation of prevention and
treatment strategies
- It includes translational and clinical research
facilities and capabilities.
6
GeneNews
Diagnostics
Sdn Bhd
Canada (FDI) Research, development and commercialisation
(R,D&C) of blood-based diagnostics for the detection
of colorectal cancer.
7
Aseacyte Sdn
Bhd
United Kingdom
(FDI)
Joint venture/partnership with Avanticell, Cancer
Research Initiatives Foundation (CARIF) and Sime
Darby Bhd in chemical analysis to complement
companys cell-based analysis, to form an integrated
service for the evaluation of natural products as
potential new therapeutics.
8
Eurocor Asia
Sdn Bhd
Singapore (FDI) Manufacturing of Cardiac stents (Percutaneous
Trans-lumnial Coronary Angioplasty and Percutaneous
Trans-luminal Angioplasty Cathethers).
9
Opto Circuits (M)
Sdn Bhd
Singapore (FDI) Manufacturing of cardiac catheters, cardiac stents,
patients monitors and orthopaedic implants.
10
GMMI Sdn Bhd Germany (FDI) Manufacturing, marketing and R&D of single-use
medical endoscopy products.
11
MOSTDI
Innovations Sdn
Bhd
Singapore (FDI) R,D&C of mini dental implants. 12
69
Collaboration with other
agencies and leveraging
on their expertise e.g.
MIDA, PEMANDU, State
Agencies (JSIC)
Performance,
Management and Delivery
Unit (PEMANDU)
PEMANDU Healthcare
NKEA Medical Devices
Entry Point Projects
(EPPs)
Working closely with other sister agencies such as Malaysian Industrial
Development Authority (MIDA) has helped BDI Healthcare in closing
several high impact projects in the recent years. BDI Healthcare continues
to leverage on their manufacturing expertise and attractive incentives,
specifically for high capital investment manufacturing projects. As for
State Agencies such as JSIC and NCIA, BDI Healthcare will need to work
closely for land availability and fit-out business models to be proposed to
potential investors and corporations.
In 2011, the Ministry of Health in collaboration with PEMANDU has
announced the addition of seven (7) new EPPs under the Healthcare
NKEA. They are:
EPP 7: Tap into the fast-growing In-Vitro Diagnostics (IVD) market
through academic-industry partnerships
EPP 8: Create next generation of single-use devices (SUD)
EPP 9: Build hub for high-value medical device contract manufacturing
EPP 10: Create Malaysian clinical devices champions
EPP 11: Orchestrate contract manufacturing supply chain
EPP 12: Medical equipment refurbishment hub
EPP 13: Build medical hardware and furniture cluster
PEMANDU labs are good platforms for BDI Healthcare to propose
potential projects for the Governments uptake and implementation. In
addition, the Medical Devices EPPs are seen as a significant opportunity,
in view of the ASEANs Medical Devices Harmonisation that will be
implemented soon. There is increasing importance of diagnostics for
monitoring, testing and predicting as global healthcare shifts from 'sickness'
to 'wellness'.
Agila Specialties
(M) Sdn Bhd
India (FDI) Established Sterile Formulation, Fill & Finish Facility
and Biosimilars Project.
1
Esclapeus
Genomics Sdn
Bhd
USA (FDI) Commercialisation of genomic-based services and
biomarkers for personalised medicine.
2
B-Crobes Sdn
Bhd
Taiwan/Australia
(FDI)
Commercialisation of bacteria strain BCMC-New
Strain for management of hypercholesterolemia.
3
Aurigene
Discovery
Technologies (M)
Sdn Bhd
India (FDI) Provision of analytical research and development
(R&D) services for drug discovery and development.
4
Cheminnova
Remedies
Pvt Ltd
India (FDI) Manufacturing of processed Active Pharmaceutical
Ingredients (API) in the form of granulates.
5
AMC Life
Science-Perdana
Life Sciences
Research Centre
&Technopark
(Johns Hopkins)
USA (FDI) Research program collaboration between Johns
Hopkins with Perdana University directed for
discovery and translation of prevention and
treatment strategies
- It includes translational and clinical research
facilities and capabilities.
6
GeneNews
Diagnostics
Sdn Bhd
Canada (FDI) Research, development and commercialisation
(R,D&C) of blood-based diagnostics for the detection
of colorectal cancer.
7
Aseacyte Sdn
Bhd
United Kingdom
(FDI)
Joint venture/partnership with Avanticell, Cancer
Research Initiatives Foundation (CARIF) and Sime
Darby Bhd in chemical analysis to complement
companys cell-based analysis, to form an integrated
service for the evaluation of natural products as
potential new therapeutics.
8
Eurocor Asia
Sdn Bhd
Singapore (FDI) Manufacturing of Cardiac stents (Percutaneous
Trans-lumnial Coronary Angioplasty and Percutaneous
Trans-luminal Angioplasty Cathethers).
9
Opto Circuits (M)
Sdn Bhd
Singapore (FDI) Manufacturing of cardiac catheters, cardiac stents,
patients monitors and orthopaedic implants.
10
GMMI Sdn Bhd Germany (FDI) Manufacturing, marketing and R&D of single-use
medical endoscopy products.
11
MOSTDI
Innovations Sdn
Bhd
Singapore (FDI) R,D&C of mini dental implants. 12
70
Next Steps for Healthcare Biotechnology:
In bringing further growth to the industrial healthcare segment, BiotechCorp will focus on the
following areas moving forward:
In line with the goals of the National Biotechnology Policy (NBP) Phase II, one of the key
objectives is to promote healthcare biotechnology industrys growth through attracting
international and domestic investments, creating employment opportunities and
contribution to the nations GDP via revenue generation.
Efforts are |ntens|f|ed to secure h|gh va|ue |nvestment |nto Ma|ays|a by |dent|fy|ng
MNO/g|oba| compan|es. Targeted MNOs have been |dent|f|ed for h|gh |mpact projects,
promot|ng |nvestment |nto Ma|ays|a by so||d|fy|ng Ma|ays|a`s pos|t|on as a reg|ona| hub.
BDl Hea|thcare w||| be assess|ng opportun|t|es |n deve|oped and emerg|ng markets.
Targeted compan|es are sought through |dent|f|cat|on of key market and new emerg|ng
markets. Development of innovative business models to suit the opportunities identified in
developed or emerging markets would also be one of the strategies implemented.
For the growth of the |oca| b|otechno|ogy |ndustry, re|nvestment opportun|t|es w||| be
promoted among BioNexus companies, in addition to identifying and promoting spin-off
companies from BioNexus. Biotechnology opportunities will also be promoted to
Ma|ays|an |nvestors and major |oca| corporat|ons, bes|des deve|op|ng act|on p|an to work
with other local government investment agencies. Promoting BioNexus companies to the
|nvestors w||| be another strategy |n secur|ng |nvestment. BDl Hea|thcare w||| cont|nue to
play a major role in coordinating business matching between foreign companies and local
companies in looking for collaboration opportunities.
Evo B|otec Sdn
Bhd
Ma|ays|a DDl} Development and commercialisation of an innovative
drug e|ut|ng coat|ng techno|ogy for coat|ng on PTOA
De||very Systems.
24
Orthomedic
lnnovat|ons Sdn
Bhd
Ma|ays|a DDl} R,D&C of orthopaedic medical devices for the
healthcare industry.
25
Amcare Biotech
Research Sdn
Bhd
SA FDl} Clinical reference laboratory offering specialised
services in laboratory medicine.
13
Strov| Te| Sdn
Bhd
Ma|ays|a DDl} Undertakes the development, operations, and
ma|ntenance of the f|rst Nat|ona| P|asma Fract|onat|on
P|ant |n Ma|ays|a.
14
MySMO Sdn Bhd Ma|ays|a DDl} Provides full-range of Phase II - IV clinical research
serv|ces to Pharmaceut|ca| and Med|ca| Techno|ogy
Industry.
15
Natureceuticals
Sdn Bhd
Ma|ays|a DDl} Commercialisation of natural products ("misai
kucing") that mainly target angiogenesis related
ailments.
16
M Pharmauj|
Sdn Bhd
Ma|ays|a DDl} Drug discovery and development. 17
OOM-|onza Ma|ays|a DDl} Estab||shment of an onco|ogy drug manufactur|ng
facility.
18
Royal Birds Nest
Sdn Bhd
Ma|ays|a DDl} R,D&C on edible birds nest based pharmaceuticals,
neutraceuticals, and cosmeticeuticals. Conducts
clinical studies on standardised edible-birdnest
extracts for therapeutic application in wound
healing, stroke, osteoarthritis, and cosmetics.
19
Redhacare
B|o|abs Sdn Bhd
Ma|ays|a DDl} Provides full-range of Phase II - IV clinical research
Industry.
20
Fjord D|agnost|cs Ma|ays|a DDl} R,D&C of cell-based medical diagnostic products
and its consumables.
21
Hyg|e|a lnnovat|on
Sdn Bhd
Ma|ays|a DDl} The company |s undertak|ng denta| pu|p stem ce||
banking and R&D activities.
22
Biotech
Diagnostics
Ma|ays|a DDl} The company |s deve|op|ng an ant|body based
diagnostic kit for detection of Clostridium difficile (C.
Difficile) toxins in the faecal specimens of diarrhoea
patients.
23
71
Next Steps for Healthcare Biotechnology:
In bringing further growth to the industrial healthcare segment, BiotechCorp will focus on the
following areas moving forward:
In line with the goals of the National Biotechnology Policy (NBP) Phase II, one of the key
objectives is to promote healthcare biotechnology industrys growth through attracting
international and domestic investments, creating employment opportunities and
contribution to the nations GDP via revenue generation.
Efforts are |ntens|f|ed to secure h|gh va|ue |nvestment |nto Ma|ays|a by |dent|fy|ng
MNO/g|oba| compan|es. Targeted MNOs have been |dent|f|ed for h|gh |mpact projects,
promot|ng |nvestment |nto Ma|ays|a by so||d|fy|ng Ma|ays|a`s pos|t|on as a reg|ona| hub.
BDl Hea|thcare w||| be assess|ng opportun|t|es |n deve|oped and emerg|ng markets.
Targeted compan|es are sought through |dent|f|cat|on of key market and new emerg|ng
markets. Development of innovative business models to suit the opportunities identified in
developed or emerging markets would also be one of the strategies implemented.
For the growth of the |oca| b|otechno|ogy |ndustry, re|nvestment opportun|t|es w||| be
promoted among BioNexus companies, in addition to identifying and promoting spin-off
companies from BioNexus. Biotechnology opportunities will also be promoted to
Ma|ays|an |nvestors and major |oca| corporat|ons, bes|des deve|op|ng act|on p|an to work
with other local government investment agencies. Promoting BioNexus companies to the
|nvestors w||| be another strategy |n secur|ng |nvestment. BDl Hea|thcare w||| cont|nue to
play a major role in coordinating business matching between foreign companies and local
companies in looking for collaboration opportunities.
Evo B|otec Sdn
Bhd
Ma|ays|a DDl} Development and commercialisation of an innovative
drug e|ut|ng coat|ng techno|ogy for coat|ng on PTOA
De||very Systems.
24
Orthomedic
lnnovat|ons Sdn
Bhd
Ma|ays|a DDl} R,D&C of orthopaedic medical devices for the
healthcare industry.
25
Amcare Biotech
Research Sdn
Bhd
SA FDl} Clinical reference laboratory offering specialised
services in laboratory medicine.
13
Strov| Te| Sdn
Bhd
Ma|ays|a DDl} Undertakes the development, operations, and
ma|ntenance of the f|rst Nat|ona| P|asma Fract|onat|on
P|ant |n Ma|ays|a.
14
MySMO Sdn Bhd Ma|ays|a DDl} Provides full-range of Phase II - IV clinical research
Industry.
15
Natureceuticals
Sdn Bhd
Ma|ays|a DDl} Commercialisation of natural products ("misai
kucing") that mainly target angiogenesis related
ailments.
16
M Pharmauj|
Sdn Bhd
Ma|ays|a DDl} Drug discovery and development. 17
OOM-|onza Ma|ays|a DDl} Estab||shment of an onco|ogy drug manufactur|ng
facility.
18
Royal Birds Nest
Sdn Bhd
Ma|ays|a DDl} R,D&C on edible birds nest based pharmaceuticals,
neutraceuticals, and cosmeticeuticals. Conducts
clinical studies on standardised edible-birdnest
extracts for therapeutic application in wound
healing, stroke, osteoarthritis, and cosmetics.
19
Redhacare
B|o|abs Sdn Bhd
Ma|ays|a DDl} Provides full-range of Phase II - IV clinical research
Industry.
20
Fjord D|agnost|cs Ma|ays|a DDl} R,D&C of cell-based medical diagnostic products
and its consumables.
21
Hyg|e|a lnnovat|on
Sdn Bhd
Ma|ays|a DDl} The company |s undertak|ng denta| pu|p stem ce||
banking and R&D activities.
22
Biotech
Diagnostics
Ma|ays|a DDl} The company |s deve|op|ng an ant|body based
diagnostic kit for detection of Clostridium difficile (C.
Difficile) toxins in the faecal specimens of diarrhoea
patients.
23
72
For more details on Malaysian Biotechnology Industry, reference materials include:
1) UNCTAD World Investment Report 2011
2) Asia Pacific Biotechnology Market (2008-2012)
3) RMK-9 Industry Score Card Report (2011)
4) Business Insights 2010
5) PricewaterhouseCoopers Report
6) Datamonitor Biotechnology in Asia Pacific 2010
7) Biotechnological Innovations in Asia: Policy & Governance Challenges (Paper for IDRC)
8) Frost & Sullivan Report 2009/2010
9) Episcom, 2008
10) BioWorld
INDUSTRIAL BIOTECHNOLOGY
Industrial biotechnology (IB) is a key technology for future economic development. Touted as
one of the emerging Megatrends leading to 2020, IB is now an area of growing interest and
it is expected to revolutionise the economy and social development within the next 10-15 years.
IB presents a compelling economic development opportunity for Malaysia. BiotechCorp with a
mandate to develop the IB industry strives to facilitate the growth of the industry and to further
accelerate commercialisation.
Industrial Biotechnology Strategies:
Six IB strategies have been identified to be implemented under the Commercialisation phase.
These are:-
1. Securing new investment and funding.
2. Adoption of IB as a strategic technology backbone, leveraging on the nations bioresources
and developing solutions for energy security, carbon emission reduction and environmental
protection.
3. Commercialisation which includes nurturing local IB players, initiating offshore
opportunities and internationalising these local players so they can become global
industry players.
4. Setting up of 1st generation feedstock production to meet the immediate requirements of
IB companies.
5. Securing high impact Domestic Direct Investments (DDIs).
6. Reinvestment.
Key Results
Securing new
investments
B|otechOorp has secured RM2 b||||on |ndustr|a| b|otechno|ogy
investment in the East Coast Economic Region (ECER).
The RM2 billion investment was from a Foreign Joint Venture Company
between South Koreas CJ Cheiljedang Corporation and Frances Arkema
SA to set up the Worlds First bio-methionine plant and Asias first
thiochemical platform in Kertih Polymer Park, Terengganu.

The project is expected to generate about RM20 billion in cumulative sales
by 2020 and provide employment opportunities to almost 500 knowledge
workers.
Sime Darby Bhd and Mitsui Engineering and Shipbuilding Co. Ltd
(MES) has built and will operate the Worlds First Bioethanol
Demonstration Plant using empty fruit bunches (EFB) as feedstock.
A foreign BioNexus Status company to commercialise enzyme-based
product for the cleaning and decontamination of Heating, Ventilation
and Air Conditioning (HVAC) system.
Securing high impact
Domestic Direct
Investments (DDIs)
A local BioNexus Status company in Southern Malaysia has started its
Enzymatic production of Betapol Base and eCBE (enzymatic cocoa
butter equivalents).
(a) Leverage on the
nations
bioresources
(b) As strategic
solutions to energy
security, carbon
emission reduction
(c) Environmental
protection.
Bioeconomy Initiative Malaysia (BIM) was launched by the Prime Minister
during BioMalaysia in November 2011 and BiotechCorp as secretariat to
drive the BIM. The BIMs labs to highlight areas concerning Bioeconomy
was conducted from March to April 2012.
BiotechCorp has actively engaged in discussions on biomass initiatives
with relevant agencies including Ministry of Science, Technology and
Innovation (MOSTI), Global Science and Innovation Advisory Council
(GSIAC), Agensi Inovasi Malaysia (AIM), Malaysian Industry-Government
Group for High Technology (MIGHT) and key industrial players. Subsequent
to this, biomass initiatives become the focus areas in national agenda.
Nat|ona| B|omass Strategy deve|oped by AlM was |aunched dur|ng
BioMalaysia in November 2011.
Estab||shment of MyB|omass Sdn Bhd, a spec|a| purpose veh|c|e SPv}
that will facilitate a sustainable supply of biomass.
B|otechOorp had s|gned a Strateg|c Oo||aborat|on Agreement w|th AlM
on development, promotion, facilitation and funding of innovation in
biotechnology/life sciences.
BiotechCorp had signed a Strategic Collaboration with MIGHT in
biomass initiatives.
Strategy Results
73
For more details on Malaysian Biotechnology Industry, reference materials include:
1) UNCTAD World Investment Report 2011
2) Asia Pacific Biotechnology Market (2008-2012)
3) RMK-9 Industry Score Card Report (2011)
4) Business Insights 2010
5) PricewaterhouseCoopers Report
6) Datamonitor Biotechnology in Asia Pacific 2010
7) Biotechnological Innovations in Asia: Policy & Governance Challenges (Paper for IDRC)
8) Frost & Sullivan Report 2009/2010
9) Episcom, 2008
10) BioWorld
INDUSTRIAL BIOTECHNOLOGY
Industrial biotechnology (IB) is a key technology for future economic development. Touted as
one of the emerging Megatrends leading to 2020, IB is now an area of growing interest and
it is expected to revolutionise the economy and social development within the next 10-15 years.
IB presents a compelling economic development opportunity for Malaysia. BiotechCorp with a
mandate to develop the IB industry strives to facilitate the growth of the industry and to further
accelerate commercialisation.
Industrial Biotechnology Strategies:
Six IB strategies have been identified to be implemented under the Commercialisation phase.
These are:-
1. Securing new investment and funding.
2. Adoption of IB as a strategic technology backbone, leveraging on the nations bioresources
and developing solutions for energy security, carbon emission reduction and environmental
protection.
3. Commercialisation which includes nurturing local IB players, initiating offshore
opportunities and internationalising these local players so they can become global
industry players.
4. Setting up of 1st generation feedstock production to meet the immediate requirements of
IB companies.
5. Securing high impact Domestic Direct Investments (DDIs).
6. Reinvestment.
Key Results
Securing new
investments
B|otechOorp has secured RM2 b||||on |ndustr|a| b|otechno|ogy
investment in the East Coast Economic Region (ECER).
The RM2 billion investment was from a Foreign Joint Venture Company
between South Koreas CJ Cheiljedang Corporation and Frances Arkema
SA to set up the Worlds First bio-methionine plant and Asias first
thiochemical platform in Kertih Polymer Park, Terengganu.

The project is expected to generate about RM20 billion in cumulative sales
by 2020 and provide employment opportunities to almost 500 knowledge
workers.
Sime Darby Bhd and Mitsui Engineering and Shipbuilding Co. Ltd
(MES) has built and will operate the Worlds First Bioethanol
A foreign BioNexus Status company to commercialise enzyme-based
product for the cleaning and decontamination of Heating, Ventilation
and Air Conditioning (HVAC) system.
Securing high impact
Domestic Direct
Investments (DDIs)
A local BioNexus Status company in Southern Malaysia has started its
Enzymatic production of Betapol Base and eCBE (enzymatic cocoa
butter equivalents).
(a) Leverage on the
nations
bioresources
(b) As strategic
solutions to energy
security, carbon
emission reduction
(c) Environmental
protection.
Bioeconomy Initiative Malaysia (BIM) was launched by the Prime Minister
during BioMalaysia in November 2011 and BiotechCorp as secretariat to
drive the BIM. The BIMs labs to highlight areas concerning Bioeconomy
was conducted from March to April 2012.
BiotechCorp has actively engaged in discussions on biomass initiatives
with relevant agencies including Ministry of Science, Technology and
Innovation (MOSTI), Global Science and Innovation Advisory Council
(GSIAC), Agensi Inovasi Malaysia (AIM), Malaysian Industry-Government
Group for High Technology (MIGHT) and key industrial players. Subsequent
to this, biomass initiatives become the focus areas in national agenda.
Nat|ona| B|omass Strategy deve|oped by AlM was |aunched dur|ng
BioMalaysia in November 2011.
Estab||shment of MyB|omass Sdn Bhd, a spec|a| purpose veh|c|e SPv}
that will facilitate a sustainable supply of biomass.
B|otechOorp had s|gned a Strateg|c Oo||aborat|on Agreement w|th AlM
on development, promotion, facilitation and funding of innovation in
biotechnology/life sciences.
BiotechCorp had signed a Strategic Collaboration with MIGHT in
biomass initiatives.
Strategy Results
74
ln April 2011, during the Prime Minister of Malaysia Yang Amat
Berhormat Dato Sri Najib Tun Razaks visit to the Republic of Korea, a
Memorandum of Agreement (MOA) was signed between BiotechCorp
and Korea Gas Corporation (KOGAS) to set up a demonstration plant
to produce compressed biogas and bio-dimethyl ether (DME) from
POME in Malaysia.
S|me Darby Berhad and M|tsu| Eng|neer|ng and Sh|pbu||d|ng Oo. |td
(MES) have built and are operating the Worlds First Bioethanol
One fore|gn ent|ty that has a Super Or|t|ca| techno|ogy to produce
raw sugar from empty fruit bunches (EFBs) plans to collaborate with
oil palm plantation company and set up pilot plant in Malaysia.
Reinvestment
Adopt|on of lB as a
strategic technology
backbone
The CJ Arkema project which requires steam from natural gas would be
a major initiative in reinvestment. A local company has been identified
to supply steam to CJ Arkema project using woody biomass as an
alternative solution to natural gas.
The local companys technology provides solutions to energy security,
carbon emission reduction and environmental protection.
Strategy Results
lnternat|ona||se |oca|
companies into global
players
A local BioNexus Status company has been awarded a contract by an
lndones|an pub||c ||sted pa|m-based company to set up a b|ogas p|ant |n
Ka||mantan, lndones|a. The company w||| prov|de the des|gn, supp|y,
engineering, installation, commissioning and project management of the
effluent treatment plant, complete with anaerobic digester tanks and
state-of-the-art process control system of the biogas plant. The plant will
have sophisticated monitoring equipment that facilitate comprehensive
data logging, useful for plant improvements.
The lndones|an company p|ans to use b|ogas at th|s p|ant produced from
its palm oil mill effluent to generate electricity for its palm oil mills and the
surplus supply of the electricity would be directed to the community.
Nurture |oca| lB p|ayers A |oca| B|oNexus Status company w||| prov|de b|oremed|at|on serv|ce
using an integrated microbial-based palm oil mill effluent (POME)
Treatment System (PTS). The companys technology provides solutions
to carbon emission reduction and environmental protection.
A |oca| B|oNexus Status company |n East Ma|ays|a w||| produce
sweeteners from sago starch via enzymatic process.
A |oca| B|oNexus Status company w||| produce funct|ona| beverages
utilising microbial fermentation technology.
A |oca| B|oNexus Status company p|ans to produce b|op|ast|c|ser
and resins utilising enzymatic process.
A local BioNexus Status company will produce paper using biotechnology
process.
Setting up of first
generation feedstock
production
BiotechCorp has started initiatives to source starch-based feedstocks
name|y Oassava to meet |mmed|ate needs for lB feedstocks. The
immediate requirement is for the foreign company that will commence
production in 2014.
Adopt|on of lB as a
backbone
Two fore|gn ent|t|es based |n B|o-Oe|| Park expected to commence
operation in 2013 to produce bio-based chemicals using palm-based
biomass as the feedstock.
Strategy Results
Green Access Sdn
Bhd
DDl Commercialisation of an integrated microbial-based
palm oil mill effluent (POME) Treatment System (PTS).
The company was awarded a BioNexus Status on 11
July 2011.
No
Company
Name
Project Type
(FDI / DDI)
Activity & Achievements
1
Cardia Bioplastics
Malaysia Sdn Bhd
FDl/DDl Commercialisation of bioplasticiser and resins
utilising enzymatic process.
The company was awarded a BioNexus Status on
26 August 2011.
2
75
ln April 2011, during the Prime Minister of Malaysia Yang Amat
Berhormat Dato Sri Najib Tun Razaks visit to the Republic of Korea, a
Memorandum of Agreement (MOA) was signed between BiotechCorp
and Korea Gas Corporation (KOGAS) to set up a demonstration plant
to produce compressed biogas and bio-dimethyl ether (DME) from
POME in Malaysia.
S|me Darby Berhad and M|tsu| Eng|neer|ng and Sh|pbu||d|ng Oo. |td
(MES) have built and are operating the Worlds First Bioethanol
One fore|gn ent|ty that has a Super Or|t|ca| techno|ogy to produce
raw sugar from empty fruit bunches (EFBs) plans to collaborate with
oil palm plantation company and set up pilot plant in Malaysia.
Reinvestment
Adopt|on of lB as a
backbone
The CJ Arkema project which requires steam from natural gas would be
a major initiative in reinvestment. A local company has been identified
to supply steam to CJ Arkema project using woody biomass as an
alternative solution to natural gas.
Strategy Results
lnternat|ona||se |oca|
companies into global
players
A local BioNexus Status company has been awarded a contract by an
lndones|an pub||c ||sted pa|m-based company to set up a b|ogas p|ant |n
Ka||mantan, lndones|a. The company w||| prov|de the des|gn, supp|y,
engineering, installation, commissioning and project management of the
effluent treatment plant, complete with anaerobic digester tanks and
state-of-the-art process control system of the biogas plant. The plant will
have sophisticated monitoring equipment that facilitate comprehensive
data logging, useful for plant improvements.
The lndones|an company p|ans to use b|ogas at th|s p|ant produced from
its palm oil mill effluent to generate electricity for its palm oil mills and the
surplus supply of the electricity would be directed to the community.
Nurture |oca| lB p|ayers A |oca| B|oNexus Status company w||| prov|de b|oremed|at|on serv|ce
using an integrated microbial-based palm oil mill effluent (POME)
Treatment System (PTS). The companys technology provides solutions
to carbon emission reduction and environmental protection.
A |oca| B|oNexus Status company |n East Ma|ays|a w||| produce
sweeteners from sago starch via enzymatic process.
A |oca| B|oNexus Status company w||| produce funct|ona| beverages
utilising microbial fermentation technology.
A |oca| B|oNexus Status company p|ans to produce b|op|ast|c|ser
and resins utilising enzymatic process.
A local BioNexus Status company will produce paper using biotechnology
process.
Setting up of first
generation feedstock
production
BiotechCorp has started initiatives to source starch-based feedstocks
name|y Oassava to meet |mmed|ate needs for lB feedstocks. The
immediate requirement is for the foreign company that will commence
production in 2014.
Adopt|on of lB as a
backbone
Two fore|gn ent|t|es based |n B|o-Oe|| Park expected to commence
operation in 2013 to produce bio-based chemicals using palm-based
biomass as the feedstock.
Strategy Results
Green Access Sdn
Bhd
DDl Commercialisation of an integrated microbial-based
palm oil mill effluent (POME) Treatment System (PTS).
The company was awarded a BioNexus Status on 11
July 2011.
No
Company
Name
Project Type
(FDI / DDI)
1
Cardia Bioplastics
Malaysia Sdn Bhd
FDl/DDl Commercialisation of bioplasticiser and resins
utilising enzymatic process.
26 August 2011.
2
76
Next Steps for Industrial Biotechnology:
In ensuring that the industry continues to grow, BiotechCorp intends to carry out the following
activities:
Attract more foreign direct investment (FDI) to leverage on Malaysia as a hub for their
industrial biotechnology activities, particularly multi-national corporations (MNCs).
Work w|th |oca| agr|cu|ture p|ayers to |ncrease renewab|e feedstock supp|y for the
development of industrial biotechnology.
lncrease focus on |ncent|ves and |nfrastructure sectors to be more compet|t|ve reg|ona||y.
ln|t|ate opportun|t|es for |oca| lB compan|es to go g|oba|.
Mitsui Engineering
& Shipbuilding Co.
Ltd. Malaysian
branch
FDI Demonstration plant to produce bioethanol from
Empty Fruit Bunch.
No
Company
Name
Project Type
(FDI / DDI)
9
Konzen
Engineering
System
Sdn Bhd
DDI The company prov|des Waste Water Management
services.
10
MyBiomass
Sdn Bhd
DDI A special purpose vehicle (SPV) that will facilitate a
sustainable supply of biomass.
11
ECER investment
in CJ-ARKEMA
DDI ECER had invested a substantial amount of money
|n |and preparat|on for OJ Arkema`s project.
12
|estar| Pas|f|k
Bhd
DDI The company plans to produce bioethanol from
cellulosic biomass.
The company currently has signed a Memorandum
of Understanding (MOU) with SIRIM for the setting
up of a pilot plant utilising Bioethanol technology.
13
No
Company
Name
Project Type
(FDI / DDI)
Free The Seed
Sdn Bhd
DDI Commercialisation of paper produced using
biotechnology process.
26 August 2011.
3
Biotechnology
Diversified
Industries Sdn
Bhd
DDI Commercialisation of sweeteners from sago starch
via enzymatic process.
29 September 2011.
4
Konzen Clean
Energy Sdn Bhd
DDI Commercialisation of palm oil mill effluent (POME)
treatment system for the capture of biogas as a
source of renewable energy.
29 September 2011.
5
Bio Tree
Biotechnology
Sdn Bhd
DDI Commercialisation of functional beverages utilising
microbial fermentation technology.
11 November 2011.
6
Airestec
Innovations
Sdn Bhd
DDI Commercialisation of enzyme-based product for
the cleaning and decontamination of Heating,
Ventilation and Air Conditioning (HVAC) system.
13 December 2011.
7
OJ Arkema FDI Production of bio L-Methionine, a green essential
amino acid (EAA), methyl mercaptan, dimethyl
disulphide (DMDS), and other co-products related
to the production.
The project was approved by the Econom|c Oounc||
on 27 June 2011
8
77
Next Steps for Industrial Biotechnology:
In ensuring that the industry continues to grow, BiotechCorp intends to carry out the following
activities:
Attract more foreign direct investment (FDI) to leverage on Malaysia as a hub for their
industrial biotechnology activities, particularly multi-national corporations (MNCs).
Work w|th |oca| agr|cu|ture p|ayers to |ncrease renewab|e feedstock supp|y for the
development of industrial biotechnology.
lncrease focus on |ncent|ves and |nfrastructure sectors to be more compet|t|ve reg|ona||y.
ln|t|ate opportun|t|es for |oca| lB compan|es to go g|oba|.
Mitsui Engineering
& Shipbuilding Co.
Ltd. Malaysian
branch
FDI Demonstration plant to produce bioethanol from
Empty Fruit Bunch.
No
Company
Name
Project Type
(FDI / DDI)
9
Konzen
Engineering
System
Sdn Bhd
DDI The company prov|des Waste Water Management
services.
10
MyBiomass
Sdn Bhd
DDI A special purpose vehicle (SPV) that will facilitate a
sustainable supply of biomass.
11
ECER investment
in CJ-ARKEMA
DDI ECER had invested a substantial amount of money
|n |and preparat|on for OJ Arkema`s project.
12
|estar| Pas|f|k
Bhd
DDI The company plans to produce bioethanol from
cellulosic biomass.
The company currently has signed a Memorandum
of Understanding (MOU) with SIRIM for the setting
up of a pilot plant utilising Bioethanol technology.
13
No
Company
Name
Project Type
(FDI / DDI)
Free The Seed
Sdn Bhd
DDI Commercialisation of paper produced using
biotechnology process.
26 August 2011.
3
Biotechnology
Diversified
Industries Sdn
Bhd
DDI Commercialisation of sweeteners from sago starch
via enzymatic process.
29 September 2011.
4
Konzen Clean
Energy Sdn Bhd
DDI Commercialisation of palm oil mill effluent (POME)
treatment system for the capture of biogas as a
source of renewable energy.
29 September 2011.
5
Bio Tree
Biotechnology
Sdn Bhd
DDI Commercialisation of functional beverages utilising
microbial fermentation technology.
11 November 2011.
6
Airestec
Innovations
Sdn Bhd
DDI Commercialisation of enzyme-based product for
the cleaning and decontamination of Heating,
Ventilation and Air Conditioning (HVAC) system.
13 December 2011.
7
OJ Arkema FDI Production of bio L-Methionine, a green essential
amino acid (EAA), methyl mercaptan, dimethyl
disulphide (DMDS), and other co-products related
to the production.
The project was approved by the Econom|c Oounc||
on 27 June 2011
8
78
INDUSTRY ADVISORY AND SUPPORT
There are three units that provide industry advisory and support - Intellectual Property and
Immigration Services Unit, Regulatory Services Unit and Shared Facilities Unit.
Focus Areas
To provide advisory and facilitation services in intellectual property, regulatory and immigration
related matters to BioNexus companies.
To prov|de custom|sed tra|n|ng to B|oNexus compan|es on re|ated subjects for awareness and
capac|ty bu||d|ng.
To act as the custod|an for B|oNexus Partners Program BNP}, a programme that |s a|med at
support|ng Ma|ays|a`s b|otechno|ogy-re|ated ||fe sc|ences |ndustry by ensur|ng |ndustry access to
serv|ces, equ|pment and fac|||t|es ava||ab|e w|th|n pub||c|y-funded organ|sat|ons.
Engagement w|th
National Pharmaceutical
Control Bureau, Ministry
of Health
Fac|||tat|on |n obta|n|ng approva| for c||n|ca| tr|a| |mport ||cence OTl|}
and O||n|ca| Tr|a| Exempt|on OT}
Fac|||tat|on |n obta|n|ng product reg|strat|on
Fac|||tat|on |n obta|n|ng GMP cert|f|cat|on
Engagement w|th Med|ca|
Practice Division, Ministry
of Health
Fac|||tat|on |n obta|n|ng Pr|vate Fac|||ty and Hea|thcare Serv|ces
||cence
Device Control Division,
Ministry of Health
Fac|||tat|on |n vo|untary Reg|strat|on for Med|ca| Dev|ces Estab||shments
MEDvER Reg|strat|on}
Fac|||tat|on |n obta|n|ng Free Sa|e Oert|f|cate
Engagement w|th
Pharmaceutical
Services Department,
Ministry of Health
Fac|||tat|on |n obta|n|ng |mport perm|t of psychotrop|c drugs and
perm|t to buy and use psychotrop|c drugs
Engagement w|th
Disease Control Division,
Ministry of Health
Fac|||tat|on |n obta|n|ng |mport and export perm|t of human ce||s, t|ssue
and part thereof
Engagement w|th
Department of Biosafety
Fac|||tat|on |n obta|n|ng not|f|cat|on approva| for conta|ned used of
||v|ng mod|f|ed organ|sm |MO}
Engagement w|th
Department of Veterinary
Services
Fac|||tat|on |n obta|n|ng |mport perm|t for an|ma| products
Fac|||tat|on |n reg|strat|on of prob|ot|c for an|ma| use
Engagement w|th
Department of Agriculture
Fac|||tat|on |n obta|n|ng |mport perm|ts for m|croorgan|sm
Fac|||tat|on |n obta|n|ng phytosan|tary cert|f|cates
Participation in the
formu|at|on of new
regulatory requirements
for BioNexus companies
B|otechOorp part|c|pated |n the techn|ca| work|ng group |n the fo||ow|ng
areas:
Subcomm|ttee on Max|mum Da||y ||m|t for v|tam|ns and M|nera|s |n
Health Supplement, Ministry of Health
Subcomm|ttee on O|a|m Requ|rement for Trad|t|ona| and Hea|th
Supplement Product, Ministry of Health
Subcomm|ttee on Stab|||ty and She|f ||fe for Trad|t|ona| Product and
Health supplement, Ministry of Health
Engagements w|th the
Corporation of Malaysia
MylPO}
Fac|||tat|on |n lP f|||ngs for B|oNexus compan|es
Oreat|ng awareness on lP and commerc|a||sat|on re|ated |ssues
Engagements w|th
institutions of higher
learning
ln reach|ng out to educat|ona| |nst|tut|ons, we focused on the fo||ow|ng
areas in 2011:
lmprovement |n overa|| awareness on lP
Enhanced and |ncreased competency of |n-house lP personne|
lncreased lP f|||ngs
lncreased commerc|a||sat|on act|v|t|es
lP Sk|||s Enhancement
Workshops
ln 2011, three of such workshops were he|d as fo||ows:
The Art of Patent Draft|ng - A Gu|de for Beg|nners
The Art of Patent Draft|ng - An Advanced Workshop
lnte||ectua| Property and Oommerc|a||sat|on
Intellectual Property Services
Key Results
Regulatory Services Unit
Intellectual Property (IP) and Immigration Services Unit
79
INDUSTRY ADVISORY AND SUPPORT
There are three units that provide industry advisory and support - Intellectual Property and
Immigration Services Unit, Regulatory Services Unit and Shared Facilities Unit.
Focus Areas
To provide advisory and facilitation services in intellectual property, regulatory and immigration
related matters to BioNexus companies.
To prov|de custom|sed tra|n|ng to B|oNexus compan|es on re|ated subjects for awareness and
capac|ty bu||d|ng.
To act as the custod|an for B|oNexus Partners Program BNP}, a programme that |s a|med at
support|ng Ma|ays|a`s b|otechno|ogy-re|ated ||fe sc|ences |ndustry by ensur|ng |ndustry access to
serv|ces, equ|pment and fac|||t|es ava||ab|e w|th|n pub||c|y-funded organ|sat|ons.
Engagement w|th
National Pharmaceutical
Control Bureau, Ministry
of Health
Fac|||tat|on |n obta|n|ng approva| for c||n|ca| tr|a| |mport ||cence OTl|}
and O||n|ca| Tr|a| Exempt|on OT}
Fac|||tat|on |n obta|n|ng product reg|strat|on
Fac|||tat|on |n obta|n|ng GMP cert|f|cat|on
Practice Division, Ministry
of Health
Fac|||tat|on |n obta|n|ng Pr|vate Fac|||ty and Hea|thcare Serv|ces
||cence
Device Control Division,
Ministry of Health
Fac|||tat|on |n vo|untary Reg|strat|on for Med|ca| Dev|ces Estab||shments
MEDvER Reg|strat|on}
Fac|||tat|on |n obta|n|ng Free Sa|e Oert|f|cate
Engagement w|th
Pharmaceutical
Services Department,
Ministry of Health
Fac|||tat|on |n obta|n|ng |mport perm|t of psychotrop|c drugs and
perm|t to buy and use psychotrop|c drugs
Engagement w|th
Disease Control Division,
Ministry of Health
Fac|||tat|on |n obta|n|ng |mport and export perm|t of human ce||s, t|ssue
and part thereof
Engagement w|th
Department of Biosafety
Fac|||tat|on |n obta|n|ng not|f|cat|on approva| for conta|ned used of
||v|ng mod|f|ed organ|sm |MO}
Engagement w|th
Department of Veterinary
Services
Fac|||tat|on |n obta|n|ng |mport perm|t for an|ma| products
Fac|||tat|on |n reg|strat|on of prob|ot|c for an|ma| use
Engagement w|th
Department of Agriculture
Fac|||tat|on |n obta|n|ng |mport perm|ts for m|croorgan|sm
Fac|||tat|on |n obta|n|ng phytosan|tary cert|f|cates
Participation in the
formu|at|on of new
regulatory requirements
for BioNexus companies
B|otechOorp part|c|pated |n the techn|ca| work|ng group |n the fo||ow|ng
areas:
Subcomm|ttee on Max|mum Da||y ||m|t for v|tam|ns and M|nera|s |n
Health Supplement, Ministry of Health
Subcomm|ttee on O|a|m Requ|rement for Trad|t|ona| and Hea|th
Supplement Product, Ministry of Health
Subcomm|ttee on Stab|||ty and She|f ||fe for Trad|t|ona| Product and
Health supplement, Ministry of Health
Engagements w|th the
Corporation of Malaysia
MylPO}
Fac|||tat|on |n lP f|||ngs for B|oNexus compan|es
Oreat|ng awareness on lP and commerc|a||sat|on re|ated |ssues
Engagements w|th
institutions of higher
learning
ln reach|ng out to educat|ona| |nst|tut|ons, we focused on the fo||ow|ng
areas in 2011:
lmprovement |n overa|| awareness on lP
Enhanced and |ncreased competency of |n-house lP personne|
lncreased lP f|||ngs
lncreased commerc|a||sat|on act|v|t|es
lP Sk|||s Enhancement
Workshops
ln 2011, three of such workshops were he|d as fo||ows:
The Art of Patent Draft|ng - A Gu|de for Beg|nners
The Art of Patent Draft|ng - An Advanced Workshop
lnte||ectua| Property and Oommerc|a||sat|on
Intellectual Property Services
Key Results
Regulatory Services Unit
Intellectual Property (IP) and Immigration Services Unit
80
Networking sessions for
industry players
BNP Networking Session on Agricultural & Industrial Biotechnology,
FRIM on 26 July 2011
The BNP Networking Session in FRIM was officiated by Datuk Seri Dr
Maximus Ongkili, Minister of Science, Technology and Innovation on 26
July 2011. In conjunction with the event, BiotechCorp:
Launched the BNP Centre of Excellence in Natural Product Development
of FRIM. It consists six BNP laboratories and units which specialise in the
development of herbal products and offers services which range from
tissue culture, phytochemistry, product formulation and development,
screening of bioactivity, up to GMP manufacturing and packaging. The
BNP Centre of Excellence will be the reference and one-stop centre for
the industry to develop products based on herbs.
Launched the Second Volume of the Malaysian Herbal Monograph. It
is an official document that provides the necessary information
needed by the herbal industry involved in the quality assurance of
traditional medicines in ensuring consistent quality of the products
marketed. It serves as an international standard reference on the
quality and safety specifications of 20 selected medicinal plant
species such as dukun ganak, misai kucing and mengkudu.
Memorandum of Understanding (MoU) exchanges on collaborations
between FRIMs BNP laboratories and with local biotechnology
companies:
1. I&R Herbal Industries Sdn Bhd
Development in the research of Pre & Post Harvesting Technology
of Mas Cotek towards sustainable supply of high quality raw
material in the future.
2. Borneo Biogaharu Sdn Bhd
R&D in gaharu oil extraction, setting up of karas plantation,
inoculation of karas trees and product development.
3. Furley Bioextracts Sdn Bhd (BioNexus company)
Development of Antioxidant Standardised Extracts and Natural
Products towards commercialisation.
4. Celltis Sdn Bhd (BioNexus company)
Cell and organ culture technology of few selected plants namely
Kacip Fatimah and Aquilaria species.
5. IOI Palm Biotech Sdn Bhd (BioNexus company)
Collaboration is on "Microsatellite Genotyping Service".
6. Herbagus Sdn Bhd
Development in the research of Pre & Post Harvesting Technology,
of Misai Kucing towards sustainable supply of high quality raw
Engagements with
Immigration Department
of Malaysia (IDM) and
Talent Corporation Sdn
Bhd (TalentCorp)
Fac|||tat|on |n emp|oyment pass and other re|ated app||cat|ons for
BioNexus companies.
Facilitation in Residence Pass and Permanent Resident applications
for BioNexus companies.
Improvement in awareness and understanding of the requirements
and procedures involved in employment pass and residence pass
applications and approvals for expatriates.
Immigration Awareness
Seminars
In 2011, two seminars were held as follows:
The Role and Function of the Employment Pass Division held by the
Immigration Department of Malaysia.
Immigration Awareness Seminar entitled Residence Pass.
Development of BNP
Centres of Excellence in
Malaysia
Three BNP Centers of Excellence have also been identified to be
nurtured as Malaysias reference and one-stop-centre in their
specialised fields as follows:
1. BNP Centre of Excellence for Natural Product Development in FRIM:
Tissue Culture Laboratory
Genet|c |aboratory
Phytochem|stry |aboratory
Herba| Product Deve|opment |aboratory
Pharmacognosy |aboratory
Herba| Techno|ogy |aboratory
2. BNP Centre of Excellence for Pharmacogenomics Research in UiTM:
Whole Genome Sequencing Unit
lntegrated System|c B|o|ogy n|t
Ana|yt|ca| n|t
3. BNP Centre of Excellence for Industrial Product Development in UTM:
Metabolic Profiling Laboratory
B|oprocess Eng|neer|ng |aboratory
Herba| and Phytochem|ca| Process|ng |aboratory
H|gh Temperature Process|ng |aboratory
B|ofert|||zer Serv|ces |aboratory
Wastewater Treatment Fac|||t|es
Immigration Services
Shared Facilities Unit
81
Networking sessions for
industry players
BNP Networking Session on Agricultural & Industrial Biotechnology,
FRIM on 26 July 2011
The BNP Networking Session in FRIM was officiated by Datuk Seri Dr
Maximus Ongkili, Minister of Science, Technology and Innovation on 26
July 2011. In conjunction with the event, BiotechCorp:
Launched the BNP Centre of Excellence in Natural Product Development
of FRIM. It consists six BNP laboratories and units which specialise in the
development of herbal products and offers services which range from
tissue culture, phytochemistry, product formulation and development,
screening of bioactivity, up to GMP manufacturing and packaging. The
BNP Centre of Excellence will be the reference and one-stop centre for
the industry to develop products based on herbs.
Launched the Second Volume of the Malaysian Herbal Monograph. It
is an official document that provides the necessary information
needed by the herbal industry involved in the quality assurance of
traditional medicines in ensuring consistent quality of the products
marketed. It serves as an international standard reference on the
quality and safety specifications of 20 selected medicinal plant
species such as dukun ganak, misai kucing and mengkudu.
Memorandum of Understanding (MoU) exchanges on collaborations
between FRIMs BNP laboratories and with local biotechnology
companies:
1. I&R Herbal Industries Sdn Bhd
Development in the research of Pre & Post Harvesting Technology
of Mas Cotek towards sustainable supply of high quality raw
2. Borneo Biogaharu Sdn Bhd
R&D in gaharu oil extraction, setting up of karas plantation,
inoculation of karas trees and product development.
3. Furley Bioextracts Sdn Bhd (BioNexus company)
Development of Antioxidant Standardised Extracts and Natural
Products towards commercialisation.
4. Celltis Sdn Bhd (BioNexus company)
Cell and organ culture technology of few selected plants namely
Kacip Fatimah and Aquilaria species.
5. IOI Palm Biotech Sdn Bhd (BioNexus company)
Collaboration is on "Microsatellite Genotyping Service".
6. Herbagus Sdn Bhd
Development in the research of Pre & Post Harvesting Technology,
of Misai Kucing towards sustainable supply of high quality raw
Engagements with
Immigration Department
of Malaysia (IDM) and
Talent Corporation Sdn
Bhd (TalentCorp)
Fac|||tat|on |n emp|oyment pass and other re|ated app||cat|ons for
BioNexus companies.
Facilitation in Residence Pass and Permanent Resident applications
for BioNexus companies.
Improvement in awareness and understanding of the requirements
and procedures involved in employment pass and residence pass
applications and approvals for expatriates.
Immigration Awareness
Seminars
In 2011, two seminars were held as follows:
The Role and Function of the Employment Pass Division held by the
Immigration Department of Malaysia.
Immigration Awareness Seminar entitled Residence Pass.
Development of BNP
Centres of Excellence in
Malaysia
Three BNP Centers of Excellence have also been identified to be
nurtured as Malaysias reference and one-stop-centre in their
specialised fields as follows:
1. BNP Centre of Excellence for Natural Product Development in FRIM:
Tissue Culture Laboratory
Genet|c |aboratory
Phytochem|stry |aboratory
Herba| Product Deve|opment |aboratory
Pharmacognosy |aboratory
Herba| Techno|ogy |aboratory
2. BNP Centre of Excellence for Pharmacogenomics Research in UiTM:
Whole Genome Sequencing Unit
lntegrated System|c B|o|ogy n|t
Ana|yt|ca| n|t
3. BNP Centre of Excellence for Industrial Product Development in UTM:
Metabolic Profiling Laboratory
B|oprocess Eng|neer|ng |aboratory
Herba| and Phytochem|ca| Process|ng |aboratory
H|gh Temperature Process|ng |aboratory
B|ofert|||zer Serv|ces |aboratory
Wastewater Treatment Fac|||t|es
Immigration Services
Shared Facilities Unit
82
Next Steps for Industry Advisory and Support:
With the reorganisation of structure, the department has changed its name to Industry
Support Department with an additional new unit called the Processing and Client
Engagement Unit. Moving forward, main focus areas include:
Strengthening advisory and facilitation services to BioNexus companies.
ln a b|d to nurture and acce|erate growth of B|oNexus compan|es, more programmes w|th
|ndustry re|evant content w||| be organ|sed.
More programmes w||| a|so be he|d to encourage co||aborat|on between BNP |aborator|es
and BioNexus companies.
OPERATIONAL SERVICES
As part of its services to industry players, BiotechCorp processes and evaluates applications
from b|otech compan|es for the B|oNexus Status as we|| as app||cat|ons for |ncome tax
exemptions for BioNexus Status companies and other relevant tax incentives.
Given the importance of access to early financing for start-up companies commercialising
their products and services, BiotechCorp also looks into the awarding of grants for industry
p|ayers. B|otechno|ogy Oommerc|a||sat|on Grants have benef|ted a number of B|oNexus
Status companies, especially at the early stage of operations.
Focus Areas:
1. BioNexus Status
2. Biotechnology Commercialisation Grants
3. Tax Incentives
Networking sessions
for industry players
BNP Networking Session on Healthcare Biotechnology, UiTM on 27
December 2011
The BNP Network|ng Sess|on |n |TM was off|c|ated by Deputy Pr|me
Minister of Malaysia Yang Amat Berhormat Tan Sri Muhyiddin Yassin,
on 27 December 2011. The h|gh||ght of the event was the announcement
of the successfu| mapp|ng of the Ma|ay ethn|c genome. Th|s w||| enab|e
more understanding of gene related diseases and inter-ethnic
variations of responses towards med|c|nes. lt w||| fac|||tate su|tab|e drug
development for the Malay ethnic group specifically and Asians in
general. This is known as the personalised medicine approach and has
been pract|ced |n deve|oped countr|es. A group of researchers from
Universiti Teknologi Mara (UiTM) have successfully completed mapping
of the Malay ethnic genome, placing Malaysia at par with other
developed countries.
The event |nvo|ved co||aborat|on between the BNP |aborator|es and
Units under BNP Centre of Excellence in Pharmacogenomics Research
of UiTM, which include the Analytical Unit as well as Whole Genome
Sequencing Unit and the Integrated Systemic Biology Unit which are
both under the Pharmacogenom|cs Oentre PROMlSE}.
BioNexus Status A tota| number of 115 app||cat|ons for B|oNexus Status were rece|ved
by B|otechOorp |n 2011. For the year, 25 B|oNexus Status compan|es
were approved br|ng|ng the tota| number to 210 as at 31 December
2011. The companies approved are as follows:
1. Biogrowth Sdn Bhd
2. Fa|con ||vestock NS} Sdn Bhd
3. Biotech Diagnostics Sdn Bhd
4. Esclapeus Genomics Sdn Bhd
5. B|onestro Sdn Bhd
6. W|bawa B|otech Sdn Bhd
7. Green Access Sdn Bhd
8. Nu-Tr|no Synb|o M} Sdn Bhd
9. K|SMO Stem Oe||s Sdn Bhd
10. Cardia Bioplastics Malaysia Sdn Bhd
11. Free The Seed Sdn Bhd
12. Genomic Biotech Sdn Bhd
13. v|gor Agr|b|otech So|ut|ons Sdn Bhd
14. JQ Biotech Sdn Bhd
15. Darve| Bay Sdn Bhd
16. Persona Kosmetik Sdn Bhd
17. AquaGems BioX Sdn Bhd
18. Biotechnology Diversified Industries Sdn Bhd
Issue/Activity Results Summary
83
Next Steps for Industry Advisory and Support:
With the reorganisation of structure, the department has changed its name to Industry
Support Department with an additional new unit called the Processing and Client
Engagement Unit. Moving forward, main focus areas include:
Strengthening advisory and facilitation services to BioNexus companies.
ln a b|d to nurture and acce|erate growth of B|oNexus compan|es, more programmes w|th
|ndustry re|evant content w||| be organ|sed.
More programmes w||| a|so be he|d to encourage co||aborat|on between BNP |aborator|es
and BioNexus companies.
OPERATIONAL SERVICES
As part of its services to industry players, BiotechCorp processes and evaluates applications
from b|otech compan|es for the B|oNexus Status as we|| as app||cat|ons for |ncome tax
exemptions for BioNexus Status companies and other relevant tax incentives.
Given the importance of access to early financing for start-up companies commercialising
their products and services, BiotechCorp also looks into the awarding of grants for industry
p|ayers. B|otechno|ogy Oommerc|a||sat|on Grants have benef|ted a number of B|oNexus
Status companies, especially at the early stage of operations.
Focus Areas:
1. BioNexus Status
2. Biotechnology Commercialisation Grants
3. Tax Incentives
Networking sessions
for industry players
BNP Networking Session on Healthcare Biotechnology, UiTM on 27
December 2011
The BNP Network|ng Sess|on |n |TM was off|c|ated by Deputy Pr|me
Minister of Malaysia Yang Amat Berhormat Tan Sri Muhyiddin Yassin,
on 27 December 2011. The h|gh||ght of the event was the announcement
of the successfu| mapp|ng of the Ma|ay ethn|c genome. Th|s w||| enab|e
more understanding of gene related diseases and inter-ethnic
variations of responses towards med|c|nes. lt w||| fac|||tate su|tab|e drug
development for the Malay ethnic group specifically and Asians in
general. This is known as the personalised medicine approach and has
been pract|ced |n deve|oped countr|es. A group of researchers from
Universiti Teknologi Mara (UiTM) have successfully completed mapping
of the Malay ethnic genome, placing Malaysia at par with other
developed countries.
The event |nvo|ved co||aborat|on between the BNP |aborator|es and
Units under BNP Centre of Excellence in Pharmacogenomics Research
of UiTM, which include the Analytical Unit as well as Whole Genome
Sequencing Unit and the Integrated Systemic Biology Unit which are
both under the Pharmacogenom|cs Oentre PROMlSE}.
BioNexus Status A tota| number of 115 app||cat|ons for B|oNexus Status were rece|ved
by B|otechOorp |n 2011. For the year, 25 B|oNexus Status compan|es
were approved br|ng|ng the tota| number to 210 as at 31 December
2011. The companies approved are as follows:
1. Biogrowth Sdn Bhd
2. Fa|con ||vestock NS} Sdn Bhd
3. Biotech Diagnostics Sdn Bhd
4. Esclapeus Genomics Sdn Bhd
5. B|onestro Sdn Bhd
6. W|bawa B|otech Sdn Bhd
7. Green Access Sdn Bhd
8. Nu-Tr|no Synb|o M} Sdn Bhd
9. K|SMO Stem Oe||s Sdn Bhd
10. Cardia Bioplastics Malaysia Sdn Bhd
11. Free The Seed Sdn Bhd
12. Genomic Biotech Sdn Bhd
13. v|gor Agr|b|otech So|ut|ons Sdn Bhd
15. Darve| Bay Sdn Bhd
16. Persona Kosmetik Sdn Bhd
17. AquaGems BioX Sdn Bhd
18. Biotechnology Diversified Industries Sdn Bhd
84
8. Stemlife Berhad
9. Genting Green Tech Sdn Bhd
10. TSH Biotech Sdn Bhd
11. IOI Palm Biotech Sdn Bhd
12. Mushroom Ambra Biotech Sdn Bhd
13. M-Gen-Propagation Sdn Bhd
14. Biofusion Sdn Bhd
15. Stempeutics Research (M) Sdn Bhd
16. Furley Bioextracts Sdn Bhd
17. Cytopro (M) Sdn Bhd
18. Grand Range Biotechnology Sdn Bhd
ln add|t|on, three aud|t ver|f|cat|on exerc|ses were conducted |n
respect of mon|tor|ng rev|ew for the B|oNexus |nvestment tax
deduct|on |ncent|ve.
ln cont|nu|ng efforts to create awareness on the benef|ts and
advantages of tax |ncent|ves, a sem|nar on lmport Duty & Sa|es Tax
Exempt|on and Oomp||ance to Occupat|ona| Safety & Hea|th Act &
Regu|at|ons was conducted |n October 2011 for a|| B|oNexus Status
companies.
19. Konzen Clean Energy Sdn Bhd
20. Algae International Sdn Bhd
21. Bio Tree Biotechnology Sdn Bhd
22. Bio-Ferti Sdn Bhd
23. A|restec lnnovat|ons Sdn Bhd
24. KHL Herbal Biotech Sdn Bhd
25. RE Millennium Sdn Bhd
ln add|t|on, 14 app||cat|ons request|ng changes on spec|a| cond|t|ons
|mposed on B|oNexus Status compan|es were assessed and tab|ed
for the cons|derat|on of the B|oNexus Eva|uat|on Oomm|ttee BEO} for
recommendation to the Ministry of Finance (MOF).
Biotechnology
Commercialisation
Grants
ln 2011, a tota| e|ght B|oNexus Status compan|es rece|ved grants
under the Seed, Research and Deve|opment and lnternat|ona|
Bus|ness Deve|opment fund schemes br|ng|ng the tota| number of
grant rec|p|ent to 81 compan|es as at 31 December 2011}. The ||st of
grant rec|p|ents |n 2011 are as fo||ows:
1. Inno Integrasi Sdn Bhd
2. KLAS Farm Sdn Bhd
3. Medical Biotherapy Sdn Bhd
4. MOSTDl lnnovat|ons Sdn Bhd
5. Novotech O||n|ca| Research M} Sdn Bhd
6. Orthomed|c lnnovat|ons Sdn Bhd
7. Ronser Bio-Tech Sdn Bhd
8. Ultimate Bio-Tech Sdn Bhd
Tax Adv|sory &
Serv|ces
Tax Adv|sory &
Serv|ces
Apart from the 100% |ncome tax exempt|on on statutory |ncome
|ncent|ve granted to B|oNexus Status compan|es, a tota| of 18
app||cat|ons for other B|oNexus Status tax |ncent|ves were rece|ved
and processed |n 2011. The app||cat|ons rece|ved and processed for
other B|oNexus Status tax |ncent|ves are:
1. BioAlpha International Sdn Bhd
2. Chua Tongsan Sdn Bhd
3. Green & Smart Sdn Bhd
4. SP Aquacu|ture Sdn Bhd
6. Vigor Agribiotech Solutions Sdn Bhd
7. PureCircle Sdn Bhd
Next Steps for Operational Services:
Mov|ng forward, |n fac|||tat|ng deve|opment of B|oNexus Status compan|es, B|otechOorp w|||
focus upon the fo||ow|ng areas:
Oont|nue to conduct an object|ve, thorough and systemat|c assessment for B|oNexus
Status, tax and fund|ng app||cat|ons.
Ensure the |ntegr|ty of the B|oNexus framework.
Estab||sh the B|otechno|ogy Oommerc|a||sat|on Fund BOF} framework for |mp|ementat|on
under the 10th Malaysian Plan.
85
8. Stemlife Berhad
9. Genting Green Tech Sdn Bhd
10. TSH Biotech Sdn Bhd
11. IOI Palm Biotech Sdn Bhd
12. Mushroom Ambra Biotech Sdn Bhd
13. M-Gen-Propagation Sdn Bhd
14. Biofusion Sdn Bhd
15. Stempeutics Research (M) Sdn Bhd
16. Furley Bioextracts Sdn Bhd
17. Cytopro (M) Sdn Bhd
18. Grand Range Biotechnology Sdn Bhd
ln add|t|on, three aud|t ver|f|cat|on exerc|ses were conducted |n
respect of mon|tor|ng rev|ew for the B|oNexus |nvestment tax
deduct|on |ncent|ve.
ln cont|nu|ng efforts to create awareness on the benef|ts and
advantages of tax |ncent|ves, a sem|nar on lmport Duty & Sa|es Tax
Exempt|on and Oomp||ance to Occupat|ona| Safety & Hea|th Act &
Regu|at|ons was conducted |n October 2011 for a|| B|oNexus Status
companies.
19. Konzen Clean Energy Sdn Bhd
20. Algae International Sdn Bhd
21. Bio Tree Biotechnology Sdn Bhd
22. Bio-Ferti Sdn Bhd
23. A|restec lnnovat|ons Sdn Bhd
24. KHL Herbal Biotech Sdn Bhd
25. RE Millennium Sdn Bhd
ln add|t|on, 14 app||cat|ons request|ng changes on spec|a| cond|t|ons
|mposed on B|oNexus Status compan|es were assessed and tab|ed
for the cons|derat|on of the B|oNexus Eva|uat|on Oomm|ttee BEO} for
recommendation to the Ministry of Finance (MOF).
Biotechnology
Commercialisation
Grants
ln 2011, a tota| e|ght B|oNexus Status compan|es rece|ved grants
under the Seed, Research and Deve|opment and lnternat|ona|
Bus|ness Deve|opment fund schemes br|ng|ng the tota| number of
grant rec|p|ent to 81 compan|es as at 31 December 2011}. The ||st of
grant rec|p|ents |n 2011 are as fo||ows:
1. Inno Integrasi Sdn Bhd
2. KLAS Farm Sdn Bhd
3. Medical Biotherapy Sdn Bhd
4. MOSTDl lnnovat|ons Sdn Bhd
5. Novotech O||n|ca| Research M} Sdn Bhd
6. Orthomed|c lnnovat|ons Sdn Bhd
7. Ronser Bio-Tech Sdn Bhd
8. Ultimate Bio-Tech Sdn Bhd
Tax Adv|sory &
Serv|ces
Tax Adv|sory &
Serv|ces
Apart from the 100% |ncome tax exempt|on on statutory |ncome
|ncent|ve granted to B|oNexus Status compan|es, a tota| of 18
app||cat|ons for other B|oNexus Status tax |ncent|ves were rece|ved
and processed |n 2011. The app||cat|ons rece|ved and processed for
other B|oNexus Status tax |ncent|ves are:
1. BioAlpha International Sdn Bhd
2. Chua Tongsan Sdn Bhd
3. Green & Smart Sdn Bhd
4. SP Aquacu|ture Sdn Bhd
6. Vigor Agribiotech Solutions Sdn Bhd
7. PureCircle Sdn Bhd
Next Steps for Operational Services:
Mov|ng forward, |n fac|||tat|ng deve|opment of B|oNexus Status compan|es, B|otechOorp w|||
focus upon the fo||ow|ng areas:
Oont|nue to conduct an object|ve, thorough and systemat|c assessment for B|oNexus
Status, tax and fund|ng app||cat|ons.
Ensure the |ntegr|ty of the B|oNexus framework.
Estab||sh the B|otechno|ogy Oommerc|a||sat|on Fund BOF} framework for |mp|ementat|on
under the 10th Malaysian Plan.
86
BIO-XCELL: A DEDICATED SPACE FOR BIOTECHNOLOGY
Bio-XCell takes shape as a dedicated hub for industrial and healthcare
biotechnology
Bio-XCell - Malaysias first dedicated biotechnology park and ecosystem is being developed by
Malaysian Bio-XCell Sdn Bhd, a joint venture company formed between Malaysian
Biotechnology Corporation and property developer UEM Land Berhad.
Strategically located in Nusajaya, within the Iskandar region of Johor and close to the 2nd link
with Singapore, Bio-XCell provides global connectivity through a network of five seaports and
two international airports, all within 59 km. Bio-XCell will provide healthcare and industrial
companies with a conducive and commercially attractive environment for biomanufacturing
and bioprocessing activities including R&D, production and support services.
Bio-XCell biotechnology park to be ready for operations soon
To date, Bio-XCell has invested almost RM450 million on infrastructure and construction of the
biotechnology park. The park which spans over an area of 161 acres will be developed in three
phases across six years.
The key components of the park are expected to be completed by the third quarter (Q3) of
2012. These components include four units of standard manufacturing plants, the Central
Utilities Facility and the Central Hub. As a managed park, Bio-XCell will provide its clients with
a range of value added benefits including comprehensive infrastructure, park maintenance and
security, core shared utilities and facilities as well as options related to the purchase and hire of
process equipment.
The Central Hub of the park will house a number of lab incubators designed in adherence to
the principles Good Lab Practices (GLP), to enable companies to set up their operations and
R&D activities in compliance with GLP guidelines with ease. These lab incubators will be
supported by adjoining office space and shared core lab facilities such as cold and incubation
rooms, media preparation room, sterilisation/decontamination and washing room as well as a
storage area.
Other supporting features of the Central Hub include training and conference facilities, an
administration centre, plug & play office space, retail/ F&B outlets and other amenities.
The Central Utilities Facility (CUF) will provide steam, chilled water and waste water
management as well as cater to specific utilities requirements of clients. This centralised
service will reduce the capital expenditure for the parks clients.
Together these elements are expected to help create an ecosystem of small, medium and large
industry players which support cost effective operations and advancements in innovation and
technology transfer.
Bio-XCell attracts global biotech players
Since its global launch in May 2010, Bio-XCell has secured four clients namely Biocon and Agila
Specialties - both leading biopharmaceutical companies from India, Metabolic Explorer from
France and Glycos Biotechnologies from the United States of America. These are prominent
industrial biotechnology players who will use proprietary platform technologies in their
bioprocess development and manufacturing activities. The companies will be operational in
Bio-XCell from 2013.
It is envisaged that these clients will bring with them significant innovation and intellectual
property in biotechnology, providing for transfer of knowledge and development of specialised
skills for the local talent pool.
April 18 2011
Bio-XCell Corporate
Office, Menara Atlan,
Bio-XCell Secures RM250m Islamic Funding from Maybank
Bio-XCell and Malayan Banking Berhad (Maybank) signed an agreement
for a RM250 million Commodity Murabahah Term Financing Islamic
Facility (CMTF-i) which will partly fund the completion of Phase 1 of
Bio-XCells development.
The development of Phase 1 will require an investment of RM950 million
which will be funded through foreign direct investments, Islamic debts
and shareholders equity, reflecting strong market acceptance and
confidence in the value propositions of this project.
The agreement was signed by Chief Executive Officer of Bio-XCell, YM Raja
Ridzwa Raja Abdul Aziz and Managing Director & Corporate Banking Head
of Malayan Banking Bhd, Encik Hamzah Bachee. Chairman of Bio-XCell,
Dato Iskandar Mizal Mahmood and Group President & CEO of Maybank,
Dato Sri Abdul Wahid Omar witnessed the exchange of documents.
DATE & VENUE EVENT
Bio-XCell: event highlights of 2011
29 June 2011
BIO International
Convention 2011,
Washington DC, USA
Strides Arcolab Joins the Bio-XCell Ecosystem
Agila Specialties (Malaysia) Sdn Bhd, the specialties subsidiary of leading
Indian pharmaceutical manufacturer Strides Arcolab Ltd, and Bio-XCell
exchanged agreements for the establishment of a customised facility to
manufacture biopharmaceuticals and sterile injectables at Bio-XCell. This
represents another step towards building up a thriving biotechnology hub
and ecosystem in the southern part of Malaysia
Mr Adam Levitt, CEO- Americas of Strides Arcolab Ltd and YM Raja
Ridzwa Raja Abdul Aziz, CEO of Bio-XCell exchanged the agreements in
the presence of YAB Tan Sri Muhyiddin Yassin, Deputy Prime Minister of
Malaysia during the BIO International Convention 2011 in Washington DC.
87
BIO-XCELL: A DEDICATED SPACE FOR BIOTECHNOLOGY
Bio-XCell takes shape as a dedicated hub for industrial and healthcare
biotechnology
Bio-XCell - Malaysias first dedicated biotechnology park and ecosystem is being developed by
Malaysian Bio-XCell Sdn Bhd, a joint venture company formed between Malaysian
Biotechnology Corporation and property developer UEM Land Berhad.
Strategically located in Nusajaya, within the Iskandar region of Johor and close to the 2nd link
with Singapore, Bio-XCell provides global connectivity through a network of five seaports and
two international airports, all within 59 km. Bio-XCell will provide healthcare and industrial
companies with a conducive and commercially attractive environment for biomanufacturing
and bioprocessing activities including R&D, production and support services.
Bio-XCell biotechnology park to be ready for operations soon
To date, Bio-XCell has invested almost RM450 million on infrastructure and construction of the
biotechnology park. The park which spans over an area of 161 acres will be developed in three
phases across six years.
The key components of the park are expected to be completed by the third quarter (Q3) of
2012. These components include four units of standard manufacturing plants, the Central
Utilities Facility and the Central Hub. As a managed park, Bio-XCell will provide its clients with
a range of value added benefits including comprehensive infrastructure, park maintenance and
security, core shared utilities and facilities as well as options related to the purchase and hire of
process equipment.
The Central Hub of the park will house a number of lab incubators designed in adherence to
the principles Good Lab Practices (GLP), to enable companies to set up their operations and
R&D activities in compliance with GLP guidelines with ease. These lab incubators will be
supported by adjoining office space and shared core lab facilities such as cold and incubation
rooms, media preparation room, sterilisation/decontamination and washing room as well as a
storage area.
Other supporting features of the Central Hub include training and conference facilities, an
administration centre, plug & play office space, retail/ F&B outlets and other amenities.
The Central Utilities Facility (CUF) will provide steam, chilled water and waste water
management as well as cater to specific utilities requirements of clients. This centralised
service will reduce the capital expenditure for the parks clients.
Together these elements are expected to help create an ecosystem of small, medium and large
industry players which support cost effective operations and advancements in innovation and
technology transfer.
Bio-XCell attracts global biotech players
Since its global launch in May 2010, Bio-XCell has secured four clients namely Biocon and Agila
Specialties - both leading biopharmaceutical companies from India, Metabolic Explorer from
France and Glycos Biotechnologies from the United States of America. These are prominent
industrial biotechnology players who will use proprietary platform technologies in their
bioprocess development and manufacturing activities. The companies will be operational in
Bio-XCell from 2013.
It is envisaged that these clients will bring with them significant innovation and intellectual
property in biotechnology, providing for transfer of knowledge and development of specialised
skills for the local talent pool.
April 18 2011
Bio-XCell Corporate
Bio-XCell Secures RM250m Islamic Funding from Maybank
Bio-XCell and Malayan Banking Berhad (Maybank) signed an agreement
for a RM250 million Commodity Murabahah Term Financing Islamic
Facility (CMTF-i) which will partly fund the completion of Phase 1 of
Bio-XCells development.
The development of Phase 1 will require an investment of RM950 million
which will be funded through foreign direct investments, Islamic debts
and shareholders equity, reflecting strong market acceptance and
confidence in the value propositions of this project.
The agreement was signed by Chief Executive Officer of Bio-XCell, YM Raja
Ridzwa Raja Abdul Aziz and Managing Director & Corporate Banking Head
of Malayan Banking Bhd, Encik Hamzah Bachee. Chairman of Bio-XCell,
Dato Iskandar Mizal Mahmood and Group President & CEO of Maybank,
Dato Sri Abdul Wahid Omar witnessed the exchange of documents.
DATE & VENUE EVENT
Bio-XCell: event highlights of 2011
29 June 2011
BIO International
Convention 2011,
Washington DC, USA
Strides Arcolab Joins the Bio-XCell Ecosystem
Agila Specialties (Malaysia) Sdn Bhd, the specialties subsidiary of leading
Indian pharmaceutical manufacturer Strides Arcolab Ltd, and Bio-XCell
exchanged agreements for the establishment of a customised facility to
manufacture biopharmaceuticals and sterile injectables at Bio-XCell. This
represents another step towards building up a thriving biotechnology hub
and ecosystem in the southern part of Malaysia
Mr Adam Levitt, CEO- Americas of Strides Arcolab Ltd and YM Raja
Ridzwa Raja Abdul Aziz, CEO of Bio-XCell exchanged the agreements in
the presence of YAB Tan Sri Muhyiddin Yassin, Deputy Prime Minister of
Malaysia during the BIO International Convention 2011 in Washington DC.
88
12 September 2011
Persada Johor
International Convention
Centre, Johor Bharu,
Malaysia
Biocons Project Commencement
Biocon, Asias premier biotechnology company, held a project commencement
ceremony for its high-end biopharmaceutical manufacturing and research
and development facility to be located in Bio-XCell. This facility will cater to
the global requirements for Biocon's range of biosimilar insulin and insulin
analogs for diabetes treatment, The project will also focus on research and
development and production of other biopharmaceutical products at a later
phase. The plant will be built in compliance with US FDA cGMP standards.
The Chief Minister of Johor, Y.A.B. Dato' Haji Abdul Ghani bin Othman
unveiled the plaque commemorating the projects initiation. The
ceremony was attended by Chairman and MD of Biocon, Ms Kiran
Mazumdar-Shaw and Dato Dr Mohd Nazlee Kamal, Chairman of
Bio-XCell and CEO of BiotechCorp.
In the first phase, Biocon proposes to invest around RM500 million
(approximately US$161 million) in this facility, which is targeted to be
operational by 2014. The investment is the largest for the healthcare
biotechnology sector in Malaysia thus far.
Biocon's entry into Bio-XCell will further stimulate growth for the sector,
providing commercial opportunities for small and medium biotechnology
enterprises in Malaysia and promote a more vigorous domestic direct
investment.
DATE & VENUE EVENT
The updates on Bio-XCell included the number of clients secured and the
investments made to date as well as how Bio-XCell plans to enhance and
strengthen service delivery to its clients and the industry.
In the press release, the CEO referred to the recent results of Doing
Business 2012 report published by the World Bank in which Malaysia
was reported to climb five positions to be 18th place amongst 183
economies of the world for ease of doing business. He highlighted that
this improved competitiveness, which is a result of the broader hard and
soft infrastructure enabled by the government, will have a positive
influence on investments in biotechnology.
Eleven local media ran stories on Bio-XCell following this event. The
progress made to date especially the attraction of foreign investment and
the plans to bring more foreign biotech companies to the park were the
main messages. The media value of this exercise as measured by the MVI
(media value index) was RM145,067.
21 November 2011
BioMalaysia and Pacific
Rim Summit on Industrial
Biotechnology &
Bioenergy Kuala Lumpur
Convention Centre,
Malaysia
31 October 2011
Nusajaya Centre &
Bio-XCell Site, Iskandar,
Johor
Bio-XCell & UTM Enter Collaboration to Strengthen the Biotechnology
Ecosystem
Bio-XCell and Universiti Teknologi Malaysia (UTM) which are both
located within the Iskandar region of Johor agreed to work together to
establish strategic collaborations to strengthen the biotechnology
ecosystem at Bio-XCell. Some of the proposed initiatives include
graduate placement, specialised training, sharing of facilities and
strategic R&D collaborations.
A Memorandum of Collaboration (MoC) between the two organisations
was signed by CEO of Bio-XCell Rizatuddin Ramli and the Vice
Chancellor of UTM Professor Dato Dr Zaini Ujang, in the presence of
Prime Minister of Malaysia YAB Dato Seri Najib Tun Abdul Razak at the
Opening Ceremony of the concurrently held BioMalaysia 2011 and the
2011 Pacific Rim Summit on Industrial Biotechnology & Bioenergy
Conference and Exhibition held at the Kuala Lumpur Convention Centre.
Bio-XCell has initiated discussions with UTM on the utilisation of
facilities and services at UTM by Bio-XCell clients and the participation
of UTM within the Bio-XCell ecosystem.
One of the on-campus facilities at UTM which will expand the value
added services Bio-XCell can offer its clients is the Bioprocessing Pilot
Plant at Institute of Bioproduct Development (IBD). This is an integrated
multipurpose facility which provides a wide range of services from
primary bioprocess optimisation in small scale bioreactors of 16 litres to
a larger scale manufacturing in 1500 litres bioreactor.
DATE & VENUE EVENT
26 September 2011
Rizatuddin Ramli Appointed as New CEO of Bio-XCell
Bio-XCell announced the appointment of Rizatuddin Ramli as its Chief
Executive Officer following the resignation of its founding CEO, YM Raja
Ridzwa Raja Abd Aziz who was formerly from BiotechCorp.
Rizatuddin Ramli, 40, takes over the helm of Bio-XCell with its secured
investments of over RM750 million. Rizatuddin, a graduate in Computer
Information Systems and Operations Management from Indiana
University, Bloomington, USA, also holds a certificate in Advance
Industrial Marketing from INSEAD University, Fountainebleau, France.
He brings with him a wealth of experience in technology mapping and
management as well as industrial marketing.
31 October 2011

Nusajaya Centre &
Johor
Media Briefing and Site Visit
A visit to the Bio-XCell site in Iskandar, Johor was organised for
members of the media. The press were briefed on Bio-XCell; the
developments to date as well as the outlook for 2012 and how these
initiatives are working towards fulfilling the National Biotechnology
Policy, by its CEO, Rizatuddin Ramli.
89
12 September 2011
Persada Johor
International Convention
Centre, Johor Bharu,
Malaysia
Biocons Project Commencement
Biocon, Asias premier biotechnology company, held a project commencement
ceremony for its high-end biopharmaceutical manufacturing and research
and development facility to be located in Bio-XCell. This facility will cater to
the global requirements for Biocon's range of biosimilar insulin and insulin
analogs for diabetes treatment, The project will also focus on research and
development and production of other biopharmaceutical products at a later
phase. The plant will be built in compliance with US FDA cGMP standards.
The Chief Minister of Johor, Y.A.B. Dato' Haji Abdul Ghani bin Othman
unveiled the plaque commemorating the projects initiation. The
ceremony was attended by Chairman and MD of Biocon, Ms Kiran
Mazumdar-Shaw and Dato Dr Mohd Nazlee Kamal, Chairman of
Bio-XCell and CEO of BiotechCorp.
In the first phase, Biocon proposes to invest around RM500 million
(approximately US$161 million) in this facility, which is targeted to be
operational by 2014. The investment is the largest for the healthcare
biotechnology sector in Malaysia thus far.
Biocon's entry into Bio-XCell will further stimulate growth for the sector,
providing commercial opportunities for small and medium biotechnology
enterprises in Malaysia and promote a more vigorous domestic direct
investment.
DATE & VENUE EVENT
The updates on Bio-XCell included the number of clients secured and the
investments made to date as well as how Bio-XCell plans to enhance and
strengthen service delivery to its clients and the industry.
In the press release, the CEO referred to the recent results of Doing
Business 2012 report published by the World Bank in which Malaysia
was reported to climb five positions to be 18th place amongst 183
economies of the world for ease of doing business. He highlighted that
this improved competitiveness, which is a result of the broader hard and
soft infrastructure enabled by the government, will have a positive
influence on investments in biotechnology.
Eleven local media ran stories on Bio-XCell following this event. The
progress made to date especially the attraction of foreign investment and
the plans to bring more foreign biotech companies to the park were the
main messages. The media value of this exercise as measured by the MVI
(media value index) was RM145,067.
21 November 2011
Biotechnology &
Convention Centre,
Malaysia
31 October 2011
Nusajaya Centre &
Johor
Bio-XCell & UTM Enter Collaboration to Strengthen the Biotechnology
Ecosystem
Bio-XCell and Universiti Teknologi Malaysia (UTM) which are both
located within the Iskandar region of Johor agreed to work together to
establish strategic collaborations to strengthen the biotechnology
ecosystem at Bio-XCell. Some of the proposed initiatives include
graduate placement, specialised training, sharing of facilities and
strategic R&D collaborations.
A Memorandum of Collaboration (MoC) between the two organisations
was signed by CEO of Bio-XCell Rizatuddin Ramli and the Vice
Chancellor of UTM Professor Dato Dr Zaini Ujang, in the presence of
Prime Minister of Malaysia YAB Dato Seri Najib Tun Abdul Razak at the
Opening Ceremony of the concurrently held BioMalaysia 2011 and the
2011 Pacific Rim Summit on Industrial Biotechnology & Bioenergy
Conference and Exhibition held at the Kuala Lumpur Convention Centre.
Bio-XCell has initiated discussions with UTM on the utilisation of
facilities and services at UTM by Bio-XCell clients and the participation
of UTM within the Bio-XCell ecosystem.
One of the on-campus facilities at UTM which will expand the value
added services Bio-XCell can offer its clients is the Bioprocessing Pilot
Plant at Institute of Bioproduct Development (IBD). This is an integrated
multipurpose facility which provides a wide range of services from
primary bioprocess optimisation in small scale bioreactors of 16 litres to
a larger scale manufacturing in 1500 litres bioreactor.
DATE & VENUE EVENT
26 September 2011
Rizatuddin Ramli Appointed as New CEO of Bio-XCell
Bio-XCell announced the appointment of Rizatuddin Ramli as its Chief
Executive Officer following the resignation of its founding CEO, YM Raja
Ridzwa Raja Abd Aziz who was formerly from BiotechCorp.
Rizatuddin Ramli, 40, takes over the helm of Bio-XCell with its secured
investments of over RM750 million. Rizatuddin, a graduate in Computer
Information Systems and Operations Management from Indiana
University, Bloomington, USA, also holds a certificate in Advance
Industrial Marketing from INSEAD University, Fountainebleau, France.
He brings with him a wealth of experience in technology mapping and
management as well as industrial marketing.
31 October 2011

Nusajaya Centre &
Johor
Media Briefing and Site Visit
A visit to the Bio-XCell site in Iskandar, Johor was organised for
members of the media. The press were briefed on Bio-XCell; the
developments to date as well as the outlook for 2012 and how these
initiatives are working towards fulfilling the National Biotechnology
Policy, by its CEO, Rizatuddin Ramli.
90
This partnership will also facilitate graduate placement and industrial
training for UTM graduates. The academic programmes and specialised
short courses conducted by UTM will work towards providing the
industry with skilled manpower and expertise which will drive growth of
the biotechnology sector in Malaysia. One of the short courses cGMP
Facility for the Production of Biopharmaceuticals and Bioreactor Operation,
Maintenance and Troubleshooting was conducted specifically for
Bio-XCell staff in order to familiarise them with the needs of clients and
the industry.
6 December 2011
Bio-XCell Corporate
Kuala Lumpur,
Malaysia
21 November 2011
Biotechnology &
Convention Centre,
Malaysia
Glycos Biotechnologies Appoints Toyo Malaysia for Construction of
Biochemical Facility at Bio-XCell, to be Operational in 2013
Glycos Biotechnologies, Inc. (GlycosBio), an international biochemical
company focused on commercialising renewable, high-value specialty
chemicals, announced the appointment of Toyo Engineering & Construction
Sdn Bhd (Toyo Malaysia) to provide engineering, procurement, and
construction (EPC) services for its industrial biochemical production facility
at Bio-XCell, scheduled for completion in the second quarter of 2013.
GlycosBios commercial facility is being developed in several phases with
a targeted production rate capacity of up to 30,000 metric tons per year
by 2014 and with a subsequent scale-up to 90,000 metric tons.
Biochemicals targeted for production at GlycosBios plant include
isoprene, a key building block molecule used in the synthetic rubber industry.
GlycosBio will initially utilise the facility to validate the ability to produce
industrial ethanol from crude glycerine. The company will then further
demonstrate its flexible technology platform on a commercial scale
using a range of feedstocks including fatty acids. Production of
isoprene from low-value renewable feedstock readily available in
Malaysia at this facility is also planned for development and commercial
scale up.
DATE & VENUE EVENT
TECHNOLOGY MANAGEMENT OFFICE: ENHANCING
BIOTECH EXCELLENCE
BiotechCorp Technology Management Sdn Bhd (BTM) incorporated on 16 March 2011, is a wholly
owned subsidiary of the Malaysian Biotechnology Corporation Sdn Bhd (BiotechCorp). BTM in
the interim functions as a division of BiotechCorp also known as the Technology Management
Office (TMO). TMO is tasked to manage, develop and commercialise the technologies acquired
by BiotechCorp under the 9th Malaysian Plan Biotechnology Acquisition Programme (BAP).
Focus Areas:
Supercritical Fluid Extraction and Particle Formation Platform Technology: The
Supercritical Fluid Extraction and Particle Formation Platform Technology uses the unique
properties of carbon dioxide CO which at temperatures and pressures exceeding its
critical point will be in a high density state with properties of liquid as well as possess high
diffusivity, a characteristic of a gas. This allows for extraction beyond the limitations of
traditional extraction methods and the ability to produce standardised extracts of high
quality. The technology is housed at the Supercritical Fluid Extraction Centre (SFC) in
Universiti Putra Malaysia (UPM) that also offers Soxhlet extraction, fractionation and
particle formation (aqueous and organic) in addition to supercritical fluid extraction.
Marker Assisted Selection Platform Technology: The Marker Assisted Selection (MAS)
Platform Technology uses DNA markers to identify, link and select desired traits for
breeding. The application of this technology significantly accelerates the breeding
process from the usual 5 6 years in traditional breeding to about 2 years. MAS is
particularly useful for traits that are difficult to measure, exhibit low heritability and / or
expressed late in development. The technology is housed at the Centre for Marker
Discovery and Validation (CMDV) that offers high-throughput genotyping services such as
marker discovery, validation and selection as well as DNA finger printing for varietal /
accession identification of plants, livestock, aquaculture and commodity crops. To further
strengthen CMDVs capability as a regional centre, identification and validation of
molecular markers for crucial traits in rice, goat and watermelon have been undertaken.
Next Steps for Bio-XCell:
We will focus up the following areas to create a vibrant ecosystem for advancements in
industrial and healthcare biotechnology in Malaysia.
In the current phase of growth (phase 1) we will continue to focus on building up activities in
biomanufacturing and bioprocessing by engaging with regional and global biotech industry
players to attract foreign direct investment. Infrastructure and facilities are being developed
at Bio-XCell to support the needs of these industry leaders.

We w||| be strengthen|ng co||aborat|on w|th agenc|es, un|vers|t|es and |nst|tutes, bu||d|ng
partnerships with both public and private sectors to nurture the biotechnology ecosystem
and optimise the utilisation of the available resources and talent pool.
In gearing up for the next phase (phase II), we will focus on promoting innovation, R&D
activities and the bioeconomy. We hope to catalyse the participation of local companies in
R&D projects which will fuel future product pipelines. We also hope to develop local
capabilities through technology transfer and technology licensing in this phase.

The m|cro strateg|es for each phase w||| be ref|ned as we go a|ong, |n ||ne w|th g|oba| and
regional market trends, in optimising value creation for the local biotechnology sector and the
economy.
In achieving these objectives Bio-XCell will be an effective platform for commercialisation in
biotechnology, in meeting the objectives of Phase 2 of the National Biotechnology Policy
(NBP) the Science to Business phase.
Furthermore, initiatives by Bio-XCell are gearing up to fulfil Phase 3 of the NBP- Building and
Establishing Global Businesses in Biotechnology.
91
This partnership will also facilitate graduate placement and industrial
training for UTM graduates. The academic programmes and specialised
short courses conducted by UTM will work towards providing the
industry with skilled manpower and expertise which will drive growth of
the biotechnology sector in Malaysia. One of the short courses cGMP
Facility for the Production of Biopharmaceuticals and Bioreactor Operation,
Maintenance and Troubleshooting was conducted specifically for
Bio-XCell staff in order to familiarise them with the needs of clients and
the industry.
6 December 2011
Bio-XCell Corporate
Kuala Lumpur,
Malaysia
21 November 2011
Biotechnology &
Convention Centre,
Malaysia
Glycos Biotechnologies Appoints Toyo Malaysia for Construction of
Biochemical Facility at Bio-XCell, to be Operational in 2013
Glycos Biotechnologies, Inc. (GlycosBio), an international biochemical
company focused on commercialising renewable, high-value specialty
chemicals, announced the appointment of Toyo Engineering & Construction
Sdn Bhd (Toyo Malaysia) to provide engineering, procurement, and
construction (EPC) services for its industrial biochemical production facility
at Bio-XCell, scheduled for completion in the second quarter of 2013.
GlycosBios commercial facility is being developed in several phases with
a targeted production rate capacity of up to 30,000 metric tons per year
by 2014 and with a subsequent scale-up to 90,000 metric tons.
Biochemicals targeted for production at GlycosBios plant include
isoprene, a key building block molecule used in the synthetic rubber industry.
GlycosBio will initially utilise the facility to validate the ability to produce
industrial ethanol from crude glycerine. The company will then further
demonstrate its flexible technology platform on a commercial scale
using a range of feedstocks including fatty acids. Production of
isoprene from low-value renewable feedstock readily available in
Malaysia at this facility is also planned for development and commercial
scale up.
DATE & VENUE EVENT
TECHNOLOGY MANAGEMENT OFFICE: ENHANCING
BIOTECH EXCELLENCE
BiotechCorp Technology Management Sdn Bhd (BTM) incorporated on 16 March 2011, is a wholly
owned subsidiary of the Malaysian Biotechnology Corporation Sdn Bhd (BiotechCorp). BTM in
the interim functions as a division of BiotechCorp also known as the Technology Management
Office (TMO). TMO is tasked to manage, develop and commercialise the technologies acquired
by BiotechCorp under the 9th Malaysian Plan Biotechnology Acquisition Programme (BAP).
Focus Areas:
Supercritical Fluid Extraction and Particle Formation Platform Technology: The
Supercritical Fluid Extraction and Particle Formation Platform Technology uses the unique
properties of carbon dioxide CO which at temperatures and pressures exceeding its
critical point will be in a high density state with properties of liquid as well as possess high
diffusivity, a characteristic of a gas. This allows for extraction beyond the limitations of
traditional extraction methods and the ability to produce standardised extracts of high
quality. The technology is housed at the Supercritical Fluid Extraction Centre (SFC) in
Universiti Putra Malaysia (UPM) that also offers Soxhlet extraction, fractionation and
particle formation (aqueous and organic) in addition to supercritical fluid extraction.
Marker Assisted Selection Platform Technology: The Marker Assisted Selection (MAS)
Platform Technology uses DNA markers to identify, link and select desired traits for
breeding. The application of this technology significantly accelerates the breeding
process from the usual 5 6 years in traditional breeding to about 2 years. MAS is
particularly useful for traits that are difficult to measure, exhibit low heritability and / or
expressed late in development. The technology is housed at the Centre for Marker
Discovery and Validation (CMDV) that offers high-throughput genotyping services such as
marker discovery, validation and selection as well as DNA finger printing for varietal /
accession identification of plants, livestock, aquaculture and commodity crops. To further
strengthen CMDVs capability as a regional centre, identification and validation of
molecular markers for crucial traits in rice, goat and watermelon have been undertaken.
Next Steps for Bio-XCell:
We will focus up the following areas to create a vibrant ecosystem for advancements in
industrial and healthcare biotechnology in Malaysia.
In the current phase of growth (phase 1) we will continue to focus on building up activities in
biomanufacturing and bioprocessing by engaging with regional and global biotech industry
players to attract foreign direct investment. Infrastructure and facilities are being developed
at Bio-XCell to support the needs of these industry leaders.

We w||| be strengthen|ng co||aborat|on w|th agenc|es, un|vers|t|es and |nst|tutes, bu||d|ng
partnerships with both public and private sectors to nurture the biotechnology ecosystem
and optimise the utilisation of the available resources and talent pool.
In gearing up for the next phase (phase II), we will focus on promoting innovation, R&D
activities and the bioeconomy. We hope to catalyse the participation of local companies in
R&D projects which will fuel future product pipelines. We also hope to develop local
capabilities through technology transfer and technology licensing in this phase.

The m|cro strateg|es for each phase w||| be ref|ned as we go a|ong, |n ||ne w|th g|oba| and
regional market trends, in optimising value creation for the local biotechnology sector and the
economy.
In achieving these objectives Bio-XCell will be an effective platform for commercialisation in
biotechnology, in meeting the objectives of Phase 2 of the National Biotechnology Policy
(NBP) the Science to Business phase.
Furthermore, initiatives by Bio-XCell are gearing up to fulfil Phase 3 of the NBP- Building and
Establishing Global Businesses in Biotechnology.
92
DotScan P|atform Techno|ogy: The DotScan P|atform Techno|ogy |s an ant|body m|croarray
that uses ||ght to detect and measure amounts of target ce||s |n b|o|og|ca| samp|es such as
b|ood and serum that |s captured by an array of spec|f|c ant|bod|es. Th|s techno|ogy |s ab|e
to d|agnose and |dent|fy part|cu|ar d|seases based on the pattern that emerges from the
arrays by |dent|fy|ng |arge groups of |nteract|ons s|mu|taneous|y. Th|s h|gh-throughput
screen|ng can be app||ed to b|omarker d|scovery, d|sease d|agnos|s and prognos|s, drug
target d|scovery, and d|sease prof|||ng w|thout the need of spec|f|c b|omarkers based on the
un|que patterns that emerges from the |arge group of |nteract|ons. lnterested part|es can
sub-||cense the techno|ogy for the deve|opment of spec|f|c app||cat|ons or commerc|a||se the
c||n|ca||y va||dated app||cat|ons for the d|agnos|s and |dent|f|cat|on of spec|f|c |eukaem|a types.
Nanotechno|ogy P|atform: The Nanotechno|ogy P|atform a||ows the des|gn and synthes|s of
mu|t|funct|ona| |norgan|c nanopart|c|es of spec|f|c s|zes for a w|de range of app||cat|ons |n
f|e|ds such as mater|a|s, hea|thcare, cosmeceut|ca|, agr|cu|ture as we|| as |ndustr|a| and
env|ronmenta| d|agnost|c k|ts. The nanopart|c|es can generate phys|ca| or chem|ca|
react|ons contro||ed by an externa| source such as:
- NanoMag - Act|vat|on by a magnet|c f|e|d e.g. MRl}
- NanoPDT - Act|vat|on by a ||ght source e.g. |aser}
- NanoRay - Act|vat|on by -Ray
The fo||ow|ng are subs|d|ar|es |ncorporated under B|otechOorp Techno|ogy Management
Sdn Bhd:
|. B|otechOorp Supercr|t|ca| So|ut|ons Sdn Bhd
||. B|otechOorp Mo|ecu|ar So|ut|ons Sdn Bhd
|||. B|otechOorp D|agnost|c So|ut|ons Sdn Bhd
|v. B|otechOorp Nanotech So|ut|ons Sdn Bhd
Supercr|t|ca| F|u|d
Extract|on and
Part|c|e Format|on
P|atform Techno|ogy
The Supercr|t|ca| F|u|d Extract|on Oentre SFO} has been successfu||y
set-up at the Facu|ty of Food Sc|ence & Techno|ogy |n PM and |s
current|y undergo|ng the necessary regu|atory approva|s and |s
est|mated to commence |ts operat|ons at the end of the th|rd quarter of
2012. ln 2011, TMO promoted the p|atform by:
Part|c|pat|ng |n the Ma|ays|a Sc|ence, Techno|ogy & lnnovat|on mySTl}
2011 Expos|t|on.
Oo||aborat|ng w|th Yak|n B|o|abs Sdn Bhd to organ|se a sem|nar on
OO, Botan|ca| Extracts as the Better A|ternat|ve than Oonvent|on
So|vent Extracts" on 1 December 2011.
Key Results
Organ|s|ng a ta|k by Dr Noran|zan Mohd Adzahan from PM dur|ng the
sem|nar on OO, Botan|ca| Extracts as the Better A|ternat|ve than
Oonvent|on So|vent Extracts" on 1 December 2011.
Part|c|pat|ng |n the B|oMa|ays|a 2011 Exh|b|t|on.
Organ|s|ng a ta|k by Dr Ohong Gun Hean on Supercr|t|ca| F|u|d
Extract|on Techno|ogy and Supercr|t|ca| F|u|d Oentre |n PM dur|ng
B|oMa|ays|a 2011.
Marker Ass|sted
Se|ect|on P|atform
Techno|ogy
The Oentre for Marker D|scovery and va||dat|on OMDv} has been fu||y
set up and commenced |ts operat|ons |n 2011 after a successfu| |aunch
dur|ng B|oMa|ays|a 2011, |n the presence of Pr|me M|n|ster of Ma|ays|a
YAB Dato` Sr| Naj|b Tun Razak.
Dur|ng the |aunch, B|otechOorp and Ma|ays|an Agr|cu|tura| Research
and Deve|opment lnst|tute MARDl} had s|gned agreements w|th JEFl
Aquatech Resources Sdn Bhd, Ma|ays|an Pa|m O|| Board MPOB} and
Green Wor|d Genet|cs Sdn Bhd to ut|||se the serv|ces offered by OMDv.
TMO |ncreased pub||c awareness on the MAS P|atform Techno|ogy by:
Organ|s|ng an lntroductory Sem|nar on Oentre for Marker D|scovery
and va||dat|on on 21 June 2011.
Part|c|pat|ng |n the Ma|ays|an Sc|ence, Techno|ogy & lnnovat|on
mySTl} 2011 Expos|t|on.
Organ|s|ng a ta|k by Dr m| Ka|som b|nt| Abu Bakar from MARDl on
lntroduct|on to the Oentre for Marker D|scovery and va||dat|on
OMDv}" dur|ng B|oMa|ays|a 2011.
DotScan P|atform
Techno|ogy
The techno|ogy transfer for the DotScan P|atform Techno|ogy has been
successfu| w|th two techno|ogy custod|ans, the lnst|tute for Med|ca|
Research lMR} and PM. Both organ|sat|ons are current|y conduct|ng
research towards the deve|opment of new app||cat|ons ut|||s|ng the
DotScan P|atform Techno|ogy. ln add|t|on, th|s P|atform Techno|ogy has
garnered |nterest from severa| researchers as we|| as from the |ndustry
keen to deve|op app||cat|ons |n ||ne w|th the|r research |nterest as we|| as
to commerc|a||se the ava||ab|e |eukaem|a app||cat|on us|ng DotScan.
TMO promoted the DotScan P|atform Techno|ogy by:
Part|c|pat|ng |n the Ma|ays|a Sc|ence, Techno|ogy and lnnovat|on
93
DotScan P|atform Techno|ogy: The DotScan P|atform Techno|ogy |s an ant|body m|croarray
that uses ||ght to detect and measure amounts of target ce||s |n b|o|og|ca| samp|es such as
b|ood and serum that |s captured by an array of spec|f|c ant|bod|es. Th|s techno|ogy |s ab|e
to d|agnose and |dent|fy part|cu|ar d|seases based on the pattern that emerges from the
arrays by |dent|fy|ng |arge groups of |nteract|ons s|mu|taneous|y. Th|s h|gh-throughput
screen|ng can be app||ed to b|omarker d|scovery, d|sease d|agnos|s and prognos|s, drug
target d|scovery, and d|sease prof|||ng w|thout the need of spec|f|c b|omarkers based on the
un|que patterns that emerges from the |arge group of |nteract|ons. lnterested part|es can
sub-||cense the techno|ogy for the deve|opment of spec|f|c app||cat|ons or commerc|a||se the
c||n|ca||y va||dated app||cat|ons for the d|agnos|s and |dent|f|cat|on of spec|f|c |eukaem|a types.
Nanotechno|ogy P|atform: The Nanotechno|ogy P|atform a||ows the des|gn and synthes|s of
mu|t|funct|ona| |norgan|c nanopart|c|es of spec|f|c s|zes for a w|de range of app||cat|ons |n
f|e|ds such as mater|a|s, hea|thcare, cosmeceut|ca|, agr|cu|ture as we|| as |ndustr|a| and
env|ronmenta| d|agnost|c k|ts. The nanopart|c|es can generate phys|ca| or chem|ca|
react|ons contro||ed by an externa| source such as:
- NanoMag - Act|vat|on by a magnet|c f|e|d e.g. MRl}
- NanoPDT - Act|vat|on by a ||ght source e.g. |aser}
- NanoRay - Act|vat|on by -Ray
The fo||ow|ng are subs|d|ar|es |ncorporated under B|otechOorp Techno|ogy Management
Sdn Bhd:
|. B|otechOorp Supercr|t|ca| So|ut|ons Sdn Bhd
||. B|otechOorp Mo|ecu|ar So|ut|ons Sdn Bhd
|||. B|otechOorp D|agnost|c So|ut|ons Sdn Bhd
|v. B|otechOorp Nanotech So|ut|ons Sdn Bhd
Supercr|t|ca| F|u|d
Extract|on and
Part|c|e Format|on
P|atform Techno|ogy
The Supercr|t|ca| F|u|d Extract|on Oentre SFO} has been successfu||y
set-up at the Facu|ty of Food Sc|ence & Techno|ogy |n PM and |s
current|y undergo|ng the necessary regu|atory approva|s and |s
est|mated to commence |ts operat|ons at the end of the th|rd quarter of
2012. ln 2011, TMO promoted the p|atform by:
Part|c|pat|ng |n the Ma|ays|a Sc|ence, Techno|ogy & lnnovat|on mySTl}
2011 Expos|t|on.
Oo||aborat|ng w|th Yak|n B|o|abs Sdn Bhd to organ|se a sem|nar on
OO, Botan|ca| Extracts as the Better A|ternat|ve than Oonvent|on
So|vent Extracts" on 1 December 2011.
Key Results
Organ|s|ng a ta|k by Dr Noran|zan Mohd Adzahan from PM dur|ng the
sem|nar on OO, Botan|ca| Extracts as the Better A|ternat|ve than
Oonvent|on So|vent Extracts" on 1 December 2011.
Organ|s|ng a ta|k by Dr Ohong Gun Hean on Supercr|t|ca| F|u|d
Extract|on Techno|ogy and Supercr|t|ca| F|u|d Oentre |n PM dur|ng
B|oMa|ays|a 2011.
Marker Ass|sted
Se|ect|on P|atform
Techno|ogy
The Oentre for Marker D|scovery and va||dat|on OMDv} has been fu||y
set up and commenced |ts operat|ons |n 2011 after a successfu| |aunch
dur|ng B|oMa|ays|a 2011, |n the presence of Pr|me M|n|ster of Ma|ays|a
YAB Dato` Sr| Naj|b Tun Razak.
Dur|ng the |aunch, B|otechOorp and Ma|ays|an Agr|cu|tura| Research
and Deve|opment lnst|tute MARDl} had s|gned agreements w|th JEFl
Aquatech Resources Sdn Bhd, Ma|ays|an Pa|m O|| Board MPOB} and
Green Wor|d Genet|cs Sdn Bhd to ut|||se the serv|ces offered by OMDv.
TMO |ncreased pub||c awareness on the MAS P|atform Techno|ogy by:
Organ|s|ng an lntroductory Sem|nar on Oentre for Marker D|scovery
and va||dat|on on 21 June 2011.
Part|c|pat|ng |n the Ma|ays|an Sc|ence, Techno|ogy & lnnovat|on
Organ|s|ng a ta|k by Dr m| Ka|som b|nt| Abu Bakar from MARDl on
lntroduct|on to the Oentre for Marker D|scovery and va||dat|on
OMDv}" dur|ng B|oMa|ays|a 2011.
DotScan P|atform
Techno|ogy
The techno|ogy transfer for the DotScan P|atform Techno|ogy has been
successfu| w|th two techno|ogy custod|ans, the lnst|tute for Med|ca|
Research lMR} and PM. Both organ|sat|ons are current|y conduct|ng
research towards the deve|opment of new app||cat|ons ut|||s|ng the
DotScan P|atform Techno|ogy. ln add|t|on, th|s P|atform Techno|ogy has
garnered |nterest from severa| researchers as we|| as from the |ndustry
keen to deve|op app||cat|ons |n ||ne w|th the|r research |nterest as we|| as
to commerc|a||se the ava||ab|e |eukaem|a app||cat|on us|ng DotScan.
TMO promoted the DotScan P|atform Techno|ogy by:
94
Next Steps for Technology Management Office:
The Technology Management Office (TMO) will continue to manage and commercialise
platform technologies via the following strategies:
To assist in the development of value propositions for the technology custodians to further
develop and commercialise the technologies.
Engage w|th |ndustry p|ayers and commerc|a| partners to |ncrease awareness and
accelerate the adoption of the technologies as well as increasing the client base for the
platform technologies.
To |ncrease the techn|ca| manpower and tra|n|ng of the backup teams of each techno|ogy
to ensure the technology custodians are able to efficiently and effectively provide services
to their clientele.
To deve|op co||aborat|ons to ensure |ncreased ut|||sat|on of the p|atform techno|og|es.
To deve|op and cont|nuous|y standard|se the bus|ness and standard operat|ng
procedures (SOP) of the technology custodians. Improvement in management and SOPs
wou|d hasten the transformat|on of OMDv and SFE to a commerc|a| ent|ty that prov|des
efficient and effective services to their clients.
To ass|st the techno|ogy custod|ans |n manag|ng the|r c||ents as requ|red - before, dur|ng
and after the services are rendered.
To ||a|se w|th the techno|ogy ||censors to ensure that requ|red support |s prov|ded to the
technology custodians.
TMO will also be expanding its scope of business to offer:
Oustom|sed serv|ces to organ|sat|ons such as research |nst|tutes, un|vers|t|es, government
agencies and private companies for the commercialisation of intellectual property.
Bus|ness p|an workshops for compan|es app|y|ng for the B|oNexus Status.
Organ|s|ng a ta|k by the co-|nventor, Professor R|chard Ohr|stopherson
on Surface Prof|||ng of |eukaem|as, |ymphomas and Oo|orecta|
Oancers us|ng DotScan Ant|body M|croarrays" dur|ng B|oMa|ays|a 2011.
Organ|s|ng a ta|k by Dr Abh|manyu veerakumaras|vam from PM on
Nove| App||cat|ons for DotScan Ant|body M|croarrays" dur|ng
B|oMa|ays|a 2011.
Nanotechno|ogy
Platform
The techno|ogy transfer on the Nanotechno|ogy P|atform has been
comp|eted w|th a year-|ong tra|n|ng and the estab||shment of the
NanoB|otechno|ogy Research and lnnovat|on NanoBRl} Oentre under
the lnst|tute for Research |n Mo|ecu|ar Med|c|ne lNFORMM}. The
NanoBRl team compr|ses three pr|nc|pa| researchers from mu|t|d|sc|p||nary
backgrounds w|th ded|cated |aborator|es and state-of-the-art fac|||t|es
funded by SM |nc|ud|ng a nanomater|a|s synthes|s |aboratory, a
nanomater|a|s character|sat|on |aboratory, ce|| cu|ture fac|||t|es, |nverted
fluorescence microscopy facility and a biological laboratory. Research
by NanoBRl |nc|udes the des|gn and deve|opment of nanopart|c|es,
nanoco||o|ds, reagent des|gn, drug and mo|ecu|e carr|er des|gn and
deve|opment, ce||u|ar |mag|ng and d|agnost|c p|atforms. lt |s current|y
ab|e to produce NanoS|||ca, NanoMagnet|c, NanoGo|d and ||posome
nanoparticles. There is also an online nanotechnology platform for
pre-app||cat|on for those |nterested |n sub-||cens|ng the techno|ogy ln
add|t|on to that, |n 2011, to promote nanotechno|ogy and create more
awareness, TMO a|so carr|ed out the fo||ow|ng act|v|t|es:
Organ|s|ng a ta|k dur|ng the Hea|thcare Sem|nar for B|oNexus
Oompan|es organ|sed by the Bus|ness Deve|opment and lnvestment
D|v|s|on - Hea|thcare on 31 March 2011.
Organ|s|ng a ta|k by Assoc Prof Dr Az|an Abdu| Az|z from SM on
App||cat|on based on the Nanotechno|ogy P|atform" dur|ng
B|oMa|ays|a 2011.
95
Next Steps for Technology Management Office:
The Technology Management Office (TMO) will continue to manage and commercialise
platform technologies via the following strategies:
To assist in the development of value propositions for the technology custodians to further
develop and commercialise the technologies.
Engage w|th |ndustry p|ayers and commerc|a| partners to |ncrease awareness and
accelerate the adoption of the technologies as well as increasing the client base for the
platform technologies.
To |ncrease the techn|ca| manpower and tra|n|ng of the backup teams of each techno|ogy
to ensure the technology custodians are able to efficiently and effectively provide services
to their clientele.
To deve|op co||aborat|ons to ensure |ncreased ut|||sat|on of the p|atform techno|og|es.
To deve|op and cont|nuous|y standard|se the bus|ness and standard operat|ng
procedures (SOP) of the technology custodians. Improvement in management and SOPs
wou|d hasten the transformat|on of OMDv and SFE to a commerc|a| ent|ty that prov|des
efficient and effective services to their clients.
To ass|st the techno|ogy custod|ans |n manag|ng the|r c||ents as requ|red - before, dur|ng
and after the services are rendered.
To ||a|se w|th the techno|ogy ||censors to ensure that requ|red support |s prov|ded to the
technology custodians.
TMO will also be expanding its scope of business to offer:
Oustom|sed serv|ces to organ|sat|ons such as research |nst|tutes, un|vers|t|es, government
agencies and private companies for the commercialisation of intellectual property.
Bus|ness p|an workshops for compan|es app|y|ng for the B|oNexus Status.
Organ|s|ng a ta|k by the co-|nventor, Professor R|chard Ohr|stopherson
on Surface Prof|||ng of |eukaem|as, |ymphomas and Oo|orecta|
Oancers us|ng DotScan Ant|body M|croarrays" dur|ng B|oMa|ays|a 2011.
Organ|s|ng a ta|k by Dr Abh|manyu veerakumaras|vam from PM on
Nove| App||cat|ons for DotScan Ant|body M|croarrays" dur|ng
B|oMa|ays|a 2011.
Nanotechno|ogy
Platform
The techno|ogy transfer on the Nanotechno|ogy P|atform has been
comp|eted w|th a year-|ong tra|n|ng and the estab||shment of the
NanoB|otechno|ogy Research and lnnovat|on NanoBRl} Oentre under
the lnst|tute for Research |n Mo|ecu|ar Med|c|ne lNFORMM}. The
NanoBRl team compr|ses three pr|nc|pa| researchers from mu|t|d|sc|p||nary
backgrounds w|th ded|cated |aborator|es and state-of-the-art fac|||t|es
funded by SM |nc|ud|ng a nanomater|a|s synthes|s |aboratory, a
nanomater|a|s character|sat|on |aboratory, ce|| cu|ture fac|||t|es, |nverted
fluorescence microscopy facility and a biological laboratory. Research
by NanoBRl |nc|udes the des|gn and deve|opment of nanopart|c|es,
nanoco||o|ds, reagent des|gn, drug and mo|ecu|e carr|er des|gn and
deve|opment, ce||u|ar |mag|ng and d|agnost|c p|atforms. lt |s current|y
ab|e to produce NanoS|||ca, NanoMagnet|c, NanoGo|d and ||posome
nanoparticles. There is also an online nanotechnology platform for
pre-app||cat|on for those |nterested |n sub-||cens|ng the techno|ogy ln
add|t|on to that, |n 2011, to promote nanotechno|ogy and create more
awareness, TMO a|so carr|ed out the fo||ow|ng act|v|t|es:
Organ|s|ng a ta|k dur|ng the Hea|thcare Sem|nar for B|oNexus
Oompan|es organ|sed by the Bus|ness Deve|opment and lnvestment
D|v|s|on - Hea|thcare on 31 March 2011.
Organ|s|ng a ta|k by Assoc Prof Dr Az|an Abdu| Az|z from SM on
App||cat|on based on the Nanotechno|ogy P|atform" dur|ng
B|oMa|ays|a 2011.
96
VISIONING
THE FUTURE:
THE BIOECONOMY
IMPERATIVE
97
VISIONING
THE FUTURE:
THE BIOECONOMY
IMPERATIVE
98
BIOTECHCORPS BIOECONOMY ASPIRATIONS
Over the past two decades, substantial economic output and environmental benefits have
been attained by various economies across the globe through continued commercial
application of biotechnology. This has led to growing strategic interest in a bio-based
economy, or bioeconomy.
According to the Organisation for Economic Cooperation and Development (OECD),
bioeconomy is expected to contribute an average of 2.7% to global gross domestic product
(GDP) by 2030, and will involve all industries and economic sectors based on the values
implicit in biological materials which can be translated into new sources of income,
environmental sustainability and social well-being.
Recognising the significance of the bioeconomy to the future growth and strength of the
country, major world economies such as the United States and the European Union have
already begun initiating their own bioeconomy plans and blueprints in the recent year.
Malaysia, as one of the most competitive biotechnology hubs in the Asia Pacific region, has
also recognised the importance of bioeconomy, and has taken early critical steps in
coordinating and intensifying national efforts to harness its potential through the
implementation of the Bioeconomy Initiative Malaysia (BIM). BIM is a framework to implement
the action plan outlined in the National Biotechnology Policy (NBP) for development of the
biotechnology industry in various fields. It is envisaged to be one of the engines to improve
the national economy.
Endorsed by Malaysias Biotechnology Implementation Council and launched by the Prime
Minister of Malaysia YAB Dato Sri Najib Tun Razak during BioMalaysia 2011 in November,
BIM will enable the biotechnology industry to contribute to the nation becoming a
high-income economic powerhouse by year 2020.
Leveraging on the successes of NBP Phase 1: Capacity Building (2005-2010) at creating a
conducive, sustainable ecosystem for Research and Development (R&D) and commercialisation
in the areas of agriculture, healthcare and industrial biotechnology, the BIM is well positioned
to further enhance the role of biotechnology as a key cross-cutting technology driver in
transforming Malaysia into a high-income, knowledge-based economy.
In order to achieve this national ambition, the BIM aims to coordinate and intensify the
nations efforts to capitalise on the potential economic benefits of the entire biotechnology
ecosystem and related value chains, in line with the Economic Transformation Program. This
will be accomplished by maximising the participation of private industry in high-impact
opportunities in all industries and economic sectors that produce, manage, and utilise
biological resources, including agriculture, forestry, fisheries, food, wellness, chemicals and
renewable energy.
Through the BIM, Malaysia expects to unlock even greater opportunities in the local and
regional biotechnology industry, and enhance the participation of the private sector. At the
same time, the public sector is renewing its commitment to continue to provide and facilitate
the necessary support for the development of the approved projects.
By optimising the nations competitive edge through private and public participation,
Malaysia will continue to further strengthen its local biotechnology ecosystem for the growth
and development of a sustainable bioeconomy that will drive the countrys socio-economic
status to greater heights.
Visioning The
Future: The Bioeconomy
Imperative
99
BIOTECHCORPS BIOECONOMY ASPIRATIONS
Over the past two decades, substantial economic output and environmental benefits have
been attained by various economies across the globe through continued commercial
application of biotechnology. This has led to growing strategic interest in a bio-based
economy, or bioeconomy.
According to the Organisation for Economic Cooperation and Development (OECD),
bioeconomy is expected to contribute an average of 2.7% to global gross domestic product
(GDP) by 2030, and will involve all industries and economic sectors based on the values
implicit in biological materials which can be translated into new sources of income,
environmental sustainability and social well-being.
Recognising the significance of the bioeconomy to the future growth and strength of the
country, major world economies such as the United States and the European Union have
already begun initiating their own bioeconomy plans and blueprints in the recent year.
Malaysia, as one of the most competitive biotechnology hubs in the Asia Pacific region, has
also recognised the importance of bioeconomy, and has taken early critical steps in
coordinating and intensifying national efforts to harness its potential through the
implementation of the Bioeconomy Initiative Malaysia (BIM). BIM is a framework to implement
the action plan outlined in the National Biotechnology Policy (NBP) for development of the
biotechnology industry in various fields. It is envisaged to be one of the engines to improve
the national economy.
Endorsed by Malaysias Biotechnology Implementation Council and launched by the Prime
Minister of Malaysia YAB Dato Sri Najib Tun Razak during BioMalaysia 2011 in November,
BIM will enable the biotechnology industry to contribute to the nation becoming a
high-income economic powerhouse by year 2020.
Leveraging on the successes of NBP Phase 1: Capacity Building (2005-2010) at creating a
conducive, sustainable ecosystem for Research and Development (R&D) and commercialisation
in the areas of agriculture, healthcare and industrial biotechnology, the BIM is well positioned
to further enhance the role of biotechnology as a key cross-cutting technology driver in
transforming Malaysia into a high-income, knowledge-based economy.
In order to achieve this national ambition, the BIM aims to coordinate and intensify the
nations efforts to capitalise on the potential economic benefits of the entire biotechnology
ecosystem and related value chains, in line with the Economic Transformation Program. This
will be accomplished by maximising the participation of private industry in high-impact
opportunities in all industries and economic sectors that produce, manage, and utilise
biological resources, including agriculture, forestry, fisheries, food, wellness, chemicals and
renewable energy.
Through the BIM, Malaysia expects to unlock even greater opportunities in the local and
regional biotechnology industry, and enhance the participation of the private sector. At the
same time, the public sector is renewing its commitment to continue to provide and facilitate
the necessary support for the development of the approved projects.
By optimising the nations competitive edge through private and public participation,
Malaysia will continue to further strengthen its local biotechnology ecosystem for the growth
and development of a sustainable bioeconomy that will drive the countrys socio-economic
status to greater heights.
Visioning The
Future: The Bioeconomy
Imperative
100
STATEMENT ON
CORPORATE
GOVERNANCE
101
STATEMENT ON
CORPORATE
GOVERNANCE
102
The Board of Directors of BiotechCorp is committed to instilling a corporate culture which
emphasises on good corporate governance and the effective application of the principles
and best practises as set out in the Malaysian Code on Corporate Governance.
The Board remains fully resolved to ensuring that integrity, transparency, accountability and
professionalism are observed in the conduct of the business activities of BiotechCorp as
these core values will not only safeguard the interest of its stakeholders but will also
maximise the shareholder value.
A. Board of Directors
Composition and Balance
The Board currently comprises nine (9) members. With the exception of the Chief
Executive Officer, all the remaining members are non-executive directors.
A brief profile of each Director is contained in this Annual Report.
To ensure the balance of power and authority, the roles of the Chairman and the Chief
Executive Officer of the Company are clearly segregated.
The non-executive directors are independent of Management and are free from any
relationship that could materially affect or interfere with the exercise of their
independent judgement.
There were several changes in the Boards composition during the financial year 2011.
The changes are summarised in the table below:
* Tuan Haji Mohd. Radzi Husseins resignation on 22 August 2011 was in line with his
retirement from the civil service.
Meetings
The terms of reference of the Board provides for the Board to meet at least once in every
quarter with additional meetings convened as and when required. Meetings for the year are
scheduled early in the year. Due notice is given for scheduled meetings and additional
meetings are convened on an ad hoc basis for urgent and important matters. Where
appropriate, decisions are taken by way of circular resolutions in between scheduled meetings.
The agenda for each Board meeting and papers relating to the agenda items are
disseminated to all Directors prior to the meeting, in order to provide sufficient time for
the Directors to review the Board papers and seek clarifications, if any.
During the financial year under review, five (5) board meetings were held.
Details of attendance of each individual director in respect of the meetings held are
disclosed below:
Statement On
Corporate Governance
Name
YBhg Datuk Roseley Dato Haji Khalid - Director
YBhg Dato Iskandar Mizal Mahmood - Director and CEO
YBhg Dato Dr Mohd Nazlee Kamal - Director and CEO
YBhg Dato Sulaiman Md Zain - Director
Remarks
Resigned on 13 July 2011
Appointed on 18 July 2011
Resigned on 12 December 2011
Name
YBhg Dato Abd Wahab Maskan - Director
Puan Norsimah Ab Wahab - Director
Tuan Haji Mohd. Radzi Hussein* - Director
YBhg Tan Sri Dato Dr Jegathesan a/l
N.M. Vasagam @ Manikavasagam - Director
Dr Radzuan A. Rahman - Director
Encik Amirul Fares Wan Zahir - Director
Remarks
Resigned on 1 August 2011
Appointed on 1 August 2011
Re-appointed on 1 December 2011
Appointed on 17 October 2011
Appointed on 16 December 2011
YBhg Tan Sri Datuk Dr Ahmad Zaharudin Idrus
YBhg Dato Iskandar Mizal Mahmood
YBhg Dato Puteh Rukiah Abd Majid
YBhg Dato Madinah Mohamad
Tuan Haji Mohd. Radzi Hussein#
Professor Dr Zainul Fadziruddin Zainuddin
5/5
2/2
1/1
4/5
4/4
4/5
100
100
100
80
100
80
Name of Directors
Number of
Board Meetings attended/held in 2011
(during the Directors tenure)
Attended %
103
The Board of Directors of BiotechCorp is committed to instilling a corporate culture which
emphasises on good corporate governance and the effective application of the principles
and best practises as set out in the Malaysian Code on Corporate Governance.
The Board remains fully resolved to ensuring that integrity, transparency, accountability and
professionalism are observed in the conduct of the business activities of BiotechCorp as
these core values will not only safeguard the interest of its stakeholders but will also
maximise the shareholder value.
A. Board of Directors
Composition and Balance
The Board currently comprises nine (9) members. With the exception of the Chief
Executive Officer, all the remaining members are non-executive directors.
A brief profile of each Director is contained in this Annual Report.
To ensure the balance of power and authority, the roles of the Chairman and the Chief
Executive Officer of the Company are clearly segregated.
The non-executive directors are independent of Management and are free from any
relationship that could materially affect or interfere with the exercise of their
independent judgement.
There were several changes in the Boards composition during the financial year 2011.
The changes are summarised in the table below:
* Tuan Haji Mohd. Radzi Husseins resignation on 22 August 2011 was in line with his
retirement from the civil service.
Meetings
The terms of reference of the Board provides for the Board to meet at least once in every
quarter with additional meetings convened as and when required. Meetings for the year are
scheduled early in the year. Due notice is given for scheduled meetings and additional
meetings are convened on an ad hoc basis for urgent and important matters. Where
appropriate, decisions are taken by way of circular resolutions in between scheduled meetings.
The agenda for each Board meeting and papers relating to the agenda items are
disseminated to all Directors prior to the meeting, in order to provide sufficient time for
the Directors to review the Board papers and seek clarifications, if any.
During the financial year under review, five (5) board meetings were held.
Details of attendance of each individual director in respect of the meetings held are
disclosed below:
Statement On
Corporate Governance
Name
YBhg Datuk Roseley Dato Haji Khalid - Director
YBhg Dato Iskandar Mizal Mahmood - Director and CEO
YBhg Dato Dr Mohd Nazlee Kamal - Director and CEO
YBhg Dato Sulaiman Md Zain - Director
Remarks
Resigned on 12 December 2011
Name
YBhg Dato Abd Wahab Maskan - Director
Puan Norsimah Ab Wahab - Director
Tuan Haji Mohd. Radzi Hussein* - Director
N.M. Vasagam @ Manikavasagam - Director
Dr Radzuan A. Rahman - Director
Encik Amirul Fares Wan Zahir - Director
Remarks
Appointed on 1 August 2011
Re-appointed on 1 December 2011
Appointed on 17 October 2011
YBhg Tan Sri Datuk Dr Ahmad Zaharudin Idrus
YBhg Dato Iskandar Mizal Mahmood
YBhg Dato Puteh Rukiah Abd Majid
YBhg Dato Madinah Mohamad
Tuan Haji Mohd. Radzi Hussein#
Professor Dr Zainul Fadziruddin Zainuddin
5/5
2/2
1/1
4/5
4/4
4/5
100
100
100
80
100
80
Name of Directors
Number of
Attended %
104
Board Committees
The Board of Directors had established various Board Committees and delegated
certain responsibilities to these Committees including the Audit Committee (AC) and the
Nomination and Remuneration Committee (NRC).
These Committees operate within clearly defined terms of reference approved by the Board.
(a) Audit Committee (AC)
The Committees role is to review the Companys financial reporting and to ensure
the effectiveness of the systems of internal control and compliance.
The AC currently comprises the following members:
(i) Tuan Haji Mohd. Radzi Hussein - Chairperson
(ii) Professor Dr Zainul Fadziruddin Zainuddin
(iii) Puan Norsimah Ab Wahab
(iv) Encik Amirul Fares Wan Zahir
The AC met four (4) times during the financial year ended 31 December 2011.
(b) Nomination and Remuneration Committee (NRC)
The Committee is primarily responsible for the following:
a) to review, evaluate and analyse all matters relating to the Companys Human
Resource Policies and Procedures;
b) to review, assess and determine the Companys employee remuneration and
benefits structure; and
c) to oversee the selection and appointment of Senior Management personnel
of the Company
The NRC currently comprises the following members:
(i) YBhg Tan Sri Datuk Dr Ahmad Zaharudin Idrus Chairman
(iii) YBhg Tan Sri Dato Dr Jegathesan a/l N.M. Vasagam @ Manikavasagam

The NRC met three (3) times during the financial year ended 31 December 2011.
(c) Other Committees established by the Board, include the following:
(i) Tender Board A
(ii) Tender Board B
(iii) Programme Recommendation Committee
(iv) Programme Approval Committee
(v) Commercialisation and Technology Acquisition Grant (CTAG) Technical Committee
(vi) CTAG Approval Committee
(vii) Pre-Disbursement Committee
# The Board had during its meeting held on 12 August 2011 accepted the resignation
of Tuan Haji Mohd. Radzi Husseins membership to the Board and to all related Board
Committees with effect from 22 August 2011. Tuan Haji Mohd. Radzi Hussein was
re-appointed to the Board on 1 December 2011.
Supply of Information to the Board
Board Meetings are structured with pre-set agendas. Relevant documents and papers
to be tabled to the meeting are circulated in advance to ensure there is sufficient time
for the Directors to obtain further information where necessary and to facilitate informed
decision-making process.
All Directors have full and immediate access to information relating to the Companys
business and affairs in the discharge of their duties.
Appointment and Re-election of Directors
During the period under review, the Board had approved the appointment of YBhg Dato
Dr Mohd Nazlee Kamal, YBhg Dato Sulaiman Md Zain, Puan Norsimah Ab Wahab,
YBhg Tan Sri Dato Dr Jegathesan a/l N.M. Vasagam @ Manikavasagam, Tuan Haji
Mohd. Radzi Hussein, Dr Radzuan A. Rahman and Encik Amirul Fares Wan Zahir as
Directors of the Company.
In line with the Memorandum and Articles of Association of the Company, the election
of Directors takes place each year, where one-third of the Directors retire from office at
each Annual General Meeting (AGM); the Directors are eligible to offer themselves for
re-election.
The Articles also provide that Directors appointed in the year by the Board shall hold
office until the next following AGM, and shall be eligible for re-election thereat.
YBhg Datuk Roseley Dato Haji Khalid
YBhg Dato Abd Wahab Maskan
YBhg Dato Dr Mohd Nazlee Kamal
YBhg Dato Sulaiman Md Zain
Puan Norsimah Ab Wahab
N.M. Vasagam @ Manikavasagam
2/2
0/2
3/3
3/3
2/3
2/2
100
0
100
100
67
100
Name of Directors
Number of
Attended %
105
Board Committees
The Board of Directors had established various Board Committees and delegated
certain responsibilities to these Committees including the Audit Committee (AC) and the
Nomination and Remuneration Committee (NRC).
These Committees operate within clearly defined terms of reference approved by the Board.
(a) Audit Committee (AC)
The Committees role is to review the Companys financial reporting and to ensure
the effectiveness of the systems of internal control and compliance.
The AC currently comprises the following members:
(i) Tuan Haji Mohd. Radzi Hussein - Chairperson
(iii) Puan Norsimah Ab Wahab
(iv) Encik Amirul Fares Wan Zahir
The AC met four (4) times during the financial year ended 31 December 2011.
(b) Nomination and Remuneration Committee (NRC)
The Committee is primarily responsible for the following:
a) to review, evaluate and analyse all matters relating to the Companys Human
Resource Policies and Procedures;
b) to review, assess and determine the Companys employee remuneration and
benefits structure; and
c) to oversee the selection and appointment of Senior Management personnel
of the Company
The NRC currently comprises the following members:
(i) YBhg Tan Sri Datuk Dr Ahmad Zaharudin Idrus Chairman
(iii) YBhg Tan Sri Dato Dr Jegathesan a/l N.M. Vasagam @ Manikavasagam

The NRC met three (3) times during the financial year ended 31 December 2011.
(c) Other Committees established by the Board, include the following:
(i) Tender Board A
(ii) Tender Board B
(iii) Programme Recommendation Committee
(iv) Programme Approval Committee
(v) Commercialisation and Technology Acquisition Grant (CTAG) Technical Committee
(vi) CTAG Approval Committee
(vii) Pre-Disbursement Committee
# The Board had during its meeting held on 12 August 2011 accepted the resignation
of Tuan Haji Mohd. Radzi Husseins membership to the Board and to all related Board
Committees with effect from 22 August 2011. Tuan Haji Mohd. Radzi Hussein was
re-appointed to the Board on 1 December 2011.
Supply of Information to the Board
Board Meetings are structured with pre-set agendas. Relevant documents and papers
to be tabled to the meeting are circulated in advance to ensure there is sufficient time
for the Directors to obtain further information where necessary and to facilitate informed
decision-making process.
All Directors have full and immediate access to information relating to the Companys
business and affairs in the discharge of their duties.
Appointment and Re-election of Directors
During the period under review, the Board had approved the appointment of YBhg Dato
Dr Mohd Nazlee Kamal, YBhg Dato Sulaiman Md Zain, Puan Norsimah Ab Wahab,
YBhg Tan Sri Dato Dr Jegathesan a/l N.M. Vasagam @ Manikavasagam, Tuan Haji
Mohd. Radzi Hussein, Dr Radzuan A. Rahman and Encik Amirul Fares Wan Zahir as
Directors of the Company.
In line with the Memorandum and Articles of Association of the Company, the election
of Directors takes place each year, where one-third of the Directors retire from office at
each Annual General Meeting (AGM); the Directors are eligible to offer themselves for
re-election.
The Articles also provide that Directors appointed in the year by the Board shall hold
office until the next following AGM, and shall be eligible for re-election thereat.
YBhg Datuk Roseley Dato Haji Khalid
YBhg Dato Abd Wahab Maskan
YBhg Dato Dr Mohd Nazlee Kamal
YBhg Dato Sulaiman Md Zain
Puan Norsimah Ab Wahab
N.M. Vasagam @ Manikavasagam
2/2
0/2
3/3
3/3
2/3
2/2
100
0
100
100
67
100
Name of Directors
Number of
Attended %
106
B. Reports to Shareholders & Investors
BiotechCorp reports the Operating Expenditure (OPEX) and Development Expenditure
received from the Ministry of Science, Technology and Innovation and the Ministry of
Finance based on approved deliverables and targets set by and between the
Government and BiotechCorp.
C. Accountability and Audit
Financial Reporting
In presenting the annual financial statements to the Stakeholders, the Board aims to
present a balanced and accurate assessment of BiotechCorps position and
deliverables.

The Audit Committee assists by scrutinising the information to be disclosed, to ensure
accuracy and transparency.
Directors Responsibility Statement
The Directors are required by the Companies Act, 1965 to prepare financial statements
for each financial year which have been made out in accordance with the provisions of
the Act and applicable approved accounting standards and thus, provide a true and fair
view of the state of affairs of the Company at the end of the financial year and of the
results and cash flows of the Company for the said financial year.
The Directors are satisfied that in preparing the financial statements of the Company for
the financial year ended 31 December 2011, the Company had used the appropriate
accounting policies and applied them consistently.
The Directors are also of the view that relevant approved accounting standards were
followed in the preparation of these financial statements.
Internal Control
The Board of BiotechCorp recognises the pivotal role of a strong internal control system
in keeping the Company on course towards achieving its goals and objectives.
Towards this end, the Board had established the necessary framework for an internal
control system which covers the areas of risk management, financial, organisational,
operations and compliance with relevant laws and regulations.
Management Estab||shed Comm|ttees
Several committees were established by the Management to deliberate and decide
on administrative, operational, corporate risks issues, management reports, KPI
achievements and status of projects undertaken by divisions, departments as well as
business units within the Company.
The Committees established by the Management are, namely:
(i) Management Committee
(ii) Risk Management Committee
(iii) Operational Committee
Performance Rev|ew
The Board receives and reviews regular reports from the Management which are
required to be brought to its attention for discussion, thus ensuring that it maintains
full and effective supervision as well as appropriate control.
The Board approved Corporate Scorecard, Business Plan and Budget are closely
monitored by the Management. Variances and critical operational issues are followed
up and appropriate actions are undertaken to address the same.
At the end of the financial year, the Companys performance and financial results are
tabled to the Board.
Interna| Aud|t Funct|on
The Internal Audit Department (IAD) is independent of the activities and operations of
the Company. The duties of the Internal Auditors are performed impartially,
proficiently and with professional due care.
Overall, the IAD is responsible for advising the Company on established policies,
guidelines, controls and security procedures in order to minimise risks, prevent
losses and promote efficiency and effectiveness in achieving BiotechCorps mission
as entrusted under the National Biotechnology Policy.
Company-w|de Cont|nuous Process Improvement In|t|at|ves
Quality Management System ISO 9001:2008
The QMS initiative aims at providing support, facilitation and advisory services to
nurture and develop biotechnology companies in Malaysia through delivery of high
quality and customer-oriented services as well as efficient work processes which are
continuously reviewed and improved.
BiotechCorp passed the 2nd Surveillance audit conducted by Moody International
on 30 November 2011 with no major or minor non-conformances reported.
107
B. Reports to Shareholders & Investors
BiotechCorp reports the Operating Expenditure (OPEX) and Development Expenditure
received from the Ministry of Science, Technology and Innovation and the Ministry of
Finance based on approved deliverables and targets set by and between the
Government and BiotechCorp.
C. Accountability and Audit
Financial Reporting
In presenting the annual financial statements to the Stakeholders, the Board aims to
present a balanced and accurate assessment of BiotechCorps position and
deliverables.

The Audit Committee assists by scrutinising the information to be disclosed, to ensure
accuracy and transparency.
Directors Responsibility Statement
The Directors are required by the Companies Act, 1965 to prepare financial statements
for each financial year which have been made out in accordance with the provisions of
the Act and applicable approved accounting standards and thus, provide a true and fair
view of the state of affairs of the Company at the end of the financial year and of the
results and cash flows of the Company for the said financial year.
The Directors are satisfied that in preparing the financial statements of the Company for
the financial year ended 31 December 2011, the Company had used the appropriate
accounting policies and applied them consistently.
The Directors are also of the view that relevant approved accounting standards were
followed in the preparation of these financial statements.
Internal Control
The Board of BiotechCorp recognises the pivotal role of a strong internal control system
in keeping the Company on course towards achieving its goals and objectives.
Towards this end, the Board had established the necessary framework for an internal
control system which covers the areas of risk management, financial, organisational,
operations and compliance with relevant laws and regulations.
Management Estab||shed Comm|ttees
Several committees were established by the Management to deliberate and decide
on administrative, operational, corporate risks issues, management reports, KPI
achievements and status of projects undertaken by divisions, departments as well as
business units within the Company.
The Committees established by the Management are, namely:
(i) Management Committee
(ii) Risk Management Committee
(iii) Operational Committee
Performance Rev|ew
The Board receives and reviews regular reports from the Management which are
required to be brought to its attention for discussion, thus ensuring that it maintains
full and effective supervision as well as appropriate control.
The Board approved Corporate Scorecard, Business Plan and Budget are closely
monitored by the Management. Variances and critical operational issues are followed
up and appropriate actions are undertaken to address the same.
At the end of the financial year, the Companys performance and financial results are
tabled to the Board.
Interna| Aud|t Funct|on
The Internal Audit Department (IAD) is independent of the activities and operations of
the Company. The duties of the Internal Auditors are performed impartially,
proficiently and with professional due care.
Overall, the IAD is responsible for advising the Company on established policies,
guidelines, controls and security procedures in order to minimise risks, prevent
losses and promote efficiency and effectiveness in achieving BiotechCorps mission
as entrusted under the National Biotechnology Policy.
Company-w|de Cont|nuous Process Improvement In|t|at|ves
Quality Management System ISO 9001:2008
The QMS initiative aims at providing support, facilitation and advisory services to
nurture and develop biotechnology companies in Malaysia through delivery of high
quality and customer-oriented services as well as efficient work processes which are
continuously reviewed and improved.
BiotechCorp passed the 2nd Surveillance audit conducted by Moody International
on 30 November 2011 with no major or minor non-conformances reported.
108
Business Continuity Plan and Crisis Simulation Exercise
The Business Continuity Plan (BCP) serves as a structured framework which sets out
the planning methodology to ensure that any disruption to the operations of the
business units, as a result of any eventualities, is kept at a minimum therefore
building business resiliency. The BCP is intended to prepare the Company to manage
recovery operations in the event of any disaster.
A crisis simulation exercise was conducted on 19 September 2011 to test the
established plans. Continual improvement and documentation review of the BCP are
carried out to ensure that these plans remain effective and relevant.
Records Management System based on ISO15489:2001 and Document
Management System
In an effort to mitigate business and operational risks, the Records Management
System (RMS) based on ISO15489:2001 standards was initiated in 2010. RMS is an
expansion of the scope of the Quality Management System ISO9001:2008s Control
of Records Procedure.
A Record Management Policy (RM Policy) was established in the first phase of the
RMS project. During the implementation stage, Paradigm 3 and Document
Management System (DMS) were integrated into the RMS.
Paradigm 3, an IT integrated system, facilitates the establishment of a centralized
corporate document and records system to provide an effective storage management
and expeditious retrieval process. For the purpose of Paradigm 3, records were
identified and classified into four depending on its security level, namely Highly
Confidential, Confidential, Restricted and Public.
BiotechCorp passed the RMS Audit in December 2011 with no major or minor
non-conformances reported.
D. Relationship with External Auditors
The Company maintains a transparent and appropriate relationship with the External
Auditors.
Where necessary, the External Auditors advice are sought to ensure that the Company
complies with applicable accounting standards and all statutory requirements.
The External Auditors are invited to attend meetings to deliberate on audit plans and
annual financial results and to make necessary recommendations for the Boards
consideration.
31 March 2012
109
Business Continuity Plan and Crisis Simulation Exercise
The Business Continuity Plan (BCP) serves as a structured framework which sets out
the planning methodology to ensure that any disruption to the operations of the
business units, as a result of any eventualities, is kept at a minimum therefore
building business resiliency. The BCP is intended to prepare the Company to manage
recovery operations in the event of any disaster.
A crisis simulation exercise was conducted on 19 September 2011 to test the
established plans. Continual improvement and documentation review of the BCP are
carried out to ensure that these plans remain effective and relevant.
Records Management System based on ISO15489:2001 and Document
Management System
In an effort to mitigate business and operational risks, the Records Management
System (RMS) based on ISO15489:2001 standards was initiated in 2010. RMS is an
expansion of the scope of the Quality Management System ISO9001:2008s Control
of Records Procedure.
A Record Management Policy (RM Policy) was established in the first phase of the
RMS project. During the implementation stage, Paradigm 3 and Document
Management System (DMS) were integrated into the RMS.
Paradigm 3, an IT integrated system, facilitates the establishment of a centralized
corporate document and records system to provide an effective storage management
and expeditious retrieval process. For the purpose of Paradigm 3, records were
identified and classified into four depending on its security level, namely Highly
Confidential, Confidential, Restricted and Public.
BiotechCorp passed the RMS Audit in December 2011 with no major or minor
non-conformances reported.
D. Relationship with External Auditors
The Company maintains a transparent and appropriate relationship with the External
Auditors.
Where necessary, the External Auditors advice are sought to ensure that the Company
complies with applicable accounting standards and all statutory requirements.
The External Auditors are invited to attend meetings to deliberate on audit plans and
annual financial results and to make necessary recommendations for the Boards
consideration.
31 March 2012
110
FINANCIAL
STATEMENTS
111
FINANCIAL
STATEMENTS
112
MALAYSIAN BIOTECHNOLOGY CORPORATION SDN. BHD.
(Incorporated in Malaysia)
DIRECTORS REPORT
The directors of MALAYSIAN BIOTECHNOLOGY CORPORATION SDN. BHD. have pleasure
in submitting their report and the audited financial statements of the Group and of the
Company for the year ended 31 December 2011.
PRINCIPAL ACTIVITIES
The Company is principally engaged to act as a dedicated and professional one-stop agency
for the government in developing biotechnology industry in the country whilst the principal
activities of the subsidiaries are as stated in Note 9 to the Financial Statements. There have
been no significant changes in the nature of these principal activities during the year.
RESULTS OF OPERATIONS
The results of operations of the Group and of the Company for the financial year are as
follows:
In the opinion of the directors, the results of operations of the Group and of the Company
during the financial year have not been substantially affected by any item, transaction or
event of a material and unusual nature.
DIVIDENDS
No dividend has been paid or declared by the Company since the end of the previous
financial year. The directors do not recommend any dividend payment in respect of the
current financial year.
RESERVES AND PROVISIONS
There were no material transfers to or from reserves or provisions during the financial year.
ISSUE OF SHARES AND DEBENTURES
The Company has not issued any new shares or debentures during the financial year.
SHARE OPTIONS
No options have been granted by the Company to any parties during the financial year to
take up unissued shares of the Company.
OTHER STATUTORY INFORMATION
Before the income statements and balance sheets of the Group and of the Company were
made out, the directors took reasonable steps:
(a) to ascertain that proper action had been taken in relation to the writing off of bad debts
and the making of allowance for doubtful debts, and had satisfied themselves that all
known bad debts had been written off and that adequate provision had been made for
doubtful debts; and
(b) to ensure that any current assets which were unlikely to realise their book values in the
ordinary course of business had been written down to their estimated realisable values.
As of the date of this report, the directors are not aware of any circumstances:
(a) which would render the amount written off of as bad debts or the amount of allowance
for doubtful debts in the financial statements of the Group and of the Company to any
substantial extent; or
(b) which would render the values attributed to the current assets in the financial
statements of the Group and of the Company misleading; or
(c) which have arisen which render adherence to the existing method of valuation of assets
or liabilities of the Group and of the Company misleading or inappropriate; or
(d) not otherwise dealt with in this report or financial statements which would render any
amount stated in the financial statements of the Group and of the Company misleading.

At the date of this report, there does not exist:
(a) any charge on the assets of the Group or of the Company that has arisen since the end
of the financial year and which secures the liabilities of any other person; or
(b) any contingent liability in respect of the Group or of the Company that has arisen since
the end of the financial year.

Financial
Statements
Company
RM
Group
RM
Net profit for the year 2,833,632 8,092,369
113
DIRECTORS REPORT
The directors of MALAYSIAN BIOTECHNOLOGY CORPORATION SDN. BHD. have pleasure
in submitting their report and the audited financial statements of the Group and of the
Company for the year ended 31 December 2011.
PRINCIPAL ACTIVITIES
The Company is principally engaged to act as a dedicated and professional one-stop agency
for the government in developing biotechnology industry in the country whilst the principal
activities of the subsidiaries are as stated in Note 9 to the Financial Statements. There have
been no significant changes in the nature of these principal activities during the year.
RESULTS OF OPERATIONS
The results of operations of the Group and of the Company for the financial year are as
follows:
In the opinion of the directors, the results of operations of the Group and of the Company
during the financial year have not been substantially affected by any item, transaction or
event of a material and unusual nature.
DIVIDENDS
No dividend has been paid or declared by the Company since the end of the previous
financial year. The directors do not recommend any dividend payment in respect of the
current financial year.
RESERVES AND PROVISIONS
There were no material transfers to or from reserves or provisions during the financial year.
ISSUE OF SHARES AND DEBENTURES
The Company has not issued any new shares or debentures during the financial year.
SHARE OPTIONS
No options have been granted by the Company to any parties during the financial year to
take up unissued shares of the Company.
OTHER STATUTORY INFORMATION
Before the income statements and balance sheets of the Group and of the Company were
made out, the directors took reasonable steps:
(a) to ascertain that proper action had been taken in relation to the writing off of bad debts
and the making of allowance for doubtful debts, and had satisfied themselves that all
known bad debts had been written off and that adequate provision had been made for
doubtful debts; and
(b) to ensure that any current assets which were unlikely to realise their book values in the
ordinary course of business had been written down to their estimated realisable values.
As of the date of this report, the directors are not aware of any circumstances:
(a) which would render the amount written off of as bad debts or the amount of allowance
for doubtful debts in the financial statements of the Group and of the Company to any
substantial extent; or
(b) which would render the values attributed to the current assets in the financial
statements of the Group and of the Company misleading; or
(c) which have arisen which render adherence to the existing method of valuation of assets
or liabilities of the Group and of the Company misleading or inappropriate; or
(d) not otherwise dealt with in this report or financial statements which would render any
amount stated in the financial statements of the Group and of the Company misleading.

At the date of this report, there does not exist:
(a) any charge on the assets of the Group or of the Company that has arisen since the end
of the financial year and which secures the liabilities of any other person; or
(b) any contingent liability in respect of the Group or of the Company that has arisen since
the end of the financial year.

Financial
Statements
Company
RM
Group
RM
Net profit for the year 2,833,632 8,092,369
114
No contingent liability or other liability of any company in the Group has become
enforceable, or is likely to become enforceable within the period of twelve months after the
end of the financial year which, in the opinion of the Directors, will or may substantially affect
the ability of the Group and of the Company to meet their obligations as and when they fall due.
In the opinion of the directors, no item, transaction or event of a material and unusual nature
has arisen in the interval between the end of the financial year and the date of this report
which is likely to affect substantially the results of operations of the Group and of the
Company for the succeeding financial year.
DIRECTORS
The following directors served on the Board of the Company since the date of the last report:
Tan Sri Datuk Dr Ahmad Zaharudin bin Idrus
Dato` Mad|nah b|nt| Mohamad
Prof Dr Za|nu| Fadz|rudd|n b|n Za|nudd|n
Dr Radzuan b|n A. Rahman appo|nted on 16 December 2011}
Am|ru| Fares b|n Wan Zah|r appo|nted on 16 December 2011}
Tan Sr| Dato` Dr Jegathesan A/| N.M. vasagam @ Man|kavasagam appo|nted on 17
October 2011}
Nors|mah b|nt| Ab Wahab appo|nted on 1 August 2011}
Dato` Dr Mohd Naz|ee b|n Kama| appo|nted on 18 Ju|y 2011}
Dato` Su|a|man b|n Md Za|n appo|nted on 18 Ju|y 2011, res|gned on 12 December 2011}
Mohd. Radz| b|n Husse|n res|gned on 22 August 2011, and re-appo|nted on 1 December
2011}
Dato` Abd Wahab b|n Maskan res|gned on 1 August 2011}
Dato` lskandar M|za| b|n Mahmood res|gned on 16 Ju|y 2011}
Datuk Rose|ey b|n Dato` Haj| Kha||d res|gned on 13 Ju|y 2011}
DIRECTORS INTERESTS
None of the directors in office at the end of the financial year held shares or had beneficial
interest in the shares of the Company during and at the end of the financial year.
DIRECTORS BENEFITS
Since the end of the previous financial year, none of the directors of the Company has
rece|ved or become ent|t|ed to rece|ve any benef|t other than the benef|t |nc|uded |n the
aggregate amount of emoluments received or due and receivable by the directors as shown
in the financial statements or the fixed salary of a full time employee of the Company or of
the re|ated corporat|on} by reason of a contract made by the Oompany or a re|ated
corporation with the director or with a firm of which he or she is a member, or with a
company in which he or she has a substantial financial interest.
During and at the end of the financial year, no arrangement subsisted to which the Company
was a party whereby directors of the Company might acquire benefits by means of the
acquisition of shares in, or debentures of, the Company or any other body corporate.
HOLDING CORPORATION
The Oompany |s a subs|d|ary company of M|n|ster of F|nance lncorporated}, a body
corporate |ncorporated pursuant to the M|n|ster of F|nance lncorporat|on} Act, 1957
Rev|sed 1989}.
AUDITORS
The aud|tors, Messrs. De|o|tte Kass|mOhan, have |nd|cated the|r w||||ngness to cont|nue |n
office.
Signed on behalf of the Board
in accordance with a resolution of the Directors,
TAN SRI DATUK DR AHMAD ZAHARUDIN BIN IDRUS
DATO DR MOHD NAZLEE BIN KAMAL
Kua|a |umpur
7 May 2012
115
No contingent liability or other liability of any company in the Group has become
enforceable, or is likely to become enforceable within the period of twelve months after the
end of the financial year which, in the opinion of the Directors, will or may substantially affect
the ability of the Group and of the Company to meet their obligations as and when they fall due.
In the opinion of the directors, no item, transaction or event of a material and unusual nature
has arisen in the interval between the end of the financial year and the date of this report
which is likely to affect substantially the results of operations of the Group and of the
Company for the succeeding financial year.
DIRECTORS
The following directors served on the Board of the Company since the date of the last report:
Tan Sri Datuk Dr Ahmad Zaharudin bin Idrus
Dato` Mad|nah b|nt| Mohamad
Prof Dr Za|nu| Fadz|rudd|n b|n Za|nudd|n
Dr Radzuan b|n A. Rahman appo|nted on 16 December 2011}
Am|ru| Fares b|n Wan Zah|r appo|nted on 16 December 2011}
Tan Sr| Dato` Dr Jegathesan A/| N.M. vasagam @ Man|kavasagam appo|nted on 17
October 2011}
Nors|mah b|nt| Ab Wahab appo|nted on 1 August 2011}
Dato` Dr Mohd Naz|ee b|n Kama| appo|nted on 18 Ju|y 2011}
Dato` Su|a|man b|n Md Za|n appo|nted on 18 Ju|y 2011, res|gned on 12 December 2011}
Mohd. Radz| b|n Husse|n res|gned on 22 August 2011, and re-appo|nted on 1 December
2011}
Dato` Abd Wahab b|n Maskan res|gned on 1 August 2011}
Dato` lskandar M|za| b|n Mahmood res|gned on 16 Ju|y 2011}
Datuk Rose|ey b|n Dato` Haj| Kha||d res|gned on 13 Ju|y 2011}
DIRECTORS INTERESTS
None of the directors in office at the end of the financial year held shares or had beneficial
interest in the shares of the Company during and at the end of the financial year.
DIRECTORS BENEFITS
Since the end of the previous financial year, none of the directors of the Company has
rece|ved or become ent|t|ed to rece|ve any benef|t other than the benef|t |nc|uded |n the
aggregate amount of emoluments received or due and receivable by the directors as shown
in the financial statements or the fixed salary of a full time employee of the Company or of
the re|ated corporat|on} by reason of a contract made by the Oompany or a re|ated
corporation with the director or with a firm of which he or she is a member, or with a
company in which he or she has a substantial financial interest.
During and at the end of the financial year, no arrangement subsisted to which the Company
was a party whereby directors of the Company might acquire benefits by means of the
acquisition of shares in, or debentures of, the Company or any other body corporate.
HOLDING CORPORATION
The Oompany |s a subs|d|ary company of M|n|ster of F|nance lncorporated}, a body
corporate |ncorporated pursuant to the M|n|ster of F|nance lncorporat|on} Act, 1957
Rev|sed 1989}.
AUDITORS
The aud|tors, Messrs. De|o|tte Kass|mOhan, have |nd|cated the|r w||||ngness to cont|nue |n
office.
Kua|a |umpur
7 May 2012
116
INDEPENDENT AUDITORS REPORT TO THE MEMBERS OF MALAYSIAN
BIOTECHNOLOGY CORPORATION SDN. BHD.
Report on the Financial Statements
We have audited the financial statements of MALAYSIAN BIOTECHNOLOGY CORPORATION
SDN. BHD., which comprise the balance sheets of the Group and of the Company as of 31
December 2011 and the income statements, statements of changes in equity and cash flow
statements for the year then ended, and a summary of significant accounting policies and
other explanatory information, as set out on page 118 to 143.
Directors Responsibility for the Financial Statements
The directors of the Company are responsible for the preparation of financial statements that
give a true and fair view in accordance with Private Entity Reporting Standards and the
Companies Act, 1965 in Malaysia and for such internal control as the directors determine is
necessary to enable the preparation of financial statements that are free from material
misstatement, whether due to fraud or error.
Auditors Responsibility
Our responsibility is to express an opinion on these financial statements based on our audit.
We conducted our audit in accordance with approved standards on auditing in Malaysia.
Those standards require that we comply with ethical requirements and plan and perform the
audit to obtain reasonable assurance whether the financial statements are free from material
misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and
disclosures in the financial statements. The procedures selected depend on the auditors
judgment, including the assessment of the risks of material misstatement of the financial
statements, whether due to fraud or error. In making those risk assessments, the auditors
consider internal control relevant to the entitys preparation of financial statements that give
a true and fair view in order to design audit procedures that are appropriate in the
circumstances, but not for the purpose of expressing an opinion on the effectiveness of the
entitys internal control. An audit also includes evaluating the appropriateness of accounting
policies used and the reasonableness of accounting estimates made by the directors, as
well as evaluating the overall presentation of the financial statements.
We believe that the audit evidence that we have obtained is sufficient and appropriate to
provide a basis for our audit opinion.
Opinion
In our opinion, the financial statements have been properly drawn up in accordance with
Private Entity Reporting Standards and the Companies Act, 1965 in Malaysia so as to give
a true and fair view of the financial position of the Group and of the Company as of 31
December 2011 and of their financial performance and cash flows for the year then ended.
Report on Other Legal and Regulatory Requirements
In accordance with the requirements of the Companies Act, 1965 in Malaysia, we also report that:
(a) in our opinion, the accounting and other records and the registers required by the Act to
be kept by the Company and its subsidiaries have been properly kept in accordance with
the provisions of the Act;
(b) we are satisfied that the accounts of the subsidiaries that have been consolidated with the
financial statements of the Company are in the form and content appropriate and proper
for the purposes of the preparation of the financial statements of the Group, and we have
received satisfactory information and explanations as required by us for these purposes;
and
(c) the auditors report on the accounts of the subsidiaries were not subject to any
qualification and did not include any comment made under of Section 174(3) of the Act.
Other Matters
This report is made solely to the members of the Company, as a body, in accordance with
Section 174 of the Companies Act, 1965 in Malaysia and for no other purpose. We do not
assume responsibility towards any other person for the contents of this report.
DELOITTE KASSIMCHAN
AF 0080
KAMARUL BAHARIN BIN TENGKU ZAINAL ABIDIN
Partner - 2903/11/13 (J)
Chartered Accountant
7 May 2012
(Forward)
117
INDEPENDENT AUDITORS REPORT TO THE MEMBERS OF MALAYSIAN
BIOTECHNOLOGY CORPORATION SDN. BHD.
Report on the Financial Statements
We have audited the financial statements of MALAYSIAN BIOTECHNOLOGY CORPORATION
SDN. BHD., which comprise the balance sheets of the Group and of the Company as of 31
December 2011 and the income statements, statements of changes in equity and cash flow
statements for the year then ended, and a summary of significant accounting policies and
other explanatory information, as set out on page 118 to 143.
Directors Responsibility for the Financial Statements
The directors of the Company are responsible for the preparation of financial statements that
give a true and fair view in accordance with Private Entity Reporting Standards and the
Companies Act, 1965 in Malaysia and for such internal control as the directors determine is
necessary to enable the preparation of financial statements that are free from material
misstatement, whether due to fraud or error.
Auditors Responsibility
Our responsibility is to express an opinion on these financial statements based on our audit.
We conducted our audit in accordance with approved standards on auditing in Malaysia.
Those standards require that we comply with ethical requirements and plan and perform the
audit to obtain reasonable assurance whether the financial statements are free from material
misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and
disclosures in the financial statements. The procedures selected depend on the auditors
judgment, including the assessment of the risks of material misstatement of the financial
statements, whether due to fraud or error. In making those risk assessments, the auditors
consider internal control relevant to the entitys preparation of financial statements that give
a true and fair view in order to design audit procedures that are appropriate in the
circumstances, but not for the purpose of expressing an opinion on the effectiveness of the
entitys internal control. An audit also includes evaluating the appropriateness of accounting
policies used and the reasonableness of accounting estimates made by the directors, as
well as evaluating the overall presentation of the financial statements.
We believe that the audit evidence that we have obtained is sufficient and appropriate to
provide a basis for our audit opinion.
Opinion
In our opinion, the financial statements have been properly drawn up in accordance with
Private Entity Reporting Standards and the Companies Act, 1965 in Malaysia so as to give
a true and fair view of the financial position of the Group and of the Company as of 31
December 2011 and of their financial performance and cash flows for the year then ended.
Report on Other Legal and Regulatory Requirements
In accordance with the requirements of the Companies Act, 1965 in Malaysia, we also report that:
(a) in our opinion, the accounting and other records and the registers required by the Act to
be kept by the Company and its subsidiaries have been properly kept in accordance with
the provisions of the Act;
(b) we are satisfied that the accounts of the subsidiaries that have been consolidated with the
financial statements of the Company are in the form and content appropriate and proper
for the purposes of the preparation of the financial statements of the Group, and we have
received satisfactory information and explanations as required by us for these purposes;
and
(c) the auditors report on the accounts of the subsidiaries were not subject to any
qualification and did not include any comment made under of Section 174(3) of the Act.
Other Matters
This report is made solely to the members of the Company, as a body, in accordance with
Section 174 of the Companies Act, 1965 in Malaysia and for no other purpose. We do not
assume responsibility towards any other person for the contents of this report.
DELOITTE KASSIMCHAN
AF 0080
KAMARUL BAHARIN BIN TENGKU ZAINAL ABIDIN
Partner - 2903/11/13 (J)
Chartered Accountant
7 May 2012
(Forward)
118
AND ITS SUBSIDIARIES
INCOME STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2011
BALANCE SHEETS
AS OF 31 DECEMBER 2011
(Forward)
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Note
Non-Current Assets
Total Non-Current Assets
Property, plant and equipment
Technology platform assets
Investment in subsidiaries
ASSETS
7
8
9
93,428,013
45,100,285
-
138,528,298
50,072,679
24,957,281
-
75,029,960
3,106,773
45,100,285
4
48,207,062
9,520,839
24,957,281
2
34,478,122
Capital and Reserves
Minority interests
Total Equity
Share capital
Accumulated losses
EQUITY AND LIABILITIES
12 95,000,002
(19,212,586)
75,787,416
39,736,066
115,523,482
95,000,002
(22,046,218)
72,953,784
35,550,132
108,503,916
95,000,002
(14,044,376)
80,955,626
-
80,955,626
95,000,002
(22,136,745)
72,863,257
-
72,863,257
Current Assets
Total Current Assets
Total Assets
Other receivables, deposits
and prepayments
Cash and bank balances
10
11
8,973,660
209,328,388
218,302,048
356,830,346
16,258,970
313,480,807
329,739,777
404,769,737
115,983,497
155,759,186
271,742,683
319,949,745
119,908,518
214,703,693
334,612,211
369,090,333
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Note
4
7
5
6
49,278,354
(27,182,055)
(7,489,580)
(9,680,400)
(2,109,959)
(3,280,129)
(463,769)
(6,665)
(470,434)
-
(470,434)
3,304,066

2,833,632
45,413,249
(17,336,132)
(8,776,153)
(10,422,339)
(2,896,705)
(1,878,891)
4,103,029
(18,287)
4,084,742
(32,745)
4,051,997
(9,830)

4,042,167
48,859,923
(22,255,147)
(6,498,488)
(7,967,880)
(2,069,742)
(1,969,632)
8,099,034
(6,665)
8,092,369
-
8,092,369
-
8,092,369
44,977,618
(17,336,132)
(8,577,492)
(10,415,362)
(2,896,705)
(1,878,829)
3,873,098
(18,287)
3,854,811
-
3,854,811
-
3,854,811
Other operating income
Staff costs
Promotion and corporate
communication expenses
Administrative expenses
Depreciation
Other operating expenses
(Loss)/profit from operations
Interest expense
(Loss)/Profit before tax
Tax expense
Net (Loss)/Profit after tax
Minority interests
Net profit for the year
The accompanying Notes form an integral part of the Financial Statements.
119
INCOME STATEMENTS
BALANCE SHEETS
AS OF 31 DECEMBER 2011
(Forward)
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Note
Non-Current Assets
Total Non-Current Assets
Technology platform assets
Investment in subsidiaries
ASSETS
7
8
9
93,428,013
45,100,285
-
138,528,298
50,072,679
24,957,281
-
75,029,960
3,106,773
45,100,285
4
48,207,062
9,520,839
24,957,281
2
34,478,122
Capital and Reserves
Minority interests
Total Equity
Share capital
Accumulated losses
EQUITY AND LIABILITIES
12 95,000,002
(19,212,586)
75,787,416
39,736,066
115,523,482
95,000,002
(22,046,218)
72,953,784
35,550,132
108,503,916
95,000,002
(14,044,376)
80,955,626
-
80,955,626
95,000,002
(22,136,745)
72,863,257
-
72,863,257
Current Assets
Total Current Assets
Total Assets
Other receivables, deposits
and prepayments
10
11
8,973,660
209,328,388
218,302,048
356,830,346
16,258,970
313,480,807
329,739,777
404,769,737
115,983,497
155,759,186
271,742,683
319,949,745
119,908,518
214,703,693
334,612,211
369,090,333
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Note
4
7
5
6
49,278,354
(27,182,055)
(7,489,580)
(9,680,400)
(2,109,959)
(3,280,129)
(463,769)
(6,665)
(470,434)
-
(470,434)
3,304,066

2,833,632
45,413,249
(17,336,132)
(8,776,153)
(10,422,339)
(2,896,705)
(1,878,891)
4,103,029
(18,287)
4,084,742
(32,745)
4,051,997
(9,830)

4,042,167
48,859,923
(22,255,147)
(6,498,488)
(7,967,880)
(2,069,742)
(1,969,632)
8,099,034
(6,665)
8,092,369
-
8,092,369
-
8,092,369
44,977,618
(17,336,132)
(8,577,492)
(10,415,362)
(2,896,705)
(1,878,829)
3,873,098
(18,287)
3,854,811
-
3,854,811
-
3,854,811
Other operating income
Staff costs
Promotion and corporate
communication expenses
Administrative expenses
Depreciation
Other operating expenses
(Loss)/profit from operations
Interest expense
Tax expense
Minority interests
120
STATEMENTS OF CHANGES IN EQUITY
Share
Capital
RM
Accumulated
Losses
RM
Total
RM
Minority
Interest
RM
Total
Equity
RM
At 1 January 2010
Subscription of shares by
minority shareholder
At 31 December 2010/
1 January 2011
At 31 December 2011
Group
Company
Share
Capital
RM
Accumulated
Losses
RM
Total
RM
At 1 January 2010
At 31 December 2010/1 January 2011
At 31 December 2011
95,000,002
-
95,000,002
-
95,000,002
(25,991,556)
3,854,811
(22,136,745)
8,092,369
(14,044,376)
69,008,446
3,854,811
72,863,257
8,092,369
80,955,626
95,000,002
-
-
95,000,002
-
-
95,000,002
(26,088,385)
-
4,042,167
(22,046,218)
-
2,833,632
(19,212,586)
68,911,617
-
4,042,167
72,953,784
-
2,833,632
75,787,416
15,794
35,524,508
9,830
35,550,132
7,490,000
(3,304,066)
39,736,066
68,927,411
35,524,508
4,051,997
108,503,916
7,490,000
(470,434)
115,523,482
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Note
Non-Current Liabilities
Deferred income
Hire-purchase liabilities
Total Non-Current Liabilities
Current Liabilities
Other payables and accruals
Hire-purchase payables -
current portion
Tax liability
Total Current Liabilities
Total Liabilities
Total Equity and Liabilities
13
14
15
14
196,035,996
11,083
196,047,079
45,240,785
19,000
-
45,259,785
241,306,864
356,830,346
223,105,529
30,083
223,135,612
73,053,976
43,488
32,745
73,130,209
296,265,821
404,769,737
196,035,996
11,083
196,047,079
42,928,040
19,000
-
42,947,040
238,994,119
319,949,745
223,105,529
30,083
223,135,612
73,047,976
43,488
-
73,091,464
296,227,076
369,090,333
The accompanying Notes form an integral part of the Financial Statements. The accompanying Notes form an integral part of the Financial Statements.
Attributable to shareholders of the Company
121
STATEMENTS OF CHANGES IN EQUITY
Share
Capital
RM
Accumulated
Losses
RM
Total
RM
Minority
Interest
RM
Total
Equity
RM
At 1 January 2010
At 31 December 2010/
1 January 2011
At 31 December 2011
Group
Company
Share
Capital
RM
Accumulated
Losses
RM
Total
RM
At 1 January 2010
At 31 December 2010/1 January 2011
At 31 December 2011
95,000,002
-
95,000,002
-
95,000,002
(25,991,556)
3,854,811
(22,136,745)
8,092,369
(14,044,376)
69,008,446
3,854,811
72,863,257
8,092,369
80,955,626
95,000,002
-
-
95,000,002
-
-
95,000,002
(26,088,385)
-
4,042,167
(22,046,218)
-
2,833,632
(19,212,586)
68,911,617
-
4,042,167
72,953,784
-
2,833,632
75,787,416
15,794
35,524,508
9,830
35,550,132
7,490,000
(3,304,066)
39,736,066
68,927,411
35,524,508
4,051,997
108,503,916
7,490,000
(470,434)
115,523,482
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Note
Non-Current Liabilities
Deferred income
Hire-purchase liabilities
Total Non-Current Liabilities
Current Liabilities
Hire-purchase payables -
current portion
Tax liability
Total Current Liabilities
Total Liabilities
Total Equity and Liabilities
13
14
15
14
196,035,996
11,083
196,047,079
45,240,785
19,000
-
45,259,785
241,306,864
356,830,346
223,105,529
30,083
223,135,612
73,053,976
43,488
32,745
73,130,209
296,265,821
404,769,737
196,035,996
11,083
196,047,079
42,928,040
19,000
-
42,947,040
238,994,119
319,949,745
223,105,529
30,083
223,135,612
73,047,976
43,488
-
73,091,464
296,227,076
369,090,333
The accompanying Notes form an integral part of the Financial Statements. The accompanying Notes form an integral part of the Financial Statements.
Attributable to shareholders of the Company
122
CASH FLOW STATEMENTS
Company
2011 2010
RM RM
Group
2011 2010
RM RM
CASH FLOWS FROM
OPERATING ACTIVITIES
Adjustments for:
Tax expense
Depreciation of property, plant
and equipment
Amortisation of technology
platform assets
Allowance for doubtful debts/
(Reversal of allowance)
Interest expense
Bad debts written off
Amortisation of government grants
Interest income
Interest income on intercompany loan
Provision for accumulating
compensated absences
Operating loss before working capital
changes
Changes in working capital:
Other receivables, deposits and
prepayments
Cash Used In Operations
Tax paid
Net Cash Used In Operating
Activities
(470,434)
-
2,109,959
1,763,367
177,788
6,665
4,333
(48,413,134)
(13,043,594)
-
(34,617)
(57,899,667)
13,618,583
(1,195,666)
(45,476,750)
(32,745)
(45,509,495)
4,051,997
32,745
2,896,705
677,058
(82,527)
18,287
-
(67,293,917)
(9,210,705)
-
79,374
(68,830,983)
1,044,066
458,215
(67,328,702)
-
(67,328,702)
8,092,369
-
2,069,742
1,763,367
177,788
6,665
4,333
(48,413,134)
(10,484,165)
(2,151,698)
(34,617)
(48,969,350)
13,855,730
(3,502,410)
(38,616,030)
-
(38,616,030)
3,854,811
-
2,896,705
677,058
(82,527)
18,287
-
(67,293,917)
(8,796,075)
-
79,374
(68,646,284)
1,044,066
454,215
(67,148,003)
-
(67,148,003)
Company
2011 2010
RM RM
Group
2011 2010
RM RM
CASH FLOWS FROM
INVESTING ACTIVITIES
Purchase of property, plant
and equipment
Acquisition of technology
licenses and equipment
Interest received
Acquisition of shares in a
subsidiary
Advances to subsidiaries
Net Cash Used In Investing
Activities
CASH FLOWS FROM
FINANCING ACTIVITIES
Developmental government
grants received
Non-developmental government
grants received
Developmental grants disbursed
Hire purchase repayments
Interest paid
Subscription of ordinary shares
by minority shareholder
Subscription of Redeemable
Convertible Preferences Shares
(RCPS) by minority shareholder
Net Cash (Used In)/From
Financing Activities
(51,314,977)
(13,379,639)
8,737,238
-
-
(55,957,378)
5,000,000
26,587,292
(41,712,685)
(43,488)
(6,665)
7,490,000
-
(2,685,546)
(45,354,582)
(2,359,773)
8,438,736
-
-
(39,275,619)
47,507,000
19,407,933
(49,740,690)
(112,046)
(18,287)
360,000
35,164,508
52,568,418
(1,505,360)
(13,379,639)
6,068,089
(2)
(1,336,019)
(10,152,931)
5,000,000
26,587,292
(41,712,685)
(43,488)
(6,665)
-
-
(10,175,546)
(4,802,742)
(2,359,773)
8,196,216
-
(103,640,660)
(102,606,959)
47,507,000
19,407,933
(49,740,690)
(112,046)
(18,287)
-
-
17,043,910
(Forward) (Forward)
123
CASH FLOW STATEMENTS
Company
2011 2010
RM RM
Group
2011 2010
RM RM
CASH FLOWS FROM
OPERATING ACTIVITIES
Adjustments for:
Tax expense
Depreciation of property, plant
and equipment
Amortisation of technology
platform assets
Allowance for doubtful debts/
(Reversal of allowance)
Interest expense
Amortisation of government grants
Interest income
Interest income on intercompany loan
Operating loss before working capital
changes
Changes in working capital:
Other receivables, deposits and
prepayments
Cash Used In Operations
Tax paid
Net Cash Used In Operating
Activities
(470,434)
-
2,109,959
1,763,367
177,788
6,665
4,333
(48,413,134)
(13,043,594)
-
(34,617)
(57,899,667)
13,618,583
(1,195,666)
(45,476,750)
(32,745)
(45,509,495)
4,051,997
32,745
2,896,705
677,058
(82,527)
18,287
-
(67,293,917)
(9,210,705)
-
79,374
(68,830,983)
1,044,066
458,215
(67,328,702)
-
(67,328,702)
8,092,369
-
2,069,742
1,763,367
177,788
6,665
4,333
(48,413,134)
(10,484,165)
(2,151,698)
(34,617)
(48,969,350)
13,855,730
(3,502,410)
(38,616,030)
-
(38,616,030)
3,854,811
-
2,896,705
677,058
(82,527)
18,287
-
(67,293,917)
(8,796,075)
-
79,374
(68,646,284)
1,044,066
454,215
(67,148,003)
-
(67,148,003)
Company
2011 2010
RM RM
Group
2011 2010
RM RM
CASH FLOWS FROM
INVESTING ACTIVITIES
Purchase of property, plant
and equipment
Acquisition of technology
licenses and equipment
Interest received
Acquisition of shares in a
subsidiary
Advances to subsidiaries
Net Cash Used In Investing
Activities
CASH FLOWS FROM
FINANCING ACTIVITIES
Developmental government
grants received
Non-developmental government
grants received
Developmental grants disbursed
Hire purchase repayments
Interest paid
Subscription of ordinary shares
by minority shareholder
Subscription of Redeemable
Convertible Preferences Shares
(RCPS) by minority shareholder
Net Cash (Used In)/From
Financing Activities
(51,314,977)
(13,379,639)
8,737,238
-
-
(55,957,378)
5,000,000
26,587,292
(41,712,685)
(43,488)
(6,665)
7,490,000
-
(2,685,546)
(45,354,582)
(2,359,773)
8,438,736
-
-
(39,275,619)
47,507,000
19,407,933
(49,740,690)
(112,046)
(18,287)
360,000
35,164,508
52,568,418
(1,505,360)
(13,379,639)
6,068,089
(2)
(1,336,019)
(10,152,931)
5,000,000
26,587,292
(41,712,685)
(43,488)
(6,665)
-
-
(10,175,546)
(4,802,742)
(2,359,773)
8,196,216
-
(103,640,660)
(102,606,959)
47,507,000
19,407,933
(49,740,690)
(112,046)
(18,287)
-
-
17,043,910
(Forward) (Forward)
124
NOTES TO THE FINANCIAL STATEMENTS
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Note
11
NET DECREASE IN
CASH AND CASH
EQUIVALENTS
CASH AND CASH
EQUIVALENTS AT
BEGINNING OF YEAR
CASH AND CASH
EQUIVALENTS AT
END OF YEAR
(104,152,419)
313,480,807
209,328,388
(54,035,903)
367,516,710
313,480,807
(58,944,507)
214,703,693
155,759,186
(152,711,052)
367,414,745
214,703,693
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Deposits placed with licensed
financial institutions
12,780,415
196,547,973
209,328,388
7,842,807
305,638,000
313,480,807
9,225,186
146,534,000
155,759,186
6,065,693
208,638,000
214,703,693
Cash and cash equivalents comprise:
GENERAL INFORMATION
The Company is a private limited liability company, incorporated and domiciled in
Malaysia.
The Company is principally engaged to act as a dedicated and professional one-stop
agency for the government in developing biotechnology industry in the country whilst
the principal activities of the subsidiaries are as stated in Note 9. There have been no
significant changes in the nature of these principal activities during the year.

The total number of employees of the Group and of the Company at year end were 207
(2010: 186) and 172 (2010: 186) respectively.
The registered office and principal place of business of the Company is located at Level
23, Menara Atlan, 161B, Jalan Ampang, 50450 Kuala Lumpur.
The financial statements of the Group and of the Company have been authorised by the
Board of Directors for issuance on 7 May 2012.
BASIS OF PREPARATION OF THE FINANCIAL STATEMENTS
The financial statements of the Group and of the Company have been prepared in
accordance with the provisions of the Companies Act, 1965 and Private Entity
Reporting Standards in Malaysia.
SIGNIFICANT ACCOUNTING POLICIES
Basis of Accounting
The financial statements of the Group and of the Company have been prepared under
the historical cost convention. Historical cost is generally based on the fair value of the
consideration involved in exchange for assets and liabilities.
1.
2.
3.
125
NOTES TO THE FINANCIAL STATEMENTS
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Note
11
NET DECREASE IN
CASH AND CASH
EQUIVALENTS
CASH AND CASH
EQUIVALENTS AT
BEGINNING OF YEAR
CASH AND CASH
EQUIVALENTS AT
END OF YEAR
(104,152,419)
313,480,807
209,328,388
(54,035,903)
367,516,710
313,480,807
(58,944,507)
214,703,693
155,759,186
(152,711,052)
367,414,745
214,703,693
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Deposits placed with licensed
financial institutions
12,780,415
196,547,973
209,328,388
7,842,807
305,638,000
313,480,807
9,225,186
146,534,000
155,759,186
6,065,693
208,638,000
214,703,693
Cash and cash equivalents comprise:
GENERAL INFORMATION
The Company is a private limited liability company, incorporated and domiciled in
Malaysia.
The Company is principally engaged to act as a dedicated and professional one-stop
agency for the government in developing biotechnology industry in the country whilst
the principal activities of the subsidiaries are as stated in Note 9. There have been no
significant changes in the nature of these principal activities during the year.

The total number of employees of the Group and of the Company at year end were 207
(2010: 186) and 172 (2010: 186) respectively.
The registered office and principal place of business of the Company is located at Level
23, Menara Atlan, 161B, Jalan Ampang, 50450 Kuala Lumpur.
The financial statements of the Group and of the Company have been authorised by the
Board of Directors for issuance on 7 May 2012.
BASIS OF PREPARATION OF THE FINANCIAL STATEMENTS
The financial statements of the Group and of the Company have been prepared in
accordance with the provisions of the Companies Act, 1965 and Private Entity
Reporting Standards in Malaysia.
SIGNIFICANT ACCOUNTING POLICIES
Basis of Accounting
The financial statements of the Group and of the Company have been prepared under
the historical cost convention. Historical cost is generally based on the fair value of the
consideration involved in exchange for assets and liabilities.
1.
2.
3.
126
Basis of Consolidation
Subsidiaries
Subsidiaries are entities, including unincorporated entities, controlled by the Group.
Control exists when the Group has the ability to exercise its power to govern the
financial and operating policies of an entity so as to obtain benefits from its activities. In
assessing control, potential voting rights that presently are exercisable are taken into
account. Subsidiaries are consolidated using the purchase method of accounting.
Under the purchase method of accounting, the financial statements of subsidiaries are
included in the consolidated financial statements from the date that control commences
until the date that control ceases.
Investments in subsidiaries are stated in the Companys balance sheet at cost less any
impairment losses.
Minority interest
Minority interest at the balance sheet date, being the portion of the net identifiable
assets (excluding goodwill) of subsidiaries attributable to equity interests that are not
owned by the Company, whether directly or indirectly through subsidiaries, are
presented in the consolidated balance sheet and statement of changes in equity within
equity, separately from equity attributable to the equity shareholders of the Company.
Minority interest in the results of the Group are presented on the face of the
consolidated income statement as an allocation of the total profit or loss for the year
between minority interest and the equity shareholders of the Company.
Where losses applicable to the minority exceed the minoritys interest in the equity of a
subsidiary, the excess, and any further losses applicable to the minority, are charged
against the Groups interest except to the extent that the minority has a binding obligation
to, and is able to, make additional investment to cover the losses. If the subsidiary
subsequently reports profits, the Groups interest is allocated with all such profits until the
minoritys share of losses previously absorbed by the Group has been recovered.
Transactions eliminated on consolidation
Intra-group balances and transactions, and any unrealised income and expenses
arising from intra-group transactions, are eliminated in preparing the consolidated
financial statements.

Foreign Currency Conversion
Transactions in foreign currencies are converted into Ringgit Malaysia at the exchange
rates prevailing at the transaction dates. Foreign currency assets and liabilities at
financial year-end are converted into Ringgit Malaysia at the exchange rates prevailing
at the balance sheet date. All foreign exchange gains or losses are taken up in the
income statements.
The principal closing rates used in the translation of foreign currency amounts are as
follows:
Income Tax
Income tax comprises current and deferred tax. Current tax is the expected amount of
income taxes payable in respect of the taxable profit for the year and is measured using
the tax rates that have been enacted or substantively enacted by the balance sheet date.
Deferred tax is provided for, using the liability method, on temporary differences at the
balance sheet date between the tax bases of assets and liabilities and their carrying
amounts in the financial statements. In principle, deferred tax liabilities are recognised
for all taxable temporary differences and deferred tax assets are recognised for all
deductible temporary differences, unused tax losses and unused tax credits to the
extent that it is probable that future taxable profit will be available against which the
deductible temporary differences, unused tax losses and unused tax credits can be
utilised. Deferred tax is not recognised if the temporary difference arises from goodwill
or from the initial recognition of an asset or liability in a transaction which is not a
business combination and at the time of the transaction, affects neither the accounting
profit nor taxable profit.
The carrying amount of deferred tax assets is reviewed at each balance sheet date and
reduced to the extent that it is no longer probable that sufficient future taxable profit will
be available to allow all or part of the asset to be recovered.
Deferred tax is measured at the tax rates that are expected to apply in the year when
the asset is realised or the liability settled, based on tax rates that have been enacted
or substantively enacted by the balance sheet date. Deferred tax is recognised in the
income statements, except when it arises from a transaction which is recognised
directly in equity, in which case the deferred tax is also charged or credited directly in
equity, or when it arises from a business combination that is an acquisition, in which
case the deferred tax is included in the resulting goodwill.

Impairment of Assets Excluding Goodwill
At each balance sheet date, the Group reviews the carrying amounts of its non-current
assets to determine whether there is any indication that those assets have suffered an
impairment loss. If any such indication exists, the recoverable amount of the asset is
estimated in order to determine the extent of the impairment loss (if any). Where it is not
possible to estimate the recoverable amount of an individual asset, the Group estimates
the recoverable amount of the cash-generating unit to which the asset belongs.
2010
RM
2011
RM
1 United States Dollar
1 Euro
1 Canadian Dollar
3.17
4.11
3.10
3.08
4.08
3.08
127
Basis of Consolidation
Subsidiaries
Subsidiaries are entities, including unincorporated entities, controlled by the Group.
Control exists when the Group has the ability to exercise its power to govern the
financial and operating policies of an entity so as to obtain benefits from its activities. In
assessing control, potential voting rights that presently are exercisable are taken into
account. Subsidiaries are consolidated using the purchase method of accounting.
Under the purchase method of accounting, the financial statements of subsidiaries are
included in the consolidated financial statements from the date that control commences
until the date that control ceases.
Investments in subsidiaries are stated in the Companys balance sheet at cost less any
impairment losses.
Minority interest
Minority interest at the balance sheet date, being the portion of the net identifiable
assets (excluding goodwill) of subsidiaries attributable to equity interests that are not
owned by the Company, whether directly or indirectly through subsidiaries, are
presented in the consolidated balance sheet and statement of changes in equity within
equity, separately from equity attributable to the equity shareholders of the Company.
Minority interest in the results of the Group are presented on the face of the
consolidated income statement as an allocation of the total profit or loss for the year
between minority interest and the equity shareholders of the Company.
Where losses applicable to the minority exceed the minoritys interest in the equity of a
subsidiary, the excess, and any further losses applicable to the minority, are charged
against the Groups interest except to the extent that the minority has a binding obligation
to, and is able to, make additional investment to cover the losses. If the subsidiary
subsequently reports profits, the Groups interest is allocated with all such profits until the
minoritys share of losses previously absorbed by the Group has been recovered.
Transactions eliminated on consolidation
Intra-group balances and transactions, and any unrealised income and expenses
arising from intra-group transactions, are eliminated in preparing the consolidated
financial statements.

Foreign Currency Conversion
Transactions in foreign currencies are converted into Ringgit Malaysia at the exchange
rates prevailing at the transaction dates. Foreign currency assets and liabilities at
financial year-end are converted into Ringgit Malaysia at the exchange rates prevailing
at the balance sheet date. All foreign exchange gains or losses are taken up in the
income statements.
The principal closing rates used in the translation of foreign currency amounts are as
follows:
Income Tax
Income tax comprises current and deferred tax. Current tax is the expected amount of
income taxes payable in respect of the taxable profit for the year and is measured using
the tax rates that have been enacted or substantively enacted by the balance sheet date.
Deferred tax is provided for, using the liability method, on temporary differences at the
balance sheet date between the tax bases of assets and liabilities and their carrying
amounts in the financial statements. In principle, deferred tax liabilities are recognised
for all taxable temporary differences and deferred tax assets are recognised for all
deductible temporary differences, unused tax losses and unused tax credits to the
extent that it is probable that future taxable profit will be available against which the
deductible temporary differences, unused tax losses and unused tax credits can be
utilised. Deferred tax is not recognised if the temporary difference arises from goodwill
or from the initial recognition of an asset or liability in a transaction which is not a
business combination and at the time of the transaction, affects neither the accounting
profit nor taxable profit.
The carrying amount of deferred tax assets is reviewed at each balance sheet date and
reduced to the extent that it is no longer probable that sufficient future taxable profit will
be available to allow all or part of the asset to be recovered.
Deferred tax is measured at the tax rates that are expected to apply in the year when
the asset is realised or the liability settled, based on tax rates that have been enacted
or substantively enacted by the balance sheet date. Deferred tax is recognised in the
income statements, except when it arises from a transaction which is recognised
directly in equity, in which case the deferred tax is also charged or credited directly in
equity, or when it arises from a business combination that is an acquisition, in which
case the deferred tax is included in the resulting goodwill.

Impairment of Assets Excluding Goodwill
At each balance sheet date, the Group reviews the carrying amounts of its non-current
assets to determine whether there is any indication that those assets have suffered an
impairment loss. If any such indication exists, the recoverable amount of the asset is
estimated in order to determine the extent of the impairment loss (if any). Where it is not
possible to estimate the recoverable amount of an individual asset, the Group estimates
the recoverable amount of the cash-generating unit to which the asset belongs.
2010
RM
2011
RM
1 United States Dollar
1 Euro
1 Canadian Dollar
3.17
4.11
3.10
3.08
4.08
3.08
128
Recoverable amount is the higher net selling price less costs to sell and value-in-use. In
assessing value-in-use, the estimated future cash flows are discounted to their present
value using a pre-tax discount rate that reflects current market assessments of the time
value of money and the risks specific to the asset.
If the recoverable amount of an asset (or cash-generating unit) is estimated to be less
than its carrying amount, the carrying amount of the asset (or cash-generating unit) is
reduced to its recoverable amount. An impairment loss is recognised immediately in the
income statements.
Where an impairment loss subsequently reverses, the carrying amount of the asset (or
cash-generating unit) is increased to the revised estimate of its recoverable amount, but
the increased carrying amount should not exceed the carrying amount that would have
been determined had no impairment loss been recognised for the asset (or
cash-generating unit) in prior years. A reversal of an impairment loss is recognised
immediately in the income statements.
Property, Plant and Equipment
Property, plant and equipment are stated at cost less accumulated depreciation and
any impairment losses.
Depreciation of property, plant and equipment, other than freehold land, construction and
other work in-progress which are not depreciated, is computed on the straight-line method
at the following annual rates based on the estimated useful lives of the various assets:
Office equipment 20%
Computer equipment 33 1/3%
Furniture and fittings 20%
Motor vehicles 20%
Renovation 20%
Properties in the course of construction are carried at cost, less any impairment loss.
Cost includes professional fees and any incidental expenditure that is directly
attributable to the assets. Freehold land and property, plant and equipment under
construction are not depreciated.
The residual value, estimated useful life and depreciation method of property, plant and
equipment are reviewed at each balance sheet date and, if expectations differ from
previous estimates, the changes will be accounted for as a change in an accounting
estimate.
Gain or loss arising from the disposal of an asset is determined as the difference
between the net disposal proceeds and the carrying amount of the asset, and is
recognised in the income statements.
Assets Acquired Under Hire-Purchase Arrangements
Assets acquired under hire-purchase arrangements are capitalised in the financial
statements and the corresponding obligations are treated as liabilities. Finance charges
are allocated to the income statements to give a constant periodic rate of interest on the
remaining hire-purchase liabilities.
Technology Platform Assets
Patent and licenses
Patent, licenses and other similar purchased rights of technology platform are
recognised as intangible assets if it is probable that the future economic benefits that
are attributable to such assets will flow to the Company and the cost of such assets can
be reliably measured.
Intangible asset is stated at cost less accumulated amortisation and impairment losses.
Subsequent expenditure on capitalised intangible assets is capitalised only when it
increases the future economic benefits embodied in the specific asset to which it
relates. All other expenditures are expensed as incurred.
Amortisation is charged to the income statements on a straight-line basis over the
estimated useful lives of intangible assets unless such lives are indefinite. Intangible
assets with indefinite useful lives are tested for impairment annually and whenever there
is an indication that they may be impaired. Intangible assets are amortised from the
date that they are available for use. The estimated useful lives of the intangible assets
are determined based on the estimated life span of the patent, licences or rights of the
technology platform. The estimated useful lives for the current financial year is between
5 to 25 years.
Amortisation methods, useful lives and residual values are reviewed at the end of each
reporting period and adjusted, if appropriate.
Technology platform equipment
Technology platform equipment are stated at cost less accumulated amortisation and
Amortisation of technology platform equipment is computed on the straight-line method
for a period of 5 years based on the estimated useful lives of the equipment.
129
Recoverable amount is the higher net selling price less costs to sell and value-in-use. In
assessing value-in-use, the estimated future cash flows are discounted to their present
value using a pre-tax discount rate that reflects current market assessments of the time
value of money and the risks specific to the asset.
If the recoverable amount of an asset (or cash-generating unit) is estimated to be less
than its carrying amount, the carrying amount of the asset (or cash-generating unit) is
reduced to its recoverable amount. An impairment loss is recognised immediately in the
income statements.
Where an impairment loss subsequently reverses, the carrying amount of the asset (or
cash-generating unit) is increased to the revised estimate of its recoverable amount, but
the increased carrying amount should not exceed the carrying amount that would have
been determined had no impairment loss been recognised for the asset (or
cash-generating unit) in prior years. A reversal of an impairment loss is recognised
immediately in the income statements.
Property, Plant and Equipment
Property, plant and equipment are stated at cost less accumulated depreciation and
Depreciation of property, plant and equipment, other than freehold land, construction and
other work in-progress which are not depreciated, is computed on the straight-line method
at the following annual rates based on the estimated useful lives of the various assets:
Office equipment 20%
Computer equipment 33 1/3%
Furniture and fittings 20%
Motor vehicles 20%
Renovation 20%
Properties in the course of construction are carried at cost, less any impairment loss.
Cost includes professional fees and any incidental expenditure that is directly
attributable to the assets. Freehold land and property, plant and equipment under
construction are not depreciated.
The residual value, estimated useful life and depreciation method of property, plant and
equipment are reviewed at each balance sheet date and, if expectations differ from
previous estimates, the changes will be accounted for as a change in an accounting
estimate.
Gain or loss arising from the disposal of an asset is determined as the difference
between the net disposal proceeds and the carrying amount of the asset, and is
recognised in the income statements.
Assets Acquired Under Hire-Purchase Arrangements
Assets acquired under hire-purchase arrangements are capitalised in the financial
statements and the corresponding obligations are treated as liabilities. Finance charges
are allocated to the income statements to give a constant periodic rate of interest on the
remaining hire-purchase liabilities.
Technology Platform Assets
Patent and licenses
Patent, licenses and other similar purchased rights of technology platform are
recognised as intangible assets if it is probable that the future economic benefits that
are attributable to such assets will flow to the Company and the cost of such assets can
be reliably measured.
Intangible asset is stated at cost less accumulated amortisation and impairment losses.
Subsequent expenditure on capitalised intangible assets is capitalised only when it
increases the future economic benefits embodied in the specific asset to which it
relates. All other expenditures are expensed as incurred.
Amortisation is charged to the income statements on a straight-line basis over the
estimated useful lives of intangible assets unless such lives are indefinite. Intangible
assets with indefinite useful lives are tested for impairment annually and whenever there
is an indication that they may be impaired. Intangible assets are amortised from the
date that they are available for use. The estimated useful lives of the intangible assets
are determined based on the estimated life span of the patent, licences or rights of the
technology platform. The estimated useful lives for the current financial year is between
5 to 25 years.
Amortisation methods, useful lives and residual values are reviewed at the end of each
reporting period and adjusted, if appropriate.
Technology platform equipment are stated at cost less accumulated amortisation and
Amortisation of technology platform equipment is computed on the straight-line method
for a period of 5 years based on the estimated useful lives of the equipment.
130
Employee Benefits
(i) Short term employee benefits
Wages, salaries, bonuses and social security contributions are recognised as an
expense in the year in which the associated services are rendered by employees
of the Company. Short term accumulating compensated absences such as paid
annual leaves are recognised when services are rendered by employees that
increase their entitlement to future compensated absences.

(ii) Defined contribution plan
As required by law, companies in Malaysia make contributions to the Employees
Provident Fund (EPF). Such contributions are recognised as an expense in the
income statements as incurred.
Other receivables, deposits and prepayments
Other receivables, deposits and prepayments are stated at cost net of allowance for
doubtful debts.
Liabilities and provision
Other payables and accruals are stated at cost.
Provision for liabilities are recognised when the Company has a present obligation as a
result of a past event and it is probable that an outflow of resources embodying
economic benefits will be required to settle the obligation, and a reliable estimate of the
amount can be made. Provisions are reviewed at each balance sheet date and adjusted
to reflect the current best estimate.
Cash Flow Statements
The Group and the Company adopt the indirect method in the preparation of the cash
flow statements.
Cash equivalents are short-term, highly liquid investments that are readily convertible to
cash with insignificant risks of changes in value.
Cash and cash equivalents
Cash and cash equivalents consist of cash in hand, balances and deposits with
licensed financial institutions.

Income
(i) Services
Income from services rendered is recognised net of discounts in the income
statements as and when services are performed.
(ii) Interest income
Interest income is recognised in the income statements as and when there is
reasonable assurance that it will be received.
Expenses
Operating lease payments
Payments made under operating leases are recognised in the income statements on a
straight-line basis over the term of the lease. Lease incentives received are recognised
in the income statement as an integral part of the total lease payments made.
Government grants
Government grant is recognised initially as deferred income when there is reasonable
assurance that it will be received and that the Company will comply with the conditions
associated with the grant. Grants that compensate the Company for expenses incurred
are recognised in the income statements over the period necessary to match them with
the related costs that they are intended to compensate. Grants that compensate the
Company for the cost of an asset are recognised in the income statements on a
systematic basis over the useful life of the asset.
131
Employee Benefits
(i) Short term employee benefits
Wages, salaries, bonuses and social security contributions are recognised as an
expense in the year in which the associated services are rendered by employees
of the Company. Short term accumulating compensated absences such as paid
annual leaves are recognised when services are rendered by employees that
increase their entitlement to future compensated absences.

(ii) Defined contribution plan
As required by law, companies in Malaysia make contributions to the Employees
Provident Fund (EPF). Such contributions are recognised as an expense in the
income statements as incurred.
Other receivables, deposits and prepayments
Other receivables, deposits and prepayments are stated at cost net of allowance for
doubtful debts.
Liabilities and provision
Other payables and accruals are stated at cost.
Provision for liabilities are recognised when the Company has a present obligation as a
result of a past event and it is probable that an outflow of resources embodying
economic benefits will be required to settle the obligation, and a reliable estimate of the
amount can be made. Provisions are reviewed at each balance sheet date and adjusted
to reflect the current best estimate.
Cash Flow Statements
The Group and the Company adopt the indirect method in the preparation of the cash
flow statements.
Cash equivalents are short-term, highly liquid investments that are readily convertible to
cash with insignificant risks of changes in value.
Cash and cash equivalents
Cash and cash equivalents consist of cash in hand, balances and deposits with
licensed financial institutions.

Income
(i) Services
Income from services rendered is recognised net of discounts in the income
statements as and when services are performed.
(ii) Interest income
Interest income is recognised in the income statements as and when there is
reasonable assurance that it will be received.
Expenses
Operating lease payments
Payments made under operating leases are recognised in the income statements on a
straight-line basis over the term of the lease. Lease incentives received are recognised
in the income statement as an integral part of the total lease payments made.
Government grants
Government grant is recognised initially as deferred income when there is reasonable
assurance that it will be received and that the Company will comply with the conditions
associated with the grant. Grants that compensate the Company for expenses incurred
are recognised in the income statements over the period necessary to match them with
the related costs that they are intended to compensate. Grants that compensate the
Company for the cost of an asset are recognised in the income statements on a
systematic basis over the useful life of the asset.
132
(Forward) (Forward)
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Directors remunerations:
Employees Provident Fund
Other emoluments
Salaries and other staff costs
251,138
1,411,125
3,147,122
22,407,287
(34,617)
27,182,055
119,760
891,077
2,166,363
14,079,558
79,374
17,336,132
137,925
888,748
2,681,336
18,581,755
(34,617)
22,255,147
119,760
891,077
2,166,363
14,079,558
79,374
17,336,132
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Estimated current year
tax payable
-

32,745 - -
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Tax at statutory tax rate
of 25%
Tax effects of:
Expenses not deductible
for tax purposes
Income not taxable for
tax purpose
Realisation of deferred tax
previously not recognised
Deferred tax assets not
recognised
Tax expense for the year
(470,434)
(117,608)
29,285
(1,930,662)
-
2,018,985
-
4,084,742
1,021,186
18,415
(1,006,856)
-
-
32,745
8,092,369
2,023,092
-
(2,006,321)
(16,771)
-
-
3,854,811
963,703
-
(963,703)
-
-
-
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Note
8
Audit fee
Rental of premises
Amortisation of
technology platform
assets
Lease rental
Allowance for doubtful debts
Interest expense
Interest income on:
Fixed deposits
Amount due from subsidiary
(31,000)
(3,607,802)
(1,763,367)
(320,062)
(177,778)
(6,665)
(4,333)
13,043,594
-
(26,000)
(3,765,169)
(677,058)
(325,923)
82,527
(18,287)
-
9,210,706
-
(20,000)
(3,148,909)
(1,763,367)
(275,850)
(177,788)
(6,665)
(4,333)
10,484,165
2,151,698
(20,000)
(3,765,169)
(677,058)
(325,923)
82,527
(18,287)
-
8,796,075
-
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Note
13
13
Amortisation of
developmental grants
Amortisation of
non-developmental grants
Realised gain/(loss)
on foreign exchange
12,836,100
35,577,034
590,836
31,294,720
35,999,197
(3,172)
12,836,100
35,577,034
590,836
31,294,720
35,999,197
(3,172)
4. STAFF COSTS
5. (LOSS)/PROFIT BEFORE TAX
6. TAX EXPENSE
The total charge for the year can be reconciled to the accounting profit as follows:
(Loss)/Profit before tax is arrived at after (charging)/crediting the followings:
133
(Forward) (Forward)
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Directors remunerations:
Other emoluments
Salaries and other staff costs
251,138
1,411,125
3,147,122
22,407,287
(34,617)
27,182,055
119,760
891,077
2,166,363
14,079,558
79,374
17,336,132
137,925
888,748
2,681,336
18,581,755
(34,617)
22,255,147
119,760
891,077
2,166,363
14,079,558
79,374
17,336,132
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Estimated current year
tax payable
-

32,745 - -
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Tax at statutory tax rate
of 25%
Tax effects of:
Expenses not deductible
for tax purposes
Income not taxable for
tax purpose
Realisation of deferred tax
previously not recognised
Deferred tax assets not
recognised
Tax expense for the year
(470,434)
(117,608)
29,285
(1,930,662)
-
2,018,985
-
4,084,742
1,021,186
18,415
(1,006,856)
-
-
32,745
8,092,369
2,023,092
-
(2,006,321)
(16,771)
-
-
3,854,811
963,703
-
(963,703)
-
-
-
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Note
8
Audit fee
Rental of premises
Amortisation of
technology platform
assets
Lease rental
Allowance for doubtful debts
Interest expense
Interest income on:
Fixed deposits
Amount due from subsidiary
(31,000)
(3,607,802)
(1,763,367)
(320,062)
(177,778)
(6,665)
(4,333)
13,043,594
-
(26,000)
(3,765,169)
(677,058)
(325,923)
82,527
(18,287)
-
9,210,706
-
(20,000)
(3,148,909)
(1,763,367)
(275,850)
(177,788)
(6,665)
(4,333)
10,484,165
2,151,698
(20,000)
(3,765,169)
(677,058)
(325,923)
82,527
(18,287)
-
8,796,075
-
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Note
13
13
Amortisation of
developmental grants
Amortisation of
non-developmental grants
Realised gain/(loss)
on foreign exchange
12,836,100
35,577,034
590,836
31,294,720
35,999,197
(3,172)
12,836,100
35,577,034
590,836
31,294,720
35,999,197
(3,172)
4. STAFF COSTS
5. (LOSS)/PROFIT BEFORE TAX
6. TAX EXPENSE
The total charge for the year can be reconciled to the accounting profit as follows:
(Loss)/Profit before tax is arrived at after (charging)/crediting the followings:
134
(Forward)
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Temporary differences arising from
property, plant and equipment
Unutilised tax losses
Unutilised capital allowance
(714,054)
38,505,699
2,166,316
39,957,961
(874,530)
30,362,673
2,393,877
31,882,020
(714,054)
30,362,673
2,166,316
31,814,935
(874,530)
30,362,673
2,393,877
31,882,020
7. PROPERTY, PLANT AND EQUIPMENT
The Company has been granted a tax exemption on its statutory income under subsection
127 (3A) Income Tax Act 1967 (for all sources of income except for dividend income) for the
period of 5 years commencing from year of assessment 2006 to 2011. In previous financial
year, the Company has been granted an extension for the period of 5 years commencing
from year of assessment 2011 to 2015.
No deferred tax has been recognised for the following items:
The unutilised tax losses and deductible temporary differences do not expire under current
tax legislation. Deferred tax assets have not been recognised in respect of these items
because it is not probable that future taxable profit will be available against which the Group
and the Company can utilise the benefits.
1,279,384
837,709
99,041
2,216,134
263,293
-
-
2,479,427
813,889
-
-
813,889
-
-
-
813,889
-
-
-
-
286,091
-
-
286,091
-
36,524,927
-
36,524,927
5,469,649
-
-
41,994,576
919,088
230,564
37,593
1,187,245
89,677
-
-
1,276,922
8,004,627
1,006,620
17,400
9,028,647
1,026,179
22,000
-
10,076,826
3,322,409
6,754,762
(154,034)
9,923,137
44,180,088
(22,000)
(5,849,684)
48,231,541
14,339,397
45,354,582
-
59,693,979
51,314,977
-
(5,849,684)
105,159,272
As of 1 January 2010
Additions
Reclassification
As of 31 December 2010/
1 January 2011
Additions
Reclassification
Transfer to Technology
Platform Assets (Note 8)
As of 31 December 2011
Group
Cost
Freehold
land
RM
Office
equipment
RM
Computer
equipment
RM
Furniture
and fittings
RM
Motor
vehicles
RM
Renovation
RM
Construction
and other
work-in
progress
RM
Total
RM
Charge for the year
1 January 2011
Charge for the year
Net Book Value
Office
equipment
RM
919,088
230,564
37,593
1,187,245
76,773
-
-
1,264,018
Computer
equipment
RM
8,004,627
1,006,620
17,400
9,028,647
1,023,804
22,000
-
10,074,451
Furniture
and fittings
RM
1,279,384
837,709
99,041
2,216,134
213,383
-
-
2,429,517
Motor
vehicles
RM
813,889
-
-
813,889
-
-
-
813,889
Work-in
progress
RM
3,322,409
2,727,849
(154,034)
5,896,224
191,400
(22,000)
(5,849,684)
215,940
Total
RM
Office
equipment
RM
Computer
equipment
RM
Furniture
and fittings
RM
Motor
vehicles
RM
Work-in
progress
RM
Total
RM
14,339,397
4,802,742
-
19,142,139
1,505,360
-
(5,849,684)
14,797,815
587,210
191,255
778,465
153,926
932,391
331,627
408,780
4,743,106
2,220,805
6,963,911
1,531,540
8,495,451
1,579,000
2,064,736
922,827
332,531
1,255,358
308,307
1,563,665
865,852
960,776
471,452
152,114
623,566
75,969
699,535
114,354
190,323
-
-
-
-
-
215,940
5,896,224
6,724,595
2,896,705
9,621,300
2,069,742
11,691,042
3,106,773
9,520,839
922,827
332,531
1,255,358
318,198
1,573,556
905,871
960,776
471,452
152,114
623,566
75,969
699,535
114,354
190,323
-
-
-
28,803
28,803
257,288
-
-
-
-
-
-
41,994,576
36,524,927
587,210
191,255
778,465
154,962
933,427
343,495
408,780
4,743,106
2,220,805
6,963,911
1,532,027
8,495,938
1,580,888
2,064,736
-
-
-
-
-
48,231,541
9,923,137
6,724,595
2,896,705
9,621,300
2,109,959
11,731,259
93,428,013
50,072,679
Group
Accumulated
Depreciation
Freehold
land
RM
Office
equipment
RM
Computer
equipment
RM
Furniture
and fittings
RM
Motor
vehicles
RM
Renovation
RM
Construction
and other
work-in
progress
RM
Total
RM
Company
Cost
Additions
Reclassification
1 January 2011
Additions
Reclassification
Company
Accumulated Depreciation
Charge for the year
1 January 2011
Charge for the year
Net Book Value
135
(Forward)
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Temporary differences arising from
property, plant and equipment
Unutilised tax losses
Unutilised capital allowance
(714,054)
38,505,699
2,166,316
39,957,961
(874,530)
30,362,673
2,393,877
31,882,020
(714,054)
30,362,673
2,166,316
31,814,935
(874,530)
30,362,673
2,393,877
31,882,020
7. PROPERTY, PLANT AND EQUIPMENT
The Company has been granted a tax exemption on its statutory income under subsection
127 (3A) Income Tax Act 1967 (for all sources of income except for dividend income) for the
period of 5 years commencing from year of assessment 2006 to 2011. In previous financial
year, the Company has been granted an extension for the period of 5 years commencing
from year of assessment 2011 to 2015.
No deferred tax has been recognised for the following items:
The unutilised tax losses and deductible temporary differences do not expire under current
tax legislation. Deferred tax assets have not been recognised in respect of these items
because it is not probable that future taxable profit will be available against which the Group
and the Company can utilise the benefits.
1,279,384
837,709
99,041
2,216,134
263,293
-
-
2,479,427
813,889
-
-
813,889
-
-
-
813,889
-
-
-
-
286,091
-
-
286,091
-
36,524,927
-
36,524,927
5,469,649
-
-
41,994,576
919,088
230,564
37,593
1,187,245
89,677
-
-
1,276,922
8,004,627
1,006,620
17,400
9,028,647
1,026,179
22,000
-
10,076,826
3,322,409
6,754,762
(154,034)
9,923,137
44,180,088
(22,000)
(5,849,684)
48,231,541
14,339,397
45,354,582
-
59,693,979
51,314,977
-
(5,849,684)
105,159,272
Additions
Reclassification
1 January 2011
Additions
Reclassification
Group
Cost
Freehold
land
RM
Office
equipment
RM
Computer
equipment
RM
Furniture
and fittings
RM
Motor
vehicles
RM
Renovation
RM
Construction
and other
work-in
progress
RM
Total
RM
Charge for the year
1 January 2011
Charge for the year
Net Book Value
Office
equipment
RM
919,088
230,564
37,593
1,187,245
76,773
-
-
1,264,018
Computer
equipment
RM
8,004,627
1,006,620
17,400
9,028,647
1,023,804
22,000
-
10,074,451
Furniture
and fittings
RM
1,279,384
837,709
99,041
2,216,134
213,383
-
-
2,429,517
Motor
vehicles
RM
813,889
-
-
813,889
-
-
-
813,889
Work-in
progress
RM
3,322,409
2,727,849
(154,034)
5,896,224
191,400
(22,000)
(5,849,684)
215,940
Total
RM
Office
equipment
RM
Computer
equipment
RM
Furniture
and fittings
RM
Motor
vehicles
RM
Work-in
progress
RM
Total
RM
14,339,397
4,802,742
-
19,142,139
1,505,360
-
(5,849,684)
14,797,815
587,210
191,255
778,465
153,926
932,391
331,627
408,780
4,743,106
2,220,805
6,963,911
1,531,540
8,495,451
1,579,000
2,064,736
922,827
332,531
1,255,358
308,307
1,563,665
865,852
960,776
471,452
152,114
623,566
75,969
699,535
114,354
190,323
-
-
-
-
-
215,940
5,896,224
6,724,595
2,896,705
9,621,300
2,069,742
11,691,042
3,106,773
9,520,839
922,827
332,531
1,255,358
318,198
1,573,556
905,871
960,776
471,452
152,114
623,566
75,969
699,535
114,354
190,323
-
-
-
28,803
28,803
257,288
-
-
-
-
-
-
41,994,576
36,524,927
587,210
191,255
778,465
154,962
933,427
343,495
408,780
4,743,106
2,220,805
6,963,911
1,532,027
8,495,938
1,580,888
2,064,736
-
-
-
-
-
48,231,541
9,923,137
6,724,595
2,896,705
9,621,300
2,109,959
11,731,259
93,428,013
50,072,679
Group
Accumulated
Depreciation
Freehold
land
RM
Office
equipment
RM
Computer
equipment
RM
Furniture
and fittings
RM
Motor
vehicles
RM
Renovation
RM
Construction
and other
work-in
progress
RM
Total
RM
Company
Cost
Additions
Reclassification
1 January 2011
Additions
Reclassification
Company
Accumulated Depreciation
Charge for the year
1 January 2011
Charge for the year
Net Book Value
136
8. TECHNOLOGY PLATFORM ASSETS
9. INVESTMENT IN SUBSIDIARIES
As at 31 December 2011, the net book value of motor vehicles of the Group and of the
Company that were acquired by means of hire-purchase arrangements is RM31,254
(2010: RM77,894).
Included in property, plant and equipment of the Group and the Company are fully
depreciated assets, which are still in use, with cost amounting to RM8,942,443 (2010:
RM7,172,758).
During the financial year, the Company incorporated BiotechCorp Technology
Management Sdn. Bhd by holding the entire issued share capital comprising of 2
ordinary shares of RM1 each.
The subsidiary companies are as follows:
Technology platform assets comprises patent, licenses and equipments acquired under
the 9th Malaysia Plan (RMK-9) program under the Biotechnology Acquisition Program.
The completion of the various technologies is based on the fulfillment of specific terms
and conditions as stated under the individual agreement. Technology platform assets
are amortised on a straight line basis over its estimated useful lives when the asset is
available for use.
All the subsidiaries are audited by Deloitte KassimChan.
Group/Company
2011 2010
RM RM
Technology patent and licenses
Technology patent and licenses, at cost
As of 1 January
Additions
Less: Amortisation to income statements
As of 31 December
Technology platform equipment, at cost
As of 1 January
Additions
Transfer from property, plant and
equipment (Note 7)
As of 31 December
Total Technology Platform Assets
(a)

(b)
30,660,035
24,957,281
4,912,853
29,870,134
(1,206,175)
28,663,959
16,993,518
-
11,143,834
5,849,684
16,993,518
(557,192)
16,436,326
45,100,285
25,747,182
23,274,566
2,359,773
25,634,339
(677,058)
24,957,281
-
-
-
-
-
-
-
24,957,281
2010
RM
2011
RM
Company
Unquoted shares, at cost 4 2
BiotechCorp Investment
Holdings Sdn. Bhd.
Management Sdn. Bhd.
2011
%
100
100
2010
%
100
-
Investment holding
Investment holding
Malaysia
Malaysia
Effective
equity interest
Malaysian Bio-XCell
Sdn. Bhd.
60 60
Development and
operation of
biotechnology park
Malaysia
BiotechCorp Nanotech
Solutions Sdn. Bhd.
100 -
Commercialisation of
Nanotechnology platform
in non-cancer applications
Malaysia
100 -
DotScan
TM
antibody
microarray diagnostic
technology platform
BiotechCorp Diagnostic
Solutions Sdn. Bhd
Malaysia
100 -
Supercritical Fluid
Extraction technology
platform
BiotechCorp Supercritical
Solutions Sdn. Bhd.
Malaysia
100 -
Marker Assisted Selection
technology platform
BiotechCorp Molecular
Solutions Sdn. Bhd.
Malaysia
Subsidiary of BiotechCorp Investment Holdings Sdn. Bhd.
Subsidiaries of BiotechCorp Technology Management Sdn. Bhd.
Principal activity Name of Subsidiary
Country of
incorporation
137
8. TECHNOLOGY PLATFORM ASSETS
9. INVESTMENT IN SUBSIDIARIES
As at 31 December 2011, the net book value of motor vehicles of the Group and of the
Company that were acquired by means of hire-purchase arrangements is RM31,254
(2010: RM77,894).
Included in property, plant and equipment of the Group and the Company are fully
depreciated assets, which are still in use, with cost amounting to RM8,942,443 (2010:
RM7,172,758).
During the financial year, the Company incorporated BiotechCorp Technology
Management Sdn. Bhd by holding the entire issued share capital comprising of 2
ordinary shares of RM1 each.
The subsidiary companies are as follows:
Technology platform assets comprises patent, licenses and equipments acquired under
the 9th Malaysia Plan (RMK-9) program under the Biotechnology Acquisition Program.
The completion of the various technologies is based on the fulfillment of specific terms
and conditions as stated under the individual agreement. Technology platform assets
are amortised on a straight line basis over its estimated useful lives when the asset is
available for use.
All the subsidiaries are audited by Deloitte KassimChan.
Group/Company
2011 2010
RM RM
Technology patent and licenses
Technology patent and licenses, at cost
As of 1 January
Additions
As of 31 December
Technology platform equipment, at cost
As of 1 January
Additions
Transfer from property, plant and
equipment (Note 7)
As of 31 December
Total Technology Platform Assets
(a)

(b)
30,660,035
24,957,281
4,912,853
29,870,134
(1,206,175)
28,663,959
16,993,518
-
11,143,834
5,849,684
16,993,518
(557,192)
16,436,326
45,100,285
25,747,182
23,274,566
2,359,773
25,634,339
(677,058)
24,957,281
-
-
-
-
-
-
-
24,957,281
2010
RM
2011
RM
Company
Unquoted shares, at cost 4 2
BiotechCorp Investment
Holdings Sdn. Bhd.
Management Sdn. Bhd.
2011
%
100
100
2010
%
100
-
Investment holding
Investment holding
Malaysia
Malaysia
Effective
equity interest
Malaysian Bio-XCell
Sdn. Bhd.
60 60
Development and
operation of
biotechnology park
Malaysia
BiotechCorp Nanotech
Solutions Sdn. Bhd.
100 -
Nanotechnology platform
in non-cancer applications
Malaysia
100 -
DotScan
TM
antibody
microarray diagnostic
technology platform
BiotechCorp Diagnostic
Solutions Sdn. Bhd
Malaysia
100 -
Supercritical Fluid
Extraction technology
platform
BiotechCorp Supercritical
Solutions Sdn. Bhd.
Malaysia
100 -
Marker Assisted Selection
technology platform
BiotechCorp Molecular
Solutions Sdn. Bhd.
Malaysia
Subsidiary of BiotechCorp Investment Holdings Sdn. Bhd.
Subsidiaries of BiotechCorp Technology Management Sdn. Bhd.
Principal activity Name of Subsidiary
Country of
incorporation
138
10. OTHER RECEIVABLES, DEPOSITS AND PREPAYMENTS
11. CASH AND BANK BALANCES
12. SHARE CAPITAL
13. DEFFERED INCOME
The amount due from subsidiaries are non-trade in nature, unsecured and repayable on
demand.
During the financial year, other receivables amounting to RM1,087,086 (2010 : Nil) has
been written off against allowance for doubtful debts.

All the amount due from subsidiaries are interest-free except for an amount of RM41,186,520
(2010 : Nil) that bears interest at 4.5% per annum. Interest income of RM2,151,698 (2010 :
Nil) has been recognised in the income statement of the Company as disclosed in Note 5.
Cash and cash equivalents included in the cash flow statements comprise the following
balance sheet amounts:
Other receivables, deposits and prepayments consist of:
Included under cash and cash equivalents of the Group and of the Company are
amounts represent unutilised disbursement for the purposes of developmental projects
amounting to RM78,058,388 (2010 : RM153,061,304)
The average effective interest rates for the abovementioned deposits in the range of
2.85% to 3.6% (2010 : 2.85% to 3.1%) per annum.
2010
RM
2011
RM
Group and Company
Authorised:
100,000,000 ordinary shares of RM1 each
Issued and fully paid:
100,000,000
95,000,002
100,000,000
95,000,002
2010
RM
2011
RM
Group and Company
a) Developmental Grants
As of 1 January
Received/(reclassed) during the year:
IP Research and Management Program (IPRM)
Biotechnology Acquisition Program (BAP)
Biotechnology Commercialisation Grant (BCG)
Biotechnology Entrepreneur Program (BEP)
Biotechnology Entrepreneurship Training Program (BeST)
BioNexus Partners Program (BNP)
Biotechnology Park (Bio-XCell)
Biotechnology Commercialisation Fund (BCF)

Less: Commercialisation grants awarded
BNP grants awarded
Interest income from deposit placement
recognised to income statements
As of 31 December
b) Non-developmental Grants
As of 1 January
Additions during the year
As of 31 December
Total Deferred Income
213,353,998
(7,000,000)
-
-
-
-
-
7,000,000
5,000,000
218,353,998
(6,707,832)
(5,744,898)
(4,703,669)
201,197,599
(12,836,100)
188,361,499
9,751,531
33,500,000
(35,577,034)
7,674,497
196,035,996
239,380,486
(5,600,000)
(12,700,000)
44,807,000
5,898,750
6,450,000
8,651,250
-
-
286,887,486
(41,964,436)
(274,332)
-
244,648,718
(31,294,720)
213,353,998
12,560,728
33,190,000
(35,999,197)
9,751,531
223,105,529
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Other receivables
Less: Allowance for doubtful debts
Prepayments
Sundry deposits
Amount due from subsidiaries
7,653,419
(179,438)
7,473,981
452,225
1,047,454
-
8,973,660
15,672,701
(1,088,736)
14,583,965
650,190
1,024,815
-
16,258,970
7,557,736
(179,438)
7,378,298
378,491
917,333
107,309,375
115,983,497
15,500,591
(1,088,736)
14,411,855
650,190
1,024,815
103,821,658
119,908,518
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Fixed deposits with
licensed institutions
12,780,415
196,547,973
209,328,388
7,842,807
305,638,000
313,480,807
9,225,186
146,534,000
155,759,186
6,065,693
208,638,000
214,703,693
139
10. OTHER RECEIVABLES, DEPOSITS AND PREPAYMENTS
11. CASH AND BANK BALANCES
12. SHARE CAPITAL
13. DEFFERED INCOME
The amount due from subsidiaries are non-trade in nature, unsecured and repayable on
demand.
During the financial year, other receivables amounting to RM1,087,086 (2010 : Nil) has
been written off against allowance for doubtful debts.

All the amount due from subsidiaries are interest-free except for an amount of RM41,186,520
(2010 : Nil) that bears interest at 4.5% per annum. Interest income of RM2,151,698 (2010 :
Nil) has been recognised in the income statement of the Company as disclosed in Note 5.
Cash and cash equivalents included in the cash flow statements comprise the following
balance sheet amounts:
Other receivables, deposits and prepayments consist of:
Included under cash and cash equivalents of the Group and of the Company are
amounts represent unutilised disbursement for the purposes of developmental projects
amounting to RM78,058,388 (2010 : RM153,061,304)
The average effective interest rates for the abovementioned deposits in the range of
2.85% to 3.6% (2010 : 2.85% to 3.1%) per annum.
2010
RM
2011
RM
Group and Company
Authorised:
Issued and fully paid:
100,000,000
95,000,002
100,000,000
95,000,002
2010
RM
2011
RM
Group and Company
As of 1 January
Received/(reclassed) during the year:
IP Research and Management Program (IPRM)
Biotechnology Acquisition Program (BAP)
Biotechnology Commercialisation Grant (BCG)
Biotechnology Entrepreneur Program (BEP)
Biotechnology Entrepreneurship Training Program (BeST)
BioNexus Partners Program (BNP)
Biotechnology Park (Bio-XCell)
Biotechnology Commercialisation Fund (BCF)

Less: Commercialisation grants awarded
BNP grants awarded
Interest income from deposit placement
recognised to income statements
As of 31 December
As of 1 January
Additions during the year
As of 31 December
Total Deferred Income
213,353,998
(7,000,000)
-
-
-
-
-
7,000,000
5,000,000
218,353,998
(6,707,832)
(5,744,898)
(4,703,669)
201,197,599
(12,836,100)
188,361,499
9,751,531
33,500,000
(35,577,034)
7,674,497
196,035,996
239,380,486
(5,600,000)
(12,700,000)
44,807,000
5,898,750
6,450,000
8,651,250
-
-
286,887,486
(41,964,436)
(274,332)
-
244,648,718
(31,294,720)
213,353,998
12,560,728
33,190,000
(35,999,197)
9,751,531
223,105,529
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Other receivables
Less: Allowance for doubtful debts
Prepayments
Sundry deposits
Amount due from subsidiaries
7,653,419
(179,438)
7,473,981
452,225
1,047,454
-
8,973,660
15,672,701
(1,088,736)
14,583,965
650,190
1,024,815
-
16,258,970
7,557,736
(179,438)
7,378,298
378,491
917,333
107,309,375
115,983,497
15,500,591
(1,088,736)
14,411,855
650,190
1,024,815
103,821,658
119,908,518
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Fixed deposits with
licensed institutions
12,780,415
196,547,973
209,328,388
7,842,807
305,638,000
313,480,807
9,225,186
146,534,000
155,759,186
6,065,693
208,638,000
214,703,693
140
14. HIRE-PURCHASE PAYABLES
15. OTHER PAYABLES AND ACCRUALS
Hire-purchase payables consist of the following:
The non-current portion is repayable as follows:
The developmental grants awarded payables cover for periods up to 2 years.
The Company was awarded with government grants for the following purposes:
Intellectual Property Research and Management Program comprises a series of
programs that are targeted to enhance the efficiency and effectiveness of intellectual
property management and protection in Malaysia.
Biotechnology Acquisition Grant provides funding for the acquisition of enabling and
platform technologies within the biotechnology industry.
Biotechnology Commercialisation Program provides funding to facilitate the
establishment of biotechnology start-ups. The Biotechnology Commercialisation
Grant (BCG) comprises Seed Funding, R&D Matching Funding and International
Business Development Matching Funding. The Biotechnology Commercialisation
Fund (BCF) provides soft loan to qualified biotechnology business.
Biotechnology Entrepreneur Program seeks to develop biotechnology entrepreneurs
by providing the necessary skill sets and knowledge to commence, develop and
manage new biotechnology ventures.
Biotechnology Entrepreneurship Training Program (BeST) is an intensive and
structured training program for biotechnology graduates to equip themselves with
the necessary knowledge and skills with the aim to provide a competent workforce
in the industry.
BioNexus Partner Program (BNP) seeks to promote active collaboration between
biotechnology companies and universities, research institutes, technology parks
and incubators in the country by leveraging the facilities, infrastructure and
capabilities available.
Biotechnology Park project is an initiative approved under the Governments Second
Economic Stimulus Package to develop and operate a biotechnology park in
Iskandar Malaysia, Johor known as Bio-XCell.
The non-developmental grant received from the government is to finance the
Companys day-to-day operating activities.
2010
RM
2011
RM
Group and Company
Total outstanding obligations
Less: Interest in suspense
Principal outstanding
Less: Amount due for settlement within 12 months
(shown under current liabilities)
Non-current portion
33,646
(3,563)
30,083
(19,000)
11,083
83,799
(10,228)
73,571
(43,488)
30,083
2010
RM
2011
RM
Group and Company
Financial years ending 31 December:
2012
2013
-
11,083
11,083
19,000
11,083
30,083
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Developmental grants
awarded payables
Other payables
Accruals
36,839,896
4,796,637
3,604,252
45,240,785
66,099,850
6,389,247
564,879
73,053,976
36,839,896
2,867,519
3,220,625
42,928,040
66,099,850
6,389,247
558,879
73,047,976
141
14. HIRE-PURCHASE PAYABLES
15. OTHER PAYABLES AND ACCRUALS
Hire-purchase payables consist of the following:
The non-current portion is repayable as follows:
The developmental grants awarded payables cover for periods up to 2 years.
The Company was awarded with government grants for the following purposes:
Intellectual Property Research and Management Program comprises a series of
programs that are targeted to enhance the efficiency and effectiveness of intellectual
property management and protection in Malaysia.
Biotechnology Acquisition Grant provides funding for the acquisition of enabling and
platform technologies within the biotechnology industry.
Biotechnology Commercialisation Program provides funding to facilitate the
establishment of biotechnology start-ups. The Biotechnology Commercialisation
Grant (BCG) comprises Seed Funding, R&D Matching Funding and International
Business Development Matching Funding. The Biotechnology Commercialisation
Fund (BCF) provides soft loan to qualified biotechnology business.
Biotechnology Entrepreneur Program seeks to develop biotechnology entrepreneurs
by providing the necessary skill sets and knowledge to commence, develop and
manage new biotechnology ventures.
Biotechnology Entrepreneurship Training Program (BeST) is an intensive and
structured training program for biotechnology graduates to equip themselves with
the necessary knowledge and skills with the aim to provide a competent workforce
in the industry.
BioNexus Partner Program (BNP) seeks to promote active collaboration between
biotechnology companies and universities, research institutes, technology parks
and incubators in the country by leveraging the facilities, infrastructure and
capabilities available.
Biotechnology Park project is an initiative approved under the Governments Second
Economic Stimulus Package to develop and operate a biotechnology park in
Iskandar Malaysia, Johor known as Bio-XCell.
The non-developmental grant received from the government is to finance the
Companys day-to-day operating activities.
2010
RM
2011
RM
Group and Company
Total outstanding obligations
Less: Interest in suspense
Principal outstanding
Less: Amount due for settlement within 12 months
(shown under current liabilities)
Non-current portion
33,646
(3,563)
30,083
(19,000)
11,083
83,799
(10,228)
73,571
(43,488)
30,083
2010
RM
2011
RM
Group and Company
Financial years ending 31 December:
2012
2013
-
11,083
11,083
19,000
11,083
30,083
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Developmental grants
awarded payables
Other payables
Accruals
36,839,896
4,796,637
3,604,252
45,240,785
66,099,850
6,389,247
564,879
73,053,976
36,839,896
2,867,519
3,220,625
42,928,040
66,099,850
6,389,247
558,879
73,047,976
142
16. LEASE COMMITMENTS
18. CAPITAL COMMITMENTS
Total future minimum lease payments under non-cancellable operating leases are as follows:
17. RELATED PARTY TRANSACTIONS
During the financial year, significant related party transactions which are determined on
a basis as negotiated between the Company and its related parties are as as follows:
The capital commitments of the Group and of the Company will be recognised in the
financial statements when the goods or works are delivered or completed in
accordance to the contract it relates to.
The lease payments include rental payable and computer equipment under operating
leases. The computer equipment leases run for a period of three years. None of the
leases include contingent rentals.
2010
RM
2011
RM
Company
Interest income on intercompany loans (2,151,698) -
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Approved and contracted for:
Patent and licenses
Freehold land
Construction of building
3,663,110
5,103,650
37,813,712
198,919,608
245,500,080
3,500,460
9,900,677
33,539,000
49,550,000
96,490,137
3,663,110
5,103,650
-
-
8,766,760
3,500,460
9,900,677
-
-
13,401,137
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Approved but not contracted for:
Freehold land
-
-
-
-
245,500,080
11,143,834
8,494,200
74,100,000
93,738,034
190,228,171
-
-
-
-
8,766,760
11,143,834
-
-
11,143,834
24,544,971
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Less than one year
Between one and five years
3,434,344
4,334,506
7,768,850
3,786,818
7,465,430
11,252,248
3,121,769
3,867,879
6,989,648
3,786,818
7,465,430
11,252,248
143
16. LEASE COMMITMENTS
18. CAPITAL COMMITMENTS
Total future minimum lease payments under non-cancellable operating leases are as follows:
17. RELATED PARTY TRANSACTIONS
During the financial year, significant related party transactions which are determined on
a basis as negotiated between the Company and its related parties are as as follows:
The capital commitments of the Group and of the Company will be recognised in the
financial statements when the goods or works are delivered or completed in
accordance to the contract it relates to.
The lease payments include rental payable and computer equipment under operating
leases. The computer equipment leases run for a period of three years. None of the
leases include contingent rentals.
2010
RM
2011
RM
Company
Interest income on intercompany loans (2,151,698) -
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Approved and contracted for:
Patent and licenses
Freehold land
3,663,110
5,103,650
37,813,712
198,919,608
245,500,080
3,500,460
9,900,677
33,539,000
49,550,000
96,490,137
3,663,110
5,103,650
-
-
8,766,760
3,500,460
9,900,677
-
-
13,401,137
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Approved but not contracted for:
Freehold land
-
-
-
-
245,500,080
11,143,834
8,494,200
74,100,000
93,738,034
190,228,171
-
-
-
-
8,766,760
11,143,834
-
-
11,143,834
24,544,971
Company
2011 2010
RM RM
Group
2011 2010
RM RM
Less than one year
Between one and five years
3,434,344
4,334,506
7,768,850
3,786,818
7,465,430
11,252,248
3,121,769
3,867,879
6,989,648
3,786,818
7,465,430
11,252,248
144
The directors of MALAYSIAN BIOTECHNOLOGY CORPORATION SDN. BHD. state that,
in their opinion, the accompanying financial statements are drawn up in accordance with
Private Entity Reporting Standards and the provisions of the Companies Act, 1965 in
Malaysia so as to give a true and fair view of the financial position of the Group and of the
Company as of 31 December 2011 and of the financial performance and the cash flows of
the Group and of the Company for the year ended on that date.


7 May 2012
STATEMENT BY DIRECTORS
I, SYED AGIL BIN SYED HASHIM, the Officer primarily responsible for the financial
management of MALAYSIAN BIOTECHNOLOGY CORPORATION SDN. BHD., do
solemnly and sincerely declare that the accompanying financial statements are, in my
opinion, correct and I make this solemn declaration conscientiously believing the same to be
true, and by virtue of the provisions of the Statutory Declarations Act, 1960.
SYED AGIL BIN SYED HASHIM
Subscribed and solemnly declared by the abovenamed SYED AGIL BIN SYED HASHIM at
KUALA LUMPUR this 7th day of May 2012.
Before me,
COMMISSIONER FOR OATHS
DECLARATION BY THE OFFICER PRIMARILY RESPONSIBLE FOR THE
FINANCIAL MANAGEMENT OF THE COMPANY
145
The directors of MALAYSIAN BIOTECHNOLOGY CORPORATION SDN. BHD. state that,
in their opinion, the accompanying financial statements are drawn up in accordance with
Private Entity Reporting Standards and the provisions of the Companies Act, 1965 in
Malaysia so as to give a true and fair view of the financial position of the Group and of the
Company as of 31 December 2011 and of the financial performance and the cash flows of
the Group and of the Company for the year ended on that date.


7 May 2012
STATEMENT BY DIRECTORS
I, SYED AGIL BIN SYED HASHIM, the Officer primarily responsible for the financial
management of MALAYSIAN BIOTECHNOLOGY CORPORATION SDN. BHD., do
solemnly and sincerely declare that the accompanying financial statements are, in my
opinion, correct and I make this solemn declaration conscientiously believing the same to be
true, and by virtue of the provisions of the Statutory Declarations Act, 1960.
SYED AGIL BIN SYED HASHIM
Subscribed and solemnly declared by the abovenamed SYED AGIL BIN SYED HASHIM at
KUALA LUMPUR this 7th day of May 2012.
Before me,
COMMISSIONER FOR OATHS
DECLARATION BY THE OFFICER PRIMARILY RESPONSIBLE FOR THE
FINANCIAL MANAGEMENT OF THE COMPANY
146
EDITORIAL TEAM FOR
ANNUAL REPORT
147
EDITORIAL TEAM FOR
ANNUAL REPORT
148
Adrian Abd Ghani
VP, Policy &
Regulatory
Engagement
Editorial Team
For Annual Report
Ahmad Izral
Senior Manager,
Finance &
Accounting
Rozita Ishak
VP, Industry
Support
Arni Balkish
Manager,
Industry Talent
Development
Haslina Hamidan
Manager,
Corporate Affairs
Rohafazlyna
Executive,
Corporate
Communications
Bio-XCell
Mohd Faizal Batcha
Executive, Business
Development
Agriculture
Wong Sue May
Executive,
Secretarial
Marlia Othman
Executive,
Corporate
Affairs
Elina Jani
Senior Executive,
Healthcare
Fadzrin Azwar
VP, Monitoring &
Compliance
Zurina CheDir
VP, Corporate
Innovation Strategy
Nora Mohammad
VP, Evaluation
Lim Fook Ming
Executive,
Nanotech &
Dotscan
Ahmad Fazil Elias
Senior Manager,
Business Development Industrial
Renujeet
Executive,
Talent Management & Services
Other Contributors:
149
Adrian Abd Ghani
VP, Policy &
Regulatory
Engagement
Editorial Team
For Annual Report
Ahmad Izral
Senior Manager,
Finance &
Accounting
Rozita Ishak
VP, Industry
Support
Arni Balkish
Manager,
Industry Talent
Development
Haslina Hamidan
Manager,
Corporate Affairs
Rohafazlyna
Executive,
Corporate
Communications
Bio-XCell
Mohd Faizal Batcha
Executive, Business
Development
Agriculture
Wong Sue May
Executive,
Secretarial
Marlia Othman
Executive,
Corporate
Affairs
Elina Jani
Senior Executive,
Healthcare
Fadzrin Azwar
VP, Monitoring &
Compliance
Zurina CheDir
VP, Corporate
Innovation Strategy
Nora Mohammad
VP, Evaluation
Lim Fook Ming
Executive,
Nanotech &
Dotscan
Ahmad Fazil Elias
Senior Manager,
Business Development Industrial
Renujeet
Executive,
Talent Management & Services
Other Contributors:
150
152

BioTechCorp-Annual Report 2011

Caricato da

Informazioni sul documento

Copyright

Formati disponibili

Condividi questo documento

Condividi o incorpora il documento

Opzioni di condivisione

Hai trovato utile questo documento?

Questo contenuto è inappropriato?

Copyright:

Formati disponibili

BioTechCorp-Annual Report 2011

Caricato da

Copyright:

Formati disponibili

1

Annual Report 2011

Potrebbero piacerti anche